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Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterised by 
accumulation of ß-amyloid in extracellular plaques, intracellular neurofibrillary tangles 
composed of abnormally phosphorylated and aggregated tau, and widespread synaptic 
dysfunction and neuron loss that underlie the clinical symptoms of AD. Glial activation and a 
neuroinflammatory immune response is also a key aspect of the pathological progression of AD. 
The activation of astrocytes appears to be particularly associated with pathological changes in 
tau.  This thesis aims to investigate the association between astrocyte activation and abnormal 
tau processing using primary cell culture and human post-mortem brain. Furthermore, it aims 
to explore possible regional differences in this role of astrocytes, and the molecular signalling 
pathways by which astrocytes exert their effects on tau. 
Experiments in primary astrocyte and neuron co-cultures demonstrated that astrocytes were 
involved in accelerating Aß-induced neurotoxicity in hippocampal cultures, but not cortical 
cultures although the differences were quite subtle. Interestingly, astrocytes were important for 
the neuronal release of tau from cortical neurons under basal conditions, suggesting that 
astrocytes may be important for pathological tau spread in AD. Analysis of human post-mortem 
brain showed differences in astrocytic changes in hippocampus and cortex as AD progresses. In 
addition, these experiments also suggested regional differences in mechanisms related to 
synaptic dysfunction and loss as disease progresses. These data suggest that different 
mechanisms may underlie the neurodegenerative effects of ß-amyloid and/or activated 
astrocytes in distinct brain regions; an important consideration when considering therapeutic 
strategies for AD. 
In addition, the potential benefits for tauopathy of repurposing an already licenced drug with 
anti-inflammatory action were investigated. Despite showing significant modulation of tau 
phosphorylation in primary cultures, dimethyl fumarate had little influence on disease-
associated tau species when tested in vivo in a mouse model of tauopathy.  
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Overall, the findings of this thesis suggest that there are regional differences in astrocyte 
activation during the development of AD, that are somewhat associated with AD-relevant 
changes in tau. This work also supports a role for astrocytes in physiological tau release. Further 
elucidating these differences will increase understanding of neurodegenerative mechanisms. 
Moreover, these data suggest that regional involvement at different disease stages could be an 
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Chapter 1: Introduction 
 
1.1 Historical perspective 
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease first described by Alois 
Alzheimer in 1906. He presented the case of a fifty year old, Auguste D, who showed “a peculiar 
severe disease of the cerebral cortex” (Hippius and Neundorfer, 2003). Alzheimer went on to 
describe how Auguste D showed progressive deteriorating psychological symptoms beginning 
with paranoia and, over the five years he studied her, continued with memory problems, sleep 
disorders, aggressiveness, hallucinations and increasing confusion. After her death, Alzheimer 
was able to histologically investigate her brain, first describing the senile plaques and 
neurofibrillary tangles that are still used today to diagnose the disease post-mortem (Alzheimer 
et al., 1995).  
It is now known that AD clinically presents as progressive memory loss, confusion and often 
changes in behaviour and personality. However, diagnosis cannot be definitively confirmed until 
after death with the histopathological observation of ß-amyloid extracellular plaques and 
intracellular tau neurofibrillary tangles in the brain (McKhann et al., 1984). AD is currently the 
most common cause of dementia worldwide. The World Alzheimer Report 2015 estimates there 
are 46.8 million people living with dementia and that 58 % of these people live in developing 
countries. In 2015 the total worldwide cost of dementia was estimated to be USD 818 billion, 
1.09 % of global GDP (Prince, 2015). In the 2014 Alzheimer’s Society Dementia UK Update it was 
estimated that, in the UK alone, there are over 850,000 people living with dementia with an 
overall economic impact of £26.3 billion – approximately £32,250 per person annually. The 
number of people living with dementia is estimated to rise to over 2 million by 2051 and there 





AD brain shows clear pathology and atrophy compared to a healthy brain. Final diagnoses of AD 
can be made after demonstrating the presence of microscopic senile plaques and neurofibrillary 
tangles (NFTs) (Figure 1.1 A). In addition to the classical hallmarks of AD there is a characteristic 
pattern of neuron loss throughout the brain, with hippocampal and medial temporal lobe 
atrophy being so prominent that changes in hippocampal mass are used as a clinical diagnostic 
tool (Figure 1.1 B) (Schroder and Pantel, 2016). These changes start long before memory and 
behavioural symptoms present, with ß-amyloid and tau aggregates, synaptic dysfunction and 
axonal and dendrite loss occurring decades before the onset of symptoms (Braak and Braak, 
1991, 1995). By the time the first clinical symptoms are present and recognised as distinct from 
the normal aging process there is already widespread pathology and neuron loss. This results in 
an additional challenge in successful drug development: by the time symptoms present neuronal 
damage may already be irreversible (Cutler and Sramek, 2001). For this reason biomarkers, for 
example levels of ß-amyloid and tau in blood or cerebrospinal fluid (CSF), to diagnose or highlight 
high-risk individuals easily and reliably, are needed in order to increase the window of time 
available to treat and slow the disease (Waite, 2015). 
 
Figure 1.1: Pathological changes in AD 
A. Microscopically, ß-amyloid and tau aggregate to form extracellular senile plaques (indicated 
by black arrow) and intracellular neurofibrillary tangles (red arrow) respectively (Washington 
University School of Medicine). B. Advanced AD shows significantly reduced brain volume, 





1.2.1 ß-amyloid plaques 
ß-amyloid (Aß) or senile plaques are pathological lesions found in the grey matter of the cortex 
and hippocampus (Glenner and Wong, 1984). Amyloid plaques can be described as being diffuse 
or dense-core. Dense core plaques have deposits of fibrillar Aß at their centre. These 
hydrophobic plaques are found in the extracellular space surrounded by a halo of soluble 
oligomeric Aß species, neuron debris, activated astrocytes and microglia and degenerating 
synapses (Koffie et al., 2009; Bouvier et al., 2016). Diffuse plaques do not contain fibrillar Aß, 
have no defined structure and are usually not associated with glial responses or synaptic loss 
(Serrano-Pozo et al., 2011). The abundance and spread of Aß pathology through diseased brain 
has been described as five progressive phases (Thal et al., 2002): 
I) Aß plaques are found only in the neocortex,  
II) Aß plaque pathology has spread into allocortical brain regions, 
III)  Plaques present in some subcortical areas such as the striatum, diencephalic nuclei and 
the cholinergic nuclei of the basal forebrain, 
IV) Aß plaques have spread to the brainstem, 
V)  Spread of plaque pathology to the cerebellum.  
It was originally thought that these stages could be used to define the severity of AD, however 
it has since been found that plaque staging does not correlate with the clinical severity of the 
disease except for at the most severe phases (Boluda et al., 2014) (Figure 1.2).  
1.2.2 Neurofibrillary tau tangles  
NFTs are intracellular aggregates composed primarily of the microtubule-associated protein tau 
(Grundke-Iqbal et al., 1986) that is abnormally phosphorylated, cleaved and aggregated,  and is 
arranged into paired helical filament structures (PHFs) (Bancher et al., 1989). In most individuals, 
the spread of NFTs across diseased brain occurs in a stereotypical spatial and temporal pattern 
as AD progresses. This staging of this spread by Braak and Braak, known as Braak staging, is 
commonly used as an indicator of disease severity (Braak and Braak, 1991).  
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Braak stages I and II are pre-symptomatic, occurring many years before the clinical symptoms of 
AD are apparent (Caselli and Reiman, 2013). During stage I moderate NFT pathology is found 
only in the pre-α layer (layer II) of the transentorhinal cortex. Neuropil threads (NTs), abnormal 
neurites made from PHFs and straight filaments, are found in AD throughout disease progression 
and first appear in the pre-α layer of the transentorhinal in stage I. In stage II NFTs and NTs in 
the transentorhinal cortex are more numerous and small numbers have spread to the subiculum 
and CA1 of the hippocampus (Braak and Braak, 1991). Stages III and IV are known as the ‘limbic 
stages’ and generally correlate with a diagnosis of mild cognitive impairment (MCI). Clinically, 
individuals show some cognitive and possible memory deficits but these symptoms are not 
severe enough to interfere with everyday life (Golomb et al., 2004). Stage III is histologically 
characterised by severe NFT pathology in the pre-α layer in both the transentorhinal and 
entorhinal cortices and modest involvement of CA1. ‘Ghost tangles’, NFTs left behind in the 
extracellular space once a neuron has died, are also first seen at this stage. NFT pathology is also 
present, but mild, in the magnocellular forebrain nuclei, the anterodorsal nucleus of the 
thalamus and the amygdala. Stage IV is identified by many ghost tangles in the transentorhinal 
and entorhinal cortices and numerous NFTs in the hippocampus. NFTs also appear in some 
nuclei of the basal ganglia and severe NFT deposition is apparent in the anterodorsal nucleus of 
the thalamus. It is important to note, however, that at stages III/IV cortical areas are 
predominantly unaffected by tangle pathology (Braak and Braak, 1991). Clinical symptoms of AD 
occur mainly during stages V and VI when NFTs begin to significantly spread into cortical areas 
(Braak and Braak, 1995). Stage V is defined by significant NFT and NT formations in the temporal 
and frontal cortices and severe pathology in almost all areas of the hippocampus. Synapse 
degeneration and neuron loss is also present in affected brain areas; however, it is unclear 
whether synaptic degeneration is a cause or effect of abnormal tau function and pathology 
(Thies and Mandelkow, 2007). At this stage both primary sensory and motor cortices are still 
relatively spared. By stage VI, NFTs have spread throughout the cortex, with the exception of 
the motor cortex. Severe neuron loss and ghost tangles can be seen in the hippocampus and 
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other limbic regions with significant neuron loss also present in the cortex (Braak and Braak, 
1991). The presence of NFTs correlates well with synaptic degeneration and the clinical 
symptoms of disease, leading many to believe that their presence is necessary for 
neurodegeneration in AD (Figure 1.2) (Braak and Braak, 1995; Perez-Nievas et al., 2013). 
However, there is also a school of thought which suggests that the production of NFTs may be a 
protective mechanism, as cells attempt to prevent the damage of potentially more toxic tau 
oligomers and fibrils (Rodriguez-Martin et al., 2013). 
 
 
Figure 1.2: Aß and tau pathology spread across the brain in AD 
Representative spread of pathology across the brain as disease progresses (from left to right of 
the figure). Darker colouring indicates increased pathology density. Top row of diagrams indicate 
the pattern of Aß spread. Bottom row of diagrams indicates tau spread. Adapted from Jucker 
and Walker (2011). 
 
1.3 The genetics of AD 
AD occurs most commonly in a sporadic and late-onset form, and rarely as a familial, autosomal 
dominant, early-onset disease  (Khanahmadi et al., 2015). Autosomal dominant mutations that 
cause early-onset, familial AD are found in one of three genes: APP (St George-Hyslop et al., 
1987; Goate et al., 1991; Sorbi et al., 2001), PS1 (encoding presenilin 1; PS1) or PS2 (encoding 
presenilin 2; PS2) (Levy-Lahad et al., 1995; Sherrington et al., 1995). Indications that AD has a 
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genetic component were first found in a study of adult development in Trisomy 21 (Down’s 
syndrome) individuals. Approximately 70 % of individuals over 40 with Down’s syndrome (DS) 
begin to show AD-like symptoms (Wilcock and Griffin, 2013) with post-mortem studies finding 
the widespread presence of amyloid plaques by the age of 30 and NFTs by the age of 50 (Hyman 
et al., 1995; Lemere et al., 1996). The APP gene is located on chromosome 21, so these patients 
carry three copies of APP, suggesting that an excess of APP protein can cause disease (St George-
Hyslop et al., 1987; Wisniewski et al., 1985). Indeed, duplication of the APP gene has since been 
found to cause familial AD (Rovelet-Lecrux et al., 2006; Sleegers et al., 2006). A number of 
autosomal dominant mutations of APP have also been shown to cause familial AD. These 
pathogenic mutations occur close to the Aß domain of APP and act to enhance or alter Aß 
production (Schellenberg and Montine, 2012; Tanzi, 2012). In particular, some mutations 
increase total Aß production, some mutations increase the relative levels of the more 
pathogenic Aß42 peptide and some mutations make Aß more prone to aggregation or more 
“amyloidogenic”. Interestingly, one APP mutation has been identified that protects against AD 
and this inhibits the production of Aß (Jonsson et al., 2012). 
Mutations in PS1 and PS2 are the most common cause of familial AD. The presenilins form part 
of the γ-secretase complex that is involved in the proteolytic cleavage of APP to produce Aß (De 
Strooper and Annaert, 2010). Familial AD-linked PS1/2 mutations are loss-of-function mutations 
that alter the production of Aß from APP by influencing the specificity of γ-secretase cleavage. 
PS1/2 cause an increase in the Aß42/Aß40 ratio, either by decreasing the production of Aß40 or 
increasing the production of Aß42 (Duff et al., 1996; Scheuner et al., 1996; Bentahir et al., 2006; 
Shen and Kelleher, 2007; De Strooper and Annaert, 2010; Kretner et al., 2011; Fernandez et al., 
2014). Other PS1 mutations in FAD, such as mutations at D257A and D385A, are dominant 
negative, and cause decreased Aß peptide secretion and the accumulation of the C-terminal 
fragments of the precursor protein (Kim et al., 2001).  
Genetic variations in a number of genes increase risk of developing AD (Rosenberg et al., 2016). 
Apolipoprotein E (ApoE) is involved in cholesterol transport and, in the CNS, is mainly expressed 
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in astrocytes. Located on chromosome 19, the gene has three isoforms: ε2, ε3 and ε4. The ε3 
isoform is most common, however the presence of the ApoE ε4 isoform is the largest risk factor 
for AD development identified to date. Individuals harbouring one copy of ApoE ε4 have a three-
fold higher risk of AD, whereas those with both copies have a ten-fold higher risk. In contrast, 
the ε2 allele is neuroprotective and carriers of this allele have lower risk of AD (Strittmatter et 
al., 1993; Riedel et al., 2016). Since its discovery as an AD risk gene, ApoE has been well 
characterised as an APP chaperone and has been shown to play a role in Aß processing (Bu, 
2009). The ε4 isoform was demonstrated to increase levels of Aß production, reduce Aß 
clearance and encourage Aß oligomerisation, compared to the ε3 allele (Ye et al., 2005; 
Castellano et al., 2011; Hashimoto et al., 2012). Evidence from mouse models suggests blocking 
the ApoE/Aß interaction can ameliorate ε4-related Aß pathology further supporting the role of 
ApoE in the late-onset disease process (Pankiewicz et al., 2014). 
Recent genome-wide association studies have identified over twenty other genes that are 
associated with AD (Harold et al., 2009; Bertram et al., 2010; Seshadri et al., 2010; Hollingworth 
et al., 2011; Karch et al., 2014; Naj et al., 2014). These can be broadly grouped into genes 
involved in lipid metabolism, protein trafficking and inflammation (Schellenberg and Montine, 
2012; Karch and Goate, 2015). To date, variations in triggering receptor expressed on myeloid 
cells 2 (TREM2) are most strongly associated with developing AD, increasing risk by 2-4 fold 
(Guerreiro et al., 2013; Heneka et al., 2016; Ulrich and Holtzman, 2016). TREM2 is expressed in 
immune cells throughout the body, including microglial cells in the brain. In microglia, TREM2 is 
known to be involved in controlling reactive state, including upregulating phagocytic pathways 
possibly involved in clearing Aß deposits (Guerreiro et al., 2013; Heneka et al., 2016). Further 
support for this comes from studies demonstrating TREM2 upregulation in microglia located 
close to Aß deposits in animal models (Frank et al., 2008; Varvel et al., 2015; Heneka et al., 2016). 
It has been proposed that high risk variants of TREM2 result in a loss of function at the protein 
level, possibly increasing apoptosis and reducing microglial proliferation (Heneka et al., 2016; 
Ulrich and Holtzman, 2016; Villegas-Llerena et al., 2016). This would reduce the number of 
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microglia surrounding Aß plaques, possibly resulting in reduced phagocytosis of plaques or Aß 
oligomers in the surrounding area (Forabosco et al., 2013; Heneka et al., 2016; Ulrich and 
Holtzman, 2016).  
The MAPT gene encodes tau and resides on chromosome 17. To date, no mutations in MAPT 
have been found that cause familial AD. Instead they lead to the development of some forms of 
frontotemporal dementia (Lee et al., 2001; Spillantini and Goedert, 2013; Simic et al., 2016). 
MAPT mutations either alter the ability of tau to bind to microtubules or alter the ratio of tau 
isoforms via alternative splicing changes (Spillantini and Goedert, 2013). Both types of mutations 
are believed to enhance tau aggregation into intracellular NFTs (Spillantini and Goedert, 2013). 
 
1.4  Amyloid precursor protein and ß-amyloid 
1.4.1 Amyloid precursor protein processing 
APP is a highly-conserved large transmembrane protein found in many tissues. Within the brain, 
APP is particularly localised to the cerebral cortex and hippocampus, areas that are affected in 
AD (Bahmanyar et al., 1987; Arai et al., 1991).  APP is found at particularly high concentrations 
in synapses, where it has been implicated in synapse formation and neuronal plasticity 
underlying learning and memory (Turner et al., 2003; Priller et al., 2006). APP completely spans 
the membrane, with a large N-terminal extracellular region, a transmembrane domain and a 
smaller C-terminal intracellular region (Kang et al., 1987). The Aß encoding sequence is located 
in the extracellular and transmembrane domains (Dyrks et al., 1988). APP undergoes alternative 
splicing of exons to generate a number of different isoforms. Three major isoforms of APP are 
produced, which contain 695, 751 or 770 amino acids. The two longer isoforms contain a Kunitz 
protease inhibitor (KPI) domain and APP770 also contains an Ox2 domain. APP695 is the main APP 
isoform expressed in brain tissue, while APP751 and APP770 are expressed ubiquitously 
throughout many cell types (Kitaguchi et al., 1988; Ponte et al., 1988; Tanzi et al., 1988; 
Oltersdorf et al., 1989; Zhang et al., 2011). 
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APP processing  occurs through  two main and well-described mutually exclusive pathways: the 
first, the non-amyloidogenic pathway, is the predominant pathway in healthy individuals, but 
early in the development of AD the balance changes resulting in increased amyloidogenic 
processing of APP leading to enhanced Aß production (Zhang et al., 2011).  
The non-amyloidogenic pathway (Figure 1.3) is initiated by cleavage of APP by α-secretase in 
the extracellular region of APP close to the plasma membrane and the middle of the Aß peptide 
region. α-secretase is thought to be a metalloprotease of the a disintegrin and metalloprotease 
(ADAM) family. ADAM9, ADAM10 and ADAM17 are all capable of α-secretase cleavage of APP 
and there appears to be some functional redundancy among these proteins (Kuhn et al., 2010; 
Vingtdeux and Marambaud, 2012). Overexpression of ADAM10 leads to increased cleavage of 
APP via the non-amyloidogenic pathway (Lammich et al., 1999). The cleavage of APP by α-
secretase produces a large soluble extracellular cleavage fragment known as sAPPα (Zhang et 
al., 2011). The smaller C-terminal fragment α (CTFα) is left in the membrane and later cleaved 
by γ-secretase in the transmembrane region producing a small fragment, p3, and the APP 
intracellular domain (AICD) that translocates to the nucleus to modulate gene expression 
(Muller et al., 2008; Minogue et al., 2009).  
In the amyloidogenic pathway (Figure 1.3), cleavage of APP occurs first by ß-secretase in the 
extracellular domain close to the plasma membrane. ß-secretase has been identified as ß-
amyloid cleaving enzyme (BACE), a type-1 membrane-spanning aspartyl protease that is active 
in the low pH environment of the endosomal/lysosomal system and Golgi, where it cleaves APP 
(Shoji et al., 1992; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). APP cleavage by ß-
secretase releases the soluble N-terminal cleavage fragment sAPPß and is followed by the 
cleavage of APP by γ-secretase in the transmembrane region. This releases the AICD and Aß 
(Zhang et al., 2011) which are then secreted from the cell (Chow et al., 2010; Haass et al., 2012). 
γ-secretase is a multiprotein complex consisting of aspartic proteases PS1/2, PS enhancer 2 
(PEN-2), nicastrin and anterior pharynx-defective phenotype-1 (Aph-1). PEN-2, nicastrin and 
Aph1 are believed to be chaperone proteins or involved in targeting the γ-secretase complex to 
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its substrates (Minogue et al., 2009; De Strooper et al., 2012). The low sequence specificity of 
γ-secretase accounts for the creation of varying lengths of Aß peptide of which Aß1-40 and Aß1-42 
are the best studied (Zhang et al., 2011). Recently, N-terminal extended Aß peptides were also 
described (Welzel et al., 2014; Szczepankiewicz et al., 2015). In a physiological state, the Aß 
produced is predominantly Aß1-40 with only low levels of Aß1-42. However, in AD the Aß 40:42 
ratio is altered to promote Aß1-42 production. Aß1-42 has a higher propensity to aggregate and an 
increase in its production leads to higher levels of neurotoxic Aß oligomers being produced 
(Hellstrand et al., 2010; O'Brien and Wong, 2011; Qiu et al., 2015). 
Recently a new APP processing pathway was discovered whereby APP is cleaved by membrane-
bound metalloproteinases, now named η-secretase in the plasma membrane (Willem et al., 
2015). Evidence suggests this cleavage by η-secretase releases a larger C-terminal fragment 
(CTFη) while the remainder of APP can be cleaved again by α-secretase and ß-secretase to 
produce two new amyloid fragments: Aη-α and Aη-ß. These fragments were found to be 
enriched in dystrophic neurons, in humans and transgenic mice, and they inhibited activity in 
hippocampal slices (Willem et al., 2015). This provides evidence that APP cleavage products 
other than Aß are involved in the biological basis of learning and memory and this new APP 
cleavage pathway is likely to play some role in the development of AD, possibly providing new 
therapeutic targets for drug development. Furthermore, it may explain why drugs targeting 
traditional amyloidogenic pathway proteins, such as BACE1 inhibitors, have not been as 
successful as hoped. For example, Willem et al. found inhibiting BACE1 pharmacologically and 
genetically results in increased Aη-α and impaired long-term potentiation supporting the idea 






Figure 1.3: APP processing 
APP can be proteolytically cleaved via two pathways. The non-amyloidogenic pathway (left) 
involves APP cleavage by α and γ-secretases to produce non-toxic peptide products. The second, 




1.5.1 Protein structure 
Abnormally phosphorylated, cleaved and aggregated tau are the major component of the NFTs 
found in AD brain (Grundke-Iqbal et al., 1986). Human tau is encoded by the microtubule-
associated protein tau (MAPT) gene on chromosome 17q21.3 and comprises sixteen exons that 
can be alternatively spliced resulting in the presence of six tau isoforms in the adult human CNS.  
Exons two and three at the N-terminus can be alternatively spliced to result in tau protein that 
has 0, 1 or 2 N-terminal inserts (0, 1 or 2N). Alternative splicing of exon 10 results in tau isoforms 
that contain either three (no exon 10; 3R) or four (exon 10 included; 4R) microtubule binding 
domains (Andreadis et al., 1992) (Figure 1.4). Tau expression is developmentally regulated, and 
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during foetal development only 0N3R is expressed (Goedert and Jakes, 1990). In healthy adult 
humans the ratio of 3R to 4R tau is approximately equal, and in AD brain both 3R and 4R tau are 
deposited in NFTs (Hasegawa et al., 2014; Qian and Liu, 2014). However, other tauopathies are 
characterised by aggregation of predominantly 3R (e.g. Pick’s disease (Buee and Delacourte, 
1999)) or 4R tau (e.g. corticobasal degeneration (Kouri et al., 2011)) and there is some evidence 
that disruption of the equal ratio of the isoforms may be involved in tau aggregation in AD 
(Yasojima et al., 1999; Glatz et al., 2006). 
 
 
Figure 1.4: Tau protein structure showing the six isoforms of tau found in adult human CNS 
The six different isoforms of tau are generated upon alternate splicing of exons 2, 3 and 10. 
Inclusion of exons 2 and 3 result in additional amino acid inserts near the N-terminus of tau, N1 
and N2, respectively. Inclusion of exon 10 results in tau isoforms containing four (4R) rather than 
three (3R) microtubule binding repeats (R1-R4). R2 is encoded by exon 10. Tau contains a large 
proline rich domain to the middle of the tau protein. Tau isoforms range in size from 352 to 441 
amino acids, the size of each isoform is shown to the right. 
 
1.5.2 Post-translational modifications of tau 
Tau can be post-translationally modified in a number of ways and at many epitopes, however 
phosphorylation of tau is the best studied modification. Tau has approximately 80 
phosphorylatable serine (Ser), threonine (Thr) and tyrosine (Tyr) residues, over half of which are 
known to be abnormally or hyperphosphorylated in AD brain (Figure 1.5), in stark contrast to 
the few sites phosphorylated in healthy adult brain (Ksiezak-Reding et al., 1992; Hanger et al., 





Figure 1.5: Abnormal tau phosphorylation in AD 
Forty-five of over sixty phosphorylation sites on the tau protein found to be abnormally 
phosphorylated in AD brain. Sites cluster in the proline-rich domain (PRD) and C-terminal region. 
Five phosphorylation sites in orange were only identified by phospho-specific labelling at the 
time of the original making of this figure, rather than direct means (mass spectrometry or Edman 
degradation). E2/3: exons 2/3, M1-4: microtubule-binding regions, Y: tyrosine, S: serine, T: 
threonine. Adapted from Hanger et al. (2009). 
 
Tau phosphorylation is a dynamic process and is regulated by the activity of protein kinases and 
phosphatases. Phosphate is added to tau by the action of kinases and removed by protein 
phosphatases. Multiple kinases have been shown to phosphorylate tau in vitro and in vivo, 
including the proline-directed kinases GSK-3, cyclin-dependent protein kinase 5 (cdk5), 
extracellular signal-regulated kinase 1/2 (ERK1/2), mitogen activated protein kinase (MAPK), 
p38, c-Jun N-terminal kinases (JNK) and 5′ adenosine monophosphate-activated protein kinase 
(AMPK) (Hanger et al., 1992; Baumann et al., 1993; Hanger et al., 2009; Thornton et al., 2011; 
Martin et al., 2013), the non-proline directed protein kinases calcium and calmodulin dependent 
kinase II (CaMKII), protein kinase A,  casein kinase-1 (ck1), microtubule affinity-regulating kinases 
(MARKs), and dual specificity tyrosine-phosphorylation-regulated kinase 1A  (DYRK1A) (Hanger 
et al., 2009; Martin et al., 2013), and tyrosine kinases including Fyn, Abl and Syk (Lee et al., 2004; 
Derkinderen et al., 2005; Lebouvier et al., 2008). In addition, several phosphatases 
dephosphorylate tau, including protein phosphatase-1, -2A, and -5 (PP1, PP2A, and PP5) (Liu et 
al., 2005).  
Other post-translational modifications of tau have also been implicated in AD. Tau in post-
mortem AD brains, mouse models of AD and in in vitro studies has been found to be abnormally 
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acetylated, nitrated, glycated and glycosylated (Takahashi et al., 1999; Cohen et al., 2011; 
Beharry et al., 2014; Song et al., 2015; Liu et al., 2016). Mimicking acetylation in mice slows tau 
turnover, increases its accumulation and results in cognitive deficits. Additionally, inhibiting 
acetylation after phenotype onset in transgenic mice expressing frontotemporal dementia 
(FTD)-causing P301S tau not only reduced the levels of total tau but also rescued memory 
deficits and hippocampal atrophy (Min et al., 2015).Nitration has been found to reduce the 
ability of tau to self-associate and nitrated tau has been found in fibrillar lesions in AD and other 
tauopathies (Reynolds et al., 2006). Glycosylation of tau may be neuroprotective with a 
reduction in glycosylated tau occurring early in the disease process, possibly mediating early 
pathological phosphorylation (Liu et al., 2002). Additionally, there is evidence that tau 
glycosylation may be responsible for the formation and maintenance of the helical structure of 
PHFs (Wang et al., 1996; Takahashi et al., 1999). O-GlcNAcylation, a distinct form of glycosylation 
where tau is modified by ß-linked N-acetylglucosamine (Arnold et al., 1996), has also been linked 
to intracellular glucose metabolism. Hypotheses suggest that impaired glucose metabolism 
years before disease onset may lead to decreased O-GlcNAcylation and, later, increased tau 
phosphorylation and AD (Gong et al., 2006; Iqbal et al., 2016). 
1.5.3 Tau cleavage 
Tau can also be cleaved at multiple sites (Hanger and Wray, 2010; Zhao et al., 2016). In particular, 
cleavage at aspartate 421 (Asp421) by caspase-3 has been implicated in the progression of AD. 
Caspase-3-cleaved tau has a higher propensity to aggregate than full-length tau, and may form 
a seeding nidus that promotes the aggregation and fibrillisation of full-length tau species 
supporting a role for tau cleavage in NFT formation (Gamblin et al., 2003). The abundance of tau 
cleaved at Asp421, along with tau cleaved at Glu391, is associated with ApoE genotype and 
positively correlates with a clinical dementia index (Basurto-Islas et al., 2008).  
Several other proteases have been implicated in abnormal tau cleavage in AD (Gamblin et al., 
2003; Zhang et al., 2014a). For example, calpain-1 and -2 cleave tau at the N-terminus to produce 
a 17 kDa fragment found to cause neurotoxicity in hippocampal cultures  (Park and Ferreira, 
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2005). Investigations in human tissues have found evidence of multiple cleaved tau fragments 
including 37 kDa, 35 kDa and 26-28 kDa species (Johnson et al., 1997; Wang et al., 2007; Wray 
et al., 2008). While the functional relevance of all cleaved tau species is not fully understood, 
recent evidence has shown that sub-endogenous expression in mice of a 35 kDa tau fragment 
identified in PSP brain causes a behavioural and molecular phenotype similar to that of human 
tauopathies (Bondulich et al., 2016).  
1.5.4 Tau aggregation 
 The relationship between tau phosphorylation, cleavage and aggregation is poorly understood, 
however, the amyloid cascade hypothesis posits that post-translational modifications of tau 
directly encourage tau aggregation as disease progresses (Selkoe and Hardy, 2016). Indeed, 
induction of tau phosphorylation in transgenic models of tauopathy induces tau aggregation 
(Cruz et al., 2003; Noble et al., 2003; Engel et al., 2007), suggesting that phosphorylation 
precedes aggregation in vivo. Aggregation cannot occur while tau is bound to microtubules, 
therefore phosphorylation of specific tau epitopes is believed to occur prior to aggregation since 
phosphorylation of tau removes it from microtubules leading to increased concentration of free 
tau in the cytoplasm where it is open to other post-translational modifications including 
acetylation and cleavage (Meraz-Rios et al., 2010). These post-translational modifications, and 
further phosphorylation, not only prevent tau from re-binding to microtubules as it might under 
normal conditions but also increase its local concentration supporting aggregation (Marcus and 
Schachter, 2011; Martin et al., 2011; Wang and Mandelkow, 2016). Changes in the conformation 
of tau, also known to occur early in AD progression (Mondragon-Rodriguez et al., 2008a) 
increasing the percentage of ß-pleated sheets in the secondary structure of tau (Hanger and 
Wray, 2010), encouraging side chain/side chain interactions that promote the formation of tau 
dimers (Meraz-Rios et al., 2010). Stable tau dimers are thought to undergo a process of 
nucleation leading to fibrillisation dose- and time-dependent manner (Yin and Kuret, 2006; 
Congdon et al., 2008).  
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It is important to note here that significant evidence now suggests that tau oligomers are the 
most toxic species of tau. Tau oligomers are closely correlated with cognitive decline in vivo 
(Berger et al., 2007), have been shown to cause synaptic dysfunction and neuron death, and 
most recently to play a critical role in tau propagation across diseased brain (Lasagna-Reeves et 
al., 2011; Benilova et al., 2012). In keeping with this, tau aggregates have been proposed to be 
an inert end-stage pathology resulting from endogenous neuroprotective mechanisms in an 
attempt to minimise oligomer toxicity (Cowan and Mudher, 2013).  
1.5.5 Tau functions in health and disease 
Tau was first discovered as a protein required for tubulin to form microtubules in vitro 
(Weingarten et al., 1975). A readily post-translationally modified protein, in healthy neurons tau 
stabilises and polymerises microtubules. Found predominantly in the axon, normal tau function 
is important for maintaining efficient and successful axon transport (Spittaels et al., 1999). The 
microtubule binding strength of tau is determined largely by phosphorylation of multiple sites 
in the microtubule binding domains: increased phosphorylation results in decreased 
microtubule binding (Selden and Pollard, 1983). Phosphorylation of all sites in the microtubule 
binding domains of tau, but particularly threonine (Thr) 231, serine (Ser) 262 and Ser356 (Figure 
1.5), are thought to inhibit the ability of tau to promote microtubule polymerisation while 
phosphorylation at epitopes in the proline-rich region of tau inhibit de novo microtubule 
construction (Hanger et al., 2007). Easy assembly and disassembly of microtubules is important 
in embryonic development when neurons are growing rapidly and the cytoskeletal structure, 
including their microtubule architecture, is very dynamic (Watanabe et al., 1993). However, 
hyperphosphorylation of tau in adult neurons can result in breakdown of microtubules and 
disruption of axonal transport. In AD, tau is abnormally phosphorylated and microtubule binding 
is reduced, leading to the breakdown of microtubule structure and axonal transport (Ksiezak-
Reding et al., 1992). With microtubule integrity impaired, mitochondria, proteins and nutrients 
cannot be transported to the synapse for effective synaptic function. Organelles and protein 
build up where microtubules have broken down, further blocking transport along the axon 
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(Stamer et al., 2002). As less and less reaches the synaptic terminal, synapses become 
dysfunctional and are eventually lost (Stamer et al., 2002). The polymerisation and stabilisation 
of microtubules in the axon is the best known physiological function of tau (Weingarten et al., 
1975), however more recent evidence shows that tau has a diverse range of functions in neurons 
(Wang and Mandelkow, 2016). 
In the axon, tau actively promotes and regulates microtubule assembly including dynamic 
reorganisation of microtubules to allow for cytoskeletal flexibility (Feinstein and Wilson, 2005). 
Tau microtubule binding domains bind to heterodimers of tubulin to polymerise microtubules 
(Scott et al., 1991). Knocking down tau in cultured rat neurons results in inhibition of neurite 
growth and axon formation suggesting that tau, and microtubules, are involved in the 
development and elongation of axons (Caceres and Kosik, 1990). Tau also plays a critical role in 
microtubule-dependent axonal transport (Dixit et al., 2008), regulating kinesin- and dynein- 
dependent transport of many protein cargoes (Trinczek et al., 1999; Stamer et al., 2002; Dixit et 
al., 2008) via activation of GSK-3 and PP1 (Kanaan et al., 2011). Phosphorylation of N-terminal 
tau residues reduces GSK-3/PP1 activation and the subsequent kinesin-cargo binding inhibition 
(Kanaan et al., 2012), and reduction of tau levels can rescue Aß-induced axon transport deficits 
by blocking GSK-3 activation (Vossel et al., 2015).  
The N-terminal projection domain of tau binds to plasma membranes where it may be involved 
in signal transduction (Pooler et al., 2012). For example, in the post-synaptic terminal plasma 
membrane-bound tau binds to Fyn and directs it to dendrites where Fyn, phosphorylates NMDA 
receptor subunit 2B (NR2B) to mediate Aß toxicity at the synapse (Ittner et al., 2010). At the pre-
synaptic terminal tau can be released into the extracellular space, and extracellular tau can 
activate muscarinic receptors mediating intracellular calcium in post-synaptic neurons (Gomez-
Ramos et al., 2009). This evidence suggests that tau may play a physiological role in intercellular 
signalling.  
Finally, tau has also been found in the nucleus of cells and has been suggested to play multiple 
roles there. Particularly, it has been suggested that tau may be involved in protecting DNA and 
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RNA from cellular distress. Under heat stress and oxidative stress largely dephosphorylated tau 
binds to DNA and RNA in the nucleus protecting the nucleic acids from damage (Violet et al., 
2014). Additionally, FTD-causing P301L tau mutation are linked with chromosome instability 
(Rossi et al., 2008), and tau has also been implicated in RNA and DNA transcription (Thurston et 
al., 1996; Sjoberg et al., 2006).  
1.5.6 Tau spread and seeding 
Recent studies have shown that tau propagates through diseased brain in a ‘prion-like’ manner 
(de Calignon et al., 2012; Jucker and Walker, 2013). It is thought that monomeric and small order 
oligomers are released from neurons into the extracellular space via a currently unknown 
mechanism (Chai et al., 2012; de Calignon et al., 2012; Hanger et al., 2014) that might involve 
unconventional secretory pathways (Chai et al., 2012; Fontaine et al., 2016), tau association with 
exosomes (Saman et al., 2012; Polanco et al., 2016) or ectosomes (Dujardin et al., 2014), or 
alternatively “free” tau (Pooler et al., 2013). However, most tau is thought to be released at or 
near the synapse, resulting in the spread of pathology between synaptically connected neurons 
rather than those that are anatomically adjacent (Liu et al., 2012). Evidence suggests that most 
extracellular tau is dephosphorylated, indicating that tau is either dephosphorylated before its 
release or soon after it is extruded  (Diaz-Hernandez et al., 2010; Pooler et al., 2013). Whether 
tau is intact, C-terminally or N-terminally cleaved remains a matter of debate (Pooler et al., 
2013).  
The mechanisms underlying the spread of pathological tau forms is also under investigation. 
Injections of brain homogenate, either from post mortem AD brain or transgenic mouse models 
of tauopathy, into the brain of transgenic mice expressing wild-type human tau demonstrates 
that tau from the seeded brain material is taken up by neurons. The mechanisms for tau uptake 
remain unclear but, once in the cell, the seeded tau is able to recruit endogenous tau  (Ahmed 
et al., 2014; Iba et al., 2015). Furthermore, the conformation of the seeded tau is thought to be 
critical since injecting tau from an argyrophilic grain disease brain into wild-type human tau 
expressing mice results in grain-like tau aggregates, tau from PSP brain leads to tufted astrocyte-
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like tau pathology and CBD tau injection leads to the development of astrocytic plaques in the 
injected mice  (Clavaguera et al., 2013).  
Furthermore, pathological tau spreads further and more rapidly and causes greater 
neurotoxicity in the presence of Aß (Pooler et al., 2015). Similar effects are seen in vitro where 
Aß influences the species and amount of tau released from neurons (Kanmert et al., 2015). These 
results suggest that there is an important relationship between extracellular tau and Aß, 
however the specifics of this relationship are yet to be fully defined. 
Tau release and its subsequent functions is still a field in its infancy. There is still a lot to be 
discovered about the mechanisms of tau release and uptake, and how these mechanisms are 
involved in both physiological and pathological tau processing, spread and synaptic function.  
 
1.6 The amyloid cascade hypothesis 
The amyloid cascade hypothesis was first proposed by Hardy and Allsop in 1991 and since this 
time has been influential in directing research in the field. In its simplest form, the amyloid 
cascade hypothesis proposes that, whether due to a genetic mutation in APP or PSEN1/2 or 
through another cause, toxic forms of Aß are produced that initiate a signalling cascade leading 
to abnormal phosphorylation and cleavage of tau, impairing tau function and initiating its 
aggregation into paired helical filaments (PHFs) and NFTs that cause neurodegeneration (Hardy 
and Selkoe, 2002; Selkoe and Hardy, 2016).  
Amyloid plaques were originally thought to be the directly toxic Aß species. However, it is now 
believed that, although aggregate stress contributes to neuron disease and death, pre-fibrillar 
soluble Aß oligomers are more toxic, leading to neuron excitotoxicity and detrimental calcium 
dysregulation, particularly at synapses (Ittner et al., 2010; Cavallucci et al., 2012; Zhang et al., 
2016a). Damage caused by Aß at the synapse is thought to lead to abnormal processing of tau, 
including its hyperphosphorylation and abnormal cleavage by calpains and caspases (Decker et 
al., 2010; Kurbatskaya et al., 2016). These modifications alter tau function, resulting in instability 
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of microtubules and failure of fundamental cell processes such as axonal transport. As axons die 
back, synaptic connectivity is lost and neurons degenerate, further disrupting synapses and 
perpetuating neuronal dysfunction (Hanger et al., 2014; Iqbal et al., 2016). This pathological 
cascade, which occurs alongside continued overproduction of Aß1-42, is suggested by the amyloid 
cascade hypothesis, to eventually result in dementia and the accompanying clinical  symptoms 
typical of individuals with AD (Selkoe and Hardy, 2016). 
While the amyloid cascade hypothesis’ simplicity is appealing, the theory has been criticised for 
being too linear. A large amount of research suggests that there are multiple pathways involved 
at many stages of the cascade. For example, Aß is known to activate multiple membrane 
receptors either directly or indirectly, resulting in a complex cascade of intracellular signalling 
pathways being activated, many of which can positively and negatively regulate each other 
(Benilova et al., 2012; De Strooper and Karran, 2016). Additionally, evidence suggests that tau is 
not only affected by synaptic changes but also has important functions at synapses that may 
become detrimental in pathological conditions (Pooler et al., 2013; Pooler et al., 2014). Revisions 
to the original cascade have been made to take into account recent advances in the field. For 
example, it has become clear that the neuron-glial interactions and neuroinflammation are 
closely associated with the development of AD (Cai et al., 2013; Phillips et al., 2014; Wes et al., 
2016),  and now the inflammatory response is indicated as part of the amyloid cascade (Figure 
1.6), which, together with oxidative stress, link Aβ to pathological tau processing (McGeer and 
McGeer, 2013; Selkoe and Hardy, 2016). 
Finally, there is some research that the hypothesis struggles to explain. For example, the level 
of Aß plaques do not correlate well with the progression of disease symptoms and a small 
percentage of individuals show Aß pathology with no clinical symptoms of disease (Elobeid et 
al., 2014). In fact, tau mislocalised to the synapse and glial activation have been suggested as 
the most reliable predictors of dementia in AD suggesting that Aß oligomers and plaques may 
not be as directly critical to disease pathology as the amyloid cascade hypothesis suggests, 
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however it is possible that they are required upstream of these changes in tau and glia (Perez-
Nievas et al., 2013).  
Therefore, the causative link between Aβ generation, or even general altered APP processing 
and tau hyperphosphorylation, remains largely unknown. Indeed, most APP animal models of 
AD do not develop tau pathology, requiring mutations of both APP (or APP processing-linked) 
and MAPT genes to fully model disease (Elder et al., 2010; Richardson and Burns, 2002). Despite 
this, the genetic cause of AD cannot be ignored, and the amyloid cascade hypothesis is still a 
valuable starting point for research in this field (Selkoe and Hardy, 2016).  
 
 
Figure 1.6: Updated amyloid hypothesis cascade 
Diagram showing the updated amyloid cascade hypothesis from increased Aß (amyloid-ß) 
production to cognitive impairment and dementia, including glial activation. 
 
There is a large amount of experimental evidence supporting the role of Aß in the initiation and 
development of AD (Butterfield, 2002; Decker et al., 2010; Benito et al., 2012; Ferreira et al., 
2012; McGeer and McGeer, 2013; Sengupta et al., 2016). Studies in both cell culture and mouse 
models of AD show that Aß causes AD-like changes in tau (Selenica et al., 2013; Pooler et al., 
2015). For example, treatment of hippocampal neurons with Aß dimers isolated from AD brain 
induced tau hyperphosphorylation and neuritic degeneration. This degeneration was tau-
dependent however, as it was prevented by knocking down tau and was exacerbated by over-
expressing human tau (Jin et al., 2011). Furthermore, injections of Aß1-42 fibrils into the brains of 
a mouse model of tauopathy resulted in a localised five-fold increase in the number of NFTs with 
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tau phosphorylation and fibril formation occurring as early as 18 days after Aß fibril injections 
(Gotz et al., 2001). Crossing mouse models of tauopathy with those that over-produce Aß also 
accelerates tau-dependent neurodegeneration (Gotz et al., 2001; Lewis et al., 2001; Pooler et 
al., 2013). However, this is not a unidirectional effect since double APP/tau transgenic mouse 
models also show exacerbation of Aß production (Ribe et al., 2005).  
Evidence demonstrates Aß can cause toxicity independent of tau pathology. For example, Aß 
oligomers impair NMDA receptor function, disrupt calcium homeostasis and impair axonal 
transport (Decker et al., 2010; Ferreira et al., 2012; Talantova et al., 2013). One study found that 
synapse function is directly affected by Aß oligomers associating with post-synaptic densities as 
well as promoting dysfunction via tau pathology (Ferreira et al., 2012). Furthermore, a ‘halo’ of 
Aß oligomers have been found to collect around senile plaques. The density of this Aß ‘halo’ was 
shown to correlate with local excitatory synapse loss (Koffie et al., 2009). In addition, 
inflammation is exacerbated by Aß regardless of the presence of tau, supporting an important 
role for inflammation in AD (Benito et al., 2012; Cai et al., 2013). 
However, Aß-induced neurotoxicity is reported to be reduced in tau-deficient neurons 
(Rapoport et al., 2002), and in vivo tau knockout significantly reduces Aß-induced synaptic 
deficits, network dysfunction and cognitive decline (Roberson et al., 2007; Ittner et al., 2010; 
Roberson et al., 2011), indicating that there is likely to be a critical co-pathogenic relationship 
between tau and Aß in AD. 
1.6.1 Modelling the amyloid cascade in vitro 
To provide a tractable cell model with which to study the effects of Aß on downstream pathways, 
various species of Aß have been widely used to treat rodent neural cell cultures. Many of these 
studies have used synthetic Aß1-42 since this allows use of precisely known concentrations and 
forms of human Aß in the absence of any other biological contaminants (Finder et al., 2010). 
However, variation in synthetic Aß produced by different suppliers, and batch-to-batch 
differences, has been found to affect the properties of Aß including its solubility and propensity 
to form fibrils and ß-sheets (Soto et al., 1995). Moreover, peptide solubility and neurotoxicity 
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are thought to be affected by even very low levels of impurities in the sample, something that 
is difficult for the end user to control (Zagorski et al., 1999). Furthermore, the high 
concentrations of Aß required to generate an effect from synthetic Aß is considered to be 
unphysiological. As a result of these and other issues, the results of experiments using Aß can 
be very variable and are sometimes not reproducible, making the use of Aß in in vitro 
experiments controversial. This is partly due to there being no standard protocol for the 
preparation of the Aß, with some groups solubilising the peptide immediately before use and 
others encouraging it to aggregate into small amyloid diffusible ligands, oligomers or fibrils, 
protocols that can give extremely variable results in our hands, and using different solvents and 
different peptide lengths (Zagorski et al., 1999).  
There have been several attempts to develop a more physiologically-relevant source of Aß for 
these types of experiment. Two of the most common systems used for this purpose and that 
have been used in this thesis are: 
1. Aß released from immortalised cell lines that over-express a FAD-causing mutant human 
form of APP. For example, 7PA2 cells express the Val717Phe APP mutation.  These cells 
release small Aß oligomers at sub-nanomolar levels, similar to those seen in the brain 
and CSF of patients with AD (Walsh et al., 2002; Walsh et al., 2005). While these Aß 
oligomers do not cause cell death, they have been found to impair long term 
potentiation (LTP) and synaptic activity both in vitro and in vivo suggesting they may be 
modelling early pathology-induced changes in AD (Walsh et al., 2002; Klyubin et al., 
2005).  
However, in addition to the release of Aß, 7PA2 cells have also been found to release 
larger N-terminal fragments of APP that extended across the BACE1 cleavage site 
(Portelius et al., 2013). These fragments are distinct from the Aß oligomers released by 
7PA2 cells and have also been found to impair synaptic plasticity (Welzel et al., 2014), 
possibly resulting in difficulties in using these oligomers as a synthetic Aß alternative. 
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2. Aß released from primary neurons cultured from transgenic mice over-expressing APP 
mutations, such as the Tg2576 mice which expresses mutant human APP with the 
Swedish double APP mutations (Lys670Asn, Met671Leu)  (Wu et al., 2012). When 
wildtype neurons are treated with Aß-containing conditioned medium from cultured 
Tg2576 neurons, changes in dendritic spine numbers and morphology linked to calcium 
signalling (Wu et al., 2012) and activation of tau kinases such as GSK-3, resulting in Aß-
induced neuritic damage (DaRocha-Souto et al., 2012) have been reported. These Aß-
induced changes with Tg2576 conditioned medium treatment suggest the Aß species 
released from these neurons may also be modelling early AD stages since induction of 
degenerative pathways are observed in the absence of widespread neuron death. 
 
1.7 Neuroinflammation 
Since the amyloid cascade hypothesis was first proposed in 1991 (Hardy and Allsop, 1991), 
numerous studies have shown that neuroinflammation is a dominant feature of AD 
development (Crehan et al., 2012; Phillips et al., 2014; Heneka et al., 2015; Heppner et al., 2015; 
Zhang and Jiang, 2015). Rather than being a side-effect of abnormal Aß and tau processing, 
neuroinflammation is now thought to play an active and significant role in mediating disease 
progression. This idea has been bolstered by initial evidence from recent GWAS studies which 
demonstrated that variants of several immune genes, including TREM2, CR1 and CD33 result in 
increased susceptibility of developing AD (Di Bona et al., 2008; Guerreiro et al., 2013; Villegas-
Llerena et al., 2016).  
Astrocytes and microglial cells are the main types of cells involved in neuroinflammation. 
Activated microglia are closely associated with Aß plaques (Olabarria et al., 2010; Bouvier et al., 
2016), whereas reactive astrocytes are particularly associated with NFTs (Bouvier et al., 2016). 
Importantly, elevated levels of activated microglia and astrocytes are one of the key features 
associated with dementia in AD (Perez-Nievas et al., 2013).  
48 
 
However, the role of immune cells in AD development is unclear since microglia and astrocytes 
have both neuroprotective and neurotoxic roles, depending on their phenotype or activation 
state (Heneka et al., 2016), and this is supported from reports using different models of disease 
(Thornton et al., 2006; Bhaskar et al., 2010; Garwood et al., 2011; Kraft et al., 2013; Avila-Munoz 
and Arias, 2014; Zheng et al., 2016). Deciphering the role of individual immune mechanisms is 
likely to be complex and involve overlapping signalling pathways. However, inflammation and 
glial activation is an area with promising therapeutic options (Garwood et al., 2010; Skaper, 
2011; Birch et al., 2014; Zhang et al., 2014b). 
1.7.1 Glia 
Glia were originally thought to provide only structural support in the CNS, ‘binding’ neurons in 
the brain, however we now know glia have an active and regulatory role in the CNS. 
There are two main types of glia in the brain: microglia and macroglia (Garcia-Segura and 
McCarthy, 2004). The term macroglia encompasses four cell types:  
 ependymal cells that line the walls of the brain ventricles,  
 Schwann cells that form the myelin sheath of peripheral neurons, 
 oligodendrocytes that form the myelin sheath of axons in the CNS, 
 astrocytes. 
Astrocytes and microglia will be discussed further below since they are the best studied in the 
context of AD and the focus of this thesis.  
Astrocytes 
The word ‘astrocyte’ was first coined in 1893 by von Lenhossek when referring to star-shaped 
glial cells (Garcia-Marin et al., 2007a). Differentiated from neural stem cells, astrocytes have a 
similar developmental path to neurons and are native to the CNS (Zuchero and Barres, 2015). 
Astrocytes can be broadly split into two different classes according to their location and 
morphology: protoplasmic astrocytes reside largely within grey matter, and fibrous astrocytes 
are found mainly within white matter (Molofsky et al., 2012). Morphologically, these two classes 
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of astrocytes differ according to their function. Protoplasmic astrocytes form connections with 
neurons at the synapse, displaying dense, ramified processes for multiple local connections. 
Fibrous astrocytes, on the other hand, require long fibre-like processes to extend through white 
matter forming connections with neurons at nodes of Ranvier, the unmyelinated areas of axons 
required for successful action potential propagation (Barres, 2008). However, this two class split 
over-simplifies the differences seen in astrocyte type throughout the brain. It has been 
suggested that there may be as many types of astrocytes as there are neurons in the brain, with 
different types found in different brain regions (Grolla et al., 2013; Rodriguez et al., 2014; Hu et 
al., 2016). This idea is supported by evidence of region-specific glial cells such as Mueller cells in 
the retina and Bergmann glial cells in the cerebellum (Mochizuki et al., 2014; De Zeeuw and 
Hoogland, 2015). Furthermore, research has shown that culturing neurons with astrocytes from 
a different brain region can impair neuron outgrowth suggesting neurons are healthiest when 
cultured with their corresponding regional astrocytes (Barbin et al., 1988). From this research it 
could be suggested that astrocytes from different regions have different functions, supporting 
different neuron types according to their own specific needs. This is, perhaps, unsurprising as 
patterns of neurodegenerative disease clearly demonstrate that different neuron types can 
withstand different insults with varying levels of tolerance (Eisen and Turner, 2013). However, 
functional differences in astrocyte type also suggest that different types of astrocytes may have 
differential responses in disease, and therefore the role of astrocytes in diseases such as AD may 
change as the neurodegenerative process spreads to brain areas (Rodriguez et al., 2014).  
Astrocytes were originally thought to be passive, resting cells, providing only structural support 
to neurons (Verkhratsky et al., 2012). However, research now shows that astrocytes play an 
active and critical role in the CNS, forming a network of communicating cells that monitor and 
support neurons in multiple ways including the provision of structural, trophic and metabolic 
support, maintaining the blood brain barrier, regulating CNS energy metabolism and mediating 
neurotransmitter levels at synapses (Volterra and Meldolesi, 2005; Abbott et al., 2006; 
Bernardinelli et al., 2014).  
50 
 
Glial fibrillary acidic protein (GFAP) is the major intermediate filament (IF) protein in astrocytes, 
and at least 10 different isoforms have been discovered to date (Middeldorp and Hol, 2011; Hol 
and Pekny, 2015). In addition to GFAP, the astrocyte IF network also includes vimentin, nestin 
and synemin (Eng et al., 2000; Jing et al., 2007; de Pablo et al., 2013; Hol and Pekny, 2015). 
Together these IFs form a highly dynamic network, the most motile of cytoskeletal polymers 
(Wiche and Winter, 2011). Vimentin is the favoured polymerisation partner of GFAP, but GFAP 
can also form polymers in the absence of vimentin (Eliasson et al., 1999). Vimentin and nestin 
are also highly expressed in immature astrocytes, whereas GFAP is the main IF in mature 
astrocytes (Middeldorp and Hol, 2011). GFAP is also thought to have a role in anchoring GLAST, 
a glutamate transporter expressed by astrocytes, as well as having a role in cell motility and 
maintaining the mechanical strength of astrocytes (Hughes et al., 2004; Sullivan et al., 2007). 
Under pathological conditions the upregulation of IFs, in particular GFAP, is one of the earliest 
changes observed in astrocytes. Concomitantly, a change in astrocyte morphology is observed 
(Pekny and Pekna, 2004; Pekny and Nilsson, 2005; Sofroniew and Vinters, 2010; Middeldorp and 
Hol, 2011; Pekny et al., 2014). The extent of astrocyte activation depends on the severity of the 
triggering insult, however, severe activation can result in astrocyte proliferation and increased 
density of cells with overlapping processes. Extreme insult can lead to the production of an 
astrocytic or glial scar (Sofroniew and Vinters, 2010). Scar formation protects healthy tissue from 
areas of severe inflammation and toxicity by building a compact wall of astrocytes, glial cells and 
other cell types around the border of the damaged tissue. The benefits of glial scarring have 
been debated. Glial scarring has been demonstrated to protect from oxidative stress and 
promote the degradation of Aß. However, glial scar formation also inhibits axon regeneration 
and isolates damaged tissue (Sofroniew, 2009). 
At the synapse, astrocytes mediate multiple signalling pathways to ensure successful 
communication between neural cells.  Both neurons and astrocytes express glucose transporters 
(GLUT3 and GLUT1, respectively) (Maher et al., 1991; Maher, 1995), however, astrocyte end-
feet are well positioned to take up glucose from blood vessels (Morgello et al., 1995; McKenna, 
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2012). Glucose is the main energy substrate of the CNS under physiological conditions 
(Mergenthaler et al., 2013), and is utilised either in the tricarboxylic acid (TCA) cycle to provide 
neurons with energy or is converted into lactate or glycogen (Pellerin et al., 2007). Astrocytes 
store glucose as glycogen, and evidence suggests that astrocytes convert this glycogen into 
lactate in order to supply neurons with energy when synaptic activity is high (Pellerin et al., 1998; 
Pellerin and Magistretti, 2012). The breakdown of glycogen and lactate release via this “lactate 
shuttle” are crucial for the maintenance of long-term potentiation and long-term memory 
formation (Suzuki et al., 2011).  
In the rodent brain glutamate transporters GLAST and GLT1 (EAAT1 and EAAT2 in the human 
brain) control the uptake of glutamate by astrocytes via coupling transport of Na+ and K+ with 
the inward movement of glutamate (Allaman et al., 2011; Pellerin and Magistretti, 2012). 
Expression of both GLAST and GLT1 on astrocytes is concentrated on areas adjacent to neuronal 
dendritic spines, suggesting that these transporters play an important role in the clearance of 
synaptic glutamate (Kondo et al., 1995; Lehre et al., 1995; Matute et al., 2005; Sheldon and 
Robinson, 2007). GLAST expression is most prominent in Bergmann glia, and at lower levels in 
other astrocyte populations throughout the CNS, whereas GLT1 expression is more apparent in 
the mature CNS and abundant in the forebrain (Tanaka, 2000; Beart and O'Shea, 2007). 
Unlike neurons, astrocytes are not electrically excitable cells, but they do play an active role in 
information processing through the propagation of intracellular Ca2+ waves (Agulhon et al., 
2012; Perea & Araque, 2005; Wang & Bordey, 2008). It has since become apparent that 
communication between astrocytes is mediated independently of external stimuli through 
transient increases in intracellular Ca2+ that can spread into neighbouring astrocytes to form 
synchronised Ca2+ waves (Fiacco & McCarthy, 2006; Kuga et al, 2011; Scemes & Giaume, 2006). 
This Ca2+ signalling mechanism also allows bidirectional information processing between 
neurons and astrocytes. Intercellular Ca2+ waves can cause Ca2+ transients that trigger neuronal 
activation, whereas neuronal signalling in turn may activate Ca2+ waves within networks of 
astrocytes (Araque & Navarrete, 2010; Perea & Araque, 2005; Perea et al., 2009). Astrocytic 
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uptake and release of Ca2+ (Agulhon et al., 2012; Allen & Barres, 2009; Parpura & Verkhratsky, 
2012; Perea & Araque, 2005), allowing the cells to regulate post-synaptic excitatory activity, has 
been implicated in synaptic transmission and plasticity (Navarrete et al., 2013). Dysregulated 
astrocytic glutamate and calcium signalling is thought to be involved in synaptic dysfunction and 
loss in AD, suggesting astrocytes may play multiple roles in neurodegeneration (Agulhon et al., 
2012; Ferreira et al., 2012; Talantova et al., 2013). 
Research has shown gliotransmitters allow astrocytes to communicate with each other and 
other cell types (Liu et al., 2011b; Petrelli and Bezzi, 2016). Extracellular adenosine triphosphate 
(ATP) is important for neuron-astrocyte communication, as it can act as a signalling molecule in 
an activity dependent manner (Verderio and Matteoli, 2001; Orellana et al., 2011; Cisneros-
Mejorado et al., 2015). Additionally, it plays a crucial role in intercellular astrocyte interaction, 
due to the role of ATP signalling in the propagation of the Ca2+ wave (Guthrie et al., 1999). ATP 
binding to either metabotropic or ionotropic purinergic receptors results in Ca2+ being released 
from intracellular stores or Ca2+ membrane influx respectively. Both mechanisms are crucial for 
cellular communication and responses to disease (James and Butt, 2001; Verkhratsky et al., 
2009; Alloisio et al., 2010). 
Although astrocytes do express ionotropic receptors, a large proportion of these receptors are 
metabotropic (Perea et al., 2009). The binding of neurotransmitters to metabotropic, G-protein 
coupled receptors activate the phospholipase C/inositol 1, 4, 5-triphosphate (IP3) pathway 
resulting in the release of Ca2+ from intracellular IP3-sensitive Ca2+ stores, such as the 
endoplasmic reticulum (ER) (Fiacco and McCarthy, 2006; Scemes and Giaume, 2006; Illes et al., 
2012). Ca2+ release from the ER is considered to be crucial for gliotransmission and is highly 
regulated (Zorec et al., 2012). 
Astrocytic inflammatory activity is also becoming widely accepted as important for  
neurodegeneration in AD (Phillips et al., 2014). Astrocytes exacerbate neuroinflammation by 
releasing small signalling molecules such as cytokines and chemokines (Choi et al., 2014; 
Rothhammer and Quintana, 2015). In AD, these molecules and activated astrocytes are 
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associated with increased tau pathology and neurodegeneration (Mrak and Griffin, 2005; Zilka 
et al., 2012; Zheng et al., 2016). As a result, the role of astrocytes in AD is complicated by a mixed 
activated response, both protecting from and exacerbating Aß insult. 
Astrocyte activation is a response to multiple causes. Some, such as oxidative stress are 
environmental, while on other occasions astrocytes are responding to the release of cytokines 
from other nearby cells (Sofroniew and Vinters, 2010). Experiments have demonstrated that Aß 
can also activate astrocytes, possibly directly or by increasing oxidative stress (Butterfield, 2002), 
causing abnormal calcium signalling (Lim et al., 2013; Navarrete et al., 2013), disrupted 
glutamate processing (Talantova et al., 2013) and increased release of pro-inflammatory 
cytokines such as IL-1ß (Thornton et al., 2006; Carrero et al., 2012). By mediating many of the 
affected systems in AD, astrocytes are able to influence the progression of disease at multiple 
stages. 
At early stages of disease, astrocytes have been found to atrophy, in both transgenic mouse 
models and post-mortem AD brain (Olabarria et al., 2010; Rodriguez-Arellano et al., 2016). It has 
been suggested that this atrophy may reduce the area of the domain of each astrocyte, resulting 
in a reduction in the number of neurons and synapses that each astrocyte can maintain. This 
could lead to problems with neuronal and synaptic homeostasis as astrocytic maintenance is 
reduced, weakening synaptic connections and resulting in dysfunction, the first signs of 
pathology seen in AD (Coleman et al., 2004). In particular, this atrophy may disrupt glutamate 
and calcium homeostasis, both key roles of astrocytes at the synapse (Anderson and Swanson, 
2000; Agulhon et al., 2012).  
Astrocytic glutamate uptake by GLAST and GLT-1 is impaired by Aß treatment in astrocytic 
cultures via reductions in the levels of both transporters, increasing levels of extracellular 
glutamate (Matos et al., 2008). Additionally, pathological glutamate release by astrocytes in 
response to Aß treatment has been shown in hippocampal slices. Furthermore, this increase in 
extracellular slices results in increased excitotoxicity via activation of extrasynaptic NMDA 
receptors (Talantova et al., 2013). Furthermore, this increased excitotoxicity has been found to 
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inhibit LTP in hippocampal slices, a key mechanism underlying memory and learning (Li et al., 
2011). Excitotoxicity is also known to increase Ca2+ influx into the neuron in AD (Ferreira et al., 
2012; Navarrete et al., 2013). Alongside excess glutamate effects on neuronal Ca2+ levels, 
astrocytes appear to directly affect Ca2+ homeostasis in AD. Ca2+-dependent endoplasmic 
reticulum stress has been found to correlate with astrogliosis in Aß-treated astrocytes and in the 
3xTg-AD mouse model (Alberdi et al., 2013). However, Aß-induced astrocytic calcium signalling 
effects have not always been seen in cell culture (Toivari et al., 2011). This is likely to reflect 
functional differences between types of astrocytes. In fact regional differences have been found 
in the calcium signalling response of astrocytes to Aß treatment suggesting there could be large 
variations in the astrocytic response in AD and AD-like pathology  (Grolla et al., 2013). 
As AD progresses, both Aß and tau aggregate, resulting in increased glial activation, chronic 
inflammation and neurodegeneration (Figure 1.7). Astrocytic activation, along with levels of 
phosphorylated tau in the synapse, show good correlation to clinical disease progression (Perez-
Nievas et al., 2013). In more severe stages of AD and AD-like pathology, astrocytes, along with 
microglia, have been found to localise around Aß plaques in AD brain in a similar way to astroglial 
scar formation, possibly attempting to minimise the spread of Aß toxicity (Olabarria et al., 2010; 
Bouvier et al., 2016). Additionally, there is evidence that activated astrocytes may also take up 
phosphorylated tau, again possibly in an attempt to minimise pathological spread (de Calignon 
et al., 2012). Increasingly severe astrogliosis, along with increased microglial activation, also 
results in increased release of cytokine and chemokines, triggering chronic inflammation and a 
feed-forward neurodegenerative loop producing widespread neuronal loss (Figure 1.7) (Heneka 





Figure 1.7: Neuroinflammation in AD 
Schematic diagram demonstrating development of neuroinflammation and neurodegeneration 
in AD. Adapted from Heneka et al. (2015). 
 
Microglia 
Microglia were originally identified by Rio-Hortega in 1919 (Garcia-Marin et al., 2007a). Part of 
the mononuclear phagocytic system, they develop outside of the CNS and migrate to the brain 
in late pre- and early post-natal development (Ransohoff and Cardona, 2010). However, once 
inside the brain, normal proliferation is thought to occur locally (Lawson et al., 1992; Perry, 
2016). Microglia have traditionally been viewed as the resident ‘immune cells of the brain’, 
surveying and responding to abnormal or foreign material in order to protect neurons from 
infection and toxicity (Wirenfeldt et al., 2011; Perry, 2016). However, evidence shows microglia 
also play important roles in the maintenance and plasticity of synapses and neuronal circuits in 
the healthy brain (Ji et al., 2013). 
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Criteria for describing microglial activation state has been adapted from that used for peripheral 
macrophages (Gordon and Martinez, 2010; Martinez and Gordon, 2014), subsequently revised 
to explain the range of microglial responses to disease (Biber et al., 2014; Tam and Ma, 2014). 
In the M0 state, microglia are considered to be “resting”. These cells have a ramified morphology 
and show dynamic cytoskeletal rearrangement as they actively survey the local environment 
(Nimmerjahn et al., 2005; Sierra et al., 2014). The M1 phenotype is associated with microglia 
taking on an amoeboid morphology and increased release of pro-inflammatory factors such as 
tumour necrosis factor α (TNFα), interleukin-1ß (IL-1ß), inducible nitric oxide synthase (iNOS) 
and production of reactive oxygen species (ROS) (Block et al., 2007). Alternatively, microglia may 
adopt a M2 phenotype characterised by an increased release of anti-inflammatory mediators 
such as brain derived neurotrophic factor (BDNF), IL-10 and Arginase-1 and deactivation of the 
M1 phenotype (Biber et al., 2014). The M2 phenotype is linked with tissue regeneration and 
repair. 
Through active surveillance of their environment, microglia can transition between these 
states/phenotypes rapidly (Biber et al., 2014; Gomez-Nicola and Perry, 2016), and the resulting 
state may depend on maturity of the brain since, like astrocytes (Zhang et al., 2016b), different 
expression profiles have been observed during murine development (Crain et al., 2013). 
Similarly, repeated activation, or “priming” (Perry and Holmes, 2014) of microglia has been 
suggested to predispose them towards a pro-inflammatory phenotype. This is often associated 
with aging, and  increased sensitivity to inflammatory stimuli has been found in aged rodent and 
primate brain (Perry and Teeling, 2013). However, genetic mutations and specific genetic 
expression, such as that found in the APP/PS1 transgenic mouse have also been associated with 
primed microglia (Orre et al., 2013). The mechanisms through which microglia transition 
between activation states are unclear, however the TREM-2 receptor has been linked to an M2 
phenotype (Takahashi et al., 2005). The highly varied response of microglia to pathological 
events remains controversial, and it is to be seen whether manipulating the transition between 
M1/M2 phenotypes may provide new therapeutic opportunities (Biber et al., 2014). 
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Complement receptors on the cell surface can detect insults such as disruption of the blood 
brain barrier (Jacob and Alexander, 2014) and can trigger microglial activation (Crehan et al., 
2013). While other receptors including toll-like receptors (TLRs) and scavenger receptors can 
detect and respond to damage-associated molecular patterns (DAMPs) and pathogen-
associated molecular patterns (PAMPs) (Jack et al., 2005). A wide range of proteins and 
molecules come under the umbrella terms DAMPs (endogenous stimuli) and PAMPs (foreign 
pathogen stimuli), including heat-shock receptors, ATP, bacterial lipopolysaccharides, viral 
nucleic acids and Aß, and stimulate microglia to respond to a range of possibly toxic situations 
with the aim of protecting neuron health (Akira and Hemmi, 2003; Stewart et al., 2010; Pisetsky, 
2012; Venereau et al., 2015). Additionally, glutamate receptors are present on the surface of 
microglia allowing them to detect and respond to excess glutamate in the extracellular space, 
for example in cases of excitotoxicity (Pocock and Kettenmann, 2007). Furthermore, astrocytes 
are able to activate microglia through cytokine release in cases of infection and 
neurodegeneration (Tanuma et al., 2006; Ovanesov et al., 2008). A combined astrocyte and 
microglial immune response is important as together these two cell types may be able to 
respond more effectively to toxic stimuli such as Aß, however, as with astrocyte activation, the 
benefits of microglial activation in AD are unclear. 
Support for a microglial response in AD has been established for significantly longer than that of 
astrocyte activation (Rodriguez et al., 2010). A wealth of evidence demonstrates that microglia 
display two types of behaviour in response to Aß and AD pathology: phagocytosis and an 
inflammatory response. Microglia have been found to phagocytose Aß and debris from synapse 
loss and neuron death (Eugenin et al., 2016). Largely, removal of Aß and this possibly toxic waste 
is considered beneficial. However, as with the astrocytic immune response, the microglial 
immune response results in the release of cytokines and chemokines that can trigger 
detrimental signalling pathways in other glial cells and neurons, and lead to further disease 
progression (Pocock and Liddle, 2001; Maphis et al., 2015; Wes et al., 2016). Evidence suggests 
that Aß alone can be sufficient to activate microglia and initiate an inflammatory response 
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(Heneka et al., 2015). However, microglial priming by peripheral inflammation, and other factors 
such as obesity, could exacerbate the innate immune system response to Aß and have been 
suggested to increase risk of chronic inflammation and subsequent neurodegeneration (Figure 
1.7) (Whitmer et al., 2008; Cunningham et al., 2009; Heneka et al., 2015). 
As previously mentioned, some genetic variants of TREM2 significantly increase risk of 
developing AD (Forabosco et al., 2013; Guerreiro et al., 2013; Villegas-Llerena et al., 2016). The 
effects of these variants and TREM2 function in physiological and pathological conditions still 
remains unclear, with conflicting results from different studies (Heneka et al., 2016; Ulrich and 
Holtzman, 2016). However, it is likely TREM2 is involved in multiple stages of the development 
of chronic inflammation and neurodegeneration. For example, knocking out TREM2 in mouse 
models of AD prevents microglia clustering around Aß plaques suggesting TREM2 may be 
involved in microglial migration (Forabosco et al., 2013; Wang et al., 2015). Moreover, the same 
study found reduced levels of general microglia activation in TREM2 knock out animals, 
suggesting TREM2 is involved in a wide range of functions aiming to limit Aß pathology (Wang 
et al., 2015). Further investigations have suggested that TREM2-positive cells surrounding 
plaques are peripheral macrophages entering the CNS, rather than resident microglia (Savage et 
al., 2015). Additionally, TREM2 knock out mice showed very little infiltration of peripheral 
macrophages and significantly reduced inflammation, unexpectedly indicating a detrimental 
role for TREM2 in AD (Jay et al., 2015). Regional differences have also been seen in the influence 
of TREM2, with a reduction in both Aß plaques and soluble Aß oligomers found in the 
hippocampus, but not cortex, of TREM2 knockout transgenic mouse models of AD (Heneka et 
al., 2016). This supports findings from experiments investigating astrocyte function that suggest 
the immune response to AD pathology may differ depending on the brain region and disease 
stage (Yeh et al., 2011; Rodriguez et al., 2014). 
Analysis of TREM2 in peripheral monocytes found other AD-associated alleles of other genes 
could affect TREM2 biology. In particular, those involved in innate immunity have been found to 
affect and be effected by TREM2 variants, providing further suggestions of the complex role 
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TREM2 may play in AD development (Forabosco et al., 2013; Chan et al., 2015). Overall, results 
from investigations into the role of TREM2 have provided mixed results. However, TREM2 
appears to function together with other aspects of the immune system, in particular the innate 
immune system, in response to Aß and AD-like pathology. 
An important part of the microglial innate immune system that is likely to be involved in the 
response of TREM2 to Aß oligomers and plaques is the inflammasome. Inflammasomes are 
inducible protein complexes key to microglial function. Four different inflammasomes have been 
characterised, however the NLRP3 inflammasome seems to be most involved in pathological 
mechanisms (Gold and El Khoury, 2015). The NLRP3 inflammasome can be activated via two 
steps: the first requires activation of the transcription factor NF-κB, its translocation to the 
nucleus and the transcription of the different elements of the inflammasome, resulting in 
inflammasome ‘priming’ (Bauernfeind et al., 2009). The second step is the oligomerisation and 
construction of the inflammasome, where all three protein components join together to form 
the inflammasome complex (Baroja-Mazo et al., 2014).  
A wealth of evidence supports the role of NF-κB in AD. Activation of the transcription factor can 
be caused, indirectly, by Aß oligomers binding to TLRs. This results in increases in transcription 
of cytokines and the NLRP3 inflammasome (Kaltschmidt et al., 1997; Lin et al., 2013; Shi et al., 
2016). Furthermore, the NLRP3 inflammasome has been found to be activated in human AD 
brain and contribute to pathology in the APP/PS1 transgenic mouse model of AD, including 
possibly reducing microglial phagocytosis of Aß (Heneka et al., 2012). Once activated, the 
complex can control the release of IL-1ß, a pro-inflammatory cytokine associated with AD 
pathology (Thornton et al., 2006; Di Bona et al., 2008; Ghosh et al., 2013), along with other pro-
inflammatory cytokines (Gold and El Khoury, 2015; Freeman and Ting, 2016).  Once released, 
cytokines can activate a range of signalling pathways, switching the microglial innate immune 
response to chronic neuroinflammation, contributing to the progression of AD pathology (Figure 
1.7) (Zheng et al., 2016). 
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1.7.2 Inflammatory mediators 
As described above, astrocytes and microglia are part of the brain’s innate immune system 
(Dong and Benveniste, 2001; Barres, 2008; Graeber et al., 2011). Both microglia and astrocytes 
respond to injury and disease by altering their morphology and changing their protein 
expression and secretion profile (Allen and Barres, 2009; Rodriguez et al., 2016). Numerous 
inflammatory mediators, including both pro- and anti-inflammatory cytokines, have been 
implicated in both the progression and attenuation of AD pathology (Zheng et al., 2016). 
Furthermore, evidence suggests cytokines and chemokines are involved throughout AD 
development, including Aß accumulation, tau phosphorylation and aggregation, and synaptic 
and neuron loss (Mrak and Griffin, 2005; Rubio-Perez and Morillas-Ruiz, 2012; Avila-Munoz and 
Arias, 2014).  
Cytokines 
Cytokines are a group of small immune cell signalling molecules that aid intercellular 
communication during an immune response (Dinarello and Mier, 1986; Zheng et al., 2016). The 
group comprises of several types of signalling molecules, including interleukins (ILs), interferons 
(IFN), tumour necrosis factors (TNF) and growth factors (Rothwell and Relton, 1993). Upon glial 
activation cytokine expression and release is upregulated, however they are also released at low 
levels throughout the normal peripheral nervous system (PNS) and CNS (Tchelingerian et al., 
1994; Rothwell and Luheshi, 2000; Holmin and Hojeberg, 2004). Additionally there is some 
redundancy in these inflammatory mediators, with multiple cytokines activating similar 
signalling pathways (Anisman, 2009). Astrocytes have detrimental effects on neurons through 
cytokine production, which in turn may lead an increased production of reactive oxygen species, 
exacerbated neuroinflammation, BBB disruption and the release of potentially neurotoxic levels 
of glutamate (Sofroniew, 2009; Sofroniew and Vinters, 2010; Burda and Sofroniew, 2014; Pekny 
et al., 2014). Astrocytes also release a wide range of soluble factors including IFNγ, IL-4, IL-6 and 
TNF-α and express a variety of cytokine receptors (Cahoy et al., 2008; Wang and Bordey, 2008; 
Sofroniew, 2009; Sofroniew and Vinters, 2010; Agulhon et al., 2012; Hamby et al., 2012). 
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Consequently, cytokine signalling may occur both in an autocrine and paracrine fashion. As 
already discussed, establishing the effect of cytokine signalling is difficult as different expression 
levels can provoke distinct outcomes, and similarly interactions between secreted proteins may 
also alter their effects. For example, low concentrations of IFNγ had a beneficial effect on 
astrocytic glutamate clearance in culture, but the effect was lost when both IL-4 and IFNγ were 
added to the cultures (Garg et al., 2009). Many cytokines have been shown to have 
neuroprotective, as well as harmful, effects depending on the context. Indeed, through the 
release of soluble factors, astrocytes can regulate neuronal function, as well as that of other glial 
cells such as microglia (Sofroniew, 2009; Sofroniew and Vinters, 2010; Colangelo et al., 2014). 
Many cytokines have been found to be upregulated in AD brain, compared to control brain 
(Zheng et al., 2016), and inflammatory cytokine levels have been found to correlate with Aß 
levels in transgenic mouse models of AD (Patel et al., 2005). Cytokines have been implicated in 
almost all stages of disease development (Heneka et al., 2015; Zheng et al., 2016), for example, 
IL-1ß is robustly upregulated in disease brain and polymorphisms in the IL-1ß gene may be 
associated with an increased risk of AD (Di Bona et al., 2008). Additionally, IL-1ß has been 
associated with increased tau phosphorylation via activation of tau kinases and increased 
astrocyte-induced caspase activity in cell culture (Li et al., 2003; Thornton et al., 2006). Similarly, 
IL-1ß levels correlate well with tau phosphorylation in htau mice (Garwood et al., 2010). Treating 
the mice with minocycline, a tetracycline with anti-inflammatory action, reduces IL-1ß levels and 
rescues tau pathology (Garwood et al., 2010). A study crossing another mouse model of AD with 
mice overexpressing IL-1ß further supported the role of IL-1ß in tau phosphorylation. However, 
mice also showed reduced Aß load, possibly due to the 4-6-fold increase in plaque-associated 
microglia suggesting an increase in Aß phagocytosis. In addition to demonstrating the 
complexity of the immune response and cytokine roles in AD, this paper highlights a divergence 




Increased expression of IL-18 has also been found in post-mortem AD brain suggesting it may 
have a role in disease progression (Ojala et al., 2009). In particular, evidence supports a role for 
IL-18 in early AD pathology since increases in peripheral IL-18 levels are found in individuals with 
MCI (Salani et al., 2013). Furthermore, increases in peripheral IL-18 correlate with cognitive 
impairment suggesting that IL-18 may play an active role in disease pathogenesis (Bossu et al., 
2008). The mechanisms underlying this role are unclear, however, IL-18 has been demonstrated 
to increase BACE1 and PSEN1 levels in neuron-like cells possibly leading to increases in Aß1-42 
production during the early stages of disease (Sutinen et al., 2012). IL-18 has also been 
implicated in the development of tau pathology via the regulation of NMDA receptor function 
(Curran and O'Connor, 2001). NMDA receptor activity influences tau pathology in multiple ways, 
including increasing phosphorylation and cleavage of tau that is mediated by elevated 
extracellular-signal related kinase (ERK) and calpain activity (Amadoro et al., 2006). 
Furthermore, tau release is dependent on synaptic activity both in vivo and in vitro, suggesting 
that IL-18 may influence the spread of tau pathology via NMDA receptor function (Pooler et al., 
2013; Yamada et al., 2014). 
In addition to IL-1ß and IL-18, there is evidence to support the role of many other cytokines in 
AD progression. Studies attempting to tease apart which cytokines influence which pathological 
signalling pathways are on-going and complex. However, it is thought that cytokines could be 
promising drug targets for AD treatment, hopefully allowing specific signalling pathways to be 
carefully controlled (Jiwrajka et al., 2016; Zheng et al., 2016). 
Chemokines 
Chemokines are a group of small (8-10 kDa) cytokines first described by Oppenheim in 1991 
(Oppenheim et al., 1991). The name chemokine is derived from their ability to induce 
chemotaxis, movement in response to a chemical stimulus, in nearby cells. Like other cytokines, 
chemokines are released from both astrocytes and microglia and they bind G-protein linked 
receptors on both neuronal and other glial cells (Griffith et al., 2014). Chemokine function can 
be split into two broad categories: homeostatic or inflammatory, either controlling cell 
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migration during normal development or recruiting cells to sites of infection, respectively. All 
chemokines share similar structural and genetic characteristics and can alternatively be 
classified in four subfamilies: CXC, CC, CX3C and XC however, these subfamilies are not 
definitively associated with chemokine function (Liu et al., 2014). Chemokine receptors have 
also been classified, approximately according to the chemokine to which they bind. For example, 
chemokine CXCL1, also known as GRO-α, binds to receptor CXCR1 (Lu et al., 2005). However, 
this system has become confused as new research has demonstrated that many chemokines can 
bind to multiple receptors (CXCL1 can also bind to CXCR2), and many receptors interact with 
multiple chemokines (evidence suggests CXCR2 can bind more than nine different chemokines) 
(Liu et al., 2014). 
Multiple chemokines have been implicated in the development or progression of AD (Azizi et al., 
2014), including MCP-1 (Madrigal et al., 2009; Vukic et al., 2009), SDF-1α (Laske et al., 2008), 
MIP-1α (Xia et al., 2000), IP-10 (Lai et al., 2013), IL-8 (Ashutosh et al., 2011), and RANTES 
(Tripathy et al., 2010). Like cytokines, the signalling pathways triggered and the effects caused 
by these molecules is complex. For example, robust evidence supports the role of fractalkine 
(CX3CR1) in AD (Kim et al., 2008; Sheridan and Murphy, 2013). However, it is currently unclear 
whether fractalkine activity promotes or helps rescue the progression of AD. Knocking out the 
fractalkine receptor in htau transgenic mice exacerbates tau phosphorylation and aggregation 
via p38/MAPK, and overexpression of fractalkine suppresses tau pathology in vivo,  suggesting 
a neuroprotective role for this chemokine that is dependent upon keeping microglia in a resting 
state (Bhaskar et al., 2010; Nash et al., 2013). However, when mice overexpressing mutant 
human APP and PSEN1 (APP/PS1) were crossed with fractalkine receptor knockout mice, 
reduced Aß deposition was found (Lee et al., 2014), which again might reflect an upregulation 
of microglial phagocytosis as their “rest” signal from neurons is removed. Indeed,  fractalkine is 
suggested to influence autophagy leading to an accumulation of Aß and changes in tau clearance 
(Hebron et al., 2013).  
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The studies described here, and others in the literature, demonstrate the complexity of cytokine 
and chemokine signalling. There is abundant evidence showing that distinct inflammatory 
mediators play important roles in many stages of disease, and this might diverge depending on 
whether tau or Aß-mediated neurodegeneration is being studied. Moreover, both cytokines and 
chemokines mediate multiple signalling pathways, often displaying overlapping functions. This 
makes elucidating the roles of specific mediators very complex. However, drugs targeting one 
or several inflammatory mediators may have potential benefit in AD, and there has been 
renewed interest in anti-inflammatory treatment strategies in recent years (Heneka et al., 2016). 
1.7.3 Neuroinflammation as a therapeutic target in AD 
Broad anti-inflammatory agents, such as non-steroidal anti-inflammatory drugs (NSAIDs) have 
shown promise as treatments for Parkinson’s disease (Powers et al., 2008). However, multiple 
clinical trials investigating NSAID efficacy as treatment for AD have found no improvement or 
prevention of symptoms following NSAID treatment (Miguel-Alvarez et al., 2015). However, glial 
cell behaviour can both exacerbate and protect from disease progression and it is possible that 
more specific anti-inflammatory drugs may be needed to ensure that appropriate signalling 
pathways are up- or downregulated. Drugs targeting specific cytokines are beginning to be 
tested. For example, IL-1ß receptor antagonists, aiming to rescue or reduce IL-1ß-mediated tau 
phosphorylation and aggregation, are currently in use for other inflammatory diseases 
(Braddock and Quinn, 2004). Additionally, evidence from AD mouse models suggests that IL-1ß 
receptor antagonists show promising effects and may improve AD symptoms (Ben-Menachem-
Zidon et al., 2014).  
Repurposing drugs already in the clinical is a quick and effective way to find new disease-
modifying drugs. Since clinical trials investigating the safety of the drug for humans do not have 
to be repeated, only the later stages of the trial, investigating the efficacy of the drug for the 
specific disease, have to be implemented. This shortens the length of time and reduces the cost 
of clinical trials, making it easier to get effective drugs to AD patients more rapidly. Furthermore, 
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this approach has been shown to have better clinical trial safety as toxic drugs have already been 
excluded (Appleby et al., 2013). 
In this thesis, two drugs, both already in clinical use for other conditions, and highlighted as 
being potentially promising repurposing candidates, were investigated. The first, minocycline, is 
currently in early-stage clinical trials for AD and was used here to investigate the role of 
astrocytes in the development of tau pathology in primary cell cultures. The second, dimethyl 
fumarate (DMF) was tested to investigate whether it could reduce tau pathology in primary cell 
cultures and in a mouse model of AD. Both drugs will be briefly introduced here. 
Minocycline 
Minocycline is a tetracycline-antibiotic derivative with anti-inflammatory action that is regularly 
prescribed for the treatment of acne and can cross the blood-brain barrier. Treatment of htau 
mice, a mouse model of tauopathy, with minocycline significantly reduced the number of 
activated astrocytes,  and levels of pro-inflammatory cytokines and chemokines released 
(Garwood et al., 2010). Minocycline treatment also reduced tau phosphorylation, cleavage and 
aggregation in the mice suggesting that the astrocyte-directed anti-inflammatory action of 
minocycline may be down-regulating pathological signalling pathways that contribute to the 
development and progression of tau pathology (Noble et al., 2009b). Further investigations of 
the possible mechanisms of drug action in primary cell culture found that the effects of 
minocycline were astrocyte-dependent, with minocycline application reducing the release of 
inflammatory mediators, including IL-1ß, from astrocytes (Garwood et al., 2011). However, 
cytochrome c and multiple caspases were also downregulated, albeit in a manner dependent on 
astrocyte presence, suggesting that minocycline may downregulate multiple pathways that 
affect tau cleavage and aggregation, and potentially also the turnover of other proteins (Noble 
et al., 2009a; Garwood et al., 2011).   
66 
 
Dimethyl fumarate (DMF) 
DMF is a known nuclear factor erythroid 2-related factor 2 (Nrf2) activator, however it also has 
poorly understood anti-inflammatory actions. It is these anti-inflammatory effects, via 
reductions in oxidative stress (Lee et al., 2012), which are thought to be exploited in the 
treatment of multiple sclerosis, a clinical use approved by the FDA in March 2013. Clinical trials 
for multiple sclerosis have shown that DMF is both non-toxic to humans at therapeutic levels 
and it is also able to cross the blood-brain barrier, two characteristics that are critical for a 
possible AD drug treatment (Fox et al., 2012; Gold et al., 2012). Furthermore, studies 
investigating the effects of DMF in rodent models have found reductions in both spatial memory 
impairments and hippocampal degeneration (Majkutewicz et al., 2016), two symptoms 
particularly relevant to AD. This evidence highlights the potential of DMF as a candidate drug for 
repurposing efforts in AD. Therefore, experiments in this thesis have investigated the effects of 
DMF on astrocytes and tau in primary cell cultures and the htau mouse model of tauopathy. 
 
1.8 Aims and objectives of this thesis 
This broad aim of this thesis is to investigate the association between astrocytes and tau in 
models of AD.  
Specifically, this thesis aims to: 
1. Investigate the influence of astrocytes on disease-associated changes in tau proteins in 
the cortex and the hippocampus using primary neural cell cultures. 
2. Examine the relationship between changes in tau, glial activation and synaptic markers 
in cortex and hippocampus during the progression of AD in Braak-staged brain.  
3. Investigate the potential of DMF as a repurposing drug candidate for AD in primary 




Chapter 2: Materials and Methods 
 
All materials were obtained from Sigma Aldrich (St Louis, MO, US) unless otherwise stated. Stock 
solutions and buffers were prepared using ultrapure water from a Triple Red purification system. 
Solution sterilisation, when required, was carried out by autoclaving for 15 min at 121 °C using 
a Systec VX-150 autoclave (Systec GmbH, Linden, Germany). 
 
2.1 General buffer solutions 
 
Phosphate buffered saline (PBS, pH 7.4) 137 mM sodium chloride, 2.7 mM potassium 
chloride, 10 mM disodium phosphate, 1.8 
mM monopotassium phosphate 
  
PBS-Tween (PBS-T) 1 x PBS with 0.05 % (v/v) Tween-20 
  
Tris-buffered saline (TBS, pH 7.4) 50 mM Tris-base, 150 mM sodium chloride 
  




2.2 Cell culture 
2.2.1 Rat primary neurons 
Materials 
Poly-D-lysine 10 µg/ml poly-D-lysine hydrobromide 
(molecular weight 4000 – 15000; Sigma-
Aldrich P6403) 
 
Supplemented Neurobasal medium Phenol red free Neurobasal® medium 
(Invitrogen, Paisley, UK), 2 % (v/v) B-27 
(Invitrogen), 2 mM GlutaMax (Invitrogen), 
100 μg/ml penicillin (PAA Laboratories, 
Piscataway, NJ, US), 100 μg/ml streptomycin 
(PAA Laboratories) 
 
Hank’s Balanced Salt Solution Hank’s Balanced Salt Solution (HBSS) without 
Ca2+ or Mg2+ (Invitrogen) 
 
Trypsinising solution TrypLE ™ Express Enzyme (1x), phenol red 
(Invitrogen) 
 
Trypan blue 0.4 % sterile filtered trypan blue 
  
Foetal bovine serum (FBS) Foetal bovine serum, qualified, heat 
inactivated, E.U.-approved, South America 








Neurons were obtained from embryonic day 18 (E18) Sprague-Dawley rat embryos (Charles 
River, Margate UK). Pregnant female rats were delivered to the animal house when embryoes 
were E13. Rats were housed singly for 5 days on a 12 h light-dark cycle and at constant 




All plates used for cell culture were sterile. Nunc cell culture plates were coated with 10 µg/ml 
poly-D-lysine (PDL) and left overnight at 37 °C. On the day of the dissection, excess PDL was 
removed and plates were washed with sterile ultrapure H2O three times. Phenol red free 
Neurobasal medium was added to each well at incubated at 37 °C until neurons were ready to 
be plated.  
If coverslips were being used, 18 mm glass coverslips (Paul Marienfeld GmbH & Co., Lauda-
Königshofen, Germany) were autoclaved and placed in the bottom of 12-well plates using sterile 
forceps. Plates were then coated with PDL as above. 
 
Neuron dissection 
Isolation of the embryonic brain 
Pregnant female Sprague-Dawley rats were sacrificed using Schedule 1 methods in accordance 
with the Animals (Scientific Procedures) Act, 1986. The abdominal wall was cut through and the 
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uterus removed and placed in Hank’s Balanced Salt Solution (HBSS) in a sterile petri dish. 
Foetuses were removed from the uterus and decapitated. Foetal heads were placed in a fresh 
petri dish containing HBSS. Brains were removed by making an incision in the skull from the top 
of the spinal cord toward the olfactory bulb. The skin and the skull were peeled back to expose 
the cortices. Cortices were removed using curved forceps and placed in a new sterile petri dish 
containing HBSS on ice. 
Dissection and dissociation of the cortices 
Midbrain, hindbrain and meninges were removed before the cortex and hippocampus were 
separated and placed into petri dishes containing HBSS on ice. Dissection took place for a 
maximum of 1 h from the death of the mother rat. After 1 h, cortices were cut into 3-5 parts and 
separated into 15 ml falcons (1 falcon/brain). All hippocampi were added to the same 15 ml 
falcon. For both cortices and hippocampi dissociation, 1 ml trypsinising solution was added to 
each falcon for 10 min at 37 °C. The trypsinisation solution was removed and brain sections were 
washed three times with HBSS. 1 ml of phenol red free Neurobasal medium was added to each 
falcon and cortices were triturated using a P1000 Gilson pipette until cells were fully dissociated. 
4 ml phenol red free Neurobasal medium was added to the hippocampal cell falcon to make the 
total volume 5 ml. Primary neural cells were filtered through a sterile 70 µm cell strainer (Sigma 
Aldrich). The number of neurons was determined using Trypan blue and a haemocytometer.  
Primary cortical neurons were plated in phenol red free Neurobasal medium supplemented with 
5 % (v/v) foetal bovine serum (FBS) at a density of 4x106 in 10 ml medium for 10 cm dishes, 1x106 
in 4 ml medium per well for 6-well plates or 330,000 in 2 ml medium per well for 12-well plates. 
Hippocampal neurons were plated in phenol red free medium at a density of 250,000 in 2 ml 
medium per well in 12 well plates. Cells were cultured at 37 °C with 5 % CO2. After 24 h, medium 
was removed from cultures and replaced with phenol red free Neurobasal medium without FBS 
supplement. The health of the cell cultures was checked every 3-4 days but, except for 




Cytosine arabinoside (AraC) treatment for neuronal cultures 
In order to investigate the roles of astrocytes in Aß-induced neuron death in primary cell culture 
two different primary neuron cultures were used. The first was made as described above, 
resulting in both neurons and astrocytes in the same cell cultures. These are referred to as mixed 
cultures throughout this thesis. Neuronal cultures were also made to allow a comparison of 
neuron cultures containing astrocytes with neuron cultures without astrocytes. Primary neuron 
cultures without cultures are referred to hereafter as neuronal cultures. 
To produce neuronal cultures, primary cultures were treated with cytosine arabinoside (AraC) 
at 3 DIV to prevent astrocyte proliferation (Garwood et al., 2011). Briefly, primary cultures 
underwent a 50 % medium change at 3 DIV at which time 0.5 μM AraC or vehicle (Neurobasal 
medium without phenol red) was added. After 8 days (at 11 DIV) the AraC-containing medium 
was removed and this was replaced with fresh medium and the remaining conditioned medium 
(part-conditioned medium).  
To confirm neuronal cultures did not contain astrocytes, both mixed and neuronal cultures were 
stained with the astrocyte marker GFAP using immunocytochemistry (ICC) and western blots 
(described in Chapter 3, sections 3.3.1, 3.3.3 and 3.3.4). 
 
2.2.2 Cell lines 
7PA2 Chinese hamster ovary (CHO) cells stably transfected with DNA coding for the APP751 gene 
with the Val717Phe Alzheimer’s disease causing mutation were kindly donated by Dominic 
Walsh. These CHO cells naturally secrete Aß monomers into the culture medium (Walsh et al., 
2002). Cells were cultured in supplemented high glucose phenol-red free Dulbecco’s Modified 
Eagle’s Medium (DMEM) at 37 °C with 5 % CO2. When cells reached 100 % confluency, medium 
was collected as a source of physiologically secreted Aß. Wild type (WT) CHO cells were cultured 





Supplemented DMEM Dulbecco’s modified Eagle’s medium (DMEM) 
with 4.5 g/L D-glucose, without phenol red 
(Invitrogen) supplemented with 10 % (v/v) 
FBS, 2 mM L-glutamine, 100 μg/ml penicillin, 
100 μg/ml streptomycin 
  
Trypsin 2.5 % trypsin 
 
Methods 
Passaging CHO cells 
CHO cells grown for passaging, rather than medium collection were split when they reached 65 
- 80 % confluency (approximately every 3-4 days). CHO cells were trypsinised using 2.5 % trypsin 
for 5 min at 37 °C. Cells were split 1/20 into 2 flasks: one for medium collection and one to 
continue the cell line. WT CHO cells were passaged in the same way. 
 
Freezing and thawing CHO cells 
CHO cells were frozen in supplemented high glucose phenol-red free DMEM with 10 % (v/v) 
dimethyl sulfoxide (DMSO). Cells were trypsinised as described in passaging section and added 
to 1 ml DMEM medium with 10 % DMSO. Immediately cells were placed in a polystyrene 
Eppendorf holder at -80 °C for 24 h. After 24 h cells were stored in liquid nitrogen. 
To thaw cells, tubes were removed from liquid nitrogen and incubated at 37 °C until defrosted. 
Thawed CHO cells and medium were immediately added to flasks containing supplemented high 
glucose phenol-red free DMEM and incubated at 37 °C with 5 % CO2. After 24 h culture medium 
was replaced with fresh medium. 
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2.2.3 ß-amyloid characterisation 
Dynamic light scattering (DLS) 
DLS is a technique used to measure the size of small molecules using the principles of Brownian 
motion of small particles in suspension (Berne and Pecora, 1976). Laser light shone through a 
sample is scattered when light waves hit a molecule with between 0.5 nm and 1000 nm radius. 
Scattered waves can interfere with each other resulting in fluctuations in the intensity of light 
detected by the detector. Faster Brownian motion results in increased frequency of intensity 
fluctuations as particle diffusion is faster. Therefore, larger molecules can be distinguished from 
smaller molecules based on the frequency of intensity fluctuations. 
100 µM stock Aß1-42 was made up by diluting 500 µM stock with autoclaved ultrapure H2O and 
centrifugation at 13000 g(av) for 10 min to remove any dust and contaminating particles. 90 µl 
of diluted Aß was added to one well of a 96-well Corning UV Transparent Microplate (Scientific 
Laboratories Ltd, Hessle, Yorkshire, UK). The plate was added to a Dyna Pro Plate reader (Wyatt 
Technology, Santa Barbara, CA, US) with temperature control and auto-attenuation function and 
was read at 25 °C for 5 sec. To ensure accurate readings, the final distribution was averaged 
from five individual 5 sec DLS collections. This was repeated three times to ensure a stable 
overall reading. 90 µl of autoclaved ultrapure H2O was also read with the plate reader as a 
background control. The percentage of the total Aß mass at each possible radius of Aß molecule 
(e.g. the radius of a monomer, dimer, trimer etc.) for each sample was obtained by the plate 
reader and plotted as a line graph using GraphPad Prism 6.0. Interpretation of results was 
qualitative so no statistical tests were carried out. 
 
Electron microscopy 
Synthetic Aß samples were prepared for electron microscopy as previously published (Guo and 
Lee, 2011). Briefly, samples were resuspended by vortexing for 1-2 sec, twice, and then agitated 
further by drawing up and ejecting 5 µl of sample 10 times. 5 µl undiluted sample was places on 
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a formar/carbon coated copper grid for 3 min. 2 drops of 50 nM Tris-HCl buffer, pH 7.5, were 
added for 5 min each to rinse samples. The samples were negatively stained by dripping 15-20 
drops of 2 % (v/v) aqueous uranyl acetate with 0.5 % (v/v) glacial acetic acid over the grid before 
being air dried in closed containers for at least 1 h prior to viewing in a FEI Tecnai-10 TEM at 80 
kV. Samples were then diluted 1:5 in PBS and the procedure was carried out again. 
Representative images were collected using AMT-XR-50 software. 
Field and image selection were chosen as follows: 
The entire grid was viewed at 2600x to determine the number and distribution of oligomers. A 
representative area was chosen and images were taken at 24000, 65000 and 160000x from the 
same grid hole opening. A second and third grid hole was chosen and images were again taken 
at 65000 and 160000x.  
 
Meso Scale Discovery (MSD) assays 
Assays were run according to manufacturer’s instructions. Two types of MSD assay were used. 
Aß-peptide panel 1 (6E10) V-Plex plates 
Materials 
V-PLEX Aß Peptide Panel 1 (6E10) Kit (K15200E-1, Meso Scale Discovery, Rockville, MD, US). 
All reagents supplied complete by manufacturer. 
Methods 
These plates were used to investigate levels of Aß1-38, Aß1-40 and Aß1-42 in samples of synthetic 
Aß1-42, 7PA2 CHO medium and Tg2576 primary mouse neuron medium. Each well of the 96-well 
plates provided were pre-coated with antibodies that specifically bind to Aß1-38, Aß1-40 and Aß1-
42. Reagents and solutions provided in the MSD assay kit were used in the assay. In brief, non-
specific binding was blocked for 1 h using the blocking solution provided at ambient temperature 
with vigorous shaking. After washing three times with phosphate buffered saline – Tween 20 
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(PBS-T), the Sulfo-tag detection antibody, MSD kit controls and samples (diluted in 
manufacturer’s diluting solution) were added to the plate and incubated for 2 h at ambient 
temperature with vigorous shaking. Plates were washed a further three times with PBS-T. 2x 
Read Buffer, diluted in ultrapure H2O as instructed, was added to the plates and the signals 
produced were read immediately using an MSD Plate Reader. The settings for reading the plate 
were determined automatically by the plate reader by scanning the plate bar code. Standard 
curves were produced from the kit controls according to the manufacturer’s instructions. Aß 
concentrations were interpolated from each standard curve. Both blanks with no protein and 




Blocking buffer 3 % (w/v) bovine serum albumin (BSA) in 1 x 
PBS 
  
Wash buffer 1x PBS 
  
2x Read buffer 4x Read buffer (Meso Scale Discovery) diluted 
1:1 with 1x PBS 
Antibodies 
MSD assays were blocked with the blocking buffer provided in the assay kit. Coating antibodies 







Antibody Species Epitope Concentration Source 
3D6 Mouse 
monoclonal 
Amino acids 1-5 
of Aß 









Table 2.1: Coating antibodies used in MSD assays 
Antibody name, species, reactivity, concentration and source shown. 
 
 
Antibody Species Epitope Concentration Source 
3D6 Mouse 
monoclonal 
Amino acids 1-5 
of Aß 
0.5 µg/ml Eli Lilly and 
Co. 
Biotinylated 3D6 Mouse 
monoclonal 
Amino acids 1-5 
of Aß 
0.5 µg/ml Eli Lilly and 
Co. 
 
Table 2.2: Detection antibodies used in MSD assays 
Antibody name, species, reactivity, concentration and source shown. 
 
 
Antibody Dilution Source 
Goat anti-mouse Sulfo-tag  1 µg/ml Meso Scale Discovery  
Streptavidin Sulfo-tag 1 µg/ml Meso Scale Discovery 
 
Table 2.3: Secondary antibodies used in MSD assays 
Antibody reactivity, dilution and source shown. 
 
Methods 
Multi-array® plates were used to determine the levels of Aß oligomers in samples of synthetic 
Aß1-42, 7PA2 CHO medium and Tg2576 primary mouse neuron medium.  
To obtain Tg2576 primary mouse neuron medium enriched with Aß, neurons overexpressing 
human APP containing the Swedish mutation (K670N/M671L) were cultured for 14 days without 
changing the medium (Hsiao et al., 1996). At 14 DIV medium was collected from primary cultures 
and used in Multi-array® plates to investigate Aß concentrations. WT primary mouse neurons 
were cultured in the same way to produce control neuronal medium. 
Briefly, plates (Multi-array® 96-well plates, #L15XA-3, Meso Scale Discovery) were coated with 
primary capture antibody at 100 ng/well in PBS and were incubated overnight at 4 °C (Table 2.1). 
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Plates were washed three times with wash buffer and non-specific binding was blocked with 
blocking buffer for 1 h at ambient temperature with vigorous shaking. Plates were washed three 
times in PBS. Samples were diluted in PBS, and 25 µl per well were added to the plates in 
duplicate. For CHO cell and Tg2576 culture medium, samples were added neat for the highest 
concentration, while medium from synthetic Aß-treated cells was diluted 1:3 for A11 capture 
antibody assays and 1:9 for 3D6 capture antibody assays. All samples were then diluted in a 3-
fold dilution series at least three times. This was to ensure sample concentrations were within 
the detection range for each antibody. Optimisation of this range was carried out by others in 
the group prior to these experiments taking place. Plates were incubated at ambient 
temperature for 1 h with vigorous shaking, the samples removed and the plates washed three 
times with wash buffer. 25 µl per well of detection antibody (Table 2.2), diluted in 1 % bovine 
serum albimun (BSA) in PBS, was added to the plates and incubated at ambient temperature for 
1 h with vigorous shaking. Plates were washed three times with wash buffer. Sulfo-tag labelled 
secondary antibody (Table 2.3) diluted in 1 % BSA in PBS was added to the plate at 25 µl per well 
and incubated at ambient temperature for 1 h with vigorous shaking. The secondary antibody 
was removed and plates were washed three times with wash buffer. Next, 150 µl/well of 2x 
Read Buffer was added to the plates. Plates were read immediately at using an MSD Plate 
Reader. The settings for reading the plate were determined automatically by the plate reader 
by scanning the plate bar code. Standard curves were produced from the kit controls according 
to the manufacturer’s instructions. Aß concentrations were interpolated from each standard 





Human Aß1-42 ELISA kit (Invitrogen). 
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All reagents supplied complete by manufacturer. 
 
Methods 
Collected CHO cell medium was run neat on Aß1-42 ELISAs according to the manufacturer’s 
instructions (Kurbatskaya et al., 2016). The Aß1-42 standard was reconstituted in 55 mM sodium 
bicarbonate, pH 9.0, before dilution to provide a standard curve containing 0, 15.63, 31.25, 62,5, 
125, 250, 500 and 1000 pg/ml of human Aß1-42 for the assay. 50 µl of sample and standard was 
loaded in duplicate onto the provided ELISA plate, pre-coated with primary antibody to the N-
terminus of Aß1-42. 50 µl rabbit primary antibody against the C-terminus of Aß1-42 was added and 
incubated at ambient temperature for 4 h. Plates were washed with provided wash buffer four 
times before 100 µl anti-rabbit horseradish peroxidase (HRP)-linked secondary antibody was 
added to each well and incubated for 30 min at ambient temperature. Plates were washed four 
times before adding the stabilised chromogen substrate for 30 min. The reaction was stopped 
by adding the provided stop solution, resulting in a yellow colour that was detected at 450 nm 
using a Wallac 1420 Victor3™ plate reader (Perkin Elmer, Waltham, MA, US). The absorbance 
values of the Aß1-42 protein standards were used to create a standard curve. Sample protein 
concentrations were calculated from the standard curve in pg/ml. 
 
2.2.4 Cell treatment 
Materials 





ß-amyloid1-42 (Aß1-42) 500 µM synthetic human Aß1-42 (California 
Peptide Research, Salt Lake City, UT, US) in 
sterile H2O 
  
Conditioned CHO cell medium Neat collected CHO medium diluted 1:1 with 
phenol red free Neurobasal medium 
  
Dimethyl fumarate 100 mM dimethyl fumarate (DMF) in 
dimethyl sulfoxide (DMSO) 
  
S-α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) 
100 µM S-AMPA (Tocris Bioscience, Bristol, 
UK) in autoclaved H2O 
 
   




Minocycline treatment was carried out according to a protocol previously published by this 
group (Garwood et al., 2011). A 4 mM minocycline stock solution was made by dissolving 
minocycline hydrochloride in sterile H2O at 60 °C. At 11 DIV, the medium was removed from 
neuronal or mixed cultures and this was replaced with part-conditioned medium. Cultures were 
pre-treated with 20 μM minocycline or sterile ultrapure H20 (vehicle) for 24 h prior to ß-amyloid 
(Aß1-42) addition. To ensure minocycline was not neurotoxic, cell death was measured using a 




Synthetic Aß1-42 (California Peptide, CA, US) was dissolved in sterile ultrapure H20 to make a 500 
μM stock solution. Aß1-42 was added directly to primary cultured cells of 12 DIV for 48 h to give 
final Aß concentrations of 10 µM (Noble et al., 2009b; Garwood et al., 2011). Control wells were 
treated with vehicle only. 
Conditioned CHO cell medium 
Medium was collected from 7PA2 and WT CHO cells when cells were 100 % confluent and this 
was stored in 1 ml aliquots in 15 ml falcons at -20 °C since these showed low absorbance of Aß. 
For primary cell culture treatment, CHO medium was thawed and mixed 1:1 with conditioned 
Neurobasal medium. 2 ml or 4 ml of CHO cell-conditioned medium was applied to 12-well and 
6-well plates, respectively. Primary neural cell cultures were treated with CHO cell conditioned 
medium for 48 h. 
Dimethyl fumarate (DMF) 
A 100 mM stock solution was made by dissolving DMF in DMSO before further diluting the 
resulting solution in Neurobasal medium to produce a 1 mM DMF / 0.01 % DMSO solution. This 
working stock of DMF was added directly to the primary culture wells at 14 DIV for 24 h to give 
final concentrations of 30 µM – 60 µM DMF. Controls were treated with 0.01 % DMSO only giving 
final DMSO concentrations of 0.0006 % (for 60 µM DMF) or 0.0003 % (for 30 µM DMF). DMF 
concentrations were chosen based on previous research using DMF in cell culture (Wierinckx et 
al., 2005; Ellrichmann et al., 2011; Scannevin et al., 2012) and preliminary experiments 
investigating the toxicity of DMF at these concentrations (described in Chapter 4, section 4.3.1). 
S-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (S-AMPA) and ionomycin treatment 
S-AMPA is a specific agonist for the AMPA receptor at the post-synaptic membrane of neurons. 
S-AMPA was used to mimc glutamate, stimulating glutamatergic neurons in mixed primary 
cultures in order to investigate the effects of neuronal stimulation on levels of extracellular tau. 
As a positive control, the ionophore ionomycin was used to induce neurotoxicity resulting in the 
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breakdown of the neuronal plasma membrane and the release of all intracellular proteins, 
including tau, into the extracellular space. Primary rat neurons cultured in 10 cm dishes were 
used for S-AMPA and ionomycin cell treatment. Immediately prior to treatment, rat primary 
culture medium was replaced with 4 ml B27-free phenol red-free Neurobasal medium so not to 
block columns when concentrating the medium. Treatment of primary cell cultures with S-AMPA 
and or ionomycin were for 30 min. S-AMPA and ionomycin were added directly to the B27-free 
medium at 100 µM or 10 µM, respectively (Pooler et al., 2013). For ionomycin treatments, an 
equal concentration of DMSO was added to control cell cultures as a vehicle control. 
 
2.2.5 Cell viability LIVE/DEAD assay 
Methods 
4 % Paraformaldehyde (PFA) 4 % (v/v) PFA in PBS from 16 % liquid stock 
(Alfa Aesar, Ward Hill, MA, US) 
 
LIVE/DEAD® Fixable Far Red Dead Cell Stain kit (Thermo Fisher Scientific, Waltham, MA, US). 
Except PFA all reagents supplied complete by manufacturer. 
 
Materials 
LIVE/DEAD® Fixable Far Red Dead Cell Stain Assays (L10120, Invitrogen) were carried out 
according to the manufacturer’s instructions. The LIVE/DEAD assay stains dying cells as the Far 
Red dye is taken up only by cells with compromised plasma membranes. Once inside the cell, 
the dye reacts with intracellular free animes resulting in fluroescent staining with a 665 nm 
wavelength. This results in cells with comprised membranes fluorescing with an intense red 
colour, while healthy cells are not stained (Niger et al., 2012; Sestero et al., 2012).  
Briefly, LIVE/DEAD dye was dissolved in DMSO before diluting 1:500 in PBS. Cultures were 
washed in PBS before incubation with LIVE/DEAD solution (30 min, ambient temperature). Cells 
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were washed twice with PBS before being fixed with 4 % paraformaldehyde (PFA: 10 min, 
ambient temperature). All incubation periods were carried out in the dark. The intensity of 
labelling can be used as a measure of cell death. The intensity of dye incorporation was 
visualised and quantified using the Odyssey Imaging System and Odyssey Sa Software Version 
1.1 software (Li-Cor Biosciences, Cambridge, UK). Red dye uptake of dead cells in experimental 
groups were anaylsed as a percentage of control group red dye uptake.  
For culture characterisation, cells were also imaged using immunocytochemistry. Far Red dye 
stained cells were counted alongside the number of Hoescht stained nuclei and dead cells were 
calculated as a percentage of total nuclei counted. 
 
2.3 Htau mice  
Htau mice (Andorfer et al., 2003) were obtained from Jackson Laboratories (Bar Habor, Maine, 
US). These tau transgenic mice were generated by crossing 8c mice, which express the entire 
wild-type human tau gene under the control of the human MAPT promoter (Duff et al., 2000), 
with tau knockout mice that have a targeted disruption of exon 1 of tau caused by the 
introduction of eGFP (Tucker et al., 2001). Mice were then crossed onto a C57BL/6 background. 
Mice progressively develop tangle pathology and cognitive deficits with age (Andorfer et al., 
2003; Andorfer et al., 2005; Kelleher et al., 2007; Noble et al., 2009b; Polydoro et al., 2009). 
 
2.3.1 Genotyping and polymerase chain reaction (PCR) 
Materials 





1x Ten9 buffer 15 mM Tris-HCl, 35 mM Tris-base, 20 mM 
EDTA, 40 mM NaCl 
  
Proteinase K storage buffer 50 mM Tris-HCl, pH 8.0, 5 mM calcium 
chloride, 50 % (v/v) glycerol 
  
Digestion mix 1x Ten9 buffer, 1 % (w/v) SDS, 1 mg/ml 
proteinase K stored in storage buffer 
  
PCR 
Primer sequences (Eurogentec, Seraing, Belgium) 
Human MAPT gene forward (oIMR3115) 5′-ACTTTGAACCAGGATGGCTGAGCC-3′ 
 reverse (oIMR3116) 5′-CTGTGCATGGCTGTCCACTAACCTT-3′ 
Mouse Mapt gene forward (oIMR3092) 5′-CTCAGCATCCCACCTGTAAC-3′ 
 reverse (oIMR3093) 5′-CCAGTTGTGTATGTCCACCC-3′ 
Disrupted Mapt gene / 
Egfp 
forward (oIMR0872) 5′-AAGTTCATCTGCACCACCG-3′ 
reverse (oIMR1416) 5′-TCCTTGAAGAAGATGGTG CG-3′ 
 
 
PCR reaction mixture 5 % (v/v) extracted template DNA, 10 μM 
forward primer, 10 μM reverse primer, 50 % 
(v/v) REDExtract-N-Amp™ PCR Reaction Mix 
(containing buffer, salts, deoxynucleoside 
triphosphates (dNTPs), Taq 95 polymerase, 
REDTaq dye, and JumpStart Taq antibody), 35 
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1.5 % agarose gel 1.5 % (w/v) agarose, 40 mM Tris-base (pH 
7.6), 20 mM acetic acid, 1 mM EDTA, 0.67 
μg/ml ethydium bromide 
  
TAE buffer 40 mM Tris-base (pH 7.6), 20 mM acetic acid, 
1 mM EDTA 
  
100 bp DNA ladder Quick-Load® 100 bp DNA Ladder consisting of 
12 pre-stained bands with sizes 100 bp, 200 
bp, 300 bp, 400 bp, 500/517 bp, 600 bp, 700 
bp, 800 bp, 900 bp, 1000 bp, 1200 bp, 
1500/1517 bp when visualised with ethidium 
bromide on 1.5 % agarose gels (New England 




Once weaned, mice were ear punched for genotyping. 20 µl digestion mix was added to each 
sample and incubated for 20 min at 55 °C. Samples were removed from the water bath, vortexed 
and return for a further 20 min, after which 80 µl of nuclease-free H2O was added to each 
sample. Samples were incubated at 100 °C for 10 min to inactivate Proteinase-K and melt DNA 
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strands. 20 µl of each sample was collected and added to 60 µl nuclease-free H2O. Samples were 
used in PCR immediately or stored at -20 °C.  
Polymerase chain reaction (PCR) 
PCR was carried out to amplify DNA. Briefly forward and reverse primers (human tau, mouse 
tau, eGFP, Eurogentec, Seraing, Belgium) and 1 μL of extracted DNA was mixed with REDExtract-
N-AmpTM PCR ReadyMixTM in nuclease-free H2O to a final volume of 20 µl resulting in 3 primer 
solutions per sample. Samples were loaded into G-Storm PCR plates and set to run on in G-Storm 
PCR machines. 
The following PCR programme was used for all primer solutions: 
Initial denaturing at 94 °C for 5 min then 25 cycles of 94 °C for 30 sec (denaturation), 52 °C for 
30 min (annealing) and 72 °C for 1 min (extension), with 3 min at 72 °C for a final extension step. 
1.5 % agarose gels 
Agarose was added to Tris-acetate-EDTA (TAE) buffer to give a final concentration of 1.5 %. The 
solution was heated until the agarose dissolved. Once cool, 0.67 μg/ml ethidium bromide was 
added before gels were poured and set. Gels were loaded with PCR samples and 100 bp DNA 
ladder and placed in electrophoresis tanks filled with TAE buffer. Gels were run at 150 V for 30 
min. DNA was visualised immediately after running using a GelDoc-It® Imaging System and 
Visionworks (Ultra-Violet Products Ltd, Cambridge, UK). 
2.3.2 Treatment and testing of htau mice 
In this study two groups of homozygous htau mice were examined: (i) 8-9 months old, that 
display abnormal tau phosphorylation and the early tau aggregation, and (ii) 13-14 months old, 
in which a significant burden of insoluble tau is apparent. Once crossed onto a C57BL/6 
background mice were bred and reared in-house. Pups were weaned at 3 weeks of age. Mice 
had unlimited access to rodent chow (RM3, Special Diet Services, Essex, UK) and water. Mice 
were housed singly or in groups (miximum of 4 animals) at a constant temperature (21 °C) on a 





Dimethyl fumarate (DMF) solution 1.875 mg/ml DMF in vehicle solution of: 20 % 
(w/v) Splenda (Tate and Lyle, London, UK), 
0.08 % (w/v) methocel, 0.1 % (v/v) chocolate 
flavouring for taste (Cupcake World, 
Holmfirth, UK) made fresh daily. 
  




Morris water maze 
The Morris water maze is commonly used to evaluate spatial memory in rodents (Morris, 1984). 
Rodents learn the location of a visible platform in the maze using fixed visual cues in the 
experimental room. When the animal has found the platform it is rewarded by being removed 
from the water maze. Once the rodents have learnt the escape platform location the platform 
is submerged in cloudy water, making it invisible. The rodent’s spatial memory is then tested by 
measuring how long the animal takes to navigate to the submerged platform using the 





Htau mice were run in a Morris water maze with a 1.2 m diameter. Opacifer was added to make 
the water cloudy, obscuring the escape platform when necessary. Visual cues were placed 
around the maze to ensure an easily navigable environment. On day 1, the mice were allowed 
to associate the platform with escaping the maze and learn where the platform was relative to 
visual cues. For this learning period the escape platform was visible above the water. The maze 
was split into four quadrants: same quadrant as the platform, opposite the platform and to the 
left and right of the platform (Figure 2.1). Mice were gently placed into the water in one of the 
four quadrants and the timer was started. Mice were allowed to swim until they reached the 
escape platform or for 60 secs, whichever was quickest. Once on the platform the timer was 
stopped and the mouse was retrieved from the water, dried and returned to its cage. Each 
mouse swam with the platform visible for a total of four times: from each of the four quadrant 
Figure 2.1: Morris water maze 
The Morris water maze is divided into four quadrant according to their relation to the 




start points. The order of quadrants was randomised for each mouse. On days 2-5 mice were 
tested, swimming from each quadrant, with the platform submerged. 1 h after the final swim 
on day 5 a probe test was also carried out. For this test the escape platform is completely 
removed from the maze and the percentage of time spent swimming in each quadrant is 
recorded. Timing, swim speed and path length of each swim were recorded using EthoVision XT 
7 (Noldus, Wageningen, Netherlands). Spatial learning was analysed using a one-way ANOVA. 
 
Treatment of htau mice 
Mice were administered 15 mg/kg DMF in chocolate-flavoured vehicle solution via oral syringe 
twice daily (Schilling et al., 2006) for 18-20 days (Figure 2.2), vehicle mice were given the vehicle 
solution only. DMF was freshly prepared prior to each dosing. In the first group of mice an 
“untreated” group of mice were also included to control for possible stresses caused by the 
treatment. 4 h after the final treatment mice were sacrificed by cervical dislocation, at which 







Figure 2.2: Time course for DMF mouse treatments 
Two cohorts of htau mice were treated with DMF. The first cohort underwent treatment 1: 1 
day of training and 4 days of testing on the Morris water maze (MWM) pre-treatment. Mice 
were then treated twice daily with 15 mg/kg DMF. Training and testing of mice on the MWM 
was then repeated from day 21-25 while still being treated with DMF. Mice were culled at day 
26 and their brains were snap-frozen for biochemical analysis. Treatment 2: mice underwent 
twice daily treatment of 15 mg/kg DMF for 18 days. On day 18 mice were sacrificed four hours 
after final treatment and brains were snap-frozen in liquid nitrogen for biochemical analysis. 
 
 
2.4 Sample preparation and standardisatoin 
2.4.1 Sample preparation 
Materials 
Extra strong lysis buffer (XSLB) 10 mM tris-hydrochloride (HCl), pH 7.5, 75 
mM sodium chloride, 0.5 % (w/v) sodium 
dodecyl sulfate (SDS), 20 mM sodium 
deoxycholate, 1 % (v/v) Triton X-100, 1 mM 
sodium pyrophosphate, 2 mM sodium 
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orthovanadate, 1.25 mM sodium fluoride, 10 
mM Ethylenediaminetetraacetic acid (EDTA), 
Mini cOmplete protease inhibitor cocktail 
tablet (Roche Diagnostics, West Sussex, UK) 
  
Laemmli sample buffer (2x) (Laemmli, 1970) 125 mM Tris-HCl, pH 6.8, 4 % (w/v) SDS , 1 mM 
dithiothreitol (DTT), 20 % (v/v) glycerol, 0.01 % 
(w/v) bromophenol blue, Mini cOmplete 
protease inhibitor cocktail tablet 
 
  
Tau fractionation buffer 50 mM sodium phosphate, pH 7.0, 10 nM 
sodium pyrophosphate, 2 mM Ethylene glycol 
tetraacetic acid (EGTA), 2 mM EDTA, 20 mM 
sodium fluoride, 1 mM DTT, Phosphatase 
inhibitor cocktail 2, Mini cOmplete Protease 
inhibitor cocktail tablet, 2 mM sodium 
orthovanadate 
  
Homogenisation buffer 50 mM TBS, pH 7.4, 2 mM EGTA, 10 mM 
sodium fluoride, 1 mM sodium 
orthovanadate, cOmplete protease inhibitor 
cocktail 
  






Cells were washed once with PBS and lysed in extra strong lysis buffer (XSLB) before brief 
sonication (15 sec, 40 %) using a Vibra-Cell sonicator (Sonics & Materials, Newtown, CA, US) and 
centrifugation in a benchtop Spectrafuge 24D (Jencons-PLS, East Grinstead, West Sussex, UK; 
16,300 g(av) for 20 min at 4 °C). XLSB is a lysis buffer with high concentrations of detergent in 
order to ensure full breakdown of cell membranes. If necessary, the resulting supernatant was 
standardised for total protein and normalised samples were diluted 1:1 with 2x Laemmli buffer. 
Samples used for Alphascreen assays were lysed in tau fractionation buffer as the high levels of 
detergents in XSLB interfere with the Alphascreen assay. 
 
Concentrating tau from primary cell culture medium 
For use on the tau sandwich ELISA, cell culture medium as concentrated using a protocol 
previously published by this group (Pooler et al., 2013). 2 ml cell culture medium was collected 
from primary cultured neurons and spun at 4 °C at 16100 g(av) for 5 min. Supernatants were 
pipetted into filters of constructed centrifugal filter units (with a molecular weight cut off of 30 
kDa) and spun in a Sorvell Legend RT centrifuge with swinging bucket at 4 °C at 3000 g(av) for 
20 min. Once finished, the filtrate collection tube was removed and discarded, the rest of the 
unit was inverted and centrifuged again at 4 °C at 1000 g(av) for 5 min. The filter was removed 
and discarded. Concentrate was pipetted from collection tube to Eppendorfs, and the volume 
of concentrate was recorded. 2x Laemmli buffer was added to concentrate so concentrate to 





Human brain homogenisation  
London Neurodegenerative Disease Brain Bank, Brains for Dementia Research and the Medical 
Research Council provided all frozen human brain samples as frozen blocks (500 mg for cortical 
samples, 200 mg for hippocampal samples). For each individual one frozen block of temporal 
cortex was tested. Hippocampal samples (one 200 mg frozen block) were obtained from as many 
individuals providing cortical samples as possible however, due to the small volume of the 
hippocampus, it was not possible to obtain hippocampal samples for each individual. For full 
details of individuals samples refer to Chapter 5, section 5.2.  
Samples in pilot experiments (using only temporal control and Braak stages V/VI samples) were 
homogenised directly in 2x Laemmli buffer with 5 % (v/v) ß-mercaptoethanol with a Tissue 
Master-125 Omni International mechanical homogeniser (Kennesaw, GA, US), at 200 mg/ml. All 
other samples (temporal and hippocampal control and Braak stages I-VI) were homogenised in 
XSLB (Kurbatskaya et al., 2016). Whilst being kept on ice, all samples were sonicated for 15 sec 
using a Vibra-Cell sonicator and then centrifuged in an Eppendorf 5415 R benchtop centrifuge 
(Eppendorf UK Limited, Stevenage, UK) at 16300 g(av) for 20 min at 4 °C. Supernatants were 
collected and, if not already, mixed 1:1 with 2x Laemmli buffer with 5 % (v/v) ß-
mercaptoethanol. Samples were run on western blots to standardise for neuron-specific enolase 
(NSE) levels. Based on the amounts of NSE detected, samples were standardised to give equal 
NSE content using 2x Laemmli buffer. Aliquots were stored at -80 °C until used for western 
blotting. 
 
Mouse brain homogenisation 
Cortical sections 
Frozen cortical sections of htau mouse brain were homogenised in XSLB using a Tissue Master-
125 Omni International mechanical homogenised with a final concentration of 100 mg/ml. 
Whilst being kept on ice, all samples were sonicated for 15 sec using a Vibra-Cell sonicator and 
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then centrifuged in an Eppendorf 5415 R benchtop centrifuge at 16300 g(av) for 20 min at 4 °C. 
Supernatants were collected and mixed 1:1 with 2x Laemmli buffer. Samples were run on 
western blots to standardise for ß-actin levels. Based on the amounts of ß-actin detected, 
samples were standardised to give equal ß-actin content using 2x Laemmli buffer. Aliquots were 
stored at -20 °C until used for western blotting. 
Hippocampal sections (Sarkosyl extraction preparation) 
Sarkosyl extraction preparation is a method of extracting insoluble and soluble tau from brain 
homogenates or cell lysates using sarkosyl as a detergent to separate insoluble tau from soluble 
tau. Since the initial publication of the method, sarkosyl-insoluble tau has been considered a 
good approximation to aggregated tau, while sarkosyl-soluble tau is thought to consist of soluble 
tau monomers and oligomers (Greenberg and Davies, 1990; Julien et al., 2012).  
For sarkosyl extraction, frozen mouse hippocampal sections were homogenised in fresh 
homogenisation buffer using a Tissue Master-125 Omni International mechanical homogeniser 
with a final concentration of 100 mg/ml. Samples were centrifuged in a desktop centrifuge 
(Spectrafuge 24D, Jencons-PLS) at 16,300 g(av) for 20 min at 4 °C. Supernatant (low speed 
supernatant, LSS) was collected and an aliquot was frozen at -20 °C for total brain western blots. 
This fraction is the total brain homogenate fraction. Pellets are stored at -20 °C. Sodium lauroyl 
sarcosinate (sarkosyl) was added to the rest of the supernatant resulting in a final sarkosyl 
concentration of 1 %. Samples are incubated at ambient temperature for 30 min with shaking 
before centrifuging at 100,000 g(av) for 1 h at ambient temperature using a Beckman 
Ultracentrifuge with a TLA 55 rotor. High speed supernatant (HSS) was collected at stored at -20 
°C, this is the sarkosyl-soluble tau fraction. The remaining pellet was washed with 1 % sarkosyl 
by centrifuging at 100,000 g(av) for 10 min, then resuspended in 2x Laemmli buffer with 5 % 
(v/v) ß-merceptoethanol. This is the sarkosyl insoluble tau fraction and was stored at -20 °C. For 





2.4.2 Protein standardisation 
Two protein standardisation assays were used in this thesis. The first, the bicinchoninic acid 
(BCA) assay was used for all experiments (all experiments except Alphascreen assays) carried 
out at King’s College London. However, the Bradford assay was used to standardise protein for 
Alphascreen experiments carried out at Eli-Lilly UK, as this was the standard total protein assay 
used in this laboratory. 
 
Bicinchoninic acid (BCA) assay (Smith et al., 1985) 
Materials 
BSA 2 mg/ml BSA (Thermo Fisher Scientific) 
 
BCA protein assay BCA Reagent A (Thermo Fisher Scientific) 
BCA Reagent B (Thermo Fisher Scientific) 
 
Methods 
2 mg/ml BSA was diluted with XSLB to create a set of protein standards ranging in concentration 
from 0 mg/ml to 2 mg/ml. Protein standards were made fresh for each assay. Equal volumes of 
samples and protein standards were added to a 96-well plate in duplicate and BCA assay 
reagents were added according to the manufacturer’s instructions. Samples were incubated in 
the dark at 37 °C for 30 min before the plate was read at 550 nm using a Wallac 1420 Victor3™ 
plate reader. A standard curve was determined and the sample readings were compared to this 
to determine sample concentrations in µg/ml. Samples were diluted as appropriate using XSLB 






BSA 2 mg/ml BSA 
  
Coomassie Plus  Coomassie Plue protein assay reagent 
(Thermo Fisher Scientific) 
 
Methods 
Medium samples used in Alphascreen assays were standardised to the total protein 
concentration of their equivalent cell lysates. Total protein concentration was determined using 
a Bradford assay (Bradford, 1976). 2 mg/ml BSA was diluted in tau fractionation buffer according 
to the manufacturer’s instructions to create a set of standards of known protein concentration 
ranging from 0 mg/ml to 2 mg/ml. Cell lysates were diluted 1:1 with tau fractionation buffer. 
Samples and protein standards were added to a 96-well plate in duplicate. 300 µl coomassie plus 
reagent was added to each well. The colour reaction was read at 595 nm immediately using a 
Molecular Devices Precision Microplate Reader. A standard curve was determined and the 
sample readings were compared to this to determine sample concentrations in µg/ml. Samples 
were diluted as appropriate using tau fractionation buffer to normalise protein concentrations. 
 
2.5 Immunostaining 
2.5.1 Immunocytochemistry (ICC) of primary rat cultures 
Materials 




Permeabilisation solution 0.1 % (v/v) Triton X-100 in PBS 
  
Blocking solution 3 % (w/v) BSA in PBS with 0.05 % (v/v) Tween 
20 
  
Hoechst 33342 5 µg/ml Bisbenzimide H33342 
trihydrochloride in PBS 
 
Antibodies 
Immunocytochemistry (ICC) antibodies were blocked with 3 % BSA with 0.05 % Tween-20. 
Primary antibodies were incubated for 2 h. Secondary antibodies were incubated for 1 h. 
 
 
Table 2.4: Primary antibodies used in ICC 
Antibody name, species, reactivity, dilution and source shown. 
 
 
Antibody Species Dilution Source 
Anti-mouse Alexa-Fluor 568  Goat 1:1000 Invitrogen 
Anti-rabbit Alexa-Fluor 488  Goat 1:1000 Invitrogen 
 
Table 2.5: Secondary antibodies used in ICC 
Antibody reactivity, species, dilution and source shown. 
 
Antibody Species Epitope Dilution Source 
GFAP Rabbit polyclonal 
Glial fibrillary acidic 
protein 
1:1000 Dako (Ely, UK) 
MAP2 Rabbit polyclonal 
Microtubule-
















Residues 120-239 on 








ICC was carried out according to the protocol published in Garwood et al. (2011). Cells grown on 
coverslips were washed in PBS, fixed with 4 % PFA (10 min, ambient temperature) and 
permeabilised with permeabilisation solution (3 min, ambient temperature). Blocking solution 
was used to block non-specific binding for 30 min at ambient temperature. Cultures were 
incubated, in the dark, with primary antibodies in blocking solution for 2 h at ambient 
temperature (for antibody list, see Table 2.4). The primary antibodies were removed and the 
cells were washed and fluorophore conjugated secondary antibodies diluted blocking solution 
added (see Table 2.5; 1 h, ambient temperature, in the dark). After washing, DNA in cell nuclei 
was stained with Hoescht-33342 dye (5 µg/ml, 2 mins, ambient temperature, dark) before being 
washed and mounted onto microscope slides using fluorescent mounting medium (Dako). Cells 
were visualised, and images taken, using a Leica DM5000 B fluorescence microscope (Leica 
Miscrosystems CMS, Mannheim, Germany). 
 
2.5.2 Immunohistochemical (IHC) staining of human post-mortem brain sections 
Materials 
BOND Polymer Detection 3,3’-
diaminobenzidine (DAB) kit 
All reagents supplied complete by 
manufacturer, except the following: 
  
Formic acid 80 % (v/v) formic acid 
  
Hydrogen peroxidase 3 % (v/v) hydrogen peroxidase 
 
Methods 
As previously published (Kurbatskaya et al., 2016) staining of human post-mortem brain samples 
was carried out as follows: 7 µm tissue sections were cut from formalin-fixed, paraffin-
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embedded post-mortem human brain samples. Sections were stained using a BOND-MAX 
autostainer (Leica) and BOND Polymer Detection (DAB) kits.  
For tau staining, sections were incubated with BOND Epitope Retrieval Solution 1 for 20 mins for 
heat induced epitope retrieval to improve antigen binding. Sections were deparaffinised and 
endogenous peroxidase activity inhibited by a 30 min sample incubation in hydrogen 
peroxidase. Sections were incubated overnight with a total tau antibody (AT8, Thermo Scientific; 
dilution factor 1:500) at 4 °C. Sections were incubated with the linking post-primary antibody 
and then the polymeric HRP-secondary antibody conjugates, according to the manufacturer’s 
instructions. The antibody complex was visualised with DAB. 
For Aß staining, sections were pre-treated with 80 % formic acid for 1 h. Sections were 
deparaffinised and endogenous peroxidase activity inhibited by a 30 min sample incubation in 
hydrogen peroxidase. Sections were incubated overnight with a Aß antibody (ß-A4; Covance; 
dilution factor 1:6000) at 4 °C. Sections were incubated with the linking post-primary antibody 
and then the polymeric HRP-secondary antibody conjugates, according to the manufacturer’s 
instructions. The antibody complex was visualised with DAB. 
All samples were counterstained with hematoxylin and eosin (H&E). 
 
2.6 Western blotting 
2.6.1 Materials 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Gels for SDS-PAGE were prepared using stock solutions purchased from National Diagnostics 





10 % Resolving gel, pH 8.8 10 % (v/v) acrylamide, 25 % (v/v) resolving 
buffer, 0.01 % (w/v) ammonium persulphate 
(APS), 0.1 % (v/v) N,N,N’,N’ 
tetramethylethylenediamine (TEMED)  
  
12 % Resolving gel, pH 8.8 12 % (v/v) acrylamide, 25 % (v/v) resolving 
buffer, 0.01 % (w/v) APS, 0.1 % (v/v) TEMED 
  
4 % Stacking gel, pH 6.8 4 % (v/v) acrylamide, 25 % (v/v) stacking buffer 
0.075 % (w/v) APS, 0.1 % (v/v) TEMED 
  
Running buffer 25 mM Tris (Fisher Scientific, Fairlawn, NJ), 192 
mM glycine (Fisher Scientific), 1 % (w/v) SDS 
  
Protein molecular weight marker Precision Plus Protein™ All Blue Prestained 
Protein Standards (BioRad Laboratories, 
Hercules, CA) 
Tris-tricine gels 
Tris-HCl/SDS, pH 8.45 3 M Tris-HCl, pH 8.45 with 0.3 % (w/v) SDS 
  
16 % Resolving gel 990 mM Tris-HCl/SDS, pH 8.45, 16 % (v/v) 
acrylamide, 10 % (v/v) glycerol, 0.025 % (w/v) 




10 % Spacing gel 990 mM Tris-HCl/SDS, pH 8.45, 10 % (v/v) 
acrylamide, 10 % (v/v) glycerol, 0.025 % (w/v) 
APS, 0.05 % (v/v) TEMED 
  
4 % Stacking gel 750 mM Tris-HCl/SDS, pH 8.45, 4 % (w/v) 
acrylamide, 0.1 % (w/v) APS, 0.025 % (v/v) 
TEMED 
  
Cathode buffer, pH 8.25 100 mM Tris-base, pH 8.2, 100 mM tricine, 1 
% (w/v) SDS 
  




Transfer buffer 25 mM Tris-base, 192 mM glycine, 20 % (v/v) 
methanol in ultrapure H20 
  
Washing buffer TBS containing 0.05 % (v/v) Tween-20 (TBS-T) 
  
Blocking solutions 5 % (w/v) non-fat skimmed milk powder in 
TBS-T 
Odyssey block buffer (Li-Cor Biosciences, 





Native PAGE gels and western blots 
All reagents were diluted in ultrapure H2O unless otherwise stated. 
 
Tris-borate EDTA (TBE), pH 8.3 90 mM Tris, 90 mM boric acid, 2 mM EDTA, 
pH 8.0 
  
4 % Non-denaturing resolving gel 1 % (v/v) TBE, 4 % (w/v) acrylamide, 0.05 % 
(w/v) APS, 0.06 % (v/v) TEMED 
  
22 % Non-denaturing resolving gel 1 % (v/v) TBE, 22 % (w/v) acrylamide, 0.05 % 
(w/v) APS, 0.06 % (v/v) TEMED 
  
4 % Non-denaturing stacking gel 1 % (v/v) TBE, 4 % (w/v) acrylamide, 0.05 % 
(w/v) APS, 0.1 % (v/v) TEMED 
  
4x Loading buffer 60 % (w/v) sucrose, 0.1 % (w/v) bromophenol 
blue 
  
Protein molecular weight marker NativeMark molecular weight marker 
(Invitrogen) 
  
Ponceau S solution 0.1 % (w/v) ponceau S, 5 % (v/v) acetic acid 
  





Blocking buffer 7 % (w/v) non-fat powdered milk in TW buffer 
 
Enhanced chemiluminesence (ECL) 
ECL detection solution Pierce ECL Detection Reagent A (Thermo 
Fisher Scientific) and Pierce ECL Detection 
Reagent B (Thermo Fisher Scientific) mixed 





Antibodies were blocked with 5 % non-fat skimmed milk in TBS-T, unless otherwise stated. 
Primary antibodies were incubated overnight. Secondary antibodies were incubated for 1 h. 
 












Residues 1-5 on ß-
amyloid 






























serine residue 202 
1:400 














Table 2.6: Primary antibodies used in western blotting 




GFAP Rabbit polyclonal 



















Serine 32 region on 
IκBα 
1:1000 Abcam 





Nrf2 (Ser40) Rabbit polyclonal 
Nrf2: phosphorylated 





























1:2000 P. Davies 
















Synapsin-1 1:1000 Merck Millipore 









1:5000 Merck Millipore 
Total tau Rabbit polyclonal 
Tau: residues 243-441 
on C-terminus 
1:10000 Dako 
TP007 Rabbit polyclonal 
Amino acids 1-16 of 
tau (N-terminus) 
1:2000 Made in house 
TP70 Rabbit polyclonal 
Amino acids 428-441 
of tau (C-terminus) 
1:1000 Made in house 
Vimentin Rabbit polyclonal 
Epitopes surrounding 







Antibody Species Dilution Source 
Anti-mouse Alexa 
Fluor 680  










Goat 1:2000 GE Healthcare 
Anti-rabbit IRDye800  Goat 1:5000 Invitrogen 
 
Table 2.7: Secondary antibodies used in western blotting 
Antibody reactivity, species, dilution and source shown. Antibodies were compatible with Li-Cor 




All gels run were 10 % tris-tricine gels unless otherwise stated. Likewise, all western blots were 
developed using the Odyssey Imaging System unless stated otherwise. 
Tris-glycine gels 
Samples were loaded into 12 % or 10 % (w/v) tris-glycine resolving gels with 4 % (w/v) tris-glycine 
stacking gel and a protein ladder. Proteins were electrophoresed at 150 V for 80 min in tris-
glycine running buffer using BioRad Mini-PROTEAN® Tetra Cell Systems (83 mm x 73 mm gels; 
BioRad Laboratories). Proteins were transferred onto 0.45 µm nitrocellulose membrane 
(Whatman, Maidstone, UK) using a Mini Trans-Blot® Cell (BioRad Laboratories) wet transfer 
system at 100 V for 60 min in transfer buffer.  
Tris-tricine gels 
Samples were loaded onto 16 % (w/v) tris-tricine resolving gels (83 mm x 73 mm gels) with a 1 
cm 10 % (w/v) tris-tricine spacer gel and 4 % (w/v) tris-tricine stacking gel and a protein ladder. 
Proteins were electrophoresed at 80 V for 15 min, or until samples had passed through the 
stacking gel. Electrophoresis then continued at 100 V for 6 h. Electrophoresis was carried out 
using BioRad Mini-PROTEAN® Tetra Cell Systems. Proteins were transferred onto 0.2 µm 
nitrocellulose membrane using a Mini Trans-Blot® Cell (BioRad Laboratories) wet transfer 
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system at 13 V overnight (17 h) in transfer buffer. Membranes were incubated in 10 % acetic 
acid for 30 min then washed three times. 
For all membranes (except native PAGE): 
Non-specific binding was blocked by incubating membranes in blocking solution (5 % non-fat 
milk unless otherwise stated) for 1 h at ambient temperature. Membranes were then incubated 
in primary antibodies in blocking solution overnight at 4 °C with rocking (for antibody list see 
Table 2.6). After washing three times for 10 mins with TBS-T, membranes were incubated in 
secondary antibodies in blocking solution (1 h, ambient temperature, with rocking. For 
antibodies see Table 2.7). Membranes were washed three times for 10 min before visualisation 
and quantification with the Odyssey Clx Imaging System and Licor Image Studio Lite software, 
or enhanced chemiluminescence (ECL).   
ECL 
Nitrocellulose membranes incubated with HRP-conjugated antibodies were washed three times 
for 10 min and incubated in ECL detection solution (Pierce™, Thermo Scientific) according to the 
manufacturer’s instructions. Membranes were secured in a plastic wallet inside a film cassette. 
In the dark room, Amersham Hyperfilm (GE Healthcare) is exposed to the membrane in the 
cassette and then developed using a Konica Minolta SRX-101A film processor (Konica Minolta 
UK Ltd., Basildon, Essex, UK). 
Native PAGE gels 
Non-denaturing 4 % - 22 % (w/v) gradient resolving gels were cast using a two-chamber gradient 
maker and peristaltic pump system and topped with 4 % (w/v) non-denaturing stacking gel. Gels 
were pre-run at 125 V for 30 min. Samples were prepared by mixing 1:3 with 4x loading buffer 
and loaded into the gels with a NativeMark protein ladder (Thermo Scientific). Gels were 
electrophoresed according to the following steps in tris/borate EDTA (TBE) buffer, at 4 °C: 
1. 25 V for 15 min 
2. 50 V for 15 min 
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3. 60 V for 24 h 
Proteins were transferred onto 0.45 µm nitrocellulose membrane using a wet transfer system 
at 25 V for 45 min at 4 °C in transfer buffer. Prior to blocking, membranes were incubated in 
Ponceau S solution for 15 min at ambient temperature. Membranes were destained to check 
for efficient transfer and to highlight protein markers. Membranes were blocked in blocking 
buffer overnight at 4 °C with shaking. The following day, membranes were incubated in primary 
antibody in blocking buffer for 2 h at ambient temperature with shaking (for primary antibody 
list see Table 2.6). Membranes were washed three times with TW buffer before 1 h incubation 
with HRP-linked secondary antibody in blocking buffer (for secondary antibody list see Table 
2.7). Again, membranes were washed three times with TW buffer. Membranes were incubated 
in SuperSignal® West Dura Extended Duration Substrate (Thermo Scientific) for 5 min and 




2.7.1 Standard tau ELISA 
Materials 
Blocking buffer 5 % (w/v) non-fat milk in PBS  
  
TMB substrate solution  Tetramethylbenzidine (TMB)-ultra reagent 
(Thermo Scientific) 
  





Standard tau ELISA antibodies were blocked in 5 % non-fat skimmed milk in PBS. Primary 
antibodies were incubated overnight. Secondary antibodies were incubated for 2 h. 
Tau sandiwch ELISA capture antibody was incubated for 8 days and blocked with 50 % 
StartingBlock in TBS. The primary antibody was incubated overnight and blocked with 50 % 
SuperBlock in TBS. The secondary antibody was incubated for 1 h in 5 % non-fat skimmed milk 
in TBS. 
 


























Total tau Rabbit 
polyclonal 
Tau: residues 243-
441 on C-terminus 
1:40000 Dako 
 
Table 2.8: Primary antibodies used in standard tau ELISA 
Antibody name, species, reactivity, dilution and source shown. 
 








Goat 1:500 GE Healthcare 
 
Table 2.9: Secondary antibodies used in standard tau ELISA 





A standard tau ELISA measuring levels of intracellular total and phosphorylatd tau has been 
developed in house (unpublished).  
Samples were diluted to 30 µg/ml in PBS and added to Nunc Maxisorp 96-well plates in 
duplicate. XSLB diluted in PBS was used as a blank. Samples were allowed to dry onto plates 
overnight at 37 °C in a non-humidified incubator. Non-specific binding was blocked using 
blocking buffer for 1 h at ambient temperature. Primary antibodies were diluted in blocking 
buffer, added to the plates and incubated overnight at 4 °C with shaking (Table 2.8). Plates were 
washed five times with PBS-T. Secondary antibodies were diluted in blocking buffer, added to 
the plates and incubated for 2 h at ambient temperature with shaking (Table 2.9). Plates were 
washing five times with PBS-T. 3,3’,5,5’,-tetramethylbenzidine (TMB) substrate solution was 
added and incubated at ambient temperature for 1-5 minutes or until a medium strength blue 
colour was observed. The reaction was stopped with stopping solution and the plate was read 
immediately at 450 nm using a Wallac 1420 Victor3™ plate reader. 
 
2.7.2 Tau sandwich ELISA 
Materials 
ELISA coating buffer, pH 7.2 15.6 mM K2HPO4, 25.6 mM KH2PO4, 136.9 
mM NaCl, 1.3 mM EDTA, 7.7 mM NaN3 in 
ultrapure H2O 
  
ELISA wash buffer 50 mM TBS containing 0.05 % (v/v) Tween-20 
  
Block buffer 50 % (v/v) StartingBlock™ blocking buffer 




Primary antibody block buffer 20 % (v/v) SuperBlock™ blocking buffer 
(Thermo Fisher Scientific) in 50 mM TBS 
  
Secondary antibody block buffer 5 % (w/v) skimmed milk powder in 50 mM TBS 
  
TMB substrate solution TMB-ultra reagent 
  
Stopping solution 1 M HCl 
 
Antibodies 































Table 2.10: Antibodies used in tau sandwich ELISA 
Use of antibody in ELISA, antibody name, species, reactivity, dilution and source shown. 
 
Methods 
A sandwich ELISA for the detection of low concentrations of extracellular total tau has been 
developed in house (unpublished). 
The capture antibody was diluted in ELISA coating buffer and added to the required number of 
wells of a 96-well Nunc Maxi-Sorp plate (Table 2.10). The plate was sealed and incubated at 4 
°C with shaking for 8 days to allow the antibody to adsorb to the plastic. Plates were washed 
three times with ELISA wash buffer to remove any unadsorbed capture antibody before 
incubation with block buffer for 4 h at ambient temperature with shaking to block any non-
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specific binding. After 4 h, block buffer was removed and the plate was washed a further three 
times with wash buffer.  
To collect samples of medium containing extracellular tau, Neurobasal medium was removed 
from 14 DIV primary cell cultures and replaced with HBSS. Cultures were incubated for 4 h in 
normal conditions. After 4 h, HBSS was collected and centrifuged for 5 min at 7200 g(av) at 4 °C 
to remove cell debris before being added, undiluted, to the ELISA plate in triplicate. Samples 
were incubated at 37 °C, sealed without rocking, overnight. Blank HBSS was used as a negative 
control. 
Samples were removed and the plate was washed three times with wash buffer. Primary 
antibody was diluted in primary antibody blocking solution and added to the plate (Table 2.10). 
The plate incubated overnight at ambient temperature on a rocker. The primary antibody was 
removed and the plate was washed three times with wash buffer. Secondary antibody was 
diluted in secondary antibody blocking buffer and added to the plate for incubation at ambient 
temperature on a rocker for 1 h (Table 2.10). The plate was washed five times with wash buffer. 
TMB substrate solution was added to the plate and incubated to allow the solution to react with 
the secondary antibody. The solution was stopped using stopping solution when a mid-blue 




Amplified luminescent proximity homogenous assay (Alpha) screen is a bead-based assay used 
to investigate molecular interactions, particularly post-translational modifications of proteins, 
in microplates (Peppard et al., 2003). The technique is based on acceptor and donor beads 
binding to the protein of interest via two antibodies, the first conjugated to the acceptor bead, 
the second biotinylated. Once the acceptor bead and the biotinylated antibody have been 
incubated with the sample, streptavidin-coated donor beads are added. Streptavidin and biotin 
bind, strongly associating the donor bead with the biotinylated antibody. Donor beads contain 
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phthalocyanine, a photosensitiser, which converts oxygen to reactive ‘singlet oxygen’ when 
exposed to 680 nm light. Singlet oxygen is not a radical but contains one excited electron and 
has a half-life of 4 µsec allowing it to diffuse up to 200 nm in solution. If an acceptor bead is 
within range, and therefore bound to the same protein, energy from the singlet oxygen transfers 
the acceptor bead resulting in the emission of light at 520-620 nm, this can then be detected by 
a plate reader (Figure 2.3). If there are no acceptor beads within range, oxygen singlets fall back 
to their original state without producing a signal. By using a total protein antibody alongside a 
phospho-specific antibody, Alphascreens can be used to investigate levels and changes in levels 
of protein phosphorylation under different treatment conditions. 
 
 
Figure 2.3: Alphascreen assay principle 
Tau is bound by an anti-tau-conjugated Alphascreen acceptor bead and biotinylated DA9 (total 
tau antibody). When streptavidin-coated Alpha donor beads are added they bind strongly to 
biotinylated DA9. Excitation of a photosensitiser in the donor beads by 680 nm light converts 
oxygen into singlet oxygen that can transfer to donor beads also bound to the same tau protein 
and result in light emission at 615 nm. This light emission can be detected on a plate reader and 






Casein buffer 0.1 % casein (from bovine milk) in Dulbecco’s-
PBS without Ca2+ or Mg2+, pH 7.4 (Invitrogen) 
  
Acceptor beads Unconjugated Alphascreen acceptor beads 
(Perkin Elmer, Waltham, MA, US) 
  
Donor beads Alphascreen streptavidin coated donor beads, 
5mg/ml (Perkin Elmer) 
  
Edge buffer 1.25 µg/ml D-streptavidin, 1.1 mg/ml 
biotinylated-antibody, 20 µg/ml acceptor 
beads, 10 µg/ml P301S brain homogenate 
 
 
Standard Starting dilution End dilution 
P301S mouse brain 
homogenate 
1:3 1:4374528 




Table 2.11: Protein standards used in Alphascreen assays 
Standard species, starting dilution and end dilution shown. Mouse brain homogenates were 
homogenised and sonicated in tau fractionation buffer, then centrifuged at 13,000 rpm to 


































0.0245 P. Davies 
 
Table 2.12: Primary antibodies used in Alphascreen assay 
Antibody name, species, reactivity, source and the concentration of biotinylated DA9 for 
required for optimal reactivity. 
 
Methods 
Alphascreen medium concentration 
Medium from rat primary cultured neurons was concentrated using Centriprep 10K Centrifugal 
Filter Devices (Millipore). 1 ml medium from 3 wells of a 6 well plate (total 3 ml medium) was 
pooled into the sample containers of the centrifugal devices. Filters were reassembled and spun 
at 3000 g(av) for 15 min at ambient temperature in a Sigma 4-16K centrifuge with swinging 
bucket. Filtrate was decanted and discarded and filters were spun again at 3000 g(av) for 10 min 
at ambient temperature. Filtrate was discarded and the concentrated sample was collected and 
used for Alphascreen assays. This method resulted in samples approximately six times as 
concentrated as the original medium samples (approximately 500 µl volume). 
Alphascreen protocol 
Conjugated anti-phospho-tau antibody acceptor beads were diluted to 40 µg/ml (for antibody 
information see Table 2.12) and added to the 384-well assay plates. Biotinylated DA9 was also 
added to the plates at a concentration optimised for efficient interaction with each conjugated 
acceptor bead (Table 2.12). Assay plates were stored at 4 °C. Samples were added to 96-well 





















































































































































































































































































































































made. Samples and protein standards (Table 2.11) were transferred to each 384-well plate in 
duplicate (for example plate plan see Figure 2.4). Plates were sealed and stored overnight at 4 
°C. On day 2, streptavidin-coated donor beads were added to each well in a dim room. Edge 
buffer was added to the outer wells and plates were incubated in the dark at RT for 3 h with 
shaking. Plates were read using an EnVision 2103 Multilabel Reader (Perkin Elmer) and analysed 
using Microsoft Excel. 
 
2.8 Statistical analysis 
2.8.1 Protein analysis and cell death assays 
All data were assessed using the D’Agostino-Pearson omnibus normality test (Graphpad Prism 
6.0 Software) to test whether treatment groups showed a normal distribution. If this test was 
passed, all data from western blots, LIVE/DEAD assays (except experiments comparing 
hippocampal and cortical primary cultures) were analysed using a one-way analysis of variance 
(ANOVA) (Graphpad Prism 6.0 Software) with Tukey’s post-hoc analysis. Experiments comparing 
hippocampal and cortical primary cultures were analysed using a two-way ANOVA (Graphpad 
Prism 6.0 Software) as there were two independent variable categories (factors), the presence 
of astrocytes and cell treatment, influencing the results. 
One-way ANOVA compares the variability of the mean value within a group (within-group 
variation) to the mean differences of value between separate groups (between-group variation) 
(Brace, 2012). The null hypothesis for a one-way ANOVA is that there is no difference between 
the mean outcome between group and within groups. If there is a difference in the mean 
outcomes the variation between groups is larger than the variation within groups. If the 
difference is wide enough statistical significance may be achieved (Kirkwood, 2003). 
Tukey’s test is a single-step multiple comparison procedure that is used to determine which 
group means are significantly different from each other. The test is run after a one-way ANOVA 
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returns statistical significance and compares all groups to each other simultaneously. 
Differences were considered statistically significant when p<0.05. 
If data did not pass the D’Agostino-Pearson omnibus normality test, or the n number was too 
small to carry out the test, a non-parametric Kruskal-Wallis test was used in place of one-way 
ANOVA, followed by Dunn’s multiple comparisons test. This test assesses the differences 
between three or more groups by ranking all data and comparing the differences in the sum of 
the ranks from each group to a pre-determined critical chi-squared value. The null hypothesis 
for Kruskal-Wallis is that there is no difference between each group’s rank sum. If the calculated 
value is more than the chosen critical chi-squared value, then differences can be considered 
statistically significant. Differences were considered statistically significant when the calculated 
value was greater than the critical chi-squared value equivalent to p<0.05.  
Dunn’s multiple comparisons test compares the differences in the sum of the ranks of two 
groups to an expected average. This test can be carried out for all groups simultaneously or for 
specific groups of interest. The expected average is calculated based on the number of groups 
and group size. Differences were considered statistically significant when p<0.05. 
 
Two-way ANOVA is an extension of one-way ANOVA. The test still compares within-group 
variation and between-group variation for each independent variable with the null hypothesis 
being the between-groups variation is not larger than the within-group variation. If the between-
groups variation is larger, multiple comparison post-hoc tests can be carried out to investigate 
which groups differ. However, the primary aim of a two-way ANOVA is to understand if there is 
an interaction between the effects of the two independent factors on the outcome. The null 
hypothesis for a two-way ANOVA is that there is no interaction between the two factors and the 
effects of the factors are completely independent of each other. If there is an interaction 
between the two factors this means the effect of one of the factors is different for different 
groups in your second independent variable (for example, if astrocytes improved neuron health 
for minocycline treated cells but not for Aß treated cells) and statistical significance may be 
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achieved. Multiple comparison post-hoc tests were used to determine the nature of the 
interaction. Differences were considered significant when p<0.05. 
 
2.8.2 Analysis of Alphascreen and MSD data 
Using the nonlinear regression function in GraphPad Prism 6.0, a log of the protein standard 
data from Alphascreen and MSD experiments was carried out to produce a sigmoidal curve in 
order to fit the wide data range on one standard curve. The logged concentration of each 
experimental data point was then read from the curve, before being unlogged to give the 
concentration of the sample in pg/ml for MSD assays, or an arbitrary value for Alphascreens. 
MSD assay results were then averaged and plotted as a bar chart to show the concentrations of 
Aß species. Alphascreen data was subsequently analysed using a two-way ANOVA, as described 
earlier. 
 
2.8.3 Behavioural analysis of htau mice 
Differences in the mouse performance on the Morris water maze were examined using one-way 
ANOVA with Tukey’s post-hoc test or Kruskal-Wallis test, depending on data passing the 
D’Agostino-Pearson omnibus normality test, for the first DMF trial. The second DMF trial only 
used two groups of mice: vehicle-treated and DMF-treated so Student’s unpaired t-test was 
used to assess differences between the two groups. The null hypothesis for an unpaired t-test 
would be that the population mean of two independent groups with an approximately normal 





Chapter 3: Investigating regional differences in Aß-induced 
effects of astrocytes in primary neuron cultures  
3.1 Introduction  
As discussed in Chapter 1:, there is a wealth of evidence demonstrating important roles of 
astrocytes in both physiological and pathological brain function (Volterra and Meldolesi, 2005; 
Sofroniew and Vinters, 2010; Garwood et al., 2011; Navarrete et al., 2013; Zuchero and Barres, 
2015; Hu et al., 2016), including in the development of tau pathology and synaptic dysfunction 
in AD (McGeer and McGeer, 2003; Heneka et al., 2010; Vincent et al., 2010; Liu et al., 2014; 
Phillips et al., 2014; De Strooper and Karran, 2016).  
Most recent updates of the amyloid cascade hypothesis have suggested glial activation and an 
immune response may bridge the gap between Aß plaques and the development of tau NFTs 
(Selkoe and Hardy, 2016). Our laboratory has previously shown that in mixed neuron and 
astrocytic primary cortical cultures, astrocytes accelerate Aß-induced cell death and tau 
phosphorylation (Garwood et al., 2011). These events were accompanied by an increased 
release of pro-inflammatory mediators from astrocytes and could be rescued by treatment with 
minocycline, a tetracycline with anti-inflammatory action (Noble et al., 2009b; Garwood et al., 
2011). These findings suggested that soluble factors released by astrocytes into the culture 
medium are responsible for downstream effects on tau and neuron health. Several other cell 
culture studies have indicated the important role of astrocytes in mediating the neurotoxic 
effects of Aß. For example, increasing the levels of astrocyte-released growth factors, such as 
insulin-like growth factor 1, as opposed to pro-inflammatory signalling factors, was 
demonstrated to attenuate Aß toxicity (Zhou and Klein, 2012). Furthermore, astrocytes have 
been found to phagocytose Aß actively removing the toxic peptide (Eugenin et al., 2016).  
There is a vast body of evidence linking individual cytokines with tau abnormalities and the 
development of other AD-related pathology (Curran and O'Connor, 2001; Thornton et al., 2006; 
Bhaskar et al., 2010; Ashutosh et al., 2011; Ghosh et al., 2013; Tan et al., 2014; Chakrabarty et 




and redundancy (Anisman, 2009). There are some points of convergence, however, including 
the inflammatory pathways initiated by the transcription factor NF-κB (Granic et al., 2009; Shi 
et al., 2016). NF-κB activation as shown in Figure 3.1 (Lawrence, 2009). Once in the nucleus NF-
κB is transcriptionally active and upregulates the production of multiple pro-inflammatory 
cytokines, resulting in their release into the extracellular space and activation of multiple 
inflammatory pathways in both other glial cells and neurons (Lawrence, 2009). Aß and other 
pro-inflammatory signals, such as oxidative stress or pro-inflammatory cytokines, are thought 
to activate NF-κB via TLRs and other cell surface receptors (Murgas et al., 2012; Lin et al., 2013). 
Treatment of cultured glia and neurons with pathological, but not physiological, levels of Aß 
induces NF-κB activation (Chami et al., 2012). Oxidative stress-induced neurotoxicity, including 
that caused by high concentrations of Aß, is also mediated by NF-κB-controlled transcriptional 
upregulation of pro-inflammatory mediators (Jia and Misra, 2007). Finally, some pro-
Figure 3.1: NF-κB is activated by IκBα 
NF-Κb activation occurs via IκBα, a cytoplasmic protein that inhibits NF-κB activity. 
Phosphorylation of IκBα by TLR-mediated kinases releases NF-κB allowing it to translocate to 
the nucleus, while IκBα is ubiquitinated and degraded. Adapted from Lawrence (2009). 
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inflammatory mediators can feedback to further upregulate pro-inflammatory NF-κB 
transcriptional activity. For example, IL-1ß and TNF-α both increase NF-κB nuclear localisation in 
neuronal progenitor cells (Taoufik et al., 2011). Thus, induction of NF-κB-driven 
neuroinflammatory responses can promote many potentially damaging cascades that 
cumulatively impact on tau processing, synapse and neuron health in AD. 
Another area of interest is the trans-synaptic spread of tau pathology through AD brain 
(Clavaguera et al., 2015). Our laboratory showed that tau release is mediated via neuronal 
activity in primary culture (Pooler et al., 2013). Astrocytes are critical for synaptic function, 
therefore it is reasonable to assume that astrocytes may play a role in regulating neuronal tau 
release and/or tau propagation. Indeed, astrocytes show accumulation of tau that has spread 
from anatomically connected brain regions (de Calignon et al., 2012). While the mechanisms 
implicated in these events are not yet understood, activated astrocytes increase their 
production and release of pro-inflammatory cytokine, IL-18 (Ojala et al., 2009), which can 
regulate NMDA receptor function (Curran and O'Connor, 2001). Since stimulation of NMDA 
receptors increases tau release in vivo (Yamada et al., 2014), astrocytes may indirectly mediate 
tau release and spread through the action of IL-18, and possibly other inflammatory mediators.  
It is also important to consider the role of astrocytes in different brain regions since this is 
important, not only for their potential roles in tau spread, but also their other functions in a 
diseased environment. There is evidence suggesting that astrocyte function is specialised 
according to brain region, thereby allowing astrocytes in each region to best support the specific 
needs of local neurons (Barbin et al., 1988). Therefore, it is possible that astrocytes may 
contribute differently to the development of disease-associated tau changes depending on their 
regional origin. It is important that we develop a better understanding of these regional effects 
in tractable models of disease.  
Previous cell culture work from this laboratory has used synthetic Aß1-42 treatments to induce 
AD-like changes in primary cell cultures (Noble et al., 2009b; Garwood et al., 2011). However, 
synthetic Aß has been criticised for being non-physiological and often varying in efficacy and 
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species composition (Soto et al., 1995; Stohr et al., 2012). Aß produced by cell lines containing 
a mutant form of APP, such as the 7PA2 CHO cell line (Walsh et al., 2002), or Aß produced by 
primary neuron cultures from transgenic mice, such as Tg2576 neurons (DaRocha-Souto et al., 
2012), is thought to be more physiological and is more widely accepted as a cell culture 
treatment. Aß produced by 7PA2 CHO cells has been found to be synaptotoxic, but does not 
induce neuron death, at low concentrations (Walsh et al., 2002; Walsh et al., 2005). However, it 
is not clear whether this Aß is a suitable alternative cell treatment to synthetic Aß. In order to 
investigate this further, it is important to compare differences between the two Aß sources. 
To address these questions, the aims of this chapter are to: 
 Characterise different preparations of Aß and compare their effects on astrocytes and 
neuron health. 
 Confirm that astrocytes mediate Aß-induced tau changes and cell death in primary 
cortical cultures. 
 Determine if Aß-stimulated astrocytes have similar influences in primary hippocampal 
cultures. 




The materials and methods used in this chapter, including detailed methodology for the 
production of primary cell cultures, are described in Chapter 2 (section 2.2.1). In brief, primary 
cell cultures were treated for 48 h with 0.5 µM AraC at 3 DIV, 20 µM minocycline at 11 DIV and 
10 µM synthetic Aß1-42 at 12 DIV. At 14 DIV cultures were lysed or fixed using methods described 
in Chapter 2, section 2.4.1.  
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Lysates were standardised to total protein concentration using a BCA assay (Chapter 2, section 
2.4.2) and run on 10 % tris-glycine gels for western blotting (Chapter 2, section 2.6). LIVE/DEAD 
and ICC were carried out with fixed cells at 14 DIV according to methods described in Chapter 2 
(sections 2.5.1).  
Medium for the tau sandwich ELISA and Alphascreens were also collected from 14 DIV primary 
cultures. For the tau sandwich ELISA medium was concentrated approximately 40 times, as 
described before use (Chapter 2, section 2.3). For Alphascreens medium was concentrated 
approximately 6 times and was standardised to total lysate protein after use in Alphascreen 
assays (Chapter 2, section 2.7.3). 
7PA2 and WT CHO medium was collected when cells were 100 % confluent and stored in 1 ml 
aliquots in 15 ml falcons at -20 °C. Medium was thawed before use in MSD assays (as described 
in Chapter 2, section 2.2.3) or as a cell culture treatment, when it was diluted 1:1 with 
Neurobasal medium as described in Chapter 2 (section 2.2.4). 
Synthetic Aß1-42 was frozen a maximum of once after being resuspended at 500 µM in autoclaved 
Ultrapure H2O (as described in Chapter 2, section 2.2.4). For native and SDS PAGE gels, Aß was 
standardised to multiple protein concentrations and mixed with the appropriate gel loading 
buffer before being loaded directly into the gel (Chapter 2, section 2.6). For dynamic light 
scattering (DLS), electron microscopy (EM) and Meso Scale Discovery assay (MSD) protocols, 
synthetic Aß was diluted further to 50 µM in autoclaved Ultrapure H2O. Aß was used 
immediately for DLS and MSD protocols as described in Chapter 2 (section 2.2.3). Aß was re-
frozen and sent for analysis at Covance for electron microscopy (Princeton, NJ, US; according to 





3.3.1 Preliminary work 
Primary culture characterisation 
Before experiments were carried out it was necessary to characterise the cell composition of 
primary cell cultures to enable proper interpretation of experimental results. Rat primary mixed 
cultures were prepared from E18 Sprague-Dawley rat embryos and cultured for up to 14 DIV. 
Cortical and hippocampal cells were cultured separately. At 7 and 14 DIV cultured cells were 
fixed for LIVE/DEAD assays and ICC. 
In order to explore average levels of cell death as untreated cell cultures aged, LIVE/DEAD assays 
were carried out at 7 and 14 DIV, as described in Chapter 2 (section 2.1). Incorporation of dead 
cell dye by cells with compromised membranes gives a measure of cell death. Cell cultures were 
subsequently stained with an antibody against GFAP as described in Chapter 2 (section 2.5), as 
a marker for astrocytes, to investigate how much total cell death was accounted for by astrocyte 
death. Cells were also stained with Hoescht-33342, a nuclear dye. Dead astrocytes are indicated 
by the incorporation of dead cell dye in cells labelled with the GFAP antibody. Cell cultures 
prepared using these methods contain only neurons and astrocytes, with negliable microglia (as 
shown in Garwood et al., 2011). Therefore, if a cell is stained with dead cell dye but not GFAP it 
can be assumed that the cell is neuronal.  
Images taken using a fluorescent microscope showed an increase in cell death as cultures aged 
for both cortical and hippocampal primary cultures. Furthermore, dead cell dye was largely 
incorporated into cells that are not labelled with GFAP indicating that cell death was 
predominantly neuronal. However, a number of large, healthy, Hoechst 33342-labelled nuclei 
can be observed that are not associated with astrocytes, indicating that even at 14 DIV there are 





Figure 3.2: Neuronal cell death increases in rat primary mixed glial neuronal cultures with 
increasing DIV 
Representative images, at 40x magnification, showing dead cell dye staining (red), GFAP 
immunolabelling (green) and Hoescht-33342 (blue) incorporation into cell nuclei in cortical and 
hippocampal cell cultures at 7 and 14 DIV. Culture type and age are shown on left. Right column 
shows merge of images. N = 14. 
 
To further investigate the health of untreated primary cell cultures at 7 and 14 DIV, cortical and 
hippocampal cell cultures were cultured for 7 or 14 DIV before being fixed and 
immunofluorescently labelled with antibodies against microtubule-associated protein 2 (MAP2), 
a neuron specific marker, GFAP, an astrocyte specific marker and Hoescht-33342, a nuclear 
specific dye. Cell morphology was examined as an indicator of dystrophic neurons and activated 
astrocytes, both found in unhealthy and dying cell cultures (Chen and Herrup, 2008; Avila-Munoz 
and Arias, 2014). The collected images showed MAP2-labelled neurons with clear axonal and 
dendritic processes. In all cell culture types and ages these processes were continuous and 
showed little evidence of breaks or blebbing indicating that cells are healthy (Chen and Herrup, 
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2008). In addition, in both cortical and hippocampal cultures, neuronal processes became more 
complex and lengthened with increasing culture time. GFAP labelling within the same cultures 
showed long astrocytic processes indicative of activated astrocytes, as expected in primary 
culture conditions (Figure 3.3).  
 
 
Figure 3.3: Astrocytes and neurons in rat primary mixed glial neuronal hippocampal and 
cortical cultures 
Representative images, at 40x magnification, showing cells in 7 and 14 DIV cortical and 
hippocampal cell cultures immunolabelled with antibodies against the neuron marker MAP2 
(red), and astrocyte marker GFAP (green). Nuclei are stained with Hoescht-33342 (blue). Culture 
type and age are shown on the left. The right column shows a merged image. N = 14. 
 
As the main aim of experiments in this chapter were to investigate the contribution of astrocytes 
to Aß-induced tau pathology in primary cell cultures it is important to know the proportion of 
astrocytes in these cultures. Quantification of astrocyte numbers showed that at 7DIV, primary 
approximately 10 % of cells in primary cortical cultures were GFAP-positive, rising to 19 % at 14 
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DIV. In primary hippocampal cultures, the proportion of GFAP-positive cells was approximately 
13 % at both 7 and 14 DIV (Table 3.1). Astrocytes are known to rapidly proliferate when 
activation (Sofroniew and Vinters, 2010), and these results might suggest that cortical and 
hippocampal cultures show different rates of astrocytic proliferation and/or activation. It should 
be noted that culture health varied between preparations and there were periods of time in 
which culture health was poor. However, care was taken to use only healthy cultures in the 






Culture type, age, and average ± SEM % of GFAP-stained cells is shown for 7 DIV and 14 DIV 
cortical and hippocampal cultures. N = 14. 
 
As a primary aim of the experiments conducted in this chapter was to examine changes in tau 
levels and phosphorylation, it was important to determine the optimum culture DIV for these 
experiments. Therefore, total and phosphorylated tau amounts were examined in primary 
cortical cultures at 4, 7, 10 and 14 DIV. Western blotting with antibodies against total and 
phosphorylation-dependent tau antibodies was performed. Total tau was examined using 
antibodies raised against the extreme N-terminus (TP007), extreme C-terminus (TP70) and mid-
region (DAKO) of tau. Western blots showed that amounts of tau with an intact N-terminus, as 
detected by TP007, increased as cultures age, being significantly higher at 14 DIV compared to 
4 DIV (p<0.05; Figure 3.4 A, B). Similar changes were observed for tau with an intact C-terminus 
(TP70) which was significantly higher at 14 DIV compared to 4 and 7 DIV (p<0.001 and p<0.05, 
Figure 3.4 A, C). These data indicate that amounts of total tau increase the longer cultures are 
maintained. Similar findings are reported during development in vivo (Larcher et al., 1992).  
 % GFAP-stained cells 
 Average ± SEM 
7 DIV cortical 10.7 1.7 
14 DIV cortical 18.6 1.6 
7 DIV hippocampal 13.6 2.9 
14 DIV hippocampal 13.4 4.2 
 
Table 3.1: The percentage of GFAP-stained cells in 7 DIV and 14 DIV rat primary mixed glial 
neuronal cortical and hippocampal cultures 
127 
 
Phosphorylation of tau was investigated in these cultures using several different 
phosphorylation-specific antibodies. The antibodies selected for this characterisation are used 
regularly in the literature and bind to epitopes that are abnormally phosphorylated in AD (Evans 
et al., 2000; Hashiguchi et al., 2002; Noble et al., 2009b; Garwood et al., 2011). Tau-1 recognises 
tau dephosphorylated at Ser199/202/Thr 205, and no significant changes in Tau-1 levels were 
found with increasing time in culture (Figure 3.4 A, D). CP13 detects tau phosphorylated at 
Ser202. Tau is normally phosphorylated at this site, with the extent of phosphorylation 
increasing in AD (Hanger et al., 2009). There were no significant changes in CP13 amounts with 
increasing time in culture (Figure 3.4 A, E). Finally, amounts of tau detected with the PHF1 
antibody, which recognises tau phosphorylated at Ser396/404, were significantly increased in 7, 
10 and 14 DIV cultures when compared to those cultured for 4 DIV (p<0.05, Figure 3.4 A, F). 
Phosphorylation at the PHF1 sites has been found to occur early in AD and is associated with tau 
detachment from the microtubules (Evans et al., 2000). In human brain, PHF1 is aberrantly 
phosphorylated in disease conditions (Hanger et al., 2009), however, tau is commonly 
phosphorylated at this epitope in primary cultures (Bloom et al., 2005; Garwood et al., 2011; 
Pooler et al., 2012), possibly as a result of the culture conditions.  
This preliminary characterisation of primary cell cultures suggests that even though they can 
display higher levels of cell death, 14 DIV cultures are better suited to the planned experiments 
since they show a higher composition of astrocytes, together with higher levels of total and 
phosphorylated tau. Importantly, synapse development occurs between 9-11 DIV in cortical (van 
Huizen et al., 1985) and slightly earlier in hippocampal (Grabrucker et al., 2009) cultures, and it 





Figure 3.4: Total and phosphorylated tau amounts in rat primary mixed glial neuronal cortical 
cultures 
A. Representative western blots of primary cortical cell culture lysates (4 DIV, 7 DIV, 10 DIV, 14 
DIV) probed with antibodies against total tau (DAKO), Tau-1 (tau dephosphorylated at 
Ser199/202/Thr205), PHF1 (tau phosphorylated at Ser396/404), CP13 (tau phosphorylated at 
Ser202), TP70 (C-terminal tau), TP007 (N-terminal tau) and ß-actin as a loading control. 
Molecular weight markers are shown on the right. B-F. Bar charts show quantification of B. TP70 
and C. TP007 normalised to ß-actin, D. Tau-1, E. CP13 and F. PHF1 as a proportion of total tau 
(DAKO). N=9. Values are mean ± SEM as a percentage of 4 DIV. Statistical test used: one-way 




An important aim of this chapter was to compare different preparations of Aß for use in primary 
cell cultures. Much of the previous work in this laboratory has used synthetic Aß(Noble et al., 
2009b; Garwood et al., 2011).  This type of work has been increasingly criticised since it is not 
considered to represent physiological events in AD brain (Finder et al., 2010). However, since 
there are standard and highly reproducible methods of preparation and it provides robust 
results, synthetic Aß is still in regular use in pharmaceutical companies. However, it was 
important to determine if more physiological sources of Aß provide comparable results. 
Therefore, different sources of Aß were also characterised.  

Synthetic Aß1-42 characterisation 
To characterise the synthetic Aß1-42 used in this chapter, 500 µM stock synthetic Aß1-42 was 
further diluted to 50 µM in autoclaved Ultrapure H2O and analysed using a dynamic light 
scattering Dyna Pro Plate Reader which provides information about the size of small molecules 
in suspension. This allows information about the size of monomers, oligomers and fibrils, and 
the percentage of total Aß of each size in a sample of Aß. Two types of synthetic Aß1-42 provided 
by Eli Lilly and Co. were used for comparison. The results obtained showed the synthetic 
preparations used in our laboratory Aß1-42 were comprised mainly of medium-high weight 
oligomers together with a smaller amount of large kDa Aß1-42 fibrils (Table 3.2). These oligomers 
were slightly larger than those comprising the synthetic Aß1-42 preparations obtained from Eli 
Lilly (Figure 3.5 A).  
To further investigate the size of oligomers in synthetic Aß1-42 preparations, different 
concentrations (25, 50 and 75 µM) of Aß1-42 were run on native PAGE immunoblots and 
membranes were probed with 3D6 or 6E10, antibodies against total Aß. Native PAGE gels do not 
contain detergent and therefore do not break up detergent-soluble oligomers, allowing 
identification of intact oligomer sizes. Immunoblots showed a strong band indicating Aß1-42 
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oligomers of approximately 100-140 kDa. Several additional bands were apparent at higher 
molecular weights indicating the presence of larger oligomers, supporting the results obtained 
from DLS experiments (Figure 3.5 B, 3D6 western blots not shown). 50 µM synthetic Aß1-42 
preparations were further assessed using electron microscopy also showed the relatively 
uniform presence of predominantly elongated Aß1-42 oligomers (Figure 3.5 C). Further diluting 
the synthetic Aß1-42 to 10 µM in water allowed visualisation of fibrils, associated with the 
oligomers, which likely represent the high molecular weight species apparent in the DLS profile 
(Figure 3.5 D). Taken together the results of these experiments provide strong evidence that the 
synthetic Aß1-42 preparations used here contain approximately 86 % medium-high weight 
oligomers of approximately 100-140 kDa, with the remainder of the peptide aggregating into 
larger fibrils. 
 




Peak 1 9.365 117 86.1 
Peak 2 46.496 2147 13.9 
 
Table 3.2: Dynamic light scattering profile showing that synthetic Aß1-42 is composed of mainly 
medium-high weight oligomers 
The average radius (nm), average molecular weight (kDa) and average percentage mass is shown 
for each DLS peak. N=3. 
 
To investigate the stability of these Aß1-42 oligomers, samples of Aß1-42 were subject to SDS-PAGE 
immunoblotting.  SDS can break weak bonds within molecules (Kramer et al., 1980), including 
Aß,and could, therefore,break the Aß oligomers down into their constituent monomers, 
dimers and low-weight oligomers which will be reflected in the molecular weights of the 
peptides detected on western blots. The same synthetic Aß1-42 samples as were run on the native 
PAGE gels were used for this work, and membranes were probed with the same total Aß 
antibody (6E10). Western blots showed the presence of Aßpeptides at approximately 4, 8 and 
12 kDa corresponding to the expected mass of Aßmonomers, dimers and trimers respectively 
(Figure 3.6), thereby demonstrating that the Aßoligomers in synthetic Aß1-42 preparations are 
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SDS-sensitive, whereas the dimers and trimmers are SDS-stable. There were also smears of Aß 
at the top of the gel, which were particularly apparent when 50 and 75 µM synthetic Aß1-42 was 
loaded. This suggests the presence of stable Aßoligomers or possibly fibrils in conditions of high 
Aß concentrations. This is further reflected by the absence of a dose-dependent increase in the 
amounts of monomers, dimers and trimers. 
 
Figure 3.5: Synthetic Aß1-42 preparations are composed mainly of medium-high weight 
oligomers 
A. Line graph showing DLS profile of synthetic Aß1-42 with percentage of total Aß1-42 mass against 
radius of molecule detected. Radius of molecule is directly correlated with oligomer size. CalPep 
1, 2 and 3 indicate triplicate readings for Aß1-42 preparations from our laboratory. Stable 
oligomers and Lilly Aß indicate positive controls provided by Eli Lilly. B. Representative native 
PAGE gel loaded with Aß1-42 samples of different concentrations probed with 6E10 (antibody 
dilutions: 1:1000), an antibody for total Aß. Secondary antibody used at 1:2000. Molecular 
markers are shown on the left. C. Representative electron microscopy image of 50 µM synthetic 
Aß1-42 sample. Scale bar at bottom right of image. D. Representative electron microscopy image 
of 10 µM synthetic Aß1-42 sample, diluted in H2O. White arrows indicate example fibrils. Scale 




Figure 3.6: Synthetic Aß1-42 oligomers are SDS-sensitive 
Representative SDS-PAGE western blot using synthetic Aß1-42 of different concentrations 
(indicated at the bottom of the blot), probed with 6E10 (antibody dilution: 1:1000), a total Aß 
antibody. Secondary antibody used at a 1:10000 dilution. Molecular weight markers are shown 
on the left. Aß monomers, dimers and trimers are indicated. 
 
Furthermore, synthetic Aß1-42 treated primary cell culture medium was collected from cells 
immediately before lysis and run on two types of MSD assays to investigate the concentration 
of Aß and to attempt to detect Aß oligomers. First, Multi-array® plates that were coated with 
primary capture antibodies 3D6, for total Aß, and A11, for oligomeric Aß, in house at Eli Lilly. 
Results found nanomolar levels of total Aß (790 nM), very low levels of Aß oligomers (120 nM, 
Table 3.3), suggesting only a small percentage of the Aß in treated cell culture medium is 
oligomeric. This is inconsistent with DLS and native PAGE results suggesting that synthetic Aß 
samples are made up predominantly of medium-high weight oligomers. However, this may be 
due to the structure of the oligomers obscuring a large number of A11 antibody binding areas, 
resulting in a false, reduced concentration of oligomeric Aß being measured by the MSD assay. 
Synthetic Aß-treated primary cell culture medium was also tested on 6E10 V-Plex plates that 
test for levels of Aß1-38, Aß1-40 and Aß1-42. Results found no detectable Aß1-38 or Aß1-40 in the 
samples (data not shown). This is expected as these samples contain synthetic Aß, containing 
only Aß1-42 peptide. The concentration of Aß1-42, however was found to be 2.6 µM (Table 3.3). 
This is much less than the original 10 µM concentration treatment originally added to the culture 
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medium, likely due to the propensity of Aß to stick to surfaces (particularly plastic surfaces) and 
cells (Hoshino et al., 2002). 
However, there is also a discrepancy between the concentration of total Aß as measured by 3D6 
and 6E10 in the V-Plex plate (Table 3.3). This could be explained by the different primary 
antibodies binding to different areas of the Aß peptide, with 3D6 only binding to amino acids 1-
5 and 6E10 binding to amino acids 1-16. As mentioned previously, the structure of oligomers 
could be obscuring more of the smaller 3D6 binding regions, resulting in a lower concentration 
of Aß being detected by the 3D6 antibody. 
 
Antibody Concentration (µM) 
3D6 0.79 
A11 0.12 
Aß1-42 (6E10 V-Plex plate) 2.6 
 
Table 3.3: MSD results for synthetic Aß-treated primary cell culture medium 
Antibody used and concentration of Aß (in µM) are shown. 
 
Taken together, the results described in this section demonstrate that the synthetic Aß1-42 used 
in many of the experiments in this chapter is composed of a mixture of SDS-sensitive and 
insensitive medium-high molecular weight oligomers. Based on the DLS profile and EM images, 
these oligomers are likely to be a similar size to Aß fibrils found in AD brain, suggesting they may 
not be as toxic as smaller Aß oligomers (Sengupta et al., 2016). 
 
Characterisation of two more physiological alternatives to synthetic Aß 
 Two main sources of Aß were investigated as alternatives to synthetic Aß. The first is derived 
from 7PA2 CHO cells that express the familial AD-causing V717F APP mutation and secrete low 
levels of Aß oligomers into culture medium that are synaptotoxic (Walsh et al., 2002). The 
second alternative source is Aß secreted from primary neurons prepared from Tg2576 mice that 
over-express the familial AD-causing Swedish APP mutation. These neurons also secrete low 
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levels of Aß into culture medium (DaRocha-Souto et al., 2012) that induces synapse loss (Wu et 
al., 2012).  
 
Figure 3.7: Aß1-42 concentrations in 7PA2 CHO cell medium vary between passages 
Bar chart showing results from an Aß1-42 ELISA showing Aß1-42 concentration (pg/ml) in 7PA2 CHO 
medium at different passages of this cell line (N=1).  
 
The amounts and species of Aß secreted into culture medium from these cell sources were first 
investigated. Medium was collected from 7PA2 CHO cells and wild-type controls as they were 
passaged from passage (P)9 to P22. The amounts of Aß1-42 in medium was determined using Aß1-
42 ELISAs. The results of this analysis showed that Aß1-42 in the medium were at picomolar 
concentrations and varied with passage (Figure 3.7). The lack of Aß detected at P15 suggests a 
problem with this particular sample. The variation is likely due to changes in cell proliferation, 
and cell density at the time medium was collected and cells were split. However, it was apparent 
that, at least up to P22, there appeared to be no considerable decrease in the amount of Aß 
secreted into culture medium from 7PA2 cells.  
In order to further characterise the levels and species of Aß in 7PA2 CHO cell medium, MSD 
assays were used. Samples were collected from cells at P15 (not those shown in Figure 3.7), and 
total levels of Aß1-38, Aß1-40 and Aß1-42 were determined using a V-PLEX Aß Peptide Panel 1 (6E10) 
kit. Additionally, a sample of culture medium from Tg2576 primary mouse neurons was used in 
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this MSD assay to investigate the species of Aß released from these neuronal cultures. Results 
found levels of Aß1-38 and Aß1-40 were too low to be detected in 7PA2 CHO medium (Table 3.4). 
However, levels of Aß1-42 were found to be 140 pM (648 pg/ml), consistent with the Aß1-42 ELISA 
results described above (Figure 3.7). Tg2576 neuronal medium was found to have detectable 
concentrations of Aß1-38 and Aß1-40, with both being detected at nanomolar concentrations 
(Table 3.4). The concentration of Aß1-42 in the Tg2576 medium was approximately 10 % of the 
concentration of synthetic Aß species and was at picomolar levels. These concentrations are 
higher than those of total Aß previously reported (DaRocha-Souto et al., 2012), however, this 
could be due to differences in the density of neurons plated per ml of medium. 
 
Aß source Aß1-38 (nM) Aß1-40 (nM) Aß1-42 (nM) 
7PA2 CHO - - 0.14 
Tg2576 5.73 6.21 0.58 
 
Table 3.4: Concentrations of Aß species from different Aß sources 
Aß source and concentration of Aß1-38, Aß1-40 and Aß1-42 shown. 
 
Taken together these results indicate that both Aß release from 7PA2 CHO cells and Aß released 
from primary Tg2576 mouse neurons is present at much lower concentrations than that at which 
synthetic Aß is used. If found to be induce similar AD-like effects in primary neuronal cultures, 
7PA2 CHO cells would be a much more sensitive and physiological Aß source. However, results 
also indicate that it will be important to determine the Aß concentration of each batch of 
conditioned medium prior to experimental use.  
To be considered a synthetic Aß alternative, Aß from an alternative source needs to produce 
AD-like changes in treated primary cultures. To determine if Aß-containing 7PA2 culture medium 
affects neuron health, 12 DIV primary cortical cultures were treated with 7PA2 CHO medium in 
a 1:1 ratio with Neurobasal medium for 48 h. WT CHO medium was used as a control. In addition, 
cells were treated with 10 µM synthetic Aß1-42 or vehicle as a comparison. For this and all future 
experiments using 7PA2 CHO Aß, medium from cells at passage 19 (Figure 3.7) were used since 
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this batch contained the highest levels of Aß1-42 (approximately 950 pg/ml). A LIVE/DEAD assay 
was used to determine the extent of dead cell dye incorporation as a measure of cell death.  
The results indicated that synthetic Aß1-42 application resulted in an approximately 0.2-fold 
increase in cell death relative to its respective control, a difference that was not statistically 
significant in this experiment (p = 0.07). In contrast, 7PA2 cell medium did not result in a marked 
increase in cell death relative to its control (WT CHO cell medium, Figure 3.8). Interestingly, 
however, CHO medium significantly reduced cell death relative to CTRL and synthetic Aß 
treatments (data not shown). This is likely to be due to the FBS in the CHO cell medium.  
 
Figure 3.8: Synthetic, but not 7PA2-derived Aß decreases rat primary mixed glial neuronal 
culture viability 
Bar chart showing the incorporation of dead cell dye in cells treated for 48 h with 10 µM 
synthetic Aß1-42 or vehicle (H2O), and 7PA2 CHO cell medium relative to its respective control of 
wild-type (WT) CHO cell medium. N=9. Values are mean ± SEM as a percentage of the 





Figure 3.9: Treatment with synthetic and 7PA2-derived Aß does not affect neuronal 
morphology  
Representative images at 20x objective magnification immunostaining of 14 DIV rat primary 
mixed neuronal glial cortical cell cultures treated with Aß (synthetic Aß1-42, 10 µM) and CTRL 
(control: ultrapure H2O), or (7PA2 CHO medium, 70 pM) and its control WT (WT CHO medium) 
for 48 h. MAP2 (red), GFAP (green) and Hoescht-33342 nuclear staining. Treatment is shown on 
left. Second column from right shows merged images, the far right column shows merged 
images at 40x objective magnification. N = 3. 
 
ICC was used to examine the morphology of neurons and astrocytes in these cultures. 
Fluorescent images showed that there are no obvious changes in neuronal morphology when 
cells were treated with synthetic Aß1-42 or 7PA2-derived Aß when compared to their respective 
controls (Figure 3.9), which likely reflects the mild neurotoxic effects of synthetic Aß1-42 in this 
experiment. This suggests that, if 7PA2 CHO Aß is having any effects on primary cortical cultures, 
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the effects are likely to be subtle and may more accurately represent events in early AD, prior 
to substantial neuronal loss.  
Although 7PA2 CHO cell medium does not cause overt cell death, it is reported to be 
synaptotoxic (Walsh et al., 2002). Therefore, to investigate subtler effects of 7PA2 cell -derived 
Aß on primary cortical cultures, changes in tau, caspase-3 and synaptic proteins were examined 
in these cultures. Abnormal tau processing and synaptic dysfunction are some of the earliest 
changes observed in AD brain (Horowitz et al., 2004; Amadoro et al., 2011; Lasagna-Reeves et 
al., 2011; Minano-Molina et al., 2011). Previous results from this laboratory using 7 DIV mixed 
cortical cultures showed that synthetic Aß1-42 leads to increased tau phosphorylation, caspase-3 
activation and increased cleavage of tau by caspase-3 (Garwood et al., 2011). Therefore, 
immunoblots of cell lysates were probed with antibodies against total, phosphorylated and 
caspase-cleaved tau, cleaved (active) caspase-3 and pre- and post-synaptic markers (Figure 3.10 
A).  
Treatment with either synthetic Aß1-42 or 7PA2-derived Aß did not cause any changes in total tau 
amounts in comparison to their respective controls (Figure 3.10 B). This is not unexpected since 
total tau levels are thought to only increase at later stages of AD, when tau aggregates 
accumulate (Gerson and Kayed, 2016). Similarly, neither source of Aß affected tau 
phosphorylation at the PHF1 (Ser396/404) epitope and 7PA2-derived Aß significantly reduced 
phosphorylation at the CP13 (Ser202) epitope (Figure 3.10 C, D). This is somewhat unexpected 
since tau phosphorylation, particularly at the PHF1 site, is known to occur early during AD 
development (Evans et al., 2000) and is commonly found to increase following Aß treatment of 
primary neuronal cultures (Rapoport et al., 2002; Noble et al., 2009a; Jana and Pahan, 2010; 
Amadoro et al., 2011; Garwood et al., 2011). The reason for this discrepancy is not known, but 




Figure 3.10: 7PA2-derived Aß increases caspase-3 activity and reduces post-synaptic protein 
markers 
A. Representative western blots of primary cortical cell culture lysates treated with 10 μM 
synthetic Aß1-42 or vehicle (H2O), and 7PA2 CHO cell medium relative to its respective control of 
wild-type (WT) CHO cell medium. Blots were probed with antibodies against total tau, PHF1 (tau 
phosphorylated at Ser396/404), CP13 (tau phosphorylated at Ser202), caspase-cleaved tau 
(Asp421), cleaved caspase-3, synaptophysin, PSD-95 and ß-actin as a loading control. Molecular 
weight markers are shown on the left. B-H. Bar charts show quantification of B. Total tau relative 
to ß-actin. C. PHF1, D. CP13 and E. caspase-cleaved tau a proportion of total tau. F. cleaved 
caspase-3, G. synaptophysin and H. PSD-95 relative to ß-actin. N=9. Values are mean ± SEM as a 





susceptibility of 14 DIV cultures (used here) and the 7 DIV cultures used in previous reports 
(Garwood et al., 2011). 
The activity of caspase-3 and the abundance of caspase-cleaved tau were examined since 
increased levels of cleaved and fragmented tau encourage tau aggregation, resulting in toxic tau 
oligomers and eventually NFTs (Horowitz et al., 2004; Park and Ferreira, 2005; Wang et al., 
2007). Caspase 3 is activated by cleavage of pro-caspase-3 at aspartate (Asp) 175 to generate 
active 17 kDa and 19 kDa fragments. Caspase-3 cleaves tau at Asp 421, producing large, possibly 
toxic, tau fragments of approximately 50 kDa (Chung et al., 2001; Liu et al., 2011a; Snigdha et 
al., 2012). In these experiments, neither synthetic Aß1-42 or 7PA2-derived Aß caused significant 
changes in the amounts of caspase-cleaved tau antibody relative to their respective controls 
(Figure 3.10 E). In contrast, 7PA2-derived Aß caused a marked increase in the appearance of 
cleaved (active) 17 kDa caspase-3 species in comparison to WT CHO medium (Figure 3.10 F). 
While apparently not resulting in increased cleavage of tau, caspase-3 is an executioner caspase 
(Snigdha et al., 2012), linked with AD (Chung et al., 2001; Gamblin et al., 2003; Liu et al., 2011a), 
and this finding is indicative that 7PA2-derived Aß may have the capacity to affect neuronal 
viability in the long term. 
Finally, synaptic proteins were examined as an indication of the effects of each Aß species on 
synapse health. Western blots were probed with antibodies against synaptophysin and PSD-95. 
Synaptophysin is a synaptic vesicle glycoprotein that regulate vesicle positioning and release by 
interacting with synaptobrevin (Yao et al., 2003). PSD-95 is an important scaffolding protein at 
the post-synapse but is also commonly used as a post-synaptic marker (Savioz et al., 2014). 
Synaptic dysfunction is closely linked with tau in AD, and is one of the earliest pathologies 
detected during AD pathogenesis (LaFerla and Oddo, 2005; Lasagna-Reeves et al., 2011; Crimins 
et al., 2013; Talantova et al., 2013). In the experiments shown here, neither synthetic Aß1-42 or 
7PA2-derived Aß affected the amounts of synaptophysin in comparison to their respective 
controls (Figure 3.10 G). However, 7PA2-derived Aß significantly reduced PSD-95 levels in 
comparison with the WT CHO medium control (Figure 3.10 H). This suggests that 7PA2-derived 
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Aß treatment is resulting in significant degeneration at the synapse, and may affect neurons in 
a more sensitive manner than synthetic Aß. This is consistent with results from others in the 
laboratory (not shown here) that have shown treatment of mouse cortical neurons with 7PA2-
derived Aß reduces the density of synaptic spines, and with previous reports from Walsh et al. 
(2002).  
In conclusion, these results indicate that 7PA2-derived Aß is having little effect in primary 
cortical cultures on AD-like tau changes or cell viability. However, significant alterations in 
caspase-3 activity and a reduction in PSD-95 levels were observed. This suggests 7PA2-derived 
Aß may be having more long-term effects on cell viability, possibly due to detrimental effects on 
dendritic levels and synaptic function. Unfortunately, by the time these findings were gained, 
there was not sufficient time to establish a new set of analysis criteria in this project, therefore 
synthetic Aß1-42 was used for the following experiments in this chapter in which the effect of 
astrocytes on Aß-induced changes were investigated. 
 
3.3.3 Astrocytes do not affect Aß-induced changes in 14 DIV primary cortical cultures 
Previous research from this laboratory and others shows that astrocytes have an important 
effect in mediating the effects of Aß on disease-associated tau changes, synapse and neuron 
health (Noble et al., 2009a; Garwood et al., 2011). In work from this laboratory, astrocytes were 
found to accelerate Aß-induced cell death, possibly via increased pro-inflammatory cytokine 
release and caspase-3 activation in 7 DIV cortical cultures. Additionally, astrocytes were required 
for Aß-induced tau phosphorylation (Garwood et al., 2011).  Garwood et al. (2011) also found 
that found minocycline, a tetracycline derivative with anti-inflammatory action, prevented these 
Aß-induced effects in astrocyte-containing cultures.  
To determine if the same effects are observed in more mature neurons, that have functional 
synapses, these experiments were repeated here using 14 DIV primary cortical cultures. Primary 
cortical cells were cultured as described previously (Chapter 2, section 2.1). At 3 DIV some cells 
were treated with 0.5 µM AraC for 48 h, preventing astrocyte proliferation and resulting in 
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neuronal cultures, which was verified by western blotting and immunocytochemistry with cell-
type specific markers. At 11 DIV, cell cultures were pre-treated with 20 µM minocycline for 24 
h, prior to treatment with 10 µM synthetic Aß1-42 for 48 h. AraC-treated cultures showed only 
trace amounts of GFAP when cells were lysed and western blotted.  Clear ß-actin bands were 
apparent in these samples indicating the presence of remaining cells, predominantly neurons 
(Figure 3.11). As tau itself is a neuron-specific marker, the presence of live neurons was further 
confirmed by western blotting and probing resulting blots with tau to investigate changes in 
total and phosphorylated tau levels (Figure 3.13). 
 
 
Figure 3.11: AraC treatment leaves only trace amounts of GFAP-positive cells 
Representative western blot of primary cortical cultures treated with AraC (neuronal) or not 
(mixed) and treated with minocycline and/or Aß. Blots were probed with antibodies against 
GFAP and ß-actin as a loading control. Molecular weight markers are shown on the left. 
 
The effect of synthetic Aß1-42 on primary culture health in the presence and absence of astrocytes 
was next determined using LIVE/DEAD cell assays. The effect of minocycline on cell death in 
these cultures was also examined. The results appeared to show increases in cell death following 
Aß treatment of both mixed and neuronal cultures, however these differences did not reach 
statistical significance (Figure 3.12). In addition, minocycline had no effect on Aß-induced cell 
death in either mixed or neuronal cultures. These data suggest that astrocytes do not accelerate 
Aß-induced neuronal loss.  
Previously, Garwood et al. (2011) found that astrocytes facilitated tau changes, including tau 
phosphorylation and cleavage, in 7 DIV primary cortical cultures. To determine if these are 
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replicated at 14 DIV, western blots were used to assess tau changes in mixed and neuronal 
culture lysates. In addition, an antibody against cleaved caspase 3 was used to allow comparison 
with caspase-cleaved tau amounts.  
 
Figure 3.12: Astrocytes do not affect Aß-induced neurotoxicity in 14 DIV primary cortical 
cultures 
Bar chart showing incorporation of dead cell dye in mixed (neuron + astrocyte) and neuronal 
cultures treated with 10 µM Aß for 48 h, with and without 3 h pre-treatment with 20 µM 
minocycline. Data is mean ± SEM as a percentage of mixed or neuronal culture CTRL conditions. 
N=5. Statistical test used: two-way ANOVA. 
 
The results of this analysis showed that there were no effects of minocycline or Aß on total tau 
amounts or tau phosphorylation at the CP13 and PHF1 epitopes in either mixed or neuronal 
cultures (Figure 3.13 A, B-D). There were also no significant changes in caspase-cleaved tau 
levels in mixed or neuronal cultures treated with minocycline and/or Aß (Figure 3.13 A, E). Again 
this contradicts previous research showing that, while Aß-induced increases in caspase-cleaved 
tau occur in the absence of astrocytes, astrocytes can exacerbate tau cleavage (Garwood et al., 
2011). In addition, the results here showed that cleaved caspase-3 levels were significantly 
increased following Aß treatment in neuronal, but not mixed, cultures (Figure 3.13 A, F).  
Astrocytes may play a role in physiological tau release 
Recent evidence demonstrates that tau can be released into the extracellular space under both 
physiological and pathological conditions (de Calignon et al., 2012; Pooler et al., 2013; Hanger 
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et al., 2014; Wu et al., 2016). Pathological tau release is thought to underlie the trans-synaptic 
spread of tau pathology along anatomical connections in diseased brains (Clavaguera et al., 
2015). Tau release in physiological conditions may be involved in inter-cellular signalling (Pooler 
et al., 2013; Hanger et al., 2014). Little is known about the possible contributions of astrocytes 
to tau release. However, synaptic activity has been shown to mediate tau release, suggesting 
that the influence of astrocytes at synapses may be an important component of this process 
(Pooler et al., 2013; Avila-Munoz and Arias, 2014; Yamada et al., 2014; Wu et al., 2016).  
Before investigating the role of astrocytes in tau release, it was important to first characterise 
the species of tau that 14 DIV mixed primary cortical cultures release. Tau release was therefore 
measured under basal and following stimulation with 100 µM AMPA, which this laboratory has 
previously shown to stimulate tau release from healthy cultured neurons (Pooler et al., 2013). 
As a positive control, cells were also treated with a toxic concentration (0.1 µM) of the calcium 
ionophore, ionomycin.  Treatments were applied for 30 min at which time cells were lysed and 
medium was concentrated according to the protocol described in Chapter 2 (section 2.1). 
Concentrated samples of cell lysates and culture medium were determined using western blots 
probed with tau antibodies. Qualitative assessment of the results suggested that the amounts 
of tau released into culture medium are somewhat increased following AMPA treatment, as 
indicated by the increased density of total tau (DAKO) bands (Figure 3.14), supporting our 
previous findings (Pooler et al., 2013). There were no apparent changes in total tau amounts in 
the corresponding cell lysates. As expected, very low levels of tau can be seen in ionomycin-
treated cell lysates since this treatment is toxic, and the high levels of tau detected in the 
corresponding culture medium mirror this decrease in intracellular tau (Figure 3.14). These 
experiments establish that tau release can be readily measured in culture medium under basal 




Figure 3.13: Astrocytes do not cause Aß-induced changes in tau in 14 DIV primary cortical 
cultures 
A. Representative western blots of lysates from mixed (neuron + astrocyte) and neuronal 
cultures treated with 10 µM Aß for 48 h, with and without 3 h pre-treatment with 20 µM 
minocycline. Blots were probed with antibodies against total tau, PHF1 (tau phosphorylated at 
Ser396/404), CP13 (tau phosphorylated at Ser202), caspase-cleaved tau (Asp421), cleaved 
caspase 3, and β-actin as a loading control. Molecular weight markers are shown on the left. B-
H. Bar charts show quantification of B. total tau as a proportion of ß-actin. C. PHF1, D. CP13 and 
E. caspase-cleaved tau as a proportion of total tau. F. cleaved caspase 3 as a proportion of ß-
actin. N=9. Data is mean ± SEM as a percentage of mixed or neuronal culture CTRL conditions 





To examine the phosphorylation status of the released tau, western blots were probed with Tau-
1 antibody, which detects tau dephosphorylated at Ser199/202/Thr205. Strong immunoreactive 
bands are detected by this antibody in the culture medium samples (Figure 3.14), indicating that 
extracellular tau is largely dephosphorylated at these epitopes, as previously reported (Pooler 
et al., 2013).  
To determine if the tau that is released is cleaved, as suggested by Kanmert and colleagues 
(Kanmert et al., 2015), or intact, as we previously reported (Pooler et al., 2013), antibodies raised 
against the extreme C-terminus (TP70) and N-terminus (TP007) were used. These antibodies 
appeared to detect the majority of tau present in culture medium at the expected size of full-
length tau (Figure 3.14), further supporting previously published research demonstrating that 
extracellular tau is predominantly full-length and dephosphorylated (Pooler et al., 2013; Hanger 
et al., 2014). 
To investigate possible contributions of astrocytes to basal and stimulated tau release, mixed 
and neuronal cortical cultures were established as described above. At 14 DIV, Neurobasal 
medium was removed and HBSS containing Ca2+ and Mg2+ applied for 30 mins. This is essential 
since Neurobasal medium components interfere with tau sandwich ELISAs (Pooler et al., 2013). 
The HBSS was collected and total tau amounts in medium were determined using a tau sandwich 
ELISA that we developed in-house (Chapter 2, section 2.7). Cell viability was measured using 
LIVE/DEAD assays to ensure that any changes in tau release found were not as a result of 
increased cell death.  
The results obtained show that there are no differences in cell death between neuronal and 
mixed cultures (Figure 3.15 A). In contrast, tau content in culture medium is significantly 
increased in neuronal cortical cultures, when compared to mixed cortical cultures (Figure 3.15 







Figure 3.14: Tau released from rat primary mixed glial neuronal cortical cultures upon AMPA 
stimulation is intact and dephosphorylated 
Representative western blots of rat primary mixed glial neuronal cortical culture lysates and 
concentrated medium samples from cells treated with vehicle (CTRL), 100 µM AMPA or 0.1 µM 
ionomycin (Ion.). Blots were probed with antibodies against total tau (DAKO), Tau-1 (tau 
dephosphorylated at Ser199/202/Thr205), TP007 (N-terminus of tau) and TP70 (C-terminus of 
tau). Molecular weight markers are shown on the left. N = 2. 
 
 
Figure 3.15: Extracellular tau amounts are increased in neuronal cultures in basal conditions 
A. Bar chart showing cell death, as measured using LIVE/DEAD cell assay, in mixed (CTRL) and 
neuronal (AraC-treated) cortical cultures B. Bar chart showing total tau (DAKO) content in 
culture medium from these cells. N=15. Values are mean ± SEM as a percentage of CTRL. 




To further investigate the possible contributions of astrocytes to tau release, mixed and 
neuronal cortical cultures were treated with 20 µM minocycline at 11 DIV and 10 µM synthetic 
Aß1-42 at 12 DIV as previously described (section 3.3.3). At 14 DIV, 48 h after Aß treatment, 
culture medium was collected and concentrated for Alphascreen assays (for method see Chapter 
2, section 2.7) which allow detection of total and phosphorylated tau in the medium. 
Alphascreen is a bead-based assay based on similar principles to ELISA. Samples are incubated 
with two primary antibodies: a biotinylated total tau antibody, and either a total or phospho-
specific tau antibody conjugated to acceptor beads. In parallel, cells were lysed and protein 
content determined using a Bradford protein assay (Chapter 2, section 2.4.2). This allowed 
amounts of extracellular tau to be standardised to total protein content in each sample.  
Despite concentrating the medium, Alphascreens using PHF1 and CP13 antibodies conjugated 
to acceptor beads, were not sufficiently sensitive to detect tau in culture medium (data not 
shown). This problem may have been exacerbated since extracellular tau is largely 
dephosphorylated (Pooler et al., 2013). Using acceptor beads conjugated to Tg5, another total 
tau antibody, the Alphascreen results showed that there are no significant differences following 
Aß or minocycline treatment or between mixed or neuronal cultures (Figure 3.16). This is 
unexpected as these results could contradict the ELISA results described above. This 
inconsistency could possibly be explained by the reduced sensitivity of Alphascreens, the use of 
different total tau antibodies, potential artefacts or variation introduced when medium is 
concentrated for use in this assay. It is possible that repeating these experiments with different 
combinations of antibodies, raised to different parts of tau, may provide a more accurate 
determination of levels of extracellular tau in mixed and neuronal cultures under different 
conditions. 
Overall, this set of experiments suggests that astrocytes might play a role in regulating the 
concentration of extracellular tau in 14 DIV primary cortical cultures under basal conditions. 
Further experiments are required to validate these findings and to determine the precise 




Figure 3.16: Alphascreen results suggest that tau release is not influenced by astrocytes or Aß 
Bar chart showing Alphascreen results with samples from mixed (neuron + astrocyte) and 
neuronal cultures treated with 10 µM Aß for 48 h, with and without 3 h pre-treatment with 
minocycline.  All results are standardised to mixed control (CTRL) levels of total tau (Tg5) in the 
medium.  N=3. Values are mean ± SEM as a percentage of CTRL. Statistical test used: two-way 
ANOVA. 
 
Astrocytes show an inflammatory response to Aß treatment 
The transcription factor NF-κB may mediate inflammatory roles of astrocytes, increasing 
production and release of pro-inflammatory cytokines in response to Aß (Shi et al., 2016). To 
begin to determine if Aß affects astrocytic inflammatory responses in these cultures, 
immunofluorescence was used to examine NF-κB in 14 DIV mixed cortical cultures, treated with 
Aß and minocycline treatment as described above. Cells were fixed and immunolabelled with 
anti-NF-κB and GFAP antibodies. Nuclear material was stained with Hoescht-33342. Images 
taken with a fluorescent microscope showed an increase in the intensity of NF-κB 
immunoreactivity following Aß treatment. Furthermore, this increase was reduced when 
cultures were pre-treated with minocycline (Figure 3.17). Average intensity of NF-Κb in each 
image was quantified using Image J and standardised to the average intensity of DAPI staining. 
Quantification confirmed a statistically significant increase in the average intensity of NF-κB 
staining in Aß-treated cultures compared to all other treatment groups (Figure 3.18), suggesting 
an increase in NF-κB production with Aß treatment with monocycline pre-treatment resucing 
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this effect. This data suggests that the cells in 14 DIV mixed primary cultures are reactive to Aß, 
with NF-κB induction in neural cells possibly linked to an inflammatory response. It should be 
noted that NF-κB immunoreactivity also appeared to be localised to neurons.  
 
 
Figure 3.17: Aß-induces increases in NF-κB levels that are attenuated by minocycline pre-
treatment 
Representative 20x magnification images showing NF-κB (red) and GFAP (green) 
immunolabelling and Hoescht-33342 nuclear staining of 14 DIV mixed cortical cell cultures 
treated with CTRL (control: Ultrapure H2O), Aß (synthetic Aß1-42), minocycline or minocycline + 
Aß. Treatment is shown on left. Second column from right shows merged images, the far right 





Figure 3.18: NF-κB levels are increased with Aß treatment 
Bar chart show quantification of average NF-κB staining intensity as a proportion of average 
DAPI staining intensity. N=6. Data is mean ± SEM as a percentage of CTRL conditions. Statistical 
test used: Kruskal-Wallis. * = p < 0.05, ** = p < 0.01. 
 
IκBα amounts were also examined in mixed and neuronal cultures. In astrocytes, IκBα binds to 
NF-κB, inactivating the transcription factor. Therefore, a decrease in IκBα results in an increase 
in NF-κB activity (Frakes et al., 2014). Western blots probed with an antibody specific to IκBα 
showed lower IκBα levels in neuronal samples when compared to those from mixed cultures 
(Figure 3.19). This is expected since IκBα is found predominantly in glia (Kopitar-Jerala, 2015). 
However, treatment with Aß or minocycline in either mixed or neuronal cultures did not appear 
to affect IκBα levels. IκBα must be phosphorylated in order to release NF-Κb. Unfortunately, 
reagents to examine IκBα phosphorylation were not available to allow any further 
investigations. In summary, the results of experiments using 14 DIV primary cortical cultures 
suggest that astrocytes are not important mediator of Aß-induced cell death, tau 
phosphorylation or cleavage. However, cortical astrocytes may play a role in mediating levels of 





Figure 3.19: Minocycline and Aß treatment has no effect on IκBα levels in primary cortical 
cultures 
A. Representative western blots of lysates from mixed (neuron + astrocyte) and neuronal 
cultures treated with 10 µM Aß for 48 h, with and without 3 h pre-treatment with 20 µM 
minocycline. Blots were probed with antibodies against IκBα and ß-actin as a loading control. 
Molecular weight markers are shown on the left. B. Bar chart show quantification of IκBα as a 
proportion of ß-actin. N=9. Data is mean ± SEM as a percentage of mixed or neuronal culture 
CTRL conditions. Statistical test used: two-way ANOVA.  
 
3.3.4 Astrocytes may mediate some Aß-induced changes in primary hippocampal cultures 
To determine if hippocampal astrocytes and neurons respond differently to stimulation with Aß, 
the experiments described above were repeated in primary hippocampal cultures. Mixed and 
primary hippocampal cells were cultured and treated with 20 µM minocycline and/or 10 µM 
synthetic Aß1-42 treatment as described above. At 14 DIV cells were lysed and standardised to 
total protein levels before being run on western blots. As described for cortical neurons, lysates 
were first assessed using western blots probed with an antibody against GFAP to confirm the 
effectiveness of AraC treatment. These results showed that AraC had reduced, but not removed, 
astrocytes (Figure 3.20). For simplicity, these cultures are referred to as “neuronal”, however, it 
should be noted that there is still an astrocyte component to these cultures. 
In 14 DIV primary cortical cultures, astrocytes did not appear to influence the effects of Aß on 
neuron death (Figure 3.12). The contributions of astrocytes to Aß-induced hippocampal neuron 
death were investigated using the same methods. These results showed that Aß treatment 
significantly increased cell death compared to the control group in mixed (p<0.01), but not 
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neuronal cultures, suggesting that astrocytes contribute to Aß-induced neurotoxicity in 
hippocampal cultures (Figure 3.21). The Aß-induced increases in cell death in mixed cultures 
were not reduced by minocycline pre-treatment, however cell death in neuronal cultures pre-
treated with minocycline were significantly reduced compared to cultures treated with Aß.  
 
 
Figure 3.20: AraC treatment of primary hippocampal cultures reduces GFAP levels 
Representative western blot of lysates from primary hippocampal cultures treated with AraC 
(neuronal) or vehicle (mixed) in addition to 20 µM minocycline and/or 10 µM Aß and probed 
with antibodies against GFAP. ß-actin was used as a loading control. Molecular weight markers 
are shown on the left. 
 
To investigate this difference between primary cortical and hippocampal cultures further, 
experiments investigating the contributions of astrocytes to Aß-induced tau phosphorylation 
and cleavage were carried out in primary hippocampal cultures. As explained before, primary 
hippocampal cultures were treated with 0.5 µM AraC to create mixed and neuronal culture 
types. Cultures were treated with 20 µM minocycline at 11 DIV, before 10 µM synthetic Aß1-42 
treatment at 12 DIV. At 14 DIV cells were lysed and standardised to total protein levels before 
being run on western blots. Protein levels in each treatment group were also standardised to 
the levels seen in the control group of each culture type (e.g. mixed minocycline-treated cells 
standardised to mixed control cells). 
It was next important to determine if hippocampal astrocytes affect Aß-induced changes in tau 
in hippocampal neurons. Therefore, lysates from these cells were immunoblotted with 
antibodies against total and phosphorylated tau. The results obtained showed that there was 
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no significant change in total tau levels in mixed or neuronal treatment groups following Aß 
treatment when compared to the control conditions for each group (Figure 3.22 A, B).  
Aß did not affect tau phosphorylation at the PHF1 (tau phosphorylated at Ser396/404) or CP13 
(tau phosphorylated at Ser202) epitopes in either mixed or neuronal cultures. In contrast, 
minocycline significantly increased phosphorylation at the PHF1 sites in mixed cultures (p<0.01) 
and at the CP13 residue in both mixed and neuronal cultures (p<0.05 for both, Figure 3.22 A, C).  
No significant changes were found in amounts of caspase-cleaved tau following treatment with 
Aß in mixed or neuronal hippocampal cultures (Figure 3.22 A, E). There were apparent increases 
in cleaved (active) caspase-3 amounts in cells treated with Aß in both mixed and neuronal 
hippocampal cultures. However, statistical analysis of these results indicated that the increases 
were not significant, likely because of variability within groups (Figure 3.22 F). These results 
suggest that hippocampal astrocytes do not mediate tau cleavage by caspase 3, in contrast to 
findings in cortical cultures (Garwood et al., 2011). 
 
Figure 3.21: Astrocytes are involved in Aß-induced hippocampal cell death 
Bar chart showing incorporation of dead cell dye in mixed (neuron + astrocyte) and neuronal 
hippocampal cultures treated with 10 µM Aß for 48 h, with and without 3 h pre-treatment with 
20 µM minocycline. Data is mean ± SEM as a percentage of mixed or neuronal culture CTRL 







Figure 3.22: Minocycline increases tau phosphorylation in primary hippocampal cultures 
A. Representative western blots of lysates from primary mixed and neuronal hippocampal cell 
cultures treated with 20 µM minocycline and/or 10 µM synthetic Aß1-42 (Aß), and probed with 
antibodies against total tau, PHF1 (tau phosphorylated at Ser396/404), CP13 (tau 
phosphorylated at Ser202), caspase-cleaved tau (Asp421), cleaved caspase 3, IκBα and ß-actin 
as a loading control. Molecular weight markers are shown on the left. B-H. Bar charts show 
quantification of B. Total tau as a proportion of ß-actin. C. PHF1, D. CP13 and E. caspase-cleaved 
tau as a proportion of total tau, and F. cleaved caspase-3 as a proportion of ß-actin. N=5. Values 
represent mean ± SEM as a percentage of respective controls (CTRL). Statistical test used: two-




Overall, these results suggest that there are subtle differences in the contribution of astrocytes 
to Aß-induced cell death in hippocampal and cortical cultures. Astrocytes exacerbated Aß-
induced cell death in hippocampal, but not cortical cultures.  In addition, minocycline was found 
to have marked effects on tau phosphorylation in hippocampal, but not cortical cultures.  
 
3.3.5 Summary 
To summarise, the main findings of this chapter were: 
 Synthetic Aß1-42 is composed primarily of middle-high molecular weight oligomers, some 
of which are sensitive to SDS. 
 7PA2-derived Aß does not cause overt increases in tau phosphorylation and cleavage or 
cell death. However, this Aß causes robust cleavage and activation of caspase-3.  
 Astrocytes appear to mediate Aß-induced cell death in 14 DIV primary hippocampal, but 
not cortical cultures, in contrast to previous findings in 7 DIV cortical cultures (Garwood 
et al., 2011). 
 Astrocytes may be involved in mediating levels of extracellular tau in basal conditions. 
 Primary hippocampal cultures respond to minocycline treatment differently from 
primary cortical cultures.  
 
3.4 Discussion 
The main aim of this chapter was to investigate possible differences in the contributions of 
astrocytes to Aß-induced tau changes and cell death in primary cortical and hippocampal 
cultures. To do this, an established model in which Aß-induced effects were mediated by the 
anti-inflammatory actions of minocycline on astrocytes was used (Garwood et al., 2011). The 
results outlined here suggest that hippocampal, but not cortical, astrocytes may mediate the 
toxic effects of Aß. No effects of Aß on tau phosphorylation or cleavage were indicated, 
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however, evidence from this chapter implicates astrocytes in the maintenance of extracellular 
tau levels in basal conditions. In addition, there were differences in the way that primary cultures 
from different brain regions respond to minocycline. Finally, investigations into signalling 
pathways mediating Aß-induced changes in primary cortical cultures demonstrate that NF-κB 
levels are increased in cortical neural cells following Aß treatment. Together, these results 
suggest that astrocytes may play different roles in different brain regions. However, further 
investigations are required to determine the reproducibility of these results and the mechanisms 
involved. 
 
3.4.1 Aß characterisation 
The synthetic Aß1-42 used to treat cells in this chapter was extensively characterised. Results from 
multiple characterisation methods demonstrated consistently that the synthetic Aß1-42 used 
here is comprised mainly of medium-high molecular weight oligomers of around 100-140 kDa. 
This is important since evidence suggests that the most toxic species of Aß may be lower weight 
oligomers (Fa et al., 2010), although this is a highly debated issue (Walsh and Selkoe, 2007). 
While larger oligomers and tau aggregates are thought to still be toxic, the particular batches of 
Aß used in these experiments may not contain the most toxic Aß species, possibly explaining 
why robust Aß-induced tau changes and increased neuronal death were not reliably observed.  
Synthetic Aß has come under much criticism in the literature, as there is no standard preparation 
protocol or methods of interpreting results (Soto et al., 1995; Zagorski et al., 1999), discussed in 
greater detail in Chapter 6 (section 6.4.1). To determine if more physiological sources of Aß are 
a valid alternative, Aß derived from immortalised cell lines and from primary neurons expressing 
familial AD-causing mutant human APP (Walsh et al., 2002; Wu et al., 2012) were characterised.  
The first of these alternatives was Aß from primary mouse neurons cultured from Tg2576 mice 
(Wu et al., 2012). These mice overexpress human APP with the Swedish mutation and develop 
extensive amyloid pathology and age-dependent cognitive deficits (Hsiao et al., 1996). Results 
from this chapter found cultured neurons secrete low levels of Aß1-38 and Aß1-40. Aß1-42 is also 
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secreted at picomolar concentrations. No oligomeric Aß was detected from this conditioned 
medium, however when attempting to characterise such low concentrations it may be that Aß 
oligomer levels are below the levels of detection of the assay. These concentrations make 
Tg2576-derived Aß a possible alternative source providing treatment of primary neuronal 
cultures produces AD-like effects. Unfortunately, time constraints meant preliminary tests to 
investigate any effects of Tg2576-derived Aß were not possible. 
7PA2 CHO cells stably expressing familial AD causing mutant (V717F) human APP (Walsh et al., 
2002) were investigated as a second alternative source of soluble Aß. In culture, these cells 
release pg/ml levels of Aß into culture medium, which can be collected and used to treat primary 
cells. Like Tg2576-derived Aß, no oligomers were detected by MSD assay, however oligomers 
may be present but be at such low concentration that they were undetectable. As these are an 
immortalised cell line, cultures are much easier to maintain compared to transgenic primary 
neurons, allowing larger volumes of Aß-containing medium to be readily collected. Previous 
research has shown that treating neurons with 7PA2-derived Aß results in synapse dysfunction 
and LTP inhibition (Walsh et al., 2002), may impair actin cytoskeleton changes in response to 
learning and memory (Davis et al., 2011), effects neuronal microRNA expression via the NMDA 
receptor, and possibly increases reactive oxygen species (Li et al., 2014a). Results shown in this 
chapter demonstrate that 7PA2-derived Aß did not cause changes in tau phosphorylation or 
cleavage or in primary cortical culture viability. However, 7PA2-derived Aß did cause increased 
cleavage, and activation of caspase-3, an executioner caspase closely linked with cell death in 
AD (Chung et al., 2001; Snigdha et al., 2012). These data may suggest that 7PA2-derived Aß is 
detrimental to neurons, but that neurotoxicity takes place over longer periods of time than 
examined here. In further support of this, reduced levels of PSD-95, a post-synaptic marker, was 
also found with 7PA2-derived Aß treatment suggesting neurotoxicity could be beginning with 
synaptic dysfunction. Additionally, others in our laboratory have also shown marked decreases 




3.4.2 Aß-induced cell death and tau changes were not observed in 14 DIV primary cortical 
cultures 
Results from this chapter found no Aß-induced increases in cell death, tau phosphorylation or 
cleavage in primary cortical cultures, or differences in the effects of Aß in mixed or neuronal 
cultures, although trends towards significant increases in Aß-induced cell death were present in 
mixed but not neuronal cultures. These results do not support previously published research 
supporting an important role of astrocytes in mediating disease-associated changes in tau and 
neuron death in AD (Garwood et al., 2010; Sofroniew and Vinters, 2010; Garwood et al., 2011; 
Perez-Nievas et al., 2013; Jo et al., 2014b; Phillips et al., 2014). The reasons for these 
discrepancies are not clear. However, one major difference between Garwood et al. (2011) and 
the work presented here is the age of cultures used, 14 DIV here versus 7 DIV previously. There 
are a number of reports showing marked differences in the species of tau, maturity of astrocytes 
and neurons, and the susceptibility of different ages of primary neural cell cultures to specific 
insults (Larcher et al., 1992; Lesuisse and Martin, 2002; Cullen et al., 2010; Schildge et al., 2013; 
Calvo et al., 2015), and these effects may account for some of the differences observed between 
this study and published data.  
In addition, the synthetic Aß1-42 used to treat the cells in these experiments can show significant 
variability. Each batch of synthetic Aß1-42 bought by this laboratory is batch-tested to ensure it 
causes Aß-induced neurotoxicity in primary cultures. However, as previously mentioned, the 
literature suggests that synthetic Aß can vary not only between, but also within, batches (Stohr 
et al., 2012). This implies batch testing may not be thorough enough to ensure all synthetic Aß 
samples will cause neurotoxicity. 
Furthermore, at the time that these experiments were being conducted, there were some 
serious problems with infrastructure, and essential repairs were not made because of our 
pending move to a new building. There were problems with tissue culture sterility because of 
failing air-flow fans, and laboratory-grade water was infected for periods of time. As a result of 
these, and other issues, baseline cell death in primary cultures was often higher than desired. 
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Although all reasonable efforts were made to use the healthiest cultures possible for these 
experiments, it is possible that poor culture health will have masked the effects of Aß or 
minocycline, particularly in the primary cortical culture experiments conducted during this 
period of time.  
Nevertheless, the mechanisms underlying Aß-induced cell changes were investigated to explore 
possible influences of astrocytes. ICC experiments showed that NF-κB, a transcription factor 
involved in astrocyte activation and glial inflammatory responses (Lawrence, 2009), was visibly 
increased with Aß treatment, an increase rescued by minocycline pre-treatment. There is a 
wealth of evidence to suggest NF-κB and its downstream pathways have important 
contributions to the development of tau and other pathology in AD (Granic et al., 2009; Vincent 
et al., 2010; Cai et al., 2013; Shi et al., 2016). NF-κB is activated when IκBα is phosphorylated, 
thereby releasing NF-κB allowing it to translocate to the nucleus (Lawrence, 2009) and have 
transcriptional activity. Phosphorylation of IκBα is mediated by TLR function that is, in turn, 
mediated by stressors in the extracellular environment, for example, toxic Aß or high levels of 
oxidative stress (Yu and Ye, 2015). Activation of NF-κB is thought to trigger two main 
inflammatory reactions: upregulation of cytokine production by increasing their transcription in 
the nucleus (Wang et al., 2002), and secondly, induction of the inflammasome (Heneka et al., 
2015). This protein complex regulates caspase-1-mediated cleavage and activation of pro-
cytokines, including IL-1ß and IL-18 (Choi and Ryter, 2014). Together, these two main functions 
of NF-κB allow Aß and other triggers to initiate a glial inflammatory response by increasing 
cytokine transcription, maturation and release.  
However, Aß-induced increases in NF-κB appeared not to be predominantly co-localised with 
GFAP, suggesting that NF-κB increases occurred in neurons. NF-κB also acts as a neuronal 
transcription factor (Kaltschmidt et al., 1994; Deng et al., 2014). Activation of neuronal NF-κB 
contributes to cell death in ischaemia and is also implicated in AD (Zhang et al., 2005). 
Furthermore, treatment with a neuroprotective antioxidant was shown to prevent NF-κB 
activation and inhibit neuronal death (Stephenson et al., 2000). However, NF-κB is also required 
161 
 
for neuronal survival (Lilienbaum and Israel, 2003) and may play some neuroprotective role in 
neurons in response to Aß (Kaltschmidt et al., 1997). However, the same paper found increases 
in NF-κB activation in neurons closest to Aß plaques and concluded that this increase in activity 
is responsible, partly, for the increase in pro-inflammatory gene transcription seen in diseased 
neurons (Kaltschmidt et al., 1997).  
Western blots investigating the levels of IκBα did not show changes with Aß or minocycline 
treatment. This does not necessarily contradict the results obtained with NF-κB 
immunofluorescence, since IκBα must be phosphorylated to activate NF-κB (Shi et al., 2016), 
and there may be changes in IκBα phosphorylation following treatment with Aß or minocycline. 
Unfortunately, antibodies raised against phosphorylated IκBα were not available to pursue this 
avenue of research further. 
Pro-inflammatory cytokines associated with AD, such as IL-1α and TNF-α, are thought to trigger 
activation of neuronal NF-κB (Pugazhenthi et al., 2013), which then upregulates transcription of 
a range of proteins, including BACE1, involved in APP processing and the production of Aß, 
inducing a pathological Aß production loop (Shi et al., 2016). While there was no robust evidence 
of Aß-induced cell death in these cultures, it is possible that events leading to neurotoxicity over 
longer periods of time may have been initiated. Observing the effects of Aß treatment (of any 
source) over longer periods of time may help to elucidate possible toxic outcomes related to NF-
κB. 
 
3.4.3 Astrocytes may regulate extracellular tau concentrations 
Recent evidence suggests that tau pathology is released and spreads trans-synaptically along 
anatomical connections throughout diseased brain (de Calignon et al., 2012; Liu et al., 2012; 
Hanger et al., 2014). Characterisation of tau species released from primary cortical neurons 
showed extracellular tau is largely dephosphorylated and full-length, as has been previously 
published (Pooler et al., 2013). Furthermore, results presented here show that the amount of 
extracellular tau is significantly increased in the absence of astrocytes. There were no significant 
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differences in cell viability between neuronal and mixed cultures, indicating that the increased 
extracellular tau did not arise from unhealthy cells with compromised plasma membranes. 
While there was not time to fully explore the mechanisms involved in this phenomenon here, 
astrocytes are known to take up extracellular tau following its propagation in vivo (de Calignon 
et al., 2012), and this may also occur in primary culture. Alternatively, in the absence of 
astrocytes, excess glutamate at the synapse may not be cleared from the synaptic space 
(Anderson and Swanson, 2000) dysregulating glutamatergic synaptic activity in neuronal 
cultures and increasing physiological tau release.  
Additional results examined tau release using Alphascreen assays and these did not substantiate 
the results showing the possible effects of astrocytes in regulating extracellular tau levels. The 
Alpha screen assay is known to be a less sensitive method for examining tau release, and this 
combined with the concentration of medium required for Alphascreens, may have affected 
these findings. Further investigations are required to better dissect possible functions of 
astrocytes in tau release and pathological tau propagation.  
 
3.4.4 Differences in Aß and minocycline effects in hippocampal cultures versus cortical 
cultures 
One of the main aims of this chapter was to determine if there are differences in roles of 
astrocytes in different brain regions. Therefore, hippocampal cultures were also treated with 
minocycline and synthetic Aß1-42. The results of these experiments showed Aß significantly 
increased cell death in hippocampal cultures containing astrocytes, but not neuronal cultures, 
and minocycline only rescued the (non-significant) increases in Aß-induced neuron death in 
neuronal cultures. This is directly opposite to what has been previously published in primary 
cortical cultures (Garwood et al., 2011) and is also not consistent with results from primary 
cortical experiments described in this chapter. The potential reasons for these discrepancies are 
discussed above.  
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Furthermore, although Aß was found not to effect phosphorylation of tau at Ser396/404 or 
Ser202 epitopes in hippocampal cultures, phosphorylation at both epitopes was significantly 
increased following minocycline treatment. Some of these increases were also reduced when 
cultures were also treated with Aß, implying Aß treatment is rescuing the effects of minocycline. 
These results were unexpected and very difficult to rationalise. However, differences in the 
response of cytokines to minocycline in the hippocampus and cortex have been described 
previously (Levkovitz et al., 2015). It is possible that there are different targets of minocycline in 
different brain regions, indeed many different effects of this antibiotic have been described 
including downregulation of protein kinases and aggregation, reduced oxidative stress and 
increased scavenging of free radicals, and suppressed apoptosis (Chen et al., 2000; Tikka and 
Koistinaho, 2001; Lin et al., 2003; Familian et al., 2006; Ryu et al., 2006).  
In conclusion, these results described here show that astrocytes may show differential 
responses in different brain regions, however, it was difficult to fully elucidate these in the 
cultures described here. Since this project started, there is an increasing body of research 
indicating astrocytes contribute differently to neuronal health in different brain regions and 
suggesting there are regional subspecies of astrocytes (Grolla et al., 2013; Rodriguez et al., 2014; 
Magnusson and Frisen, 2016). If therapeutic compounds targeting astrocytes are taken forward 
to clinical trials for AD, it will be of great importance to have better described these regional 
differences to increase the likelihood of obtaining disease modifying effects of treatments at 
different stages of AD.  
 
3.4.5 Conclusions 
To conclude, this chapter provides evidence that astrocytes are involved in mediating Aß-
induced neurotoxicity, particularly in 14 DIV primary hippocampal cultures. There were subtle 
differences in responses to Aß in cortical and hippocampal cultures. In addition, experiments in 
primary cortical cultures provide evidence in support of the idea that astrocytes mediate 
extracellular tau concentrations in basal conditions. Perhaps most importantly, the experiments 
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described in this chapter clearly highlight the challenges with using synthetic and naturally 
secreted species of Aß. Experiments generally showed considerable variation, often preventing 




Chapter 4: Exploring the potential of dimethyl fumarate 
repurposing for Alzheimer’s disease 
 
4.1 Introduction 
As discussed in Chapter 1:, there is a large amount of research suggesting that 
neuroinflammation plays an important role in the development of AD pathology, rather than 
being merely a side-effect of disease progression (Olabarria et al., 2010; Perez-Nievas et al., 
2013; Phillips et al., 2014; Heppner et al., 2015). Evidence suggests inflammation has an 
important role in the progression of early-onset AD, caused by mutations in the APP or PSEN 
genes, with activated astrocyte and microglia collecting around Aß plaques in cases with PSEN1 
mutations (Shepherd et al., 2005). Furthermore, PSEN1 plays a key role in both age-dependent 
Aß accumulation and related inflammation, including glial and pro-inflammatory gene activation 
with early-onset AD-causing PSEN mutations accentuating inflammation (Saura, 2010). 
However, neuroinflammation has been particularly associated with late-onset AD as an 
increasing number of genes related to the immune response, including TREM2, CR1 and CD33, 
have been highlighted as genetic risk factors for late-onset AD (Guerreiro et al., 2013; Heneka 
et al., 2015; Karch and Goate, 2015; Villegas-Llerena et al., 2016). It is thought genetic variants 
of these inflammation-linked genes may increase the innate immune reaction and initial glial 
activation to a range of triggers, including aging and environmental factors. In turn, with 
additional activation of glia by Aß oligomers and deposits, this initial non-pathological 
inflammation can become chronic and pathological resulting in the synaptic dysfunction and 
neuron loss seen in AD (Heneka et al., 2015; Heneka et al., 2016).  
In support of inflammation as an important trigger in late-onset AD, treatments aimed at 
reducing neuroinflammation and astrocyte activation have shown some success at improving 
AD-like pathology. For example, work in our laboratory has shown that minocycline, a 
tetracycline antibiotic derivative with anti-inflammatory action, described in Chapter 3:, reduces 
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tau pathology, astrogliosis and CNS cytokine content in htau mice (Noble et al., 2009b; Garwood 
et al., 2010). More recently, JQ1, a BET-bromodomain inhibitor was found to reduce pro-
inflammatory modulators and tau phosphorylation at an AD-relevant site in another AD mouse 
model (Magistri et al., 2016). Emerging evidence suggests there are differences in the effects of 
anti-inflammatory treatments on amyloid- and tau-mediated neurodegeneration (Phillips et al., 
2014). Attempts to attenuate astrocyte activation and inflammatory processes in AD mouse 
models by crossing APP/PS1 mice with GFAP and vimentin knockout mice resulted in 
exacerbation of Aß plaque pathology and increased dystrophic neurons (Kraft et al., 2013). 
However, over-expression of the pro-inflammatory mediator IL-1ß reduces Aß burden, yet 
exacerbates the development of tau pathology in 3xTg-AD mice (Ghosh et al., 2013). 
The potential benefit of anti-inflammatory treatments for AD patients is also unclear. A review 
of the overall chance of individuals exposed to anti-inflammatory drugs developing AD, 
compared to the general population, suggested anti-inflammatory drugs have a protective effect 
against AD development (McGeer and McGeer, 1996). However, there is a lot of variability in 
the outcome of such epidemiological studies. For example, non-selective anti-inflammatory 
drugs such as NSAIDs (non-steroidal anti-inflammatory drugs, e.g. ibuprofen) have shown few 
effects in multiple clinical trials for AD and overall meta-analysis of these studies suggest NSAIDs 
do not improve or prevent AD symptoms (Miguel-Alvarez et al., 2015).  
Astrocyte and microglial activation results in the initiation of multiple independent 
inflammatory signalling pathways that could be involved in either the acceleration or inhibition 
of disease pathology (Morales et al., 2014). By investigating the mechanisms and effects of each 
pathway it may be possible to highlight those that need to be upregulated, and those that need 
to be suppressed, in order to reverse or prevent the progression of AD. Inflammatory signalling 
pathways induced by astrocyte activation commonly involve an increase in the release of specific 
cytokines and chemokines from astrocytes into the extracellular space. These small signalling 
molecules are then able to activate receptors on nearby neurons, initiating signalling cascades 
that affect abnormal processing of Alzheimer’s-relevant proteins, including tau (Zheng et al., 
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2016). Effective drugs are likely to target specific inflammatory pathways, inhibiting destructive 
pathways or upregulating protective pathways. For example, treatment with minocycline 
resulted in the reduction of multiple pro-inflammatory cytokines suggesting the reduction in tau 
pathology could be due to reduced activity of downstream signalling pathways (Garwood et al., 
2011). Furthermore, modulation of specific cytokines, such as IL-1ß and IL-10, by both 
pharmacological and genetic means, have shown that changes in specific cytokine levels have 
clear beneficial effects on the severity of tau and other AD-like pathology (Kitazawa et al., 2012; 
Ghosh et al., 2013; Chakrabarty et al., 2015). Thus, further investigation of compounds that have 
anti-inflammatory effects might reveal novel signalling targets that could be specifically targeted 
in future studies. 
Once a drug has been shown to improve pathology and/or behavioural deficits in culture and 
rodent models, clinical trials investigating the efficacy and safety of these treatments must be 
carried out before its clinical benefit is tested in long-term, high-powered, clinical trials. These 
tests are time-consuming and highly costly (Institute of Medicine (US) Forum on Drug Discovery, 
2010), increasing the time taken for successful treatments to reach patients. Initial phases of 
clinical trials (Phases 0 and I) focus on the pharmacodynamics and pharmacokinetics of 
therapies, for example, bloodstream absorbance, blood-brain barrier penetrance, and side 
effect/safety profiles. An alternative to new treatments is to focus on the repurposing of 
treatments already in clinical use or those that have failed efficacy trials for other medical 
problems. Such an approach is suggested to increase clinical trial safety since drugs with severe 
side effects have already been excluded (Appleby et al., 2013). Several publications have now 
highlighted the possibility of repurposing anti-inflammatory medications as a possible avenue 
for Alzheimer’s drug discovery (Corbett et al., 2012; Appleby et al., 2013).  
Dimethyl fumarate (DMF), also known as Tecfidera or BG-12, is a nuclear factor erythroid 2-
related factor 2 (Nrf2) activator with poorly understood anti-inflammatory actions. DMF readily 
crosses the blood-brain barrier and was recently licenced for use in multiple sclerosis patients 
in both the US and the EU (FDA, March 2013; EU CHMP, Feb 2014) based on Phase III clinical 
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trials which demonstrated that DMF significantly reduced relapse rate and slowed rate of 
disability progression in relapsing-remitting multiple sclerosis (Fox et al., 2012; Gold et al., 2012). 
DMF was thought to have good potential for repurposing since it appears to be protective 
against oxidative stress (Lee et al., 2012), attenuates spatial memory impairments and 
hippocampal degeneration in rats (Majkutewicz et al., 2016) and reduces synucleinopathy in 
Parkinson’s models (Lastres-Becker et al., 2016).  
Therefore, it was of interest to determine the effects of DMF treatment on astrocyte-mediated 
changes in tau. The effects of DMF on astrocyte activation and tau phosphorylation were first 
investigated in rat primary mixed neuron and astrocyte cultures. Promising findings in this model 
prompted investigation of DMF effects in a model of tauopathy in vivo with the main hypothesis 
that DMF would reduce tau phosphorylation and related pathology (e.g. tau aggregation) in the 
htau mouse brain. 
The in vivo studies were conducted using htau mice. This mouse model, generated by crossing 
mice over-expressing the entire wildtype human tau gene (Duff et al., 2000) with a tau knock-
out mouse line (Tucker et al., 2001), was developed by Andorfer and colleagues (Andorfer et al., 
2003). The resulting htau offspring overexpress the six isoforms of human tau found prominently 
in adult human CNS on a mouse tau knockout background. Htau mice show an age-dependent 
degenerative phenotype with a range of pathological brain changes. Increased tau 
phosphorylation, cleavage and aggregation into paired helical filaments and tangle-like 
structures have been well documented in these mice (Andorfer et al., 2003; Kelleher et al., 2007; 
Noble et al., 2009b), accompanied by astrocyte activation and neuroinflammatory changes 
(Garwood et al., 2010). Furthermore, htau mice show impairments in object recognition and 
spatial memory (Polydoro et al., 2009) followed by significant neuronal loss and cortical thinning 
in 8 month-old and older mice (Andorfer et al., 2005). While htau mice have no Aß pathology, 
the nature of the tau pathology, such as the formation of paired helical filaments 
indistinguishable from those extracted from AD brain when examined by electron microscopy 
(Andorfer et al., 2003), and marked tau-dependent behavioural deficits (Polydoro et al., 2009) 
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indicate that these animals are a good model for examining AD-relevant pathological changes in 
tau. Their relevance for examining the influence of neuron-glial interactions on tau has also been 
elegantly demonstrated (Bhaskar et al., 2010; Maphis et al., 2015).  
The aims of this chapter were to: 
 Investigate the effect of DMF treatment on astrocyte activation and tau phosphorylation 
in rat mixed primary cell cultures. 
 Conduct pilot studies to examine the effects of DMF treatment on biochemical and 
behavioural phenotypes in htau mice. 
 Explore possible mechanistic pathways linking DMF to changes in tau in primary cultures 
and htau mice. 
 
4.2 Methods 
Materials and methods used in this chapter, included detailed methodology for the production 
of primary cell cultures, were described in Chapter 2 (sections 2.1). For primer design for mouse 
genotyping see Chapter 2, section 2.3.1). 
For all cell culture experiments, 13 DIV mixed primary cortical cultures were treated with DMF 
for 24 h and then lysed using methods described in Chapter 2, section 2.4.1. Lysates were 
standardised to total protein concentration using a BCA assay (Chapter 2, section 2.4.2) and run 
on 10 % tris-glycine gels for western blotting (see Chapter 2, section 2.6). 
Htau mice were genotyped as outlined in Chapter 2 (section 2.3.1). Two separate cohorts of 
homozygous htau mice were used in this study to represent different disease stages: 
1.  8-9 months old, show only small increases in tau phosphorylation and some tau 
aggregation. 




Both cohorts were comprised of approximately equal numbers of male and female mice. A small 
number of littermate wild-type (WT) mice of 13-14 months old were also assessed. Some htau 
mice in this cohort were left untreated to determine any effects of mouse handling for 
behavioural analysis and treatment (Table 4.1).  
 
DMF (15 mg/kg) was administered via oral syringe twice daily (Eichenbaum et al., 2011) as 
described in Chapter 2 (section 0). 13-14 month old mice were tested for spatial memory deficits 
using the Morris water maze as described in Chapter 2 (section 2.8.3).  
Following the final treatment mice were sacrificed by cervical dislocation (for full methods see 
Chapter 2, section 2.3.2) and the brains removed. The brain was crudely dissected into frontal, 
temporal, hippocampal, occipital/parietal and cerebellum regions then rapidly snap frozen in 
liquid nitrogen for biochemical analysis as described in Chapter 2, section 2.4.1. 
 















Table 4.1: Mice used in DMF pilot study 






4.3.1 Preliminary work 
Generation of primary cell cultures 
Rat primary mixed cortical cultures were prepared from E18 Sprague Dawley rat embryos and 
cultured for 13 DIV before treatment with DMF for 24 h. Cultures were assessed at 14 DIV since 
they have developed functional synapses by this developmental stage (Maeda et al., 1995; 
Grabrucker et al., 2009). These rat primary mixed cortical cell cultures are described in more 
detail in Chapter 3 (section 3.3.1). 
Assessing DMF toxicity in primary cortical cultures 
The literature and reagent safety data sheet suggest using low concentrations of DMSO as a 
vehicle for DMF, to encourage full dissolution. DMSO is a common solvent, often used for cell 
culture, however it is also toxic to cells at concentrations above 0.5 % (v/v) (Hanslick et al., 2009). 
Therefore, an assessment of primary cell culture tolerance of DMF and DMSO was first 
necessary. Previous studies suggest treating cell cultures with 10-30 µM DMF for 24 h (Wierinckx 
et al., 2005; Wilms et al., 2010; Albrecht et al., 2012). Therefore, a dose-response including these 
concentrations was first conducted.  
A stock solution of 1 mM DMF in 1 % (w/v) DMSO was prepared. Both DMF and DMSO were 
diluted in culture medium to give final concentrations in culture of 0.1 µM – 1 mM DMF and 
0.0001 – 1 % (v/v) DMSO. The corresponding concentration of DMSO was used as a control for 
each DMF treatment. Cultures were treated at 13 DIV for 24 h. Cell viability was measured at 14 
DIV using a LIVE/DEAD assay, as described in Chapter 2 (section 2.2.5). Incorporation of the dead 
cell dye by cells with compromised membranes gives a measure of cell death. The results of 
these experiments showed that treatment with 1 mM DMF and 1 % DMSO caused increased 
amounts of cell death relative to control untreated cells (CTRL). Concentrations of 100 µM DMF 
or less, and respective DMSO treatments, did not reduce cell viability in comparison to untreated 
control cultures (Figure 4.1). As a result of these experiments treatment concentrations of 30 
172 
 
µM and 60 µM DMF (0.03 % and 0.06 % DMSO, respectively) were chosen for subsequent cell 
culture experiments since these were the highest doses tested that showed no apparent toxicity. 
Breeding and genotyping of htau mice 
Htau pups were ear punched and genotyped using PCR to ensure (1) the presence of the human 
tau gene, (2) absence of endogenous tau and (3) eGFP, the targeted insertion of which disrupts 
endogenous tau expression.  Samples in which a GFP band (173 kb) is detected in the absence 
of mouse tau (187 kb) indicate a mouse with a homozygous mouse tau gene knock-out. DNA 
from htau mice homozygous for human tau showed a strong band at 187 kb when amplified 
with human tau-specific primers, while mice heterozygous for human tau show multiple faint 
bands at 187 kb and larger (Figure 4.2).  
 
 
Figure 4.1: Cell death in DMF-treated rat primary mixed cortical cultures 
Bar chart shows intensity of LIVE/DEAD dye incorporation, measured by the density of dye 
staining, as an indicator of cell death, in primary cultures treated with 0.1 µM - 1 mM dimethyl 
fumarate (DMF) in comparison to cultures treated with DMSO and untreated control (CTRL) 






Figure 4.2: Htau genotyping 
Primers against human tau amplify only the human tau transgene (187 kb), mouse tau primers 
detect endogenous tau only (187 kb), GFP primers detect a targeted insertion of GFP (173 kb) 
used to disrupt the endogenous tau gene.  Examples of transcripts detected in mice homozygous 
or heterozygous for human tau expression and mouse tau knock-out are shown. Base pair 
markers on right. Lane 1 shows transcripts amplified from an htau mouse ear-punch. 
 
4.3.2 The effects of DMF on tau and astrocytes in mixed primary cortical cultures 
To begin to understand if DMF might have benefit in models of AD, 13 DIV primary mixed cortical 
cultures containing astrocytes and neurons were treated with 30-60 µM DMF for 24 h. Following 
treatment, cell lysates were collected for analysis of changes in the astrocyte marker GFAP, total 
tau amounts and tau phosphorylation at epitopes known to be abnormally phosphorylated in 
AD brain (Hanger et al., 2009). 
DMF treatment reduces tau phosphorylation in primary cortical cultures 
Mixed primary cortical cultures were treated with 30 µM and 60 µM DMF and lysed after 24 h. 
Lysates were normalised for protein content and western blotting with antibodies against total 
and phosphorylated tau performed. Quantification of signal intensity from total tau 
immunoblots showed that there was no change in total tau levels when cells were treated with 
30 and 60 µM DMF relative to controls (Figure 4.3 A). This suggests that DMF does not affect 
either expression or turnover of tau. 
When western blots were probed with the PHF1 antibody, no changes in tau phosphorylation at 
Ser396/404 were found following DMF treatment of cells in comparison to those treated with 
vehicle (Figure 4.3 A). However, when phosphorylation at Ser202 was examined using the CP13 
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antibody, treatment of cells with 60 µM DMF resulted in reduced signal intensity. When this 
signal was quantified as a proportion of total tau, 60 µM DMF was found to have significantly 
reduced tau phosphorylation at the CP13 epitope relative to controls (p<0.05). Lysates from 
cultures treated with 30 µM DMF also showed reduced levels of CP13 on western blots, but 
quantification of this change showed that this reduction did not reach statistical significance 
(Figure 4.3 A, B).  
Western blots were also probed with the Tau-1 antibody that detects tau dephosphorylated at 
Ser199/202/Thr205 (Szendrei et al., 1993). Western blots probed with Tau-1 showed a trend 
towards increased Tau-1 immunoreactive tau with increasing concentration of DMF treatment, 
however quantification of these signals showed the differences did not reach statistical 
significance relative to lysates from control cultures (Figure 4.3 A). Since the western blotting 
data suggested that there might be subtle changes in phosphorylation of tau at the Tau-1 
epitope, lysates from these cultures were also assessed by semi-quantitative tau ELISA using 
antibodies against total tau and Tau-1 (for method see Chapter 2, section 2.7). Using this more 
sensitive method, the increase in Tau-1 amount as a proportion of total tau was found to be 
significantly increased following treatment of cells with 60 µM DMF in comparison to vehicle-
treated cultures (Figure 4.3 C). A clear dose-dependent effect of increasing DMF concentration 
could also be observed. These data indicate that DMF treatment results in significantly reduced 
tau phosphorylation at specific tau epitopes known to be abnormally phosphorylated in AD brain 
(Hanger et al., 2009) and suggest that DMF is worth pursuing to determine if it has beneficial 
effects in models of tauopathy.  
DMF treatment does not reduce astrocyte activation in primary cortical cultures 
DMF has been previously shown to have microglial and astrocytic anti-inflammatory effects 
(Wilms et al., 2010) so it was of interest to determine if the tau changes seen with DMF 
treatment may be due to DMF effects on astrocytic activation and induction of inflammatory 
signalling. There are no microglia in the primary cortical cultures used for these experiments, 
however, this laboratory has previously shown a connection between astrocytic inflammatory 
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signalling and changes in tau phosphorylation (Garwood et al., 2011). Therefore, changes in 
astrocyte activation were first explored using GFAP as a marker of activated astrocytes. Lysates 
from control and DMF treated cultures were assessed by western blotting using an antibody 
against GFAP. No apparent changes in GFAP amounts were observed on blots, and quantification 
of signal intensity relative to ß-actin showed that neither concentration of DMF reduced GFAP 
amounts relative to control cultures (Figure 4.3 A). This suggests the reductions in tau 
phosphorylation resulting from DMF treatment may not occur via alterations in astrocyte 
activity, although this does not necessarily exclude an effect of DMF on inflammatory signalling.  
Overall, these preliminary experiments show that DMF treatment readily reduces tau 
phosphorylation in primary cell cultures, likely independent of effects on astrocyte activation. 
The significantly reduced tau phosphorylation observed suggested that DMF was worth pursuing 
in pilot studies in an in vivo model of tauopathy.   
4.3.3 DMF treatment of htau mice 
Since DMF showed good potential for lowering tau phosphorylation in primary cell culture and 
has shown few side-effects when used previously to treat mice with a range of neurological 
conditions (Heiligenhaus et al., 2004; Schilling et al., 2006; Lee et al., 2012; Lastres-Becker et al., 
2016), the effect of DMF in vivo was next assessed in a pilot study using the htau mouse model 
of tauopathy. Two ages of mice were treated, 13-14 month old mice which represent a mid-
disease stage with significant tau phosphorylation and aggregation apparent, and 8-9 month old 
younger mice which have milder disease-associated tau abnormalities (Andorfer et al., 2003; 




Figure 4.3: DMF treatment reduces tau phosphorylation at some residues but has no effect on 
total tau or GFAP levels in primary rat mixed cortical cultures 
A. Representative western blots of DMF-treated lysates probed with antibodies against total 
tau, tau phosphorylated at Ser396/404 (PHF1), Ser202 (CP13), tau dephosphorylated at 
Ser199/202/Thr205 (Tau-1) and GFAP. Blots were also probed with an antibody against ß-actin 
as a loading control. Molecular weight markers are shown on the right. B. Bar chart shows 
quantification of western blotting. Tau phosphorylated at Ser202 was analysed as a proportion 
of total tau (n=15) C. Bar chart shows quantification of tau dephosphorylated at the Tau-1 
epitope as a proportion of total tau as determined by tau ELISA (n=6). Values shown are mean ± 
SEM as percentage control (CTRL). Data was analysed by one-way ANOVA. * = p<0.05.  
 
DMF treatment does not affect htau performance in the Morris water maze 
Tau is closely associated with synaptic degeneration and dementia in AD (Perez-Nievas et al., 
2013), therefore cognitive function in the 13-14 month old aged mice was examined using the 
Morris water maze during the period of time they were treated (see treatment schedule Chapter 
2, section 2.3.2).  The Morris water maze (Morris, 1984) has been used previously to 
demonstrate age-dependent spatial learning deficits in htau mice (Polydoro et al., 2009). In 
addition, the water maze is known to test hippocampal-dependent spatial memory (Bromley-
Brits et al., 2011). This is important because hippocampal pathology and deficits in hippocampal-
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dependent functions are among the earliest abnormalities observed in AD patients (Dhikav and 
Anand, 2011; Jahn, 2013).  
Mice were trained in the Morris water maze before and after treatment with DMF to find a 
hidden platform for five consecutive days. To allow the mice to learn the platform location, the 
platform was visible on the first day. A probe trial was conducted after the final day of hidden 
platform testing, during which the platform was removed. The time required to find the hidden 
platform during training, and the percentage time spent in each quadrant during the probe trial 
were determined.  
Mice were randomly assigned to treatment groups prior to the first administration of DMF and 
performance in the Morris water maze was determined for each group. Prior to administration 
of DMF, neither WT or htau mice showed changes in the time taken to find the hidden platform 
as training progressed from day 0 to day 4 (Figure 4.4 A). The average distance swum by the 
mice as the trial progressed also appeared to remain unchanged (Figure 4.4 C). Additionally, 
mice did not appear to search more in the platform quadrant when a probe test was carried out 
on day 4 (Figure 4.4 B). This might suggest that htau mouse hippocampal-dependent spatial 
memory is impaired which would be expected based on previous behavioural studies of this 
mouse model (Polydoro et al., 2009). However, results from the small number of WT mice 
included in the study appeared to follow the same pattern as that of htau mice, so it is not 
possible to state that the htau mice had a behavioural deficit with any certainty.  
 
Following administration of DMF twice daily for 14 days, the same mice were re-tested on the 
Morris water maze test during the last five days of DMF treatment. No differences were 
apparent between DMF treated and control groups (vehicle-treated and untreated controls) or 
between htau mice and WTs in either the training days or the probe trial (Figure 4.4 D-E). 
Overall, the analysis of these Morris water maze results suggests DMF treatment has had no 
effect on the hippocampal-dependent spatial memory in treated mice. However, biochemical 
changes in AD-relevant proteins are apparent a long time in advance of cognitive deficits being 
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seen (Braak et al., 2011; Mufson et al., 2016), therefore it was important to investigate the 
effects of DMF on disease-relevant protein changes in htau brain.   
 
 
Figure 4.4: DMF treatment does not improve Morris water maze performance 
A. Line graph shows time taken for 13-14 month old mice to find the hidden platform in pre-
treatment water maze according to genotype and treatment group. B. Bar chart shows time 
mice spent in target quadrant during the probe test prior to DMF treatment. C. Line graph shows 
distance swum by mice to find the hidden platform in pre-treatment water maze according to 
genotype and treatment group. D. Line graphs show time taken for mice to find the hidden 
platform post-treatment. E. Bar chart shows time mice spent in target quadrant during probe 
test after DMF treatment.  VL indicates training day when platform was visible. Days 1, 2, 3 and 
4 indicate each consecutive day of hidden platform training. DMF htau: n=4, VEH htau: n=5, CTRL 




Analysis of the effects of DMF on tau proteins in aged htau mice 
Homogenates from the frontal cortices of 13-14 month old aged mice were run on western blots 
and probed with antibodies against total and phosphorylated tau. Treatment with DMF led to 
no apparent changes in total tau as labelled by the DAKO tau antibody (Figure 4.5 A). However, 
when total tau was immunoblotted with antibody specific to human tau (CP27) there appeared 
to be a decrease in tau amounts in htau mice treated with vehicle or DMF relative to untreated 
mice, suggesting that the vehicle had an effect on human tau levels (Figure 4.5 A). Only daily 
handling and twice daily oral administration of a sugar solution differentiated the vehicle-
treated and untreated control groups in the preclinical trial. It is unexpected that handling and 
treatment of the mice with the vehicle solution could produce significant changes in brain 
biochemistry. Furthermore, since htau mice only express human tau, the CP27 and total tau 
blots should be detecting the same tau protein, so the reason for the difference in findings when 
samples were immunoblotted with DAKO and CP27 is difficult to explain. These results might 
suggest, however, that DMF has an effect on total tau amounts through a mechanism that is not 
understood. Quantification of human tau and total tau immunoreactivity in htau brain samples 
following normalisation to ß-actin confirmed that there was a significant decrease in human, but 
not total, tau in DMF treated mice (Figure 4.5 B, C).  Immunoblots of WT mouse brain showed 
less total tau than htau mice and no detectable human tau (Figure 4.5 A). This is expected as 
human tau is over expressed in htau mice, resulting in total tau amounts in homozygotes that 
are 3-4 times higher than in WT mice (Duff et al., 2000; Andorfer et al., 2003). 
Since treatment of primary cortical cultures with DMF showed an effect of treatment on tau 
phosphorylation, it was important to determine if DMF treatment of htau mice had a similar 
effect. The same brain homogenates used to investigate differences in human and total tau were 
also probed with the same range of phospho-specific antibodies as used in DMF cell culture 
experiments previously described in this chapter (section 4.3.2). These phospho-specific 
antibodies were chosen because they bind to tau epitopes known to be abnormally 
phosphorylated in AD (Augustinack et al., 2002; Hanger et al., 2009; Mondragon-Rodriguez et 
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al., 2014). When western blots were probed with the CP13 and PHF1 antibodies it was obvious 
that there was less phosphorylation in WT brain compared to htau brain, as expected (Figure 
4.5 A). The CP13 and PHF1 signals were quantified as a proportion of total tau in Figure 4.5 D, E, 
and suggest increased tau phosphorylation in htau mice as expected.  
Probing western blots with Tau-1, an antibody that binds specifically to tau dephosphorylated 
at Ser199/202/Thr205, showed stronger bands in WT than in htau brain homogenates (Figure 
4.5 A). This is reflected in the quantification of these blots in Figure 4.5 F. It is likely that a 
substantial percentage of tau in the WT mouse brain is dephosphorylated at these epitopes as 
increased phosphorylation at these sites has been associated with abnormal tau pathology and 
NFT formation (Augustinack et al., 2002). 
There were no apparent differences in tau phosphorylation in DMF-treated animals relative to 
controls in immunoblots probed with antibodies against phosphorylated tau (Figure 4.5 A). 
Quantification and statistical analysis of tau phosphorylation as a proportion of total tau 
confirmed that there were no significant differences between DMF treated, vehicle-treated and 
untreated control aged htau mice (Figure 4.5 D-F). This suggests that DMF does not reduce tau 
phosphorylation in the frontal cortex of the htau brain, at least not at the phospho-epitopes 
tested here. These in vivo findings are in contrast to the results of cell culture experiments 




Figure 4.5: Total and phosphorylated tau levels are not changed by DMF treatment in vivo 
A. Western blots of frontal brain homogenate from DMF or vehicle-treated and untreated 
control 13-14 month old htau and WT mice probed with antibodies against human tau (CP27) 
total tau (DAKO), tau phosphorylated at Ser396/404 (PHF1), Ser202 (CP13) and tau 
dephosphorylated at Ser199/202/Thr205 (Tau-1). Blots were also probed with an antibody 
against ß-actin as a loading control. Molecular weight markers are shown on the left. B.-F. Bar 
charts show quantification of western blotting. Human tau (B.) and total tau (DAKO) (C.) were 
analysed as a proportion of ß-actin. Tau phosphorylated at Ser396/404 (PHF1) (D.), Ser202 
(CP13) (E.) and tau dephosphorylated at Ser199/202/Thr205 (Tau-1) (F.) were analysed as a 
proportion of total tau (DAKO). Htau DMF: n=4, htau VEH: n=5, htau CTRL: n=3, WT DMF: n=1, 
WT VEH: n=1. Values shown are mean ± SEM as percentage htau control (CTRL). Data was 
analysed by one-way ANOVA. * = p<0.05, ** = p<0.01. 
 
Sarkosyl extraction of insoluble tau 
Insoluble tau aggregates accumulate in pathological lesions in both human AD and htau mouse 
brain (Meraz-Rios et al., 2010; Cowan and Mudher, 2013), therefore investigating changes in tau 
aggregates could determine if DMF was having any effects on tau distinct from changes in 
phosphorylation. A sarkosyl extraction protocol was used to isolate insoluble tau from htau 
hippocampus. Previously published studies have used sarkosyl insolubility as a standard test for 
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insoluble tau aggregates and tangles (Julien et al., 2012). The tau isolated from brain by sarkosyl 
is representative of that deposited in NFTs (Noble et al., 2003). The sarkosyl isolation protocol 
gives rise to several fractions – a low speed supernatant (LSS) containing both sarkosyl soluble 
and insoluble tau, a high speed supernatant (HSS) containing only soluble tau, and the high 
speed pellet which contains sarkosyl insoluble tau. The LSS and resuspended sarkosyl-insoluble 
pellets from aged htau mouse brain samples were western blotted with antibodies specific to 
total and phosphorylated tau. WT brain samples were not used as no sarkosyl insoluble tau 
would be expected in these homogenates. There were no apparent changes in tau protein 
amounts following treatment of htau mice with DMF. Quantification of total tau amounts 
showed no differences in tau phosphorylation at the PHF1 epitope as a proportion of total tau 
in the LSS following treatment with DMF (data not shown). In addition, there were also no 
significant changes in sarkosyl insoluble tau amounts, once normalised to tau content in the LSS, 
between DMF and vehicle-treated htau mice (Figure 4.6). It was clear that the sarkosyl insoluble 
tau was somewhat phosphorylated by the signals detected on western blots, however this could 
not be quantified as there was too little protein detected to produce clear bands (Figure 4.6 A). 
Taken together, these results suggest that DMF treatment does not affect the pathological 
phosphorylation and aggregation of tau characteristic of aged htau transgenic mice. However, 
it is possible that the pathology in these older mice is already too severe for DMF to have a 
significant effect. For this reason, the same treatment protocol was repeated in younger (8-9 
month old) mice which represent an early disease stage (Kelleher et al., 2007). 
Analysis of the effects of DMF on tau proteins in younger htau mice 
Frontal cortices of younger htau mice (8-9 month old) were homogenised and ran on western 
blots to investigate the effects of DMF treatment at an earlier disease stage than previously 
examined above. Blots were probed with antibodies against total and phosphorylated tau as 
before. At 8-9 months of age htau mice should show less tau pathology than those at 13-14 
months of age, however tau proteins show increased phosphorylation (Andorfer et al., 2003). 
There were no immediately apparent differences in either tau amounts or tau phosphorylation 
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when blots were imaged (Figure 4.7 A). Quantification of western blot signals and analysis of 
total tau amounts revealed no significant effect of DMF treatment (Figure 4.7 A-B). This is 
consistent with results obtained from analysis of 13-14 month old htau mice and in cell culture 
experiments (section 4.3.2). Analysis of changes in tau phosphorylation at the PHF1, CP13 and 
Tau-1 epitopes as a proportion of total tau in each sample also showed that there were no 
differences between treatment groups (Figure 4.7 C-E). This is consistent with the results found 
with the previous mouse cohort and suggest that DMF treatment does not reduce tau 
phosphorylation in vivo.  
 
 
Figure 4.6: DMF treatment does not affect the accumulation of sarkosyl-insoluble tau 
A. Western blots of sarkosyl-insoluble and LSS (sarkosyl-soluble and insoluble) fractions isolated 
from hippocampus of 13-14 month old htau mice and probed with total tau (DAKO) and PHF1 
(pSer396/404) antibodies. Molecular weight markers are shown on the right. B. Bar chart 
showing total tau amounts in the sarkosyl-insoluble fraction following normalisation to tau 
amounts in the LSS. Only DMF and vehicle-treated brain samples were included in the statistical 
analysis to reduce statistical noise. Values represent mean ± SEM as percentage vehicle (VEH). 






Figure 4.7: There is no effect of DMF treatment on tau phosphorylation in cortex from 8-9 
month old htau mice 
A. Western blots of frontal brain homogenate from DMF-and vehicle-treated 8-9 month old htau 
mice probed with antibodies against total tau (DAKO), tau phosphorylated at Ser396/404 (PHF1), 
Ser202 (CP13) and tau dephosphorylated at Ser199/202/Thr205 (Tau-1). Blots were also probed 
with an antibody against ß-actin as a loading control. Molecular weight markers are shown on 
the left. B.-E. Bar charts show quantification of western blotting. (B.) Total tau (DAKO) was 
analysed as a proportion of ß-actin. (C.) Tau phosphorylated at Ser396/404 (PHF1), (D.) Ser202 
(CP13) and (E.) tau dephosphorylated at Ser199/202/Thr205 (Tau-1) were calculated as a 
proportion of total tau (DAKO) in each sample. DMF: n=5, VEH: n=5. Values shown are mean ± 





Figure 4.8: There is a trend towards an increase in sarkosyl insoluble tau levels with DMF 
treatment 
A. Western blots of sarkosyl-insoluble and low speed supernatant (sarkosyl-soluble and 
insoluble) fractions isolated from hippocampus of 8-9 month old htau mice and probed with 
total tau (DAKO) and PHF1 (pSer396/404) antibodies. Molecular weight markers are shown on 
the right. B. Bar chart showing total tau amounts in the sarkosyl-insoluble fraction following 
normalisation to tau amounts in the LSS. Values represent mean ± SEM as percentage vehicle 
(VEH). DMF n=5, VEH n=5. 
 
Sarkosyl extraction of insoluble tau 
Brain pathology and behavioural deficits are age-dependent in the htau mouse; therefore, it 
would be expected that these younger mice have less insoluble tau aggregates than the aged 
mice. However, previous characterisation of the htau mouse model shows tau aggregates are 
present, albeit in lesser amounts, in 9 month old htau mice (Andorfer et al., 2003). Therefore, 
sarkosyl-insoluble tau was isolated from the hippocampus of 8-9 month old htau mice as 
described earlier in this chapter. Western blots showed approximately equivalent amounts of 
total tau and tau phosphorylated at the PHF1 epitope in the LSS from DMF- and vehicle-treated 
mice (Figure 4.8 A). Quantification of tau phosphorylation at PHF1 relative to total tau confirmed 
that there were no significant differences between groups (data not shown). Similarly, levels of 
tau phosphorylated at the PHF1 epitope in the sarkosyl insoluble fraction appeared to be higher 
in the DMF-treated brain homogenates (Figure 4.8 A). Quantification of tau phosphorylation at 
PHF1 relative to total tau found that this difference was not statistically significant (data not 
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shown). However, western blots showed higher levels of sarkosyl-insoluble tau in samples from 
DMF-treated htau brains in comparison to vehicle-treated htau brains (Figure 4.8 A). When the 
amounts of sarkosyl-insoluble tau were calculated as a proportion of tau in the LSS, this 
difference did not reach statistical significance (p=0.057; Figure 4.8 B), but showed a clear trend 
towards higher levels of tau aggregates in DMF-treated brains. This was an unexpected finding 
since DMF was hypothesised to reduce pathological changes in tau. In particular, results showing 
reduced tau phosphorylation in cell culture experiments would predict a reduction in tau 
aggregation since abnormally high levels of tau phosphorylation are widely believed to be an 
important driver of tau aggregation and NFT formation (Simic et al., 2016). 
 
4.3.4 Possible signalling pathways for DMF action 
The results presented above suggest that DMF may affect the aggregation of tau in vivo and tau 
phosphorylation in vitro. Elucidating some of the signalling pathways and mechanisms affected 
by DMF may provide clues as to which pathways are important for the abnormal processing of 
tau in AD and other tauopathies. DMF is a known Nrf2 activator with anti-inflammatory action 
(Wilms et al., 2010; Lastres-Becker et al., 2016) therefore the following investigations focussed 
on the effects of DMF on glial activation and Nrf2 in treated htau mice. In addition, the activities 
of key tau kinases were investigated in cortical cell lysates to determine if changes in kinase 
activity underlie the alterations observed in tau phosphorylation following DMF treatment.  
 
Glial activation is not changed by DMF treatment 
Astrocyte activation 
DMF has previous been shown to have anti-inflammatory actions so it was of interest to 
investigate whether it was having an effect on glial activation seen in htau mice. Previous 
research from our laboratory has demonstrated robust astrocyte activation and increased 
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cytokine content in the htau mouse brain (Garwood et al., 2010), so changes in astrocyte 
activation was first investigated. 
Homogenates from the hippocampus of 8-9 and 13-14 month old htau mice were 
immunoblotted and probed with an antibody against GFAP, a cytoskeletal protein that is 
increased when astrocytes become activated (Eng et al., 2000). There were no apparent 
differences in GFAP amounts in homogenates from DMF-treated relative to vehicle-treated 13-
14 month old htau mice (Figure 4.9 A). Quantification of GFAP immunoreactivity relative to ß-
actin amounts in the same sample confirmed that there was no effect of DMF treatment on 
GFAP levels (Figure 4.9 B). Similar findings were obtained when cortical homogenates from 8-9 
month old htau mice were examined (Figure 4.9 C, D). This is consistent with results previously 
described in primary cell cultures which also showed no effect of DMF on astrocyte activation.  
 
 
Figure 4.9: DMF does not change GFAP levels in 8-9 or 13-14 month old htau mice 
A. Western blot of hippocampal homogenate from 13-14 month old DMF- and vehicle-treated 
htau and WT mice probed with an anti-GFAP antibody. The blot was also probed with an 
antibody against ß-actin as a loading control. Molecular weight markers are shown on the left. 
B. Bar chart shows quantification of GFAP amounts following normalisation to ß-actin in 
homogenates from 13-14 month old mice. Data from htau samples was analysed by one-way 
ANOVA. Values shown are mean ± SEM as percentage htau control (CTRL). C. Western blots of 
frontal cortex homogenates from 8-9 month old DMF- and vehicle-treated htau mice probed 
with an anti-GFAP antibody. The blot was also probed with an antibody against ß-actin as a 
loading control. Molecular weight markers are shown on the left. D. Bar chart shows GFAP 
amounts relative to ß-actin. Data was analysed by Student’s t-test. Values shown are mean ± 
SEM as percentage vehicle-treated htau (VEH). Aged mice: DMF: n=5, VEH: n=5. Younger mice: 




Microglia are known to have key roles in the development and progression of AD, and microglial 
signalling pathways are being explored as possible drug targets for AD treatment (Crehan et al., 
2012; Wes et al., 2016). Specifically, research suggests microglia are involved in tau aggregation: 
a study crossing htau mice with fractalkine receptor knockout mice which show sustained 
microglial activation, found that reactive microglia drive the development of tau pathology, 
including tau phosphorylation and aggregation, and the spread of tau pathology across the brain 
(Maphis et al., 2015).  
To determine if DMF affects microglia in htau mice, frontal cortex homogenates from 8-9 month 
old htau mice were run on 12 % tris-glycine gels and immunoblotted for the microglial marker, 
Iba1. Iba1, though not necessarily a marker of activated microglia (Boche et al., 2013) is 
increased during inflammatory states (Streit and Xue, 2009) so any changes in the abundance of 
this protein after DMF treatment would indicate an effect of DMF on microglial inflammatory 
signalling. Despite several attempts and optimisation steps, a clear signal for Iba1 could not be 
detected by western blotting (Figure 4.10), and bands were not clear enough to allow signal 
quantification. Qualitative observation of Iba1 bands suggests that there is no obvious change 
in Iba1 levels following DMF treatment of htau mice, however, definitive conclusions about the 
potential effects of DMF on microglial inflammatory responses cannot be drawn from the data 
shown here.  
 
 
Figure 4.10: DMF treatment does not appear to affect Iba1 levels in htau mouse cortex 
Western blots of frontal cortex homogenate from 8-9 month old htau mouse brains probed with 
an antibody against the microglial marker, Iba1. Immunoblot shows a band at the correct size 
for Iba1 at 17 kDa (indicated by arrow) and several non-specific bands. Molecular weight 
markers are indicated on the left. The blot was also probed with an antibody against ß-actin as 




DMF may affect Nrf2 activation in htau mice 
DMF is a known activator of the transcription factor, Nrf2 (Brennan et al., 2016). Nrf2 is known 
to induce the transcription of a range of genes that could be involved in AD and 
neurodegeneration (Tebay et al., 2015). Under normal conditions, Nrf2 is found in the 
cytoplasm, where it is inactive and bound by Kelch-like ECH-associated protein 1 (Keap1). 
Activation of Nrf2 occurs under stressful conditions, such as oxidative stress, and is caused by 
phosphorylation of Nrf2 at Ser40. This allows Nrf2 to stabilise and translocate to the nucleus 
(Niture et al., 2014). Of particular relevance, Nrf2 controls transcription of autophagy adaptor 
protein, nuclear dot protein 52 (NDP52) (Jo et al., 2014a). NDP52 associates with 
phosphorylated tau, facilitating tau clearance by autophagy (Kim et al., 2014). In support of this, 
Nrf2 knock-out animals show reduced levels of NDP52 and neuronal accumulations of 
phosphorylated and sarkosyl-insoluble tau (Jo et al., 2014a). Therefore, it was important to 
assess the effects of DMF on Nrf2 activation in htau mouse brain and primary culture lysates. 
Western blots of frontal cortex homogenates from 8-9 month old htau mice treated with DMF 
or vehicle were probed with an antibody that detects total Nrf2. Lysates from DMF- or vehicle-
treated primary cortical cultures were immunoblotted in the same way. A single prominent band 
of approximately 64 kDa was detected in both sets of samples, corresponding to the predicted 
size of Nrf2. Western blots showed no apparent change in Nrf2 amounts between treated and 
control mouse brain homogenates. However, there was an apparent reduction in total Nrf2 
amounts in cell cultures treated with 30 µM DMF in comparison to control treated or 60 µM 
DMF treated cells. When the amounts of DMF were normalised to ß-actin content in each 
sample, and the results were quantified, analysis showed that this difference was not significant. 
No other significant changes in Nrf2 amounts were found following DMF treatment of cell 
cultures or mouse brain when compared to control samples (Figure 4.11 A-D). This data 
indicates that DMF treatment does not increase total Nrf2 amounts.  
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Nrf2 is activated when the protein is phosphorylated at Ser40, and measurements of the 
amounts of phosphorylated Nrf2 are commonly used as indicators of Nrf2 activity (Huang et al., 
2002; Tebay et al., 2015). To test the efficacy and specificity of an antibody against 
phosphorylated Ser40 on Nrf2, homogenates were prepared from rat primary cortical culture 
lysate, mouse and human brain and these were immunoblotted with a phospho-Nrf2 antibody. 
Unfortunately, the phospho-Nrf2 antibody did not display clear protein bands at the correct 
 
Figure 4.11: DMF treatment does not significantly affect Nrf2 amounts in htau mice or rat 
primary cortical cultures 
A. Western blot of frontal cortex homogenate from 8-9 month old htau mice treated with vehicle 
or DMF and probed with an antibody against total Nrf2. Blots were also probed with an antibody 
against ß-actin as a loading control. Molecular weight markers are shown on the left. B. Bar chart 
shows quantification of western blotting. Nrf2 amounts were determined following 
normalisation to ß-actin in each sample. Values represent mean ± SEM as percentage vehicle-
treated htau (VEH). Data was analysed using Student’s t-test. C. Representative western blots of 
rat primary cortical culture lysates probed with an antibody against total Nrf2. Blots were also 
probed with an antibody against ß-actin as a loading control. Molecular weight markers are 
shown on the left. D. Bar chart shows quantification of total Nrf2 amounts relative to ß-actin. 
Values represent mean ± SEM as percentage control (CTRL). Data was analysed using a Kruskal-
Wallis test. E. Representative western blot of rat cell lysate, homogenised mouse brain and 
homogenised post-mortem human brain probed with an antibody against Nrf2 phosphorylated 
at Ser40. The expected size of phospho-Nrf2 (64 kDa) is indicated with arrow. Molecular weight 
markers are shown on the left. Htau mouse brain: n=5. Cell lysates: n=3. Phospho-Nrf2 test: n=2 




size (64 kDa) for mouse and human samples and only very faint bands in rat sample lanes (Figure 
4.11 E). Therefore, it was not possible to determine if DMF has caused any changes in Nrf2 
activity, as indicated by its phosphorylation at Ser40.  In an attempt to further investigate Nrf2 
activation by determining if any proteins downstream of Nrf2 activation were affected, blots 
were also probed with an antibody against NDP52. Unfortunately, this antibody also gave 
insufficient signal and it was not possible to draw any conclusions (data not shown).  
DMF treatment reduces the activity of cdk5  
Finally, to investigate the mechanism by which DMF application caused reductions in tau 
phosphorylation in primary cell cultures, the activities of key tau kinases were examined. Many 
kinases and phosphatases are involved in post-translational modifications of tau and have been 
implicated in the development of tau pathology in AD (Hanger et al., 2009). Multiple kinases and 
phosphatases regulate phosphorylation of the same tau residues (Hanger et al., 2009), and there 
is complex interplay between kinases (Engmann and Giese, 2009) making any attempts to 
elucidate the signalling pathways regulating tau phosphorylation difficult. However, glycogen 
synthase kinase 3 (GSK-3) and cyclin-dependent kinase 5 (cdk5) are well recognised to regulate 
phosphorylation at both the Tau-1 and CP13 epitopes (Hanger et al., 2007; Hanger et al., 2009), 
the sites affected by DMF treatment in primary cultures. Therefore, lysates from primary cortical 
cultures treated with vehicle, 30 µM or 60 µM DMF were immunoblotted with antibodies against 
these kinases.  
GSK3 
Antibodies against total GSK-3α/ß and GSK-3α/ß phosphorylated at Ser21/9 were used and 
western blots were developed by ECL. GSK-3 activity is regulated by inhibitory phosphorylation 
at Ser21/9 (Fang et al., 2000) and therefore increases in phosphorylation at these sites indicates 
a decrease in GSK-3α/ß activity. Proteins of the sizes corresponding to GSK-3α/ß were detected 
by both antibodies (51 and 47 kDa, respectively). There were no apparent differences in the 
amounts of either total or phosphorylated GSK-3 on western blots, and when phosphorylated 
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GSK-3 was quantified as a proportion of total GSK-3, there was no statistical difference in 
phosphorylated GSK-3α/ß between treatment groups (Figure 4.12 C). This suggests that reduced 
GSK-3α/ß activity is likely not to be responsible for the decrease in tau phosphorylation resulting 
from DMF treatment of these cultures. 
Cdk5 
Cdk5 activity is controlled by its association with neuronal regulatory subunits including p35 
(Kesavapany et al., 2004). Evidence suggests that in neurodegenerative diseases p35 is cleaved 
to form p25. p25 has a longer turn-over rate than cdk5 and therefore not only activates cdk5, 
but sustains this activity resulting in increased tau phosphorylation and degeneration (Patrick et 
al., 1999). It should be noted that the role of p25 in neurodegeneration is somewhat 
controversial (Engmann and Giese, 2009; Giese, 2014).  
Therefore, western blots run with DMF-treated cell lysates from vehicle- and DMF- treated 
primary cell cultures. Antibodies against cdk5 and p35 were used. The p35 antibody was raised 
against the C-terminus of this protein and therefore should also detect the cleaved p25 
fragment. There appeared to be a dose-dependent reduction in cdk5 immunoreactive signals in 
lysates from cells treated with DMF (Figure 4.12 B) and quantification of signal intensity relative 
to ß-actin showed that 60 µM DMF significantly reduced cdk5 protein amounts relative to 
controls (Figure 4.12 F). The p35/p25 antibody detected p35 protein at 35 kDa, but 
unfortunately did not p25 at 25 kDa (Figure 4.12 B). However, there also appeared to be a dose-
dependent reduction in p35 amounts with DMF treatment. Quantification of the p35 signal as a 
proportion of ß–actin amount in each sample showed that 60 µM DMF significantly reduced p35 
amounts in comparison to control cultures (Figure 4.12 E). When p35 amounts were normalised 
to cdk5, this significance was lost, most likely since cdk5 amounts were also reduced (Figure 4.12 
D). This data shows that DMF reduced both total protein amounts of cdk5 as well as that of its 
main neuronal activator, p35. Therefore, it is reasonable to assume that the reduced tau 
phosphorylation observed in DMF treated cultures may have resulted from inhibition of cdk5 




Figure 4.12: DMF reduces cdk5 and p35 levels in primary mixed cultures 
Representative western blot of lysates from 13 DIV primary cortical cultures treated with vehicle 
or DMF for 24 h. Immunoblots were probed with antibodies against A. total GSK-3α/ß and GSK-
3α/ß phosphorylated at Ser21/9 (pGSK-3α/ß), and B. cdk5 and p25/p35. Blots were also probed 
with ß-actin as a loading control. Molecular weight markers are shown on the left. Bar charts 
show quantification of C. pGSK-3α/ß as a proportion of total GSK-3α/ß, D. p35 was as a 
proportion of cdk5, E. p35 as a proportion of ß-actin, F. cdk5 as a proportion of ß-actin. Values 
represent mean ± SEM as percentage control (CTRL). CTRL and 30 µM DMF:  n=4, 60 µM DMF: 
n=3. Data analysed using a Kruskal-Wallis test. * = p<0.05. 
 
4.3.5 Summary 
To summarise, the main results of this chapter were: 
 DMF treatment reduces amounts of cdk5, p35 and tau phosphorylation in primary 
cortical cultures at concentrations that do not affect cell viability. 
 The DMF-induced reduction in tau phosphorylation is not accompanied by decreases in 
markers of astrocytic activity. 
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 DMF treatment of 13-14 month old htau mice had no effect on htau mouse spatial 
memory impairment as measured by training on the Morris water maze, tau 
phosphorylation, tau aggregation or markers of active astrocytes. 
 DMF treatment of 8-9 month old htau mice did not affect amounts of total or 
phosphorylated tau, but appeared to increase insoluble tau amounts compared to age-
matched vehicle-treated htau mice. These changes were not accompanied by 
alterations in Nrf2 amounts. 
 
4.4 Discussion 
The main aim of this chapter was to investigate the possibility of repurposing DMF, a drug 
already approved for multiple sclerosis (MS), as an AD therapeutic. The results outlined in this 
chapter show that DMF robustly reduces tau phosphorylation and the activity of the tau kinase 
cdk5 in primary cell cultures. Unfortunately, similar findings were not found following treatment 
of htau mice, a more complex and pathologically accurate model of disease. In fact, data 
suggested that tau aggregation may be exacerbated when DMF is administered at early disease 
stages to 8-9 month old htau mice. Analysis of treated mouse brain failed to identify changes in 
glial activation or in Nrf2 amounts, and there were no changes in behavioural measures of 
cognitive function following DMF treatment. Further investigation into alternative mechanisms 
and signalling pathways were carried out but due to methodological difficulties these still remain 





4.4.1 DMF effects in primary cortical cultures 
DMF reduces tau phosphorylation in primary cortical cultures 
Tau phosphorylation is one of the earliest pathological changes in tau in AD and is thought to be 
a trigger for further abnormal tau processing (Ballatore et al., 2007; Hanger et al., 2009; Noble 
et al., 2013). For this reason, phosphorylation of tau at AD-relevant epitopes was investigated 
following DMF treatment of primary cortical cultures. A reduction in tau phosphorylation at the 
Ser199/202/Thr205 epitopes, as indicated by both CP13 and Tau-1 antibodies, was found.  
However, phosphorylation of tau at Ser396/404 were not similarly reduced. All five of these tau 
residues are hyperphosphorylated in NFTs isolated from AD brain (Hanger et al., 2009). 
Additionally, all sites are substrates of multiple tau kinases, including GSK-3 and cdk5 (Hanger et 
al., 2007). However, evidence suggests that phosphorylation at these sites occurs at different 
disease stages. A study of fixed sections from multiple stages of AD and Down’s syndrome brain 
found that phosphorylation at the PHF1 epitope (Ser396/404) is one of the earliest events in 
disease progression (Mondragon-Rodriguez et al., 2014). Conversely, NFTs were found to be 
enriched in tau phosphorylated at Ser199/202/Thr205 sites, suggesting that this post-translation 
modification of tau is closely associated with tau aggregation and tangle formation, an event 
that occurs later in disease progression (Augustinack et al., 2002). A different situation appears 
to exist in tau transgenic mice where increased phosphorylation at Ser202 is commonly found 
prior to that at the PHF1 epitope (Lewis et al., 2001; Sahara et al., 2002; Kelleher et al., 2007). 
The difference in timing of phosphorylation at the Tau-1 and PHF1 epitopes may explain why 
phosphorylation at Tau-1 sites, but not PHF1, was significantly reduced in these cell culture 
experiments. However, tau phosphorylation is artificially increased in embryonic stages, and in 
primary cell cultures likely as a result of cell stress, and therefore the contribution of 
developmental stage or the action of stress-activated kinases cannot be discounted.  
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4.4.2 DMF effects on the htau mouse model of tauopathy 
Two small pilot studies into the effects of DMF in htau mice were carried out. The first study 
investigated DMF treatment of 13-14 month old htau mice, which are reported to display 
phenotypic characteristics of mid-stage AD including tau phosphorylation, aggregation, 
behavioural and cognitive deficits, while the second group of 8-9 month old mice show milder 
and possibly more reversible, tau abnormalities (Andorfer et al., 2003; Andorfer et al., 2005; 
Polydoro et al., 2009). Htau mice are considered to be a highly relevant model of the tau 
pathology that develops in AD since the express only human tau on a mouse tau knockout 
background and show abnormal tau processing very similar to that observed in AD brain (Noble 
et al., 2009b). In particular, electron microscopy of filamentous tau extracted from aged htau 
brain shows that it has a paired helical filament conformation (Andorfer et al., 2003), rather than 
the straight filaments seen in other tauopathies and that are characteristic of the vast majority 
of other tau transgenic lines (Noble et al., 2010). Additionally, astrogliosis is prominent in htau 
brain (Garwood et al., 2010), further recapitulating characteristics of human AD brain and 
making the mice appropriate for experiments investigating potential astrocytic inflammatory 
changes. However, it is important to remember that abnormal APP processing and Aß over-
production are not mimicked in these mice, therefore they do not represent a full model of AD.  
However, since the experiments in this chapter are looking specifically at the effects of DMF on 
astrocyte activation and tau pathology, the htau mouse model was considered an appropriate 
model to use. 
Unfortunately, the effects of DMF treatment were limited in the htau mice. In particular, the 
reductions in tau phosphorylation observed in primary cultures were not found following 
treatment of either 8-9 or 13-14 month old htau mice. Analysis of the amounts of sarkosyl 
insoluble tau extracted from hippocampal tissue of younger, but not aged, htau mice showed a 
trend towards an increase in insoluble tau levels with DMF treatment. Sarkosyl insoluble tau is 
widely used as a marker for the presence of tangle-like tau (Hasegawa, 2006; Julien et al., 2012). 
Traditionally, insoluble tau aggregates and NFTs found in brain from tauopathy patients and the 
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brains of multiple mouse models of tauopathy have been viewed as both pathological and toxic 
(Augustinack et al., 2002; Hasegawa, 2006; Hanger et al., 2007). Tau aggregates have been 
widely reported to disrupt axonal transport, both because they block narrow axons and by 
sequestering tau, resulting in the destabilisation of axon microtubules (Terwel et al., 2002; 
Mandelkow et al., 2003; Spires-Jones et al., 2009). Additionally, insoluble tau aggregates have 
been suggested to reduce autophagy levels while reduced autophagy has been found to 
promote the formation of insoluble tau aggregates, possibly creating a pathological feed-
forward loop inhibiting autophagy and increasing aggregate formation (Lim et al., 2001; 
Rodriguez-Martin et al., 2013). The mechanistic pathways involved in this complex circular 
pathophysiology are unclear (Liu et al., 2015b). However, increasing autophagic activity 
increases aggregated tau clearance and improves neuronal function and cognitive impairments 
resulting in research into autophagy as a drug target in AD (Yang et al., 2011; Jo et al., 2014a; 
Friedman et al., 2015). 
Therefore, possible increases in insoluble tau aggregation with DMF treatment in mouse brain 
could be due to activation of cellular pathways reserved for final attempts at reducing tau 
toxicity. Mechanisms increasing tau aggregation are likely to reduce immediate toxicity of 
soluble oligomers of tau but result in serious long term problems, such as exacerbation of 
impairments in axonal transport and autophagic clearance. Moreover, another study 
investigating DMF treatment for MS also found that the drug activated mechanisms (via Nrf2) 
that lie on the border between cell protection and toxicity, supporting the results seen here (di 
Nuzzo et al., 2014). This further indicates that DMF is not an ideal candidate for the long term 
treatment of AD in human patients. 
4.4.3 Possible pathways underlying the effects of DMF 
Some of the pathways through which DMF may be acting were investigated since this 
information may provide insights into the mechanisms and signalling pathways involved in the 
development of tau pathology. The experiments in this chapter focussed on three potential 
mechanisms: glial activation, Nrf2 activation and reductions in kinase activity. 
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Glial activation does not appear to be reduced with DMF treatment 
DMF has astrocyte-mediated anti-inflammatory effects (Wilms et al., 2010) and previous 
research from this laboratory has found that anti-inflammatory agents can reduce abnormal tau 
pathology by reducing levels of activated astrocytes (Garwood et al., 2010). However, no effects 
of DMF on GFAP, a widely-used marker of astrocyte activation, were observed in primary cortical 
cultures or in treated htau mice, suggesting that perhaps astrocytic inflammation did not 
contribute to the effects of DMF on tau. However, GFAP knockout mice still display astrogliosis 
demonstrating that GFAP is not essential for astrocytic activation (Pekny et al., 1995; Yang and 
Wang, 2015). Therefore, it is not possible to exclude the possibility that DMF could have affected 
specific inflammatory pathways in the absence of a reduction in GFAP levels. Unfortunately, 
there was not sufficient time to explore this possibility in more detail.  
The primary cortical cultures used here contain only neurons and astrocytes and, as a result, any 
inflammatory effects must be mediated by astrocytes. However, the htau mouse brain also 
contains microglial cells. Microglia have long been implicated in the progression of AD and they 
modulate inflammatory pathways via the release of cytokines and other small signalling 
molecules alongside astrocytes (Meyer-Luehmann and Prinz, 2015). In addition, mutations in 
microglial genes, such as TREM2, have been found to significantly increase risk of developing 
sporadic AD suggesting that microglial activity and function are key in the development of the 
disease (Villegas-Llerena et al., 2016). Therefore, anti-inflammatory effects of DMF could occur 
via changes in microglial activation and behaviour. An attempt at measuring microglial 
activation, using an anti-Iba1 antibody, was carried out, however western blotting with this 
antibody was not successful despite attempts to optimise conditions. Time permitting, further 
investigation of microglial changes could have provided useful information about DMF 
mechanisms. Experiments using alternative antibodies for active microglial markers, such as 
CD68, or other methods, such as immunohistochemical analysis of brain sections, could provide 
useful information about possible signalling pathway affected by DMF. In addition, unbiased 
cytokine arrays could highlight specific pathways targeted by the drug treatment although 
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whether these pathways were controlled by astrocytic or microglial activity, or both, would 
remain unclear. 
The effects of DMF on Nrf2 and cdk5 activities 
As DMF is a known Nrf2 activator, differences in Nrf2 in DMF-treated cells and mouse brain 
compared to control samples were investigated. No significant changes were found in Nrf2 
amounts following treatment of primary cortical neurons with DMF. A previous study found that 
DMF treatment of Huntington’s disease mouse models increased neuronal Nrf2 activation in the 
absence of increased astrocytic Nrf2 activation (Ellrichmann et al., 2011). This suggests that DMF 
activation of Nrf2 and downstream pathways could affect tau pathology without astrocytic 
involvement, as suggested from these experiments.  
Unfortunately, it was not possible to successfully optimise the antibody against phosphorylated 
(active) Nrf2 so any changes in activation by DMF are still unknown. However, knocking out Nrf2 
in mice inhibits DMF-mediated rescue of experimental autoimmune encephalomyelitis (EAE), an 
animal model of multiple sclerosis, suggesting that Nrf2 is necessary for DMF action, at least 
when it is used as a treatment for multiple sclerosis (Brennan et al., 2016). Furthermore, the 
same study found that Nrf2 activation resulted in changes in the expression of multiple genes 
involved in oxidative stress, cell death and cell signalling, including GFAP, apolipoprotein E 
(ApoE) and NF-κB inhibitor, all of which have been implicated in AD (Chartier-Harilni et al., 1994; 
Granic et al., 2009; Garwood et al., 2011). Additionally, as mentioned earlier in this chapter, 
NDP52, an autophagy adaptor protein whose transcription is Nrf2-dependent, is known to co-
localise with phosphorylated tau and increase tau clearance (Jo et al., 2014a; Kim et al., 2014). 
Taken together, these studies suggest Nrf2 activation and downstream transcription changes 
are likely to be involved in any tau changes caused by DMF treatment. 
DMF activity through Nrf2 activation, increased NDP52 production and increased clearance of 
phosphorylated tau is another, alternative explanation for the effects of DMF treatment 
described in the cell culture experiments in this chapter. However, activation of this pathway in 
the htau mice would be expected to result in reduction, rather than the increase, in sarkosyl-
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insoluble tau observed here. However, DMF effects are wide-ranging, both via Nrf2 and 
independent of the transcription factor (Brennan et al., 2016),  making it difficult to tease out 
possible alternative pathways that could explain a trend toward increased tau aggregation 
following treatment of 8-9 month old htau mice. However, Nrf2 has been found to also be 
activated by cdk5, which primary culture data indicates is inhibited by DMF. Activation of Nrf2 
by cdk5 has been proposed as a neuronal survival mechanism in the face of reactive oxygen 
species and oxidative stress (Jimenez-Blasco et al., 2015). It is possible, therefore, that the 
increase in p35/cdk5 that is observed in aged htau mice (Kelleher et al., 2007) could potentially 
have been inhibited by DMF treatment of htau mice, leading to inhibition of Nrf2, reduced 
downstream levels of NDP52 and inhibition of autophagy, leading to an accumulation of 
insoluble tau.  If time had permitted, this potential pathway could have been explored 
experimentally.  
DMF did not affect cognitive function in htau mice 
No effect of DMF treatment on cognitive function was observed. The Morris water maze was 
used to investigate any changes in hippocampal-dependent spatial memory in aged (13-14 
month old) htau mice treated with DMF. This is considered a relevant test of cognitive function 
in AD since impairment in hippocampal-dependent tasks, including spatial memory tasks, is one 
of the first symptoms seen in individuals with AD (Dhikav and Anand, 2011; Jahn, 2013). Htau 
mice have previously been reported to show impairment in this task compared to age-matched 
WT animals (Polydoro et al., 2009). In a previous study, as training progressed, htau performance 
in the water maze improved but at a slower rate than observed for control mice (Polydoro et al., 
2009). However, in the study reported in this chapter throughout both pre-treatment and post-
treatment testing, no improvement was found in any mice (transgenic or WT) tested despite 
using the same testing methods as Polydoro and colleagues (Polydoro et al., 2009). This is 
generally regarded as a very robust behavioural task and therefore the abnormal WT results 
could simply be a result of the very low numbers used in these pilot studies (only two WT mice, 
each in a different treatment group). However, it could also potentially be due to problems 
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stemming from the relatively short testing protocol used here, possibly suggesting the mice may 
not have associated finding the platform with the reward of being removed from the water, or 
did not perceive leaving the water as a reward. This association between the platform and a 
reward is crucial as without the promise of a reward there is no reason for the mice to remember 
the location of the platform. Circling behaviour and the fact that all mice demonstrated impaired 
learning could both be associated with mice not learning a platform-reward association. If this 
study was to be repeated an increase in the number of visible platform trials could increase the 
chances of platform-reward associations. To ensure mice fully understood this pairing, visible 
platform trials could be carried out until mice consistently swum directly to the platform. In 
addition, larger group sizes would, of course, be beneficial.  
 Differences between cell culture and htau brain findings 
The potential increases in tau aggregation found in the hippocampus of the younger mice are 
particularly surprising, not just because DMF was expected to reduce htau tau pathology, but 
also because these results appear to contrast with the findings from cell culture, where DMF led 
to a dose-dependent reduction in tau phosphorylation.  While the reasons for this apparent 
discrepancy are not clear, htau mice are a model of tauopathy (Komuro et al., 2015), whereas 
the primary cell cultures used in these experiments originate from WT rats and have not been 
treated with additional reagents (e.g. synthetic Aß) to imitate abnormal AD-like processes 
including abnormal tau processing. Neurons cultured in vitro are clearly different from those 
grown normally in vivo and face more challenges and stressors than non-dissociated neurons 
(Chen and Herrup, 2008). As a result, neurons cultured in primary cultures may have increased 
levels of tau phosphorylation due to increased cellular stress (Alavi Naini and Soussi-Yanicostas, 
2015), however, generally, these neurons are representative of normal, control brain cells. 
Therefore, the in vitro experiments described in this chapter are examining the effects of DMF 
treatment on normal, physiological tau phosphorylation, rather than pathological tau 
phosphorylation seen in the htau mouse brain. Physiological tau phosphorylation is an 
important process in all neurons, particularly developing neurons. However, in normal neurons 
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tau phosphorylation occurs at much lower levels and reversibility is key to its microtubule 
stabilising functions (Wang and Mandelkow, 2016). Therefore, tau phosphorylation in 
physiological primary cell cultures may be more prone to reversal or prevention than the 
pathological phosphorylation seen in the htau mouse brain. This difference could explain the 
inconsistencies seen in the results from this chapter. Furthermore, htau tau levels are 
approximately 3-4 times those expressed in wildtype animals (Duff et al., 2000; Andorfer et al., 
2003). Small reductions in tau phosphorylation that may be seen in primary cells with normal 
total tau levels, may be obscured by increased levels of both phosphorylated and 
dephosphorylated tau in the htau mouse neurons. 
Furthermore, in light of results described in Chapter 3 (section 3.3), it is important to note that 
primary cells were cultured from the cortices of E18 rats while sarkosyl extraction preparations 
were carried out with hippocampal htau brain tissue. As previous results have shown, 
hippocampal and cortical cultures can respond very differently to both insult (e.g. Aß treatment) 
and possibly protective drugs (e.g. minocycline or DMF). Additionally, the roles of astrocytes in 
these different brain regions appear to differ significantly (Yeh et al., 2011; Grolla et al., 2013; 
Rodriguez et al., 2014). This could also partly explain the differences seen between cell culture 
and htau brain results.  
Finally, practical differences in the way primary cultures and mice are treated could also explain 
discrepancies seen. In primary culture experiments, dissolved DMF was added directly to the 
culture medium ensuring cells were in direct contact with the drug molecules. Oral treatment 
of the htau mice, however, results in much higher chances of DMF not reaching the brain. 
Research has shown DMF is both able to cross into the bloodstream from the digestive system 
and cross the blood brain barrier (Schilling et al., 2006; Moharregh-Khiabani et al., 2010). 
However, levels of absorption could vary and it is unlikely that all of the drug that is administered 
will reach the brain. Oral gavage ensures that all of the prescribed drug dose is consumed, but 
has increased health risks for the mice being treated (Schilling et al., 2006; Eichenbaum et al., 
2011). Here, DMF was administered via oral syringe, reducing the health risks to the mice as 
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feeding is not forced and there is no risk of physical damage to the oesophageal tract. This makes 
using an oral syringe more appealing as a method of drug delivery but also reduces the chances 
of all of the drug solution entering the mouse’s digestive system. As mice are not force fed it is 
possible for them to avoid drinking some drug solution. While it is very unlikely that a mouse 
could avoid a whole dose, variability of DMF concentrations reaching the brain could be 
increased. Every effort was made to encourage the mice to drink the drug solution; including 
attempting to make the taste appealing, but it is unavoidable that some mice will find the 
solution more appealing than others. If this experiment was repeated the only way of ensuring 
equal DMF concentrations reach each mouse’s brain would be via an alternative drug 
administration method, for example via gavage or intraperitoneal injection. However, both of 
these methods have drawbacks, either compromising either the mouse health risks posed or 
reducing the similarities to human drug consumption.  
In summary, differences in the results obtained following DMF treatment of primary cortical 
cultures and htau mouse brain could have multiple explanations, including the presence of 
physiological and pathological tau, the different brain regions assessed and differences in drug 
administration. It would be highly challenging to tease out these causes and determine which 
has had the greatest effect on the results presented here, however, it seems clear that the 
results from these two different experimental set-ups are not directly comparable.  
 
4.4.4 Conclusions 
To conclude, this chapter provides evidence that DMF treatment of both primary neuron cell 
cultures and the htau mouse model of tauopathy can influence pathological tau changes. In 
primary cell culture, DMF treatment reduces tau phosphorylation at some AD-related sites. 
These effects were associated with reduced cdk5 activity through an as yet, unidentified, 
pathway.  
DMF treatment of htau mice did not rescue spatial memory deficits or affect tau 
phosphorylation in aged mice (13-14 months old) but possibly increased tau aggregation in 
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younger (8-9 months old) mice. No changes in astrocyte activation were observed in association 
with increased tau aggregation. It is possible that this finding could reflect an attempt by cellular 
repair mechanisms to reduce the damage caused by highly toxic soluble tau oligomers.  
Overall, the experiments presented in this chapter do not support the repurposing of DMF as a 
potential AD therapeutic, at least not when using the models and methods of administration 




Chapter 5: Temporal and regional changes in glial markers in 
post-mortem Alzheimer’s disease brain  
5.1 Introduction 
Experiments described in the previous two chapters used primary cell cultures and transgenic 
mice to model AD-like pathology. Using these models, the contributions of astrocytes and 
possible pathology-improving drugs were investigated. However, these experiments cannot 
provide insights into the development and treatment of AD if the models used do not reflect the 
development of the human disease. 
As options for investigating neurological diseases in human brain are limited, exploration of 
disease in post-mortem brain can provide valuable insights into a disease and validate animal 
and cell culture models. Initial studies into AD and other neurodegenerative diseases were 
carried out in post-mortem brain, including Alois Alzheimer’s first report of the pathological 
changes seen in cells in AD (Alzheimer et al., 1995; Garcia-Marin et al., 2007b, a). More recently, 
IHC studies of sections of post-mortem brain have demonstrated distinctions between different 
tauopathies, showing characteristic differences in tau aggregates from different diseases 
(Kovacs, 2015). Studies showing that tau, rather than Aß, spread throughout the human brain 
correlated best with AD symptoms prior to death were also key to demonstrating tau plays an 
important role in AD pathology (Braak and Braak, 1995; Braak et al., 2011; Perez-Nievas et al., 
2013). These studies, providing robust evidence for the importance of tau spread throughout 
the human brain, have ensured tau pathology features in the amyloid cascade hypothesis, the 
major AD development theory dominating AD research (Hardy and Allsop, 1991) in the absence 
of AD-causing tau mutations (Hardy et al., 1998). Furthermore, findings from post-mortem brain 
studies, such as the discovery of a 35 kDa cleaved fragment of tau in multiple tauopathies (Wray 
et al., 2008), have directly influenced the development of new models of AD and tauopathy. In 
this example, the tau35 mouse, a mouse expressing the 35 kDa tau fragment described above, 




However, many studies focus only on differences between control and late-stage AD brain, and 
as a result changes seen in early and mid-stage disease that may provide evidence about specific 
disease mechanisms, may be over-looked. Levels of synaptic markers indicating the health or 
number of synapses, for example, are thought to vary widely as AD progresses (Mitew et al., 
2013; Savioz et al., 2014; Kurbatskaya et al., 2016). A study from this group found that during 
mid-stage disease (Braak II-III), synaptic markers are significantly increased, possibly indicating 
compensation mechanisms in the face of initial synaptic dysfunction. By late stage AD, the same 
synaptic marker levels are significantly reduced demonstrating the loss of synapses and neurons 
at end stage AD (Kurbatskaya et al., 2016).  
It is also important to note that there are some individuals with AD-like molecular pathology 
that do not show clinical AD symptoms during their lifetime. One study compared the molecular 
differences in post-mortem brain from these “mismatches” in comparison to control and AD 
cases. Activated glia and the mislocalisation of tau to synaptic compartments were found to be 
the best correlates of cognitive impairment and dementia during life (Perez-Nievas et al., 2013).  
It was important for the work presented in this thesis to investigate changes in glial markers and 
tau in post-mortem brains from all stages of AD since this should provide valuable insights in to 
the timing and contribution of astrocytes to the development of tau pathology in AD, and 
determine whether the results obtained from cell and animal models are directly relevant to 
human AD. Classification of AD stages by Braak and Braak was originally proposed based on 
correlation of the spread of tau pathology in post-mortem brain and the severity of clinical 
symptoms (Braak and Braak, 1995). It is now thought that this tau spread occurs via the trans-
synaptic release and uptake of pathological tau between anatomically connected neurons, 
creating the pattern of tau spread that Braak originally described (Clavaguera et al., 2015). 
Experiments described in Chapter 3 (section 3.3) suggested that mechanisms and signalling 
pathways driving the development of tau pathology differed in different brain regions. Research 
using mouse models and post-mortem brain also suggests that the role of astrocytes and their 
immune response, in particular, are different in distinct brain regions (Rodriguez et al., 2014; 
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Rodriguez-Arellano et al., 2016). Investigating changes in glial markers and tau in all Braak stages 
may therefore provide further insights into how astrocytes, neuroinflammatory responses and 
disease-associated changes in tau are temporally and regionally associated.  
The aims of this chapter are to use post-mortem samples from control and Braak stage I-VI AD 
temporal cortex and hippocampus to investigate changes in the following during disease 
development: 
 Disease-associated changes in tau, including phosphorylation, cleavage and aggregation   
 Activation of astrocytes and microglia 
 Markers of synapse function. 
These findings will then be compared to determine if there are specific regional associations 
between glia and tau at different stages of disease. 
 
5.2 Methods 
The methods and materials used in this chapter, including methodology for the homogenisation 
of human brain tissue, are described in Chapter 2 (section 2.4.1). Briefly, brain tissue was 
homogenised according to the protocol described in Chapter 2 (section 2.4.1). Homogenates 
were run on 10 % tris-glycine gels for western blotting and were immunoblotted with antibodies 
against NSE and ß-actin to allow normalisation of sample concentrations according to total 
neuronal proteins and all neural cells, respectively (Chapter 2, section 2.6).  
Three separate groups of post-mortem brain samples were obtained from the London 
Neurodegenerative Diseases Brain Bank for these studies: 
Group 1: Control (n=20) and Braak stages V/VI AD (n=20) temporal cortex, for which ApoE 






Table 5.1: Details of post-mortem control and Braak stage V-VI temporal cortex 
Sample number, age, sex, PMD (in h), neuropathologist notes and ApoE genotype of each 
sample is shown. 
 
 
No. Age Sex Post-mortem 
delay (PMD, h) 
Notes ApoE 
1 80 M 41 AD, Braak VI, severe amyloid 
angiopathy 
3/4 
2 91 F 29 AD, definite Braak VI 3/4 
3 88 M 46 AD, definite Braak VI 3/4 
4 92 F 42 AD, Braak VI 3/4 
5 80 F 13 AD, Braak V, mild amyloid angiopathy 3/4 
6 69 F 16 AD, Braak VI 3/4 
7 84 F <24 AD, Braak V 4/4 
8 81 F <72 AD, Braak VI 4/4 
9 81 M 74 AD, Braak VI 4/4 
10 82 F 69 AD, Braak V, mild amyloid angiopathy 4/4 
11 84 F 36 AD, Braak V/VI 4/4 
12 90 F 23 AD 3/3 
13 98 F 3.5 AD, BNE IV, CERAD probable 3/3 
14 82 M 80 AD definite 3/3 
16 89 F 15 AD, BNE stage IV, amyloid angiopathy 3/3 
17 97 F 12 AD, Braak V 2/3 
18 89 M 19 AD definite 2/3 
19 86 M 26 AD, Braak V, moderate amyloid 
angiopathy 
2/4 
20 87 F 48 AD, Braak VI, moderate amyloid 
angiopathy 
2/4 
21 82 F 43 Normal brain 3/3 
22 81 F 17 Mild ageing changes, Braak I 3/3 
23 92 F 17 Control brain, some tau deposition 3/3 
24 86 M 6 Normal adult brain 3/3 
25 55 F 12 Minimal tau pathology consistent 
with HP-tau stage I 
3/3 
26 80 M 21 Widespread acute infarcts and acute 
ischaemic changes; old infarcts 
3/3 
27 90 F 50 Control brain, mild alzheimer-type 
changes (modified Braak stage II) 
mild amyloid angiopathy 
3/3 
28 87 F 22 Normal adult brain 3/3 
29 81 M 18 Control, old cerebral infarct (Braak I) 3/3 
30 78 M 10 Ageing changes, mild 2/3 
31 79 M 47 Early tau pathology Braak II, no 
neuritic plaques 
2/3 
32 82 F 13 Argyrophilic grains low to moderate 
density 
2/3 
33 59 M 50 Normal adult brain 4/4 
34 40 M 40 Normal adult brain 3/4 
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No. Sex Age PMD Notes 
1 F 87 22 Normal adult brain 
2 M 86 6 Normal adult brain 
3 M 59 50 Normal adult brain 
4 M 40 40 Normal adult brain 
5 M 78 10 Ageing changes, mild 
6 F 82 13 Argyrophilic grains, low to moderate density 
7 F 92 17 Control brain, some tau deposition 
8 F 55 12 Minimal tau pathology consistent with HP-tau stage I 
9 F 81 17 Mild ageing changes, Braak I 
10 M 79 47 Early tau pathology, Braak II, no neuritic plaques 
11 F 90 50 Control brain, mild alzheimer-type changes (modified 
Braak stage II), mild amyloid angiopathy 
12 M 93  ~33 Mild AD type changes, Braak II 
13 F 84 35 AD changes, Braak II, consistent with normal aging 
14 M 92 11 Mild AD type changes due to ageing Braak III 
15 F 70 38 Possible AD (CERAD) Braak III (limbic), BNE stage III 
16 M 86 52 Ageing changes, AD modified Braak stage 3, suitable as 
control 
17 M 82 28 AD, modified Braak stage IV, limbic TDP-43 pathology 
18 M 86 53 AD, modified Braak stage IV, extensive severe amyloid 
angiopathy 
19 F 83 22 AD, limbic stage, modified Braak stage IV, moderate to 
severe amyloid angiopathy 
20 F 89 56 AD, HP tau stage IV severely affecting limbic system, 
moderately extending to neocortex. 
21 F 80 13 AD, Braak V, mild amyloid angiopathy 
22 F 82 69 AD, Braak V, mild amyloid angiopathy 
23 M 86 26 AD, Braak V, moderate amyloid angiopathy 
24 M 81 74 AD, Braak VI 
25 F 87 48 AD, Braak VI, moderate amyloid angiopathy 
26 M 72 5 AD, Braak VI, marked amyloid angiopathy 
 
Table 5.2: Details of temporal post-mortem brain samples 
















No. Sex Age PMD (h) Pathological diagnosis 
3 M 59 50 Normal adult brain 
7 F 92 17 Control brain, some tau deposition 
8 F 55 12 Minimal tau pathology consistent with HP-tau stage I 
10 M 79 47 Early tau pathology, Braak II, no neuritic plaques 
11 F 90 50 Control brain, mild AD-type changes, modified Braak stage 
II, mild amyloid angiopathy 
12 M 93  ~33 Mild AD type changes, Braak II 
13 F 84 35 AD changes, Braak II, consistent with normal aging 
14 M 92 11 Mild AD type changes due to ageing, Braak III 
15 F 70 38 Possible AD (CERAD), Braak III (limbic), BNE stage III 
16 M 86 52 Ageing changes, AD modified Braak stage III, suitable as 
control 
17 M 82 28 AD, modified Braak stage IV, limbic TDP-43 pathology 
18 M 86 53 AD, modified Braak stage IV, extensive severe amyloid 
angiopathy 
19 F 83 22 AD, limbic stage, modified Braak stage IV, moderate to 
severe amyloid angiopathy 
20 F 89 56 AD, HP tau stage IV, severely affecting limbic system, 
moderately extending to neocortex. 
21 F 80 13 AD, Braak V, mild amyloid angiopathy 
22 F 82 69 AD, Braak V, mild amyloid angiopathy 
23 M 86 26 AD, Braak V, moderate amyloid angiopathy 
25 F 87 48 AD, Braak VI, moderate amyloid angiopathy 
26 M 72 5 AD, Braak VI, marked amyloid angiopathy 
27 F 84 36 AD, Braak V/VI 
28 M 88 46 AD, definite Braak VI 
29 F 92 42 AD, Braak VI 
30 F 69 16 AD, Braak VI 
 
Table 5.3: Details of hippocampal post-mortem brain samples  
Sample number, sex, age, PMD (in h) and neuropathologist notes for each sample is shown. 
 
The second (temporal cortex, Table 5.2) and third (hippocampal, Table 5.3) groups contained 
control and AD brain of all stages (Braak stage I through to VI). Where possible, these samples 
were matched, with temporal and hippocampal samples coming from the same individual. It 
was not always possible to obtain hippocampal tissue from all samples due to the relative 
scarcity of these tissues. In addition, slides with brain sections from Brodmann Area 10 in the 
prefrontal cortex were obtained from the MRC London Neurodegenerative Diseases Brain Bank. 
7 µm tissue sections were stained with hematoxylin and eosin (H&E) and immunolabelled with 
antibodies against phosphorylated tau and Aß (Kurbatskaya et al., 2016). Slides were imaged 
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5.3.1 Preliminary work 
Confirmation of Braak staging in brain sections 
To confirm the progressive development of Aß and tau pathology with increasing Braak stage, 
slides of stained brain sections, taken from Brodmann Area 10 in the frontal cortex, were 
obtained from the London Neurodegenerative Diseases Brain Bank. Sections were stained with 
H&E which stains nuclei and cytoplasm, and allows visualisation of tissue damage and cell loss. 
Sections were also immunolabelled with AT8, which detects tau phosphorylated at 
Ser202/Thr205, or 6E10, which is raised against the N-terminus of Aß. 
Visualisation of these slides using an EVOS XL Core Cell Imaging System showed a progressive 
increase in tissue damage with H&E staining as Braak stage increases. In Braak stages IV-VI, H&E 
staining revealed increasing vacuolisation and decreased numbers of cells (Figure 5.1, left 
column). AT8 staining shows increasing amounts of tau phosphorylation with increasing Braak 
stage; pre-tangles and many neuropil threads being apparent in early-mid Braak stages and 
culminating with the appearance of mature NFTs at Braak stages IV and VI. (Figure 5.1, middle 
column). Immunolabelling with 6E10 clearly demonstrated the build-up of Aß as AD progresses. 
The occurrence and density of Aß plaques increases from Braak stages II through to VI in 
association with the development of tau pathology and loss of neural cells (Figure 5.1, right 
column). This allowed confirmation of the Braak stages to which tissues used in subsequent 





Figure 5.1: Characterisation of Aß and tau pathology and tissue integrity in control and Braak 
stage I-VI tissues. 
Representative immunohistochemistry images showing sections from Brodmann area 10 in 
brains at different Braak stages (I to VI) and controls. Haematoxylin and eosin (H&E) staining and 
immunohistochemistry with AT8 (tau phosphorylated at Ser202/Thr205) and 6E10 (N-terminal 





Figure 5.2: Increased tau phosphorylation in late stage AD 
Representative western blots of temporal cortex homogenates from control (CTRL) and late 
stage (Braak V/VI) AD (AD) brain probed with antibodies against total tau (DAKO) and A. PHF1 
(tau phosphorylated at Ser396/404) and B. CP13 (tau phosphorylated at Ser202). Molecular 
weight markers are shown on the right (kDa). Control n=14; AD n=19. 
 
Investigating differences in glial markers and tau in control and late stage AD brain 
In order to confirm published data showing changes in glial cell markers and tau in end-stage 
AD, western blotting was first used to examine biochemical differences in control and late stage 
(Braak V/VI) AD temporal cortex only.  
Samples were immunoblotted with antibodies against total and phosphorylated tau. Antibodies 
against the PHF1 (tau phosphorylated at Ser396/404) and CP13 (tau phosphorylated at Ser202) 
epitopes were used, since these sites are abnormally phosphorylated in PHF tau extracted from 
AD brain (Hanger et al., 2009) and phosphorylation at these sites is important for microtubule 
destabilisation and initiation of tau aggregation (Evans et al., 2000; Augustinack et al., 2002).  
Visualisation of these signals showed that total tau levels varied considerably within groups of 
post-mortem brain samples (Figure 5.2 A, B). Furthermore, while phosphorylated tau was only 
detected in AD samples, there was a high variability in the amounts of tau phosphorylated at 
PHF1 and CP13 epitopes in AD cases. This is somewhat expected in human post-mortem brain 
samples that can be affected by many parameters including cause of death, post-mortem delay, 
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tissue pH, co-occurring morbidities, and exposure to different prescribed medications (Hanger 
et al., 2009). Nevertheless, substantial amounts of phosphorylated tau were only detected in AD 
cases, supporting previous findings that tau is abnormally phosphorylated in AD (Hanger et al., 
2009; Kurbatskaya et al., 2016; Lau et al., 2016). 
Differences in astrocyte markers between control and late stage AD post-mortem brain samples 
were next investigated. Homogenised temporal cortex samples were run on western blots and 
probed with an antibody against GFAP, widely considered to be a reliable indicator of activated 
astrocytes (Eng et al., 2000). This revealed a main band of approximately 50 kDa corresponding 
to full-length GFAP and several smaller bands, which likely represent cleaved fragments of GFAP 
(Zoltewicz et al., 2012) (Figure 5.3 A). Quantification of detected proteins on western blots 
showed that GFAP levels are significantly elevated in Braak stage V-VI temporal cortex 
homogenates compared to controls, suggesting that there is a marked increase in the number 
of activated astrocytes in late stage AD (Figure 5.3 A, B). This is consistent with a wide body of 
literature showing that astrocytes are activated in AD and that these cells play an important role 
in disease progression (Simpson et al., 2010; Sofroniew and Vinters, 2010; Phillips et al., 2014; 
Zhang and Jiang, 2015; Hu et al., 2016).  
Results were next stratified according to ApoE genotype to determine if ApoE, a genetic risk 
factor for AD that is produced predominantly by astrocytes, is associated with astrocyte 
activation. The ApoE ε4 variant is the largest known genetic risk factor for AD, with over 60 % of 
individuals diagnosed with AD harbouring at least one ε4 allele (Riedel et al., 2016). In contrast 
the ε2 variant is protective against AD, significantly reducing the risk of AD in carriers (Suri et al., 
2013). Results were stratified into three groups: those carrying one copy of the ε2 variant (ε2/ε3 
or ε2/ε4), those homozygous for ε3 (ε3/ε3) or carrying one copy of the ε4 allele (ε3/ε4), and 
those homozygous for ApoE ε4 (ε4/ε4). Statistical analysis showed that there were no significant 
differences in GFAP levels between the three groups (Figure 5.3 C). However, samples with at 
least one ApoE ε4 allele appeared to contain the lowest GFAP amounts, whereas those with one 




Figure 5.3: Astrocyte activation is increased in late stage AD temporal cortex relative to 
controls 
A. Representative western blots showing homogenates of control (CTRL) and late stage (Braak 
V/VI) AD temporal cortex probed with an antibody against GFAP (50 kDa). Blots were also 
probed with an antibody against ß-actin (42 kDa) as a loading control. Molecular weight markers 
are shown on the right. B. Bar chart shows GFAP amounts following normalisation to ß-actin in 
the same sample. Data are shown as % control (CTRL). Control n=14; AD n=19. C-D. Bar chart 
show amounts of GFAP, following standardisation to ß-actin as a function of C. ApoE genotype 
(2/3 + 2/4 n = 7, 3/3 n = 13, 3/4 + 4/4 n = 13) and D. age in control and AD samples (65-79 n = 3, 
80-89 n = 20, 90+ n = 7). E. Scatter plot showing correlation between levels of GFAP/actin and 
PHF1/total tau (DAKO). ns = not significant, r = correlation coefficient. Control n=14; AD n=19. F. 
Direct comparison of representative western blots probed with antibodies against GFAP and 
PHF1 showing no correlation between antibody levels. Molecular weight markers are shown on 
the left. Sample numbers are indicated. Data in graphs are mean ± SEM. Data were analysed 
using: B. two-tailed t-test, C. one-way ANOVA, D. two-way ANOVA. E. Spearman’s correlation. 
** = p<0.01. 
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Age is also suggested to be involved in the inflammatory response in AD (Craft, 2005; Simpson 
et al., 2010; Calvo et al., 2015; Riedel et al., 2016; Rodriguez et al., 2016). Low level systemic 
inflammation accompanies normal aging and is thought to prime glia resulting in an increased 
susceptibility to AD and other age-related diseases (Franceschi and Campisi, 2014). Specifically, 
age is thought to exacerbate Aß-related inflammation in AD (Craft, 2005). To examine possible 
associations between astrocyte activation and age in these samples, results were analysed 
following stratification into three age groups: 65-79, 80-89 and 90+ years old. The small number 
of samples from individuals younger than 65 were excluded from this analysis. Since there 
appears to be dissociation between age-related effects in normal aging and disease (Liddell et 
al., 2007), samples were further stratified into control and AD groups. The results of this analysis 
showed that GFAP amounts appeared to be lower in the age 65-79 control group compared to 
all others, and all ages of control groups showed less GFAP amounts compared to their AD 
counterparts. However, statistical analysis revealed that these differences were not significant 
(Figure 5.3 D). This might be because of the limited sample size used here, particularly for the 
age 65-79 groups (control = 2, AD = 1). 
Finally, to explore possible associations between astrocyte activation and tau phosphorylation, 
a Spearman’s rank test was used to examine the correlation between GFAP and either PHF1 (tau 
phosphorylated at Ser396/404) or CP13 (tau phosphorylated at Ser202) amounts. No significant 
correlation was found between GFAP and tau phosphorylated at either epitope (CP13: data not 
shown, PHF1: Figure 5.3 E, F). This was somewhat unexpected as evidence from models of AD 
suggests that astrocyte activation induces disease-associated changes in tau such as its 
phosphorylation and cleavage (Garwood et al., 2011). However, as discussed in Chapter 4 
(section 4.4), levels of GFAP are not necessarily completely indicative of astrocyte activation. 
Therefore, it is possible that other markers of astrocytic inflammatory response or levels of 
cytokine production (such as IL-1ß, for example) may correlate with tau phosphorylation.  
Moreover, this data might suggest that results obtained in dissociated co-culture models is not 
representative of that which occurs in AD brain. These findings are likely further confounded by 
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recent results showing marked differences in the rodent and human astrocyte transcriptomes, 
variation that is further altered with aging (Zhang et al., 2016b). 
In summary, these results suggest that there is a significant increase in astrocyte activation in 
end-stage AD. Astrocyte activation is probably not affected by age or ApoE genotype, and is not 
closely correlated with the abundance of phosphorylated tau. 
To further explore the inflammatory response in late stage AD, microglial markers were also 
investigated. Microglia and the microglial inflammatory response have long been implicated in 
the development and progression of AD (Heneka et al., 2015; Jebelli et al., 2015; Heneka et al., 
2016). Microglial phenotype is altered in AD (Perry, 2016), losing protective functions that allow 
microglia to phagocytose Aß and cell debris in an attempt to reduce the toxicity of the local 
environment (Boche et al., 2013). In parallel, microglia can mount a pro-inflammatory response, 
including cytokine and chemokine release, that can activate toxic signalling pathways in other 
glial cells and neurons (Cai et al., 2013). 
To investigate microglial responses in the brain samples used in this thesis, homogenised post-
mortem temporal cortex from control and late-stage AD brain (Table 5.1) were immunoblotted 
as described above, but using 12 % acrylamide gels, with an antibody against Iba1 (Figure 5.4 
A). Iba1 is a microglia/macrophage-specific calcium-binding protein that is often used as a 
marker for microglial activation (Imai and Kohsaka, 2002). Western blots showed a single band 
of approximately 17 kDa corresponding to the expected size of Iba1. Quantification of Iba1 signal 
density, following normalisation to ß-actin amounts in the same sample, showed that there was 
no significant difference in Iba1 levels between control and late stage AD samples (Figure 5.4 B) 
suggesting that microglia are not significantly activated in these samples. Alternatively, these 
findings might suggest that Iba1 is not a good indicator of microglial activation (Boche et al., 
2013).  
Similar to described above for GFAP, further characterisation of Iba1 levels was carried out with 
respect to ApoE genotype and age. Statistical analysis showed that there is no significant 
interaction of ApoE genotype and Iba1 amounts (Figure 5.4 C). Similarly, there were no 
218 
 
significant differences in Iba1 amounts between different ages of control and AD groups (Figure 
5.4 D). Again, as described above, it is possible that effects may be masked by the relatively small 
number of samples used in this study and the significant variation observed within groups. 
Signalling between neurons and microglia is important for disease-associated changes in tau. In 
particular, knockout of microglial fractalkine receptors prevents neuron-derived fractalkine 
from maintaining microglia in a resting state, and causes neuroinflammatory responses that 
exacerbate the development of tau pathology in transgenic mouse models of AD (Bhaskar et al., 
2010). Therefore, it was important to determine if there are any associations between Iba1 
amounts and phosphorylated tau in these samples. Spearman’s rank correlations were carried 
out to examine the association between Iba1 and PHF1 (tau phosphorylated at Ser396/404) or 
CP13 (tau phosphorylated at Ser202). There was no statistically significant correlation between 
Iba1 and CP13 amounts (data not shown). However, Iba1 and PHF1 were significantly positively 
correlated (r = 0.57, p < 0.001, Figure 5.4 E), and this was apparent when Iba1 and PHF1 amounts 
were examined on western blots of the same samples (Figure 5.4 F). This data suggests that 
increased microglial activation may contribute to increased tau phosphorylation in AD, at least 
at the PHF1 epitope.  
To summarise, no significant changes were apparent in Iba1 amounts between AD and control 
brain. Iba1 amounts did not appear to dissociate with either ApoE genotype or age. Interestingly, 
however, Iba1 amounts significantly correlate with levels of tau phosphorylated at the PHF1 
epitope. This suggests that microglia activation may be involved in the signalling pathways that 
result in phosphorylation of tau at this epitope. These results might further suggest that the 
large extent of variation in post-mortem brain makes it difficult to determine changes between 
control and disease states, whereas correlation analysis might provide more informative data 





Figure 5.4: Amounts of the microglial marker Iba1 positively correlate with tau 
phosphorylation at the PHF1 epitope. 
A. Representative western blots showing homogenates of control (CTRL) and late stage (Braak 
V/VI) AD temporal cortex probed with an antibody against Iba1 (17 kDa). Blots were also probed 
with an antibody against ß-actin (42 kDa) as a loading control. Molecular weight markers are 
shown on the right. B. Bar chart shows Iba1 amounts following normalisation to ß-actin in the 
same sample. Data are shown as % control (CTRL). Control n=14; AD n=19. C-D. Bar chart show 
amounts of Iba1, following standardisation to ß-actin as a function of C. ApoE genotype (2/3 + 
2/4 n = 7, 3/3 n = 13, 3/4 + 4/4 n = 13), and D. age in control and AD samples (65-79 n = 3, 80-89 
n = 20, 90+ n = 7). E. Scatter plot showing correlation between levels of Iba1/actin and 
PHF1/total tau (DAKO). ns = not significant, r = correlation coefficient. Control n=14; AD n=19. F. 
Direct comparison of representative western blots probed with antibodies against Iba1 and 
PHF1. Molecular weight markers are shown on the left. Sample numbers are indicated. Data in 
graphs are mean ± SEM. Data were analysed using: B. two-tailed t-test, C. one-way ANOVA, D. 




Figure 5.5: Total and phosphorylated tau increase as AD progresses 
A. Representative immunoblots of temporal cortical homogenates from post-mortem control 
and Braak stage I-VI brain. Blots were probed with antibodies to detect total (phosphorylated 
and non-phosphorylated) tau (DAKO), tau phosphorylated at Ser396/404 (PHF-1) and Ser202 
(CP13), all at 50 to 70 kDa. Blots were also probed with an antibody against ß-actin as a loading 
control. Molecular weight markers are shown on the left. B. Bar chart shows quantification of 
total tau amount detected by western blotting as a proportion of ß-actin in the same sample. C-
E. Bar charts showing quantification of standard tau ELISAs using antibodies E. PHF1, F. CP13 
and G. MC1, all graphed and analysed as a proportion of total tau. Values shown are mean ± 
SEM as percentage control (CTRL). N= 3-4 per Braak stage. Data was analysed using one-way 





Having determined that there are some differences in temporal cortex between control and 
end-stage AD brain, and established methods with which to examine glial markers and tau in 
these tissues, the next step of this study was to determine if there are key points in AD 
development at which these changes occur and/or if there are regional differences. To this end, 
glial markers and tau processing was examined in temporal cortex and hippocampus from cases 
at all Braak stages.  
 
5.3.2 Characterisation of changes in tau and glia in temporal cortex during AD progression 
Total and phosphorylated tau amounts increase in temporal cortex during AD development 
Temporal cortex homogenates from control and Braak stage I-VI brain (Table 5.2) were 
immunoblotted with antibodies against total and phosphorylated (PHF1, CP13) tau, as described 
above. Blots appeared to show an increase in total and phosphorylated tau amounts with 
increasing Braak stage (Figure 5.5 A). Quantification of total tau amounts following 
normalisation to ß-actin, showed a significant accumulation of total tau with increasing Braak 
stage (Figure 5.5 B). For this and all other quantification of this sample set, sample 25, the 
second Braak VI sample shown on western blots, was excluded from analysis due to abnormal 
ß-actin levels, see Figure 5.5 A).  
Western blots probed with PHF1 and CP13 antibodies showed increased levels of tau 
phosphorylation as AD progresses (Figure 5.5 A). However, these differences were not 
statistically significant (data not shown) due to high variation between samples and the relative 
insensitivity of western blotting in detecting subtle protein changes. Therefore, tau 
phosphorylation was also assessed using semi-quantitative tau ELISAs using the CP13 and PHF1 
antibodies, in addition to an MC1 antibody which detects an abnormal conformation of tau 
(Jicha et al., 1999). Analysis of ELISA results showed that PHF1 levels were significantly increased 
in Braak stages V-VI compared to control samples and Braak stage I-II samples (Figure 5.5 C). 
CP13 amounts were also significantly increased at Braak stage V-VI compared to controls (Figure 
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5.5 D). Changes in MC1 were not statistically significant between groups suggesting that tau 
conformation does not change significantly as AD progresses (Figure 5.5 E). This is likely to be 
due to high variation between samples and low sample numbers in each group since there is 
robust evidence demonstrating that changes in tau conformation occur early in disease as tau 
aggregate formation begins (Weaver et al., 2000; Garcia-Sierra et al., 2003; Mondragon-
Rodriguez et al., 2008b). 
To determine if the increases in total tau observed in late stage AD brain reflect the 
accumulation of tau aggregates that are less prone to protein clearance and degradation 
machinery (Meraz-Rios et al., 2010), aggregated tau was isolated on the basis of its insolubility 
in sarkosyl, as we have previously described (Noble et al., 2003). This protocol results in three 
tau fractions, a low speed supernatant (LSS), sarkosyl-soluble (HSS) and sarkosyl-insoluble tau, 
all of which were immunoblotted with antibodies against total tau. These findings confirmed an 
increase in insoluble tau as a proportion of total tau in Braak stage V and VI tissues relative to 
earlier Braak stages and controls (Figure 5.6). Thus, the increase in total tau protein observed in 
Figure 5.5 A likely reflects the accumulation of this insoluble tau in temporal cortex 
homogenates. 
 
Figure 5.6: Sarkosyl insoluble tau increases as AD progresses 
Representative immunoblots of sarkosyl extraction protocols showing total, soluble and 
insoluble fractions from temporal cortical homogenates from post-mortem control and Braak 
stage I-VI brain. Blots were probed with antibodies to detect total tau (DAKO), at 50 to 70 kDa. 




Increased tau phosphorylation may be caused by increases in GSK-3 activity in early Braak 
stages 
Increases in tau phosphorylation as AD progresses are known to be caused, largely, by increases 
in tau kinase activity. Research shows GSK-3 is a key tau kinase in AD, and is significantly 
increased in AD brain (Hanger et al., 2009). GSK-3 has two isoforms: GSK-3α and GSK-3ß, both 
of which are inhibited by phosphorylation – at Ser21 and Ser9, respectively (Fang et al., 2000). 
Reduced levels of phosphorylation increase levels of GSK-3 activity, increasing tau 
phosphorylation. To investigate changes in GSK-3 activity as AD progresses, control and Braak 
stage I-VI AD post-mortem homogenates were analysed on western blots probed for antibodies 
against total and phosphorylated (Ser21/9) GSK-3α/ß. Quantification of western blots, following 
standardisation of phosphorylated GSK-3 to total GSK-3, showed a trend towards a reduction in 
phosphorylated GSK-3 amounts at Braak stage II, compared to controls (p=0.07; Figure 5.7). Only 
one prominent band was detected in the phospho GSK-3 antibody. This is likely to represent 
Ser9 on GSK-3ß as the antibody used shows a preference for this epitope. For this reason, GSK-
3α and ß were quantified together. This indicates that GSK-3 activity may be increased in early 
Braak stages, and may possibly be responsible for the increased tau phosphorylation that follows 
later in disease. However, this reduction in GSK-3 phosphorylation, and therefore increase in 
activity, is not maintained throughout disease (Figure 5.7). This suggests that GSK-3 may be 
involved in increased tau phosphorylation during early stage AD but may not be as active during 
the later, more severe stages of the disease. 
 
No significant changes in glial markers were detected in temporal cortex of different Braak 
stages 
Temporal cortex homogenates from control and Braak stage I-VI brains (Table 5.2) were western 
blotted with antibodies that detect specific astrocyte and microglial markers to determine if 
there are changes in glial activation during AD development. Unfortunately, despite extensive 
attempts at optimisation, protein bands at the correct molecular weight could not be reliably 
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detected in these samples using the anti-Iba1 antibody (data not shown), so no results for Iba1 
are described here.  
 
 
Figure 5.7: Phosphorylated GSK-3 levels are significantly reduced in early Braak stages 
A. Representative blots of temporal cortex homogenates from post-mortem control and Braak 
stage I-VI brain. Blots were probed with antibodies against total and phosphorylated (Ser21/9) 
GSK-3α/ß. Molecular weight markers are shown on the left. B. Bar charts show quantification of 
phosphorylated GSK-3α/ß as a proportion of total GSK-3α/ß in each sample. Values shown are 
mean ± SEM as percentage control (CTRL). N= 3-4 per Braak stage. Data was analysed using one-
way ANOVA. * = p<0.05. 
 
Western blots were probed with an antibody against the active astrocytic marker GFAP as 
described above, and additionally with an antibody against vimentin. Vimentin is another 
intermediate filament protein that is also reported to be upregulated in reactive astrocytes 
(Pekny and Nilsson, 2005).  Both antibodies detected bands at the expected sizes of 50 and 57 
kDa, respectively, as well as a number of smaller protein fragments (Figure 5.8 A). Vimentin 
antibodies have detected small fragments of protein in previously published paper, however it 
is unclear what vimentin fragments are present therefore only full length vimentin was 
quantified (Yang et al., 2002). Quantification of GFAP and vimentin signal intensities on western 
blots showed that there are no statistically significant changes in GFAP or vimentin in different 
Braak stages (Figure 5.8 B, C). This suggests that general astrocyte activation does not 
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significantly change in the temporal cortex as AD develops and progresses. This is inconsistent 
with both the results described in section 5.3.1 and previous publications describing that 
progressive increases in astrocyte inflammatory responses are characteristic of AD (Sofroniew 
and Vinters, 2010). It is likely that the negative finding reported here reflects the variation in 
astrocytic responses in cases of similar Braak stages, as can also be observed when examining 
other proteins. It is possible that, with larger numbers of samples in each group, significant 
differences may have become apparent. 
 
 
Figure 5.8: Astrocytic marker levels do not change with increasing Braak stage 
A. Representative blots of temporal cortex homogenates from post-mortem control and Braak 
stage I-VI brain. Blots were probed with antibodies against GFAP and vimentin. ß-actin was used 
as a loading control.  Molecular weight markers are shown on the left. Bar charts show 
quantification, following normalisation to ß-actin of B. GFAP, and C. vimentin. Values shown are 






Figure 5.9: There are no changes in IκBα levels with increasing Braak stage in temporal cortex 
A. Representative blots of temporal cortex homogenates from post-mortem control and Braak 
stage I-VI brain. Blots were probed with antibodies against IκBα and ß-actin as a loading control.  
Molecular weight markers are shown on the left. B. Bar charts show quantification of IκBα as a 
proportion of ß-actin. Values shown are mean ± SEM as percentage control (CTRL). N= 3-4 per 
Braak stage. Data was analysed using one-way ANOVA. 
 
IκBα levels suggest NF-κB activation does not change as AD progresses 
Evidence from the literature suggests the activity of NF-κB, a transcription factor known to 
control the production and release of multiple immune-related proteins (Granic et al., 2009), 
increases as part of the astrocytic activation response in AD (Shi et al., 2016). Experiments 
described in Chapter 3 (section 4.3.4), also provide evidence that NF-κB levels are increased in 
response to Aß in primary cortical cultures. To determine if there are changes in NF-κB activity 
in post-mortem AD brain, temporal cortex homogenates were western blotted and probed for 
IκBα. IκBα is an endogenous inhibitor of NF-κB, being bound to inactive NF-κB in the cytoplasm. 
When phosphorylated via signalling pathways that can be activated by Aß and other cell 
stressors (Kaltschmidt et al., 1997; Lin et al., 2013), IκBα releases NF-κB and it translocates to 
the nucleus where it can increase transcription of multiple inflammatory mediators, including 
pro-inflammatory cytokines and chemokines (Bauernfeind et al., 2009). Increased inflammatory 
mediator production can subsequently activate pathological signalling pathways in other glial 
and neuronal cells (Shi et al., 2016). Probing western blots with an IκBα antibody detected 
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proteins of 36 kDa corresponding to the expected molecular weight of IκBα. Quantification of 
IκBα amounts relative to ß-actin showed that there were no statistically significant differences 
between control tissue and any Braak stages (Figure 5.9). This data may suggest that there are 
no changes in NF-κB activation in the temporal cortex with increasing Braak stage. However, it 
is possible that changes in IκBα phosphorylation are occurring in the absence of changes in total 
IκBα, which would affect activation of NF-κB. Unfortunately, antibodies to examine phospho-
IκBα were not available for investigation in this project. 
 
Changes in synaptic markers indicate synaptic compensation in early-mid stages of AD 
Synaptic loss occurs early in AD and is thought to underlie neuron death and cognitive 
impairment (Busche and Konnerth, 2016). Both Aß and tau have been suggested to cause 
synaptic dysfunction and loss (Thies and Mandelkow, 2007; Ondrejcak et al., 2010; Crimins et 
al., 2013). Additionally, synaptic dysfunction is thought to drive abnormal tau processing, 
possibly creating a pathological feed-forward loop (Amadoro et al., 2006; Li et al., 2014b). 
Changes in synaptic markers were therefore examined in control and Braak stage I-VI post-
mortem temporal cortex (Table 5.2). Blots were probed with an antibody against post-synaptic 
density-95 (PSD-95, 95 kDa), an integral scaffolding component of the post-synapse that is also 
commonly used a marker for loss of synapses in AD models (Savioz et al., 2014). Quantification 
of PSD-95 amounts relative to ß-actin showed that PSD-95 levels appear to decrease with 
increasing Braak stage (Figure 5.10 A). However, these differences were not statistically 
significant (Figure 5.10 B) despite PSD-95 levels at all Braak stages being substantially lower than 
those detected in control samples. There is high variability in the control group and the lack of 
significance might have been the result of an anomalous sample (first control sample), that did 
not meet criteria for being removed as an outlier (Figure 5.10 A). 
Western blots were also probed with antibodies against the pre-synaptic markers, synapsin-1 
and synaptophysin. Synapsin-1 is a neuron specific phosphoprotein localized to the cytoplasmic 
side of small synaptic vesicles that plays an important role in synaptic vesicle release by 
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exocytosis (Bahler et al., 1990), and was apparent as two bands at approximately 70 and 74 kDa 
on blots (Figure 5.10 A). Synaptophysin is a 38 kDa synaptic vesicle glycoprotein that interacts 
with synaptobrevin to regulate synaptic vesicle positioning and release (Yao et al., 2003) (Figure 
5.10 A).  Quantification of synapsin-1 immunoreactivity showed that synapsin-1 levels are 
significantly increased at Braak stage III-IV compared to control samples (Figure 5.10 A, C). This 
may suggest an innate attempt to compensate for the synaptic dysfunction caused by Aß and 
other AD insults. However, this increase in synapsin is not maintained in Braak stages V-VI 
suggesting that any compensation is only temporary and is overcome by significant synaptotoxic 
challenges in later disease stages.  
 
 
Figure 5.10: Changes in synaptic markers indicate possible compensatory mechanisms prior to 
loss of synapses at late-stage AD 
A. Representative blots of temporal cortex homogenates from post-mortem control and Braak 
stage I-VI brain. Blots were probed with antibodies against PSD-95, synapsin, synaptophysin and 
ß-actin as a loading control.  Molecular weight markers are shown on the left. Bar charts show 
B. PSD-95, C. synapsin, and D. synaptophysin quantified as a proportion of ß-actin. Values shown 
are mean ± SEM as percentage control (CTRL). N= 3-4 per Braak stage. Data were analysed using 
one-way ANOVA. * = p<0.05. 
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Quantification of western blots probed with the pre-synaptic marker, synaptophsyin, showed 
significantly decreased synaptophysin amounts in Braak stage V-VI samples compared to 
controls (Figure 5.10 A, D), suggesting that synapses are lost in Braak stages V-VI. These results 
further suggest that different synaptic markers have different utilities for examining synaptic 
degeneration in post-mortem tissues, an issue discussed in detail by Honer (2003). 
Taken together, the results of these experiments suggest that there may be compensatory 
responses in prodromal AD (Braak stages III-IV) that are overcome by end-stage AD. Enhanced 
function and plasticity of healthy synapses in an area of degenerating neurons has been 
previously demonstrated (Neuman et al., 2015). If the mechanisms underlying the improved 
function of these synapses could be elucidated, it is possible they could be used to reverse 
synaptic dysfunction in AD-affected neurons. 
In summary, analysis of post-mortem temporal cortex has shown increases in total, 
phosphorylated and aggregated tau with increasing Braak stage. Changes in tau phosphorylation 
and aggregation were preceded by elevations in GSK-3 activity. There were no consistent 
changes in markers of astrocyte activation, or NF-κB activity in different Braak stages, so the 
association between astrocytes and these changes in tau remains elusive. The results suggest 
that there may be a synaptic compensatory response in Braak stages III-IV as an attempt to 
protect from synaptic dysfunction and as AD progresses, that is overcome in late-stage AD at 
which point synaptic proteins are lost.  
 
5.3.3 Characterisation of changes in tau and glia in hippocampus during AD progression 
Total and phosphorylated tau amounts increase in hippocampus during AD development 
Control and Braak stage II-VI hippocampal post-mortem homogenates (see Table 5.3) were 
western blotted and probed for antibodies against total and phosphorylated tau as described 
above for temporal cortex. Similar to changes observed in temporal cortex, quantification of 
total tau relative to NSE showed accumulation of total tau amounts with increasing Braak stage 
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(Figure 5.11 A), with a significant difference found between control and Braak stage V-VI 
hippocampus (Figure 5.11 B). This is consistent with findings from experiments using temporal 
cortex post-mortem samples (section 5.3.2) and is most likely due to the formation of tau 
aggregates and NFTs as AD progresses.  
Assessment of tau phosphorylation using the antibodies PHF1 and CP13 also showed increases 
in phosphorylated tau with advancing Braak stage (Figure 5.11 A). However, the high levels of 
variability within groups was the probable reason that these differences did not reach statistical 
significance (Figure 5.11 C, D). This is consistent with findings from temporal cortex samples 
which suggest that western blotting is not a sufficiently sensitive method to detect subtle change 
in phosphorylated tau in post-mortem brain (section 5.3.2). However, phosphorylated tau was 
more consistently detected in earlier Braak stages in the hippocampus when compared to the 
cortex, consistent with staging criteria showing that tau pathology occurring in the hippocampus 
before spreading to the temporal cortex (Braak and Braak, 1995). 
 
 
Figure 5.11: Levels of total and phosphorylated hippocampal tau are elevated with increasing 
Braak stage 
A. Representative blots of hippocampal homogenates from post-mortem control and Braak 
stage I-VI brain. Blots were probed with antibodies against total tau (DAKO), tau phosphorylated 
at Ser396/404 (PHF1) and Ser202 (CP13). NSE was used as a loading control.  Molecular weight 
markers are shown on the left. Bar charts show B.  total tau measured as a proportion of NSE, 
C. PHF1 and D. CP13 measured as a proportion of total tau. Values shown are mean ± SEM as 





Figure 5.12: Hippocampal GFAP levels increase between Braak stages II-IV and V-VI 
A. Representative blots of hippocampal homogenates from post-mortem control and Braak 
stage I-VI brain. Blots were probed with antibodies against GFAP and vimentin. ß-actin was used 
as a loading control.  Molecular weight markers are shown on the left. Bar charts show 
quantification of B. GFAP, and C. vimentin as a proportion of ß-actin. Values shown are mean ± 
SEM as percentage control (CTRL). N= 3-6 per Braak stage. Data was analysed using one-way 
ANOVA. ** = p<0.01. 
 
GFAP levels increase in late Braak stage hippocampus 
To investigate changes in astrocyte activation in the hippocampus as AD progresses, 
homogenates were run on western blots and probed with the GFAP antibody.  The results 
showed a non-significant descrease in GFAP amounts in Braak stages II-IV followed by a 
significant increase in GFAP amounts in Braak stage V-VI samples, when compared to Braak stage 
III-IV samples, but not to earlier Braak stages or controls (Figure 5.12 A, B). This might suggest 
that there is a period of intensive astrocyte activation towards end stage AD in the hippocampus. 
When western blots were probed with the vimentin antibody, no significant changes were found 
between any groups (Figure 5.12 A, C). Indeed, the vimentin immunolabelling was extremely 
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variable between groups and inconsistencies in the findings prevent any firm conclusions being 
drawn from this result.  
 
 
Figure 5.13: Hippocampal IκBα levels do not change with increasing Braak stage 
A. Representative blots of hippocampal homogenates from post-mortem control and Braak 
stage I-VI brain. Blots were probed with antibodies against IκBα and ß-actin as a loading control.  
Molecular weight markers are shown on the left. B. Bar chart shows quantification of IκBα as a 
proportion of ß-actin. Values shown are mean ± SEM as percentage control (CTRL). N= 3-6 per 
Braak stage. Data was analysed using one-way ANOVA. 
 
IκBα levels suggest hippocampal NF-κB activation does not change as AD progresses 
To investigate possible changes in NF-κB activation, as an indicator of neuroinflammatory 
responses, in the hippocampus as AD progresses, western blots of control and Braak stage II-VI 
AD hippocampal homogenates were probed with the antibody against IκBα. Quantification of 
western blots showed that there were no statistically significant changes in IκBα levels between 
groups, suggesting that there may be no global changes in NF-κB activity in hippocampus during 
AD development (Figure 5.13). This is consistent with the results from IκBα temporal cortex 
post-mortem western blots described earlier in this chapter (section 5.3.2). However, 
interpretation of these results is subject to the same caveats. IκBα amounts did appear to be 
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markedly reduced in Braak stage II-IV tissues, and while these reductions were not significant 
relative to controls, this might suggest upregulation of NF-κB occurs at the beginning of AD 
pathogenesis. 
Synaptic markers are relatively stable in the hippocampus with increasing Braak stage 
To determine if the possible synaptic compensatory mechanisms identified in temporal cortex 
(section 5.3.2) are also evident in hippocampus, hippocampal homogenates were 
immunoblotted using antibodies against the post-synaptic marker, PSD-95, and the pre-synaptic 
markers, synapsin and synaptophysin (Figure 5.14 A). Unlike results with temporal cortex 
homogenates, quantification of protein amounts following western blotting of hippocampal 
homogenates showed that there are no significant changes in either pre- or post- synaptic 
markers with increasing Braak stage (Figure 5.14 B-D). These results were unexpected since 
synaptic loss is one of the earliest changes to occur in AD (Crimins et al., 2013). However, there 
is a large and variable literature in this area, reviewed in detail by Honer (2003) and Sze et al., 
2000. A number of factors may influence the results of this type of study including sample size, 
the white/grey matter composition of tissues, pH, post-mortem delay and methods used for 
tissue processing. 
To summarise, total and phosphorylated tau were found to accumulate in hippocampus with 
advancing Braak stage. There were significant increases in astrocyte activation between Braak 
stages III-IV and V-VI, and marked, but non-significant, reductions in IκBα in the earliest Braak 





Figure 5.14: Hippocampal synaptic markers do not change with increasing Braak stage 
A. Representative blots of hippocampal homogenates from post-mortem control and Braak 
stage I-VI brain. Blots were probed with antibodies against PSD-95, synapsin, synaptophysin and 
ß-actin as a loading control. Molecular weight markers are shown on the left. Bar charts show 
quantification of B. PSD-95, C. synapsin, and D. synaptophysin as a proportion of ß-actin. Values 
shown are mean ± SEM as percentage control (CTRL). N= 3-6 per Braak stage. Data was analysed 







The results in this chapter describe changes in glial proteins and tau in post-mortem control and 
AD brain. The results reveal some differences in the stage at which changes were observed in 
different brain regions. To allow better visualisation of these alterations in glial proteins and tau 
in temporal cortex relative to hippocampus, the following table uses shade to represent 
different fold changes from control samples for different Braak stages. 
 
 
Table 5.4: Summary of protein changes in temporal cortex and hippocampal homogenates 
with increasing Braak stage 
Compared to control sample levels: white = 0-50 %, light grey = 50-100 %, mid-grey = 100-300 
%, mid-dark grey = 300-600 %, dark grey = 600+ %. * = p<0.05, ** = p<0.01, all compared to 
control, except hippocampal GFAP Braak stages V/VI which is compared to Braak stages III/IV. 
Hippo = hippocampal. 
 
This set of experiments demonstrates there are some temporal and regional differences in 
protein changes with increasing Braak stage. In particular, phosphorylated tau was increased in 
earlier Braak stages in the hippocampus relative to the temporal cortex. There was a period 
between Braak stages III-IV and V-VI in which hippocampal astrocyte activation occurred which 
was not apparent in temporal cortex, and IκBα levels showed non-significant reductions in early 
Braak stages in the hippocampus but not temporal cortex. Finally, unlike results obtained using 
temporal cortex, hippocampal homogenates did not show results indicative of synaptic 
compensation in mid-Braak stages or loss of synaptic proteins in late stage AD. In conclusion, 
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while there are clearly broad similarities between protein changes as Braak stages advance in 
the hippocampus and temporal cortex, it is also clear that there are likely region-specific 
influences that underlie AD development in different brain regions. 
 
5.4 Discussion 
The main aim of this chapter was to investigate the changes in tau phosphorylation, glial, 
inflammatory and synaptic markers in post-mortem human AD brain relative to controls.  In 
addition, regional differences in these proteins were investigated since results from cell culture 
experiments suggested different influences of astrocytes following stimulation with Aß in 
cultures prepared from different brain regions.  
Results from this chapter showing increases in total and phosphorylated tau with advancing 
Braak stage are consistent with the methods used to stage neuropathological tissues according 
to the amounts and spread of phosphorylated and aggregated tau throughout the brain (Braak 
and Braak, 1995). The results presented here show significant decreases in inhibitory 
phosphorylation of GSK-3 during early stages of disease in temporal cortex, suggesting that 
increases in GSK-3 activity precede increases in tau phosphorylation in later Braak stages. This is 
consistent with many publications showing that GSK-3 is a prominent tau kinase in AD (reviewed 
by Hanger et al., 2009).  
The results obtained from assessment of glial markers and inflammatory proteins were less 
consistent. Although analysis of a large set of control and Braak stage V-VI AD temporal cortex 
showed increased GFAP activation in AD, this was not verified when a smaller group of samples, 
including those from earlier Braak stages were assessed. There appeared to be reductions in 
IκBα in early Braak stage hippocampus but not temporal cortex, which might be indicative of the 
induction of neuroinflammatory pathways in the hippocampus during AD pathogenesis. Finally, 
some significant increases in synaptic protein amounts, followed by loss of synaptic markers 
were found in temporal cortex, but not hippocampus. The statistical analysis of these later 
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results was likely underpowered, with considerable (normal) variation within groups, reducing 
the likelihood of obtaining significant results. Unfortunately, tissues from early Braak stage cases 
were difficult to obtain, otherwise this sample set would have been extended. In addition, the 
“control” cases used in these experiments may have influenced the results. The controls were 
selected on the basis that they showed no disease-related alterations in tau or Aß. They were 
age-matched as closely as possible with AD cases in the same samples sets, and showed no 
significant difference in average post-mortem delay. However, these cases are somehow 
protected from AD, and it may be that the endogenous mechanisms that confer this protection 
affect the proteins that were studied here, thereby skewing the results obtained.  
 
5.4.1 Total and phosphorylated tau increase in the temporal cortex and hippocampus as AD 
progresses 
AD is molecularly characterised by the presence of extracellular Aß plaques and intracellular 
NFTs. A definite diagnosis of AD can only be confirmed post-mortem by the presence of these 
lesions. In particular, NFT density and spread throughout the brain post-mortem correlates well 
with symptom severity before death (Braak and Braak, 1991; Braak et al., 2011). As a result, 
post-mortem diagnostic and disease staging criteria is commonly based on the development, 
spread and density of tau aggregates (Braak and Braak, 1995). Abnormal processing of tau, 
including increased phosphorylation, is believed to precede the formation of tau aggregates 
(Bancher et al., 1989; Ding et al., 2006), therefore it would be expected that phosphorylated tau 
also increases as AD progresses. The results presented here are consistent with this literature, 
showing increases in total, phosphorylated and aggregated tau with advancing Braak stage. 
Similar findings have been reported in these tissues by multiple groups (Santpere et al., 2006; 
Hanger et al., 2007; Mondragon-Rodriguez et al., 2008b; Hanger and Wray, 2010; Braak et al., 
2011; Lau et al., 2016). It is worth noting, however, that a recent study showed that tau in 
tauopathy brain is largely dephosphorylated (Kimura et al., 2016) and this may explain the 
relative scarcity of phosphorylated tau in early Braak stage tissues. 
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Furthermore, results from this chapter suggest that increased activity of GSK-3, a prominent tau 
kinase (Fang et al., 2000), could mediate increases in tau phosphorylation, at least through its 
influence in early Braak stages. GSK-3 has long been implicated in abnormal tau phosphorylation 
in AD and is known to phosphorylate tau at multiple epitopes (Hanger et al., 2009). Several of 
these sites, including Thr231, Ser235 and Ser262, control microtubule binding of tau. Pre-
phosphorylation of these sites by one of several kinases, followed by phosphorylation by GSK-3 
has been demonstrated to result in the inhibition of tau binding to microtubules, an event also 
believed to occur early in disease development (Sengupta et al., 1998). Therefore, 
phosphorylation of tau at early Braak stages by GSK-3 may result in an increased pool of soluble 
cytosolic tau that aggregates in a concentration-dependent manner into oligomers and is 
subsequently deposited in NFTs as AD progresses.  
No alterations in tau conformation were observed in temporal cortex as AD develops, in contrast 
with previous findings (Weaver et al., 2000; Garcia-Sierra et al., 2003). The reason for this 
discrepancy is not clear, but might reflect differences in the preparation of homogenates used 
in different studies. Tau in abnormal conformations is particularly prone to aggregation (Noble 
et al., 2005), and it might be that assessing MC1 amounts in sarkosyl-insoluble fractions would 
have shown different findings. Unfortunately, there were insufficient amounts of the sarkosyl 
insoluble fraction obtained from the tissues used for these analyses to allow this work to be 
carried out.  
 
5.4.2 Glial markers are not consistently upregulated with advancing Braak stage in different 
brain regions  
A widespread activation of glial cells and associated neuroinflammatory response is increasingly 
regarded as another key hallmark of AD brain. It is thought that Aß can activate glial cells 
initiating the release of cytokines and chemokines and triggering multiple pro-inflammatory 
signalling pathways (Rubio-Perez and Morillas-Ruiz, 2012; Shi et al., 2016; Zheng et al., 2016). 
These complex inflammatory events can influence neuronal signalling pathways to increase tau 
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phosphorylation and aggregation in nearby neurons, thereby driving the progression of AD 
(Sofroniew and Vinters, 2010; Phillips et al., 2014; Selkoe and Hardy, 2016). The results 
presented here showed that increased GFAP activation in late stage AD relative to controls, that 
was not verified when a smaller group of samples, including those from earlier Braak stages, 
were later assessed. However, there were significant increases in astrocyte activation in the 
hippocampus, but not temporal cortex, between Braak stages III-IV and V-VI. The difference in 
results from these brain regions may reflect differences in the contributions of astrocytes to the 
progression of AD in different environments at different stages of disease. Previous studies from 
the literature suggest that astrocytes behave differently in different brain regions, possibly 
distinguishing different astrocyte subtypes. Astrocytes from different brain regions show 
different glycoprotein markers in culture, suggesting that, like neurons, regional astrocytes may 
represent distinct cell types (Barbin et al., 1988). Further evidence suggesting a regional 
influence of astrocyte contributions to disease have come from analysis of transgenic mouse 
models of AD. GFAP levels were shown to increase in the hypertrophied hippocampus of aging 
mice, but this same increase in astrocyte reactivity was not found in the entorhinal cortex of 
3xTg-AD mice (Rodriguez et al., 2014). This suggests different regional astrocytes may respond 
to aging differently, possibly contributing to the increased susceptibility of some brain regions 
to Aß and neurotoxicity. Additional support for this theory comes from a study that showed 
atrophy and no astrogliosis of entorhinal cortex astrocytes suggesting neurons may be 
particularly vulnerable in the absence of astrocyte activation (Yeh et al., 2011). This is consistent 
with the findings of this thesis, that suggest astrocytes are activated in the hippocampus, but 
not the temporal cortex, of AD brain. Furthermore, astrocytes in different brain regions respond 
differently to Aß, with the calcium response in different brain regions being more susceptible to 
Aß toxicity (Grolla et al., 2013). These results may further explain the susceptibility of specific 
brain regions to Aß, with astrocytes from the entorhinal cortex showing an increased sensitivity 
and calcium response to Aß, compared to the hippocampus (Grolla et al., 2013). Additionally, 
they may also explain differences seen in synaptic marker levels between the hippocampus and 
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temporal cortex in this thesis, as different calcium responses from regional astrocytes may affect 
regional neurotoxicity, synaptic health and compensation. Astrocyte activation has been 
implicated in AD progression via multiple pathways, controlled by the release of different 
cytokines and chemokines (Zheng et al., 2016). Different responses of astrocytes in different 
areas of the brain may result in the activation of different signalling pathways via the release of 
different cytokines and chemokines. These studies support the results described here which 
suggest differences in the timing of astrocyte activation in hippocampal, but not temporal, AD 
brain samples. 
ApoE is generally thought to be associated with an anti-inflammatory phenotype of astrocytes 
since ApoE treatment of cell cultures reduces macrophage activation and ApoE knockout mice 
have increased neuroinflammatory responses (Grainger et al., 2004; Baitsch et al., 2011). 
However, the ε4 variant may trigger pro-inflammatory responses, possibly exacerbating AD 
progression (Jofre-Monseny et al., 2007; Belinson and Michaelson, 2009). The number of 
samples used to investigate ApoE correlation with astrocyte activation in this study is too small 
to draw any definitive conclusions. However, they may suggest that the pro-inflammatory 
effects of ApoE ε4 are not particularly associated with astrocyte activation and induction of 
astrocytic inflammatory responses. There is evidence to suggest ApoE may help mediate 
neuroinflammation via microglia, the primary immune cells of the brain. ApoE has been found 
to be involved in the mediation of the innate immune system, via TLR4 receptor signalling 
pathways (Tai et al., 2015). Furthermore, Aß can increase production of ApoE, which in turn has 
been found in exacerbate the inflammatory response (Guo et al., 2004). Also, TREM2 production 
is lower in microglia with the ε4 allele suggesting that this allele may have similar effects to 
TREM2 variations that increase AD risk (Li et al., 2015).  
Iba1 was visualised in temporal cortex homogenates from control and Braak stage V-VI. No 
significant differences were observed in Iba1 amounts in these tissues, and for reasons that were 
never determined, this antibody failed to detect any proteins in the Braak-staged samples sets. 
It is therefore not possible to comment on changes in microglial proteins in these samples. In 
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any case, it is likely that assessment of microglial morphology might have provided more 
informative results concerning microglial activation state, since microglial phenotypes are 
complex to distinguish, as described by Perry and Teeling (2013), Perry and Holmes (2014) and 
Perry (2016).  
Finally, there appeared to be reductions in IκBα in early Braak stage hippocampus but not 
temporal cortex, which might be indicative of the induction of neuroinflammatory pathways in 
the hippocampus during AD pathogenesis. Cytokine array analysis of other post-mortem brain 
tissues by colleagues in the lab supports this idea. Indeed, there is a vast literature showing 
increased amounts of different pro-inflammatory cytokines in AD brain (Di Bona et al., 2008; 
Ojala et al., 2009; Zheng et al., 2016). Time constraints prevented similar analyses from being 
conducted for this thesis. 
5.4.3 Synaptic compensation may occur in the temporal cortex in mid-Braak stages 
Results from these experiments suggest that, in temporal cortex, there is an increase in synapsin, 
a pre-synaptic marker, during mid-stages of AD. According to general theories of the progression 
of AD, this is unexpected as synapses are meant to become dysfunctional and then be lost as AD 
progresses (Selkoe and Hardy, 2016). However, these data support those from other studies 
which suggest that there is an upregulation of some synaptic proteins in the mid-stage of disease 
which may be an innate neuroprotective mechanism in attempt to improve synaptic function 
and rescue the dysfunction that progressively develops in AD (Neuman et al., 2015). However, 
there is some evidence to suggest that synaptic compensation may actually be detrimental 
rather than protective. One study found that, in aging rats, synaptic compensation occurred only 
at large synapses, leaving smaller synapses to degenerate (Bloss et al., 2013). Furthermore, the 
head volume of thin dendritic spines, from smaller synapses, has been found to correlate best 
with cognitive status in rhesus monkeys, suggesting it is smaller synapses that may be most 
important for memory loss (Dumitriu et al., 2010). 
These studies might therefore suggest that the increases in synapsin-1 that are found in mid 
Braak stages could represent an additional neurodegenerative step rather than synaptic rescue. 
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On the other hand, local synthesis of synaptic proteins is linked with learning and memory, and 
protection from synaptic loss (Tiwari et al., 2015), so further investigations are necessary to 
untangle the significance of this finding.  
Reductions in synaptic markers, particularly synaptophysin, in Braak stage V-VI temporal cortex 
samples indicate there is a level of synaptic loss at these stages of disease. This is consistent with 
the literature, demonstrating synaptic dysfunction and subsequently synaptic loss throughout 
the brain in AD (LaFerla and Oddo, 2005), although the results of different studies vary widely 
(Sze et al., 2000; Honer, 2003). Synaptic dysfunction is particularly associated with abnormal tau 
processing. For example, activation of NMDA receptors, via increased glutamate or cytokine 
activation, may lead to excitotoxicity and activation of signalling pathways that result in 
increased kinase activity and tau phosphorylation (Curran and O'Connor, 2001; Amadoro et al., 
2006). Conversely, there is also evidence tau and Aß may converge to exacerbate synaptic 
dysfunction (Crimins et al., 2013), resulting in a feed-forward loop that continually affects 
synapse health. The reductions in synaptophysin concurrent with increased phosphorylated tau 
observed in Braak stage V-VI temporal cortex homogenates is consistent with these reports. 
Finally, the regional differences in synaptic protein alterations might suggest that temporal 
cortex synapses show greater sensitivity to toxic Aß and tau species resulting in a greater extent 
of synaptic loss than is observed in the hippocampus. Alternatively, increased activation of 
astrocytes in hippocampal brain regions may be providing protection at the synapse, 
maintaining synaptic function for longer during disease progression.  
 
5.4.4 Conclusions 
In summary, the data shown here might support the idea that there are spatiotemporal 
differences in the pathways underlying AD progression. Being able to tease out these differences 
may result in new drug targets and signalling pathways being identified. Furthermore, these 
temporal and regional differences need to be taken into account when both developing drugs 
and running clinical trials. As AD pathology spreads through different brain regions in a well-
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characterised way, it is possible that effective disease-modifying drugs could show no benefit if 
administered to an individual at the wrong stage of disease. Further characterisation of these 
regional differences will allow better stratification of patients in clinical trials. New PET ligands 
against specific astrocyte and microglial markers have been developed which should also aid in 




Chapter 6: Discussion 
The main aims of this thesis were to investigate the relationship between astrocytes and tau in 
models of AD. In addition, this thesis aimed to explore differences in the effects of astrocytes in 
different brain regions and explore how these differences may affect drug discovery and 
repurposing for AD treatment. 
The studies described in this thesis used primary cortical cultures to investigate the 
contributions of astrocytes to Aß-induced cell death and abnormal tau processing by creating 
two distinct populations of cell cultures: mixed neuron and astrocyte cultures and 
predominantly neuronal cultures. To achieve this, the two cell culture types were treated with 
synthetic Aß. In addition, cultures were treated with the anti-inflammatory agent minocycline 
to allow investigation of the role of astrocytic inflammatory signalling pathways for Aß-induced 
changes. These experiments were repeated in primary hippocampal cultures in order to 
investigate possible differences in astrocytic contributions in different brain regions. 
Primary cell culture experiments showed that there were differences in the effects of Aß in 
cortical and hippocampal cultures. Hippocampal astrocytes appeared to accelerate Aß-induced 
hippocampal neuron death, since Aß induced significant levels of toxicity in mixed, but not 
predominantly neuronal cultures. In contrast, non-significant increases in cell death of similar 
magnitude were observed following Aß treatment in both cortical mixed and neuronal cultures. 
This data might suggest different mechanisms of Aß-induced toxicity in different brain regions. 
In turn this might imply that different drugs may be more or less effective at different stages of 
disease, depending on the brain regions most affected at that time.  
Minocycline has previously been shown by this laboratory to reduce the release of pro-
inflammatory cytokines released from astrocytes upon stimulation with Aß (Garwood et al., 
2011), in keeping with its anti-inflammatory effects in various models of neurodegeneration 
(Hunter et al., 2004; Ryu et al., 2004; Festoff et al., 2006; Peng et al., 2006; Garwood et al., 2010). 
However, in the experiments described here, no neuroprotective effects of minocycline were 
identified in either mixed or predominantly neuronal hippocampal or cortical cultures. While 
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the reasons for this lack of effect in these experiments were not clear, it is clear from the 
literature that the beneficial anti-inflammatory effects of minocycline are not always clearly 
defined and appear to be highly context dependent (Diguet et al., 2004).  
There were also no clearly defined effects of Aß or astrocytes on tau phosphorylation or cleavage 
in treated cultures in these experiments. Again, this is somewhat surprising considering previous 
publications from this laboratory (Williamson et al., 2002; Garwood et al., 2011) and others 
(Town et al., 2002; Jin and Selkoe, 2015). As discussed in Chapter 3, it is possible that the lack of 
Aß-induced tau effects may have arisen from batch-to-batch Aß variations, insufficient levels of 
toxic Aß-species and/or issues with culture health.  
Nevertheless, the potential benefits of anti-inflammatory agents in other models was worthy of 
further exploration, especially considering the close association of glial activation and 
inflammatory mediators with tau pathology development in vivo (Bellucci et al., 2004; 
Schindowski et al., 2006; Garwood et al., 2010; Schwab et al., 2010). Therefore, the effects of 
DMF, an already licenced drug with anti-inflammatory action, were tested first in primary 
cortical cultures and then in a mouse model of tauopathy with the aim of determining if this 
drug has potential for repurposing for AD. In primary cortical cultures, DMF was found to dose-
dependently reduce tau phosphorylation at several epitopes known to be abnormally 
phosphorylated in AD, supporting its further investigation in tau transgenic mice. Preliminary 
trials examining DMF effects on mice at early- and mid- stages of tauopathy were less promising, 
as effects of DMF on possible cognitive impairment was unable to be determined and DMF 
treatment lead to increases in the accumulation of sarkosyl-insoluble tau aggregates. These 
differences between primary culture and transgenic mouse model may have been due to the 
accumulation of tau aggregates in htau mice, which are not present in primary cultures, since 
DMF is known to affect the activity of Nrf2, which in turn is implicated in tau-specific autophagy 
via the autophagy adapter protein NDP52 (Jo et al., 2014). Regardless of mechanism, these 
results suggest DMF does not show significant changes in htau mice. 
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Finally, since it is critical that any results from mammalian cell and animal models of AD have 
relevance to human disease, human post-mortem brain samples from control and Braak stages 
I-VI temporal cortex and hippocampus were homogenised to allow investigations of regional 
differences in glial markers and pathological changes in tau during AD progression. These data 
suggested there were increased activation states of glia in late-stage AD, coinciding with large 
increases in tau phosphorylation. However, the mechanistic links between these two 
observations remains elusive. 
To summarise, the primary findings of this thesis were: 
 Astrocytes contribute to Aß-induced cell death to different extents in primary cell 
cultures from different brain regions. Experiments presented in this thesis show 
astrocytes affect Aß-induced neurotoxicity in hippocampal, but not cortical, cell 
cultures. This suggests the underlying mechanisms driving Aß-induced cell changes are 
different in primary cell cultures from different brain regions. Furthermore, in primary 
cortical cultures, astrocytes appear to be involved in mediating extracellular tau levels 
in basal conditions. 
 DMF does not improve tauopathy-like symptoms in htau mice. Results from primary 
cell culture experiments with DMF showed dose-dependent reductions in tau 
phosphorylation in primary cortical cultures. However, small preliminary preclinical 
trials of DMF treatment of a mouse model of tauopathy failed to show any benefits 
suggesting repurposing DMF as a tauopathy durg treatment is unlikely to slow disease 
progression or symptoms. 
 Differences in astrocyte activation and abnormal tau processing are observed in 
different regions of post-mortem AD brain. Experiments investigating changes in tau, 
glial and synaptic markers as AD progressed from early Braak stages to severe AD (Braak 
stages V-VI) showed that abnormal tau phosphorylation occurred at an earlier Braak 
stage in hippocampal samples than was found in cortical samples. Additionally, 
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astrocyte activation was increased in hippocampal but not cortical samples suggesting 
astrocytes from different brain regions may contribute differently to AD progression. 
Further support for the idea that different mechanisms underlie pathological changes in 
different brain regions was shown in regional differences in synaptic marker changes: in 
cortical samples, synaptic marker levels suggest possible synaptic compensation during 
Braak stages III-IV while hippocampal samples show no indication of neuroprotective 
events as disease progresses. These findings are in partial agreement with primary cell 
culture findings. 
Taken together, these results suggest there are likely to be regional differences in astrocyte 
activation and pathological tau processing in AD. In particular, the contribution of astrocytes 
appears to differ significantly between the cortex and hippocampus. These differences should 
not be overlooked as they may have significant implications for highlighting and developing 
potential drug treatments for the treatment of AD. 
 
6.1 Regional differences in the development and progression of AD 
One of the main ideas underlying this project was that there are likely specific 
neurodegenerative mechanisms in different brain regions that will come into play at different 
stages of disease progression. There is considerable published data to support this hypothesis. 
Even in healthy brain, astrocytes from different brain regions show significant differences in 
their expression of surface glycoproteins (Barbin et al., 1988). Differences in astrocyte structure 
and function, not only between brain regions of interest (e.g. hippocampus and nearby cortex), 
but also within the same brain region, demonstrate a heterogeneity similar to that found in 
neurons. Recently Liu et al. (2015a) have shown two different subpopulations of cortical 
astrocytes, which can be distinguished by their growth patterns, exert markedly different effects 
upon neurite outgrowth. One of these subpopulations, characterised by an atypical growth 
pattern, including random orientation and homogenous cell clusters, inhibited neurite growth 
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and provoked a dystrophic appearance of neurites, but did not affect neuron survival (Liu et al., 
2015a). This has resulted in suggestions that astrocytes from the same and different brain 
regions may be distinct subspecies of cell type, in the same way as motor neurons and sensory 
neurons differ (Verkhratsky et al., 2012; Stobart and Anderson, 2013; Hu et al., 2016). This is not 
surprising as converging lines of evidence show astrocytes have a wide range of functions, 
supporting neuron health and maintaining synapse function in environments with different 
positive and negative synaptic inputs (Sofroniew and Vinters, 2010; Garwood et al., 2016; Hu et 
al., 2016; Rodriguez-Arellano et al., 2016). Furthermore, regional differences in the function and 
structure of neurons suggests different astrocytic support would be required in order to 
maintain neuronal function and health. 
In disease models, aged hippocampal neurons have higher resting calcium levels and are more 
susceptible to excitotoxicity than younger hippocampal neuron cultures (Calvo et al., 2015). 
Hippocampal sensitivity in AD is demonstrated by the early death of hippocampal neurons and 
subsequent short-term memory impairment (Braak and Braak, 1995). Hippocampal atrophy is 
evident early following AD diagnosis and now, with improved imaging resolution (e.g. for MRI 
imaging), it is possible to track disease progression based on the speed of hippocampal atrophy 
(de Flores et al., 2015). Furthermore, hippocampal sensitivity to insult has been found to not 
just be limited to Aß and AD-related pathology. For example, evidence shows the hippocampus 
is more sensitive to structural and functional damage from traumatic brain injury than other 
brain areas (Lifshitz et al., 2003; Deng and Xu, 2011).  
However, the precise mechanisms by which hippocampal neurons show increased susceptibility 
to disease-related insults are not clear. Evidence from traumatic brain injury research, where 
the injury sustained can be better controlled and monitored, suggests hippocampal neuron 
susceptibility may be due to increased mitochondrial damage and impaired response to injury, 
compared to cortical neurons (Lifshitz et al., 2003). Furthermore, hippocampal neurons have 
been found to be more sensitive to post-injury excitotoxicity (Deng and Xu, 2011). Pro-
inflammatory cytokines have been shown to increase in response to hippocampal injury, and 
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inhibition of these cytokines has been demonstrated to attenuate damage as a result of global 
cerebral ischaemia suggesting glial activation may influence hippocampal neuron susceptibility 
to injury (Xing and Lu, 2016). 
Evidence from studies described in this thesis also suggests glial activation, and possibly 
inflammation, may contribute to differences found between hippocampal and cortical neuron 
responses to Aß. Experiments from Chapter 3 show the increased sensitivity of primary 
hippocampal cultures finding increased levels of cell death in response to Aß compared to 
cortical cultures. However, higher levels of cell death are only significant in mixed neuron and 
astrocyte cultures, suggesting astrocytes may be exacerbating Aß-induced neurotoxicity in 
hippocampal cultures. In comparison, the presence of astrocytes in primary cortical cultures has 
no effect on levels of cell death or tau phosphorylation with Aß or minocycline treatment in 
these studies.  
Differences in the roles of astrocytes during AD progression have been described previously in 
the literature. Differences in hippocampal and cortical astrocyte markers including GFAP, 
glutamine synthase and s100ß in WT mice of different ages suggest astrocytes from different 
regions of the brain undergo specific remodelling as mice age (Rodriguez et al., 2014). 
Furthermore, astrocytes from the entorhinal cortex and hippocampus of control and transgenic 
mice have previously been found to respond differently to Aß, with increased activation and 
calcium sensitivity in hippocampal astrocytes while entorhinal astrocytes showed no Aß-induced 
changes (Grolla et al., 2013). This may be consistent with the results of cell culture experiments 
described here, with astrocytes appearing to contribute more to the primary hippocampal 
culture response than the cortical culture response. Thus, regional differences in the 
environment required for both physiological astrocyte and neuron function may result in these 
cells having different responses in neurodegenerative diseases such as AD, with different 
pathological mechanisms being implicated as the disease spreads across affected brain. This has 
implications for understanding disease progression as well as developing new, disease-
modifying drug targets. 
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6.1.1 Implications of regional differences in neurodegenerative mechanisms for preclinical 
and clinical trials 
Regional differences in the way astrocytic and other mechanisms drive abnormal tau processing 
and neurodegenerative pathways are of the utmost importance for understanding disease 
progression and when developing efficient drug treatment protocols with the capacity of 
slowing or halting disease development. As AD progresses, tau pathology spreads from the 
entorhinal cortex and hippocampus in the earliest, prodromal stages (Braak stages I-II) 
throughout the cortex in the latest stages (Braak stages V-VI). This pattern of spread is well-
characterised and is used to diagnose and stage AD post-mortem (Braak and Braak, 1995). This 
means that at different stages of disease, when tau and Aß pathology is developing in specific 
brain areas, region-specific neurodegenerative mechanisms could be involved. This clearly has 
important implications for the design of preclinical and clinical trials. For example, screening of 
possible disease-modifying drugs in mouse models of AD that only recapitulate one stage of 
disease may result in a drug that may provide benefits at a different stage of disease being 
overlooked, or even worse the drug deemed ineffective when it may have been beneficial if 
tested at a different stage of disease progression. As a result, it seems important to examine the 
effects of treatment at different stages or severities of disease.  
6.1.2  Importance of biomarkers for drug development 
As described above, a good knowledge of disease stage may be critical for preclinical and clinical 
testing. Early diagnosis of AD is a challenge as clinical symptoms only manifest themselves after 
widespread neuron loss across the brain (Braak and Braak, 1995). However, treatments may be 
most effective at earlier stages of disease, before substantial neuron death has occurred 
(Mattsson et al., 2015). Therefore, determination of early and mid-AD stages using a blood test 
or other non-invasive biomarker is critical to the development of potential disease-modifying 
drug treatments of AD.  
Detection of abnormally high levels of Aß, in the CSF or the blood, has been investigated as a 
potential biomarker for AD. The presence of Aß monomers and oligomers particularly in the CSF 
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can predict the severity and progression of prodromal AD, however CSF testing is invasive and 
expensive making it difficult to use on a large scale (Zhou et al., 2016). Levels of Aß in the blood, 
however, are much lower and difficult to detect, with many other proteins of higher 
concentration interfering with detection. Additionally, levels of Aß in the blood do not appear 
to be specific to AD patients or to reflect the severity of disease, suggesting blood tests for Aß 
may not be an ideal biomarker for AD (Pesaresi et al., 2006; Zhou et al., 2016). 
Detection of tau in the CSF and blood has also been considered in the search of an AD biomarker. 
However, measurements of tau in CSF have the same disadvantages as amyloid tests, while tau 
blood levels are increased in patients with other tauopathies as well as those suffering from AD 
(Mattsson et al., 2015; Shanthi et al., 2015). So, while tau levels in blood may reveal the presence 
of a tauopathy, they cannot be used to diagnose or stage AD. 
More recent attempts at developing a biomarker for AD have involved advanced imaging with 
positron emission tomography (PET), whereby Aß or tau are labelled with a specific tracer and 
measured using a PET scanner (Villemagne, 2016). These techniques, while expensive, are non-
invasive and have increasingly good resolution, allowing diagnosis of AD in individuals prior to 
the start of clinical symptoms (Schierle et al., 2016). It is hoped that these advanced diagnostic 
tools may allow more careful staging of patients (and indeed animals) for preclinical and clinical 
trials. Of considerable interest to this thesis, a number of inflammation-related PET ligands have 
recently been described. These include markers of activated astrocytes and microglia. For 
example, carbon-11-labelled (R)-PK11195 is a PET ligand for peripheral benzodiazepine sites, a 
group of receptors with increased expression on activated microglia, compared to resting 
microglia (Cagnin et al., 2001). Astrocyte levels and activation have also been measured using 
PET ligand (11)C-deuterium-L-deprenyl to measure monoamine oxidase B in astrocytes, and 
found the marker suggested increases in astrocyte activation in patients with MCI (Carter et al., 
2012). These new PET markers will obviously be of particular use for trials in which inflammatory 
pathways are being targeted. In addition, serial imaging with the astrocyte PET ligand and a tau 
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ligand will allow much more precise information about the spatiotemporal association of 
activated astrocytes and pathological tau changes to be identified.  
 
6.2 DMF and the repurposing of drugs for AD treatment 
To explore the relationship between inflammation and the development of tau pathology in 
vivo, the effectiveness of DMF to reduce abnormal tau species was investigated in the htau 
mouse model of tauopathy. Repurposing of already licenced drugs such as DMF is considered a 
valuable approach to identifying disease-modifying treatments for AD since their progression to 
the clinic can be made more rapidly (Corbett et al., 2012).   
Results from experiments investigating the effects of DMF treatment on a mouse model of 
tauopathy found no significant biochemical differences between groups of treated and 
untreated mice. Furthermore, behavioural impairment of htau mice, compared to WT mice, was 
not found to be significant preventing conclusions about DMF-related memory improvements 
and making it difficult to demonstrate that this drug is suitable for repurposing as a treatment 
for AD. No effects on astrocyte activation were apparent and biochemical analysis of the brains 
of younger mice showed a trend toward increases in sarkosyl-insoluble tau levels with DMF 
treatment, indicating the drug may be influencing the propensity of tau to aggregate. This was 
unexpected as DMF has known anti-inflammatory action and was expected to reduce astrocytic 
activity in the htau mice, a model of tauopathy. However, it is likely DMF could affect other 
inflammatory pathways that do not involve astrocytes, or that are very specific. Astrocytes and 
microglia can activate many different signalling cascades with capacity to affect neighbouring 
cells, including through the release of cytokines and chemokines into the extracellular space 
(Zheng et al., 2016). DMF treatment could affect the release and activity of multiple cytokines 
and their downstream signalling cascades. Many cytokines, for example IL-6 and TNF-α, have 
been associated with AD-like changes in tau phosphorylation (Quintanilla et al., 2004; Gabbita 
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et al., 2015) and there is evidence suggesting DMF may reduce the synthesis of some of these 
specific cytokines (Wilms et al., 2010).  
Evidence extensively supports the role of IL-1ß, in particular, in abnormal tau phosphorylation. 
Overexpression of IL-1ß in the 3xTg mouse model of AD resulted in rapid exacerbation of 
pathological tau species, while IL-1ß receptor antagonists have been found to reduce tau 
pathology and improve cognitive impairment in vivo (Ghosh et al., 2013; Ben-Menachem-Zidon 
et al., 2014). Additionally, IL-1ß inhibition reduces the activity of multiple tau kinases including 
cdk5 (Kitazawa et al., 2012), a kinase experiments presented in Chapter 4: highlight as possibly 
being involved in DMF-affected pathways. DMF was shown to reduce tau phosphorylation in 
primary cultures in this thesis (Chapter 4:), and one possible explanation of the effects seen in 
primary cortical cultures is that DMF treatment acts on activated astrocytes, reducing 
inflammatory activity such as IL-1ß production and release (Wilms et al., 2010). This would 
reduce the activation of pathological neuronal signalling cascades, including p25 levels and, 
therefore, cdk5 activity. This could account for the reduced phosphorylation observed at 
Ser199/202/Thr205 after DMF treatment, since these sites can be phosphorylated by cdk5 
(Hanger et al., 2009).  
In contrast, no effects on tau phosphorylation were observed following DMF treatment of htau 
mice, although a trend towards increased tau aggregation, indicated by accumulation of 
sarkosyl-insoluble tau species, was observed when mice at an early disease stage were treated. 
The presence of tau aggregates correlate well with symptom progression in AD and are used for 
Braak staging (Braak and Braak, 1991). However, there is now a significant body of evidence to 
suggest tau aggregates are not the cause of toxicity, as once assumed, but a neuronal attempt 
at preventing toxicity (Meraz-Rios et al., 2010; Cowan and Mudher, 2013).  
Soluble tau oligomers are increasingly thought to be the toxic tau species. Tau oligomers impair 
memory and induce tauopathy-like synaptic and mitochondrial dysfunction in wild-type mice 
(Lasagna-Reeves et al., 2011). Treatment of mouse models of tauopathy with an antibody raised 
specifically against tau oligomers improved memory impairments and reduced oligomer, but not 
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NFT, load, strongly suggesting tau oligomers underlie the characteristic memory deficits 
displayed by these mice (Ward et al., 2012; Castillo-Carranza et al., 2014). Furthermore, large 
tau aggregates, such as those species insoluble in sarkosyl, have been suggested as 
neuroprotective, acting to sequester tau oligomers and prevent them from causing further 
damage (Meraz-Rios et al., 2010). Therefore, the increased sarkosyl-insoluble tau amounts 
detected here following DMF treatment of younger htau mice could potentially be 
neuroprotective, by reducing the amount of highly toxic soluble tau oligomers in htau brain. 
Despite these preliminary studies with DMF not being conclusive, they demonstrate some 
methods by which already licenced drugs could be preclinically tested for tauopathies. In 
particular, testing a drug at multiple ages/disease stages is an important consideration. If carried 
out in conjunction with biomarkers that can more accurately determine disease stage, it is 
possible to envisage previously disregarded drugs, or drugs originally approved for other 
diseases, could be found to slow or prevent AD progression. 
Moreover, a better understanding of the contributions of glia and glial signalling pathways could 
identify new targets for drug development. Previous research into broad-range anti-
inflammatories, such as NSAIDs, have concluded there is no significant improvement in clinical 
symptoms following drug treatment (Miguel-Alvarez et al., 2015). However, significant evidence 
suggests targeting specific cytokines, such as IL-1ß, may be beneficial (Li et al., 2003; Quintanilla 
et al., 2004; Ghosh et al., 2013; Salani et al., 2013). These promising preclinical trials which 
describe improvements in biochemical and behavioural AD-like symptoms suggest controlling 
cytokine levels may provide a way of modulating disease progression (Rothwell and Luheshi, 
2000; McAlpine et al., 2009). Of particular interest is the IL-1 receptor antagonist (IL-1RA), an 
endogenous inhibitor of the IL-1 receptor, that has been found to have anti-inflammatory effects 
(Rubio-Perez and Morillas-Ruiz, 2012). A recombinant version of human IL-1RA, anakinra, has 
been licenced for treatment of rheumatoid arthritis (Hallegua and Weisman, 2002). However, a 
preclinical trial was unable to detect the drug in the CNS after perispinal injection (Roerink et al., 
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2015), and it is still unclear whether inhibition of IL-1 in the brain could cause widespread side-
effects.  
In addition to highlighting possible drug targets, further knowledge of underlying mechanisms 
of AD would allow design of trials involving therapies that may target specific mechanisms 
implicated at only some stages of disease progression. The data described above begins to 
demonstrate the continued challenges of drug discovery and trials in AD research, highlighting 
the need for further basic research into underlying mechanisms of AD progression and the need 
for understanding possible differences in signalling pathways in different brain regions and at 
different stages of the disease. 
 
6.3 Comparisons between cell culture models and post-mortem AD brain 
Models of AD, both on a cellular and whole organism level, do not accurately recapitulate human 
AD. However, they recapitulate at least some important disease aspects and can be used to 
determine useful information about underlying mechanisms and for drug discovery. Many 
mouse models, for example the htau mouse used in this thesis, model only some pathological 
aspects of AD: the htau mouse, like other tau transgenic lines, models the development of tau, 
but not Aß, pathology (Lewis et al., 2000; Andorfer et al., 2003; DaRocha-Souto et al., 2012; 
Bondulich et al., 2016). While htau mice may provide useful information about the development 
of tau pathology, it is not possible to examine pathological APP processing or Aß accumulation 
and therefore the synaptotoxic interaction of Aß and tau in these mice. As such they can be 
considered an incomplete model of AD. In general, only multigenic lines, such as the 3xTg-AD 
mouse, develop AD-like Aß and tau pathology (Lewis et al., 2001; Oddo et al., 2003; Platt et al., 
2011). The 3xTg-AD mouse line shows age-dependent Aß and tau pathology and glial 
inflammation, along with progressive cognitive deficits, suggesting this model represents AD 
progression to a good extent (Oddo et al., 2003). However, this model is widely criticised due to 
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its lack of relevance to human AD since it relies on overexpression of three mutant human 
transgenes that have never been found to co-occur in patients.  
Therefore, it is always important to validate findings from animal models using human tissues. 
However, most studies using post mortem brain samples focus on end stages of disease in 
comparison with control brain (Chen et al., 2016; Lau et al., 2016; Nasaruddin et al., 2016). This 
is partly due to difficulties in acquiring post-mortem brain from early and mid-disease stages.  
The studies using human post-mortem brain presented in this thesis aimed to investigate 
possible changes in tau, glial and synaptic markers as AD progresses using tissue from control 
and Braak-staged brain. In addition to the expected increase in total and phosphorylated tau, 
two other patterns of changes were found. The first was an apparent synaptic compensation in 
cortical samples at Braak stages III-IV, demonstrated by a significant increase in amounts of 
synapsin, a pre-synaptic marker (Kurbatskaya et al., 2016). This may suggest an attempt by these 
neurons to counteract disease-related synapse dysfunction occurring at this stage of disease. 
Interestingly, these changes were not seen in hippocampal post-mortem samples. Taken 
together with the data described in primary cultures in Chapter 3:, this might suggest 
neurodegenerative cascades are different in different regions of the brain, with hippocampal 
neurons being particularly susceptible to neurodegeneration. 
Secondly, in the set of samples including cases from all Braak stages, increases in markers of 
activated astrocytes were only seen in the hippocampus in late stage (Braak stages V-VI) AD. 
Unexpectedly, in the temporal cortex there was no evidence of any glial changes at earlier 
disease stages. As discussed throughout this thesis, astrocyte activation and neuroinflammation 
are key components of AD pathology (Phillips et al., 2014; Hu et al., 2016; Rodriguez-Arellano et 
al., 2016). However, there is also evidence from other groups suggesting glial activation is not 
present in the entorhinal cortex of aging mice, despite evidence of activation in the 
hippocampus (Rodriguez et al., 2014). Activation of astrocyte roles in the hippocampus but not 




Similarities between results from disease models and those from experiments using human 
post-mortem brain samples are important as they suggest experimental models used are 
replicating some aspects of human disease with some accuracy. These comparisons are 
reassuring as experiments using primary culture and human post-mortem brain samples show 
broadly similar results, suggesting different signalling mechanisms may be involved in the 
hippocampus and cortex, and astrocytes appear to play a more central role in degenerative 
processes in the hippocampus, compared to the cortex.  
 
6.4 Limitations of this work 
For all studies presented in this thesis, everything possible was done to ensure all experiments 
were carefully planned and controlled. However, there are limitations of this work that need to 
be discussed. 
6.4.1 Limitations of rodent primary cell culture models 
Using primary cell cultures has many advantages, including that they allow the manipulation of 
active and maturing neurons in connected networks over short periods of time. While not as 
complex or physiologically relevant as mouse models, the relative ease of maintenance, the low 
cost, and speed at which experiments can be completed make primary cell cultures a popular 
choice for biochemical experiments (Barbin et al., 1988; Chen and Herrup, 2008; Ferreira et al., 
2012; Zhou and Klein, 2012; Calvo et al., 2015). However, there are also some important 
limitations to consider when interpreting results obtained using rodent primary cultures. First 
and foremost, cells in culture are not in the same physiological conditions as if they were 
developing in a living brain. Cells no longer have the same physical contact with each other or 
the same chemicals in the extracellular environment (Chen and Herrup, 2008). In addition, the 
percentage of each neural cell type varies dramatically in different cultures. For example, at 14 
DIV there was approximately 19 % astrocytes in the mixed cortical cultures used in this thesis, 
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in comparison there are approximately five times as many astrocytes as neurons in some regions 
of the adult human brain (Sofroniew and Vinters, 2010).  
Additionally, it was assumed that the primary cultures used in experiments in this thesis do not 
contain microglia as they are made from embryonic rat brains at a developmental stage shown 
to precede microglial infiltration of the brain (Streit and Xue, 2009; Jebelli et al., 2015). Microglia 
play a key role in supporting and maintaining neuron health in a living brain and neuron cultures 
in the absence of these cells will inevitably be less resistant to stress and disease (Nimmerjahn 
et al., 2005; Jebelli et al., 2015). Additionally, the possible lack of microglia may have revealed 
additional effects of DMF treatment in line with evidence of its anti-inflammatory action in other 
studies (Heiligenhaus et al., 2004; Wierinckx et al., 2005; Schilling et al., 2006; Wilms et al., 2010; 
Brennan et al., 2016). The aim of this thesis was specifically to investigate the role of astrocytes 
and, to allow this, conditions were used in which microglia were unlikely to be present. However, 
as the absence of microglia has not been confirmed in the primary cultures used in these 
experiments, it is possible that some of the results described may be due to low levels of 
microglia in the cell cultures. 
Furthermore, while basic characterisation of the primary cell cultures was carried out, this thesis 
would have benefited from more in depth investigation into the make up and development of 
the primary cell cultures used. Phase images of cells would provide further insight into the 
development and health of cell cultures, and demonstrate clear morphological differences 
between neurons and astrocytes. Moreover, probing western blots of primary cell lysates with 
other antibodies, including both neuron- and microglia-specific markers, alongside western blots 
probed with tau, could further confirm neuron enrichment and the absence of microglia in 
predominantly neuronal cultures. Increased levels of neuron markers in predominantly neuronal 
cultures, compared to total protein markers, would indicate a higher percentage of total 
cultured cells were neurons.  
In addition, microglial cells were assumed to be absent based on previous work carried out with 
similar primary cell cultures in this laboratory (Garwood et al., 2011) and elsewhere (Streit and 
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Xue, 2009). However, using immunocytochemistry to stain primary cultures for microglial-
specific markers (such as OX42) would demonstrate primary cell cultures grown for this project 
do not contain microglia.  
An important point when considering the implication of the data presented here is that the 
primary cell culture experiments presented in this thesis were carried out during a period of 
time when our laboratories were moving to a new building. There were many issues with the 
cell culture facilities we were using such as with fans needed to provide a sterile environment in 
tissue culture hoods, with the ultrapure water supply and maintenance of CO2 supply to 
incubators.  Unfortunately, no easily accessible or convenient alternative facilities were 
available. Despite as much as possible being done to minimise artefacts from these poor tissue 
culture conditions, there were issues with higher than expected levels of cell death and 
inevitably poorer cell health. The effects of poor cell health on the development and presence 
of synapses is of particular concern. While the presence of synapses in 14 DIV neuron cultures 
is widely reported in the literature (Cullen et al., 2010; Chai et al., 2016; He et al., 2016), it may 
be that poorer cell health may be impairing synapse growth or increasing synapse degeneration. 
To demonstrate synapses are present in the primary cell cultures used in this thesis it would be 
highly beneficial to probe for synaptic markers on western blots run using primary cell lysates. 
Increased levels of cell death and poor cell health are likely to explain some of the unexpected 
findings reported in Chapter 3:. That said, the results from these primary cell culture 
experiments appear to correspond, at least in part, to findings from human post-mortem brain. 
It is also important to consider species differences. For example, human astrocytes are much 
larger and complex, with human protoplasmic astrocytes estimated to have tenfold more 
processes than their rodent counterparts (Oberheim et al., 2009). Whilst mouse astrocytes have 
been shown to promote neuronal survival and synapse formation to a similar extent as human 
astrocytes, marked changes in glutamate response and transcription profile have been 
described between murine and human astrocytes (Zhang et al., 2016b). Recent advances in 
induced pluripotent stem (iPS) cells mean that iPS cells from control and AD individuals could 
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now be used as an alternative model to primary rat cultures. For example, investigations into 
the positive effects of hypothermia using iPS cells have found tau phosphorylation is protective 
during cooling conditions, reducing oxidative stress and neurotoxicity and suggesting tau 
phosphorylation may be a physiological response under cooling conditions (Rzechorzek et al., 
2016). This study, and others like it, may provide molecular explanations for the 
hyperphosphorylation of tau and other pathological responses underlying AD progression 
(Rzechorzek et al., 2015). Alongside experiments in primary rat cultures, iPS cells could help 
eliminate problems surrounding species differences. Another alternative method to using 
primary rodent cultures is using primary human astrocytes retrieved from post-mortem human 
brain (De Groot et al., 1997). Astrocytic and microglial Aß uptake has been demonstrated to be 
dependent on Aß aggregation state and ApoE in primary human astrocytes, showing these 
primary human cells can be used as an alternative method to investigate pathological 
mechanisms in AD (Nielsen et al., 2010; Mulder et al., 2014). 
Limitations of using soluble Aß as a cell culture treatment 
As mentioned briefly in Chapter 3:, the use of soluble, synthetic Aß as a cell culture treatment 
has come under criticism due to limitations surrounding the production and use of the peptide. 
Poor consistency between and within batches causes variability between experiments despite 
batch testing (Soto et al., 1995; Stohr et al., 2012). This is likely to be due to impurities in the 
peptide and the structure of individual peptide molecules affecting the fibrillisation and 
aggregation propensity and speed (Soto et al., 1995; Finder et al., 2010). In addition, there is no 
standard protocol for resuspending or aggregating Aß peptide prior to cell treatment making it 
difficult to compare results from different research groups. Finally, synthetic Aß has been 
criticised as not being physiological, with much higher concentrations of synthetically produced 
peptide required to produce the same results as those caused by physiological Aß in a human 
brain (Walsh et al., 2005). Furthermore, physiologically released Aß, such as that from 7PA2 CHO 
cells or cultured Tg2576 neurons, have also been found to have more toxic effects at synapses 
than synthetically produced Aß (Walsh et al., 2002; Reed et al., 2011). Experiments presented in 
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this thesis show that while 7PA2-derived Aß caused activation of caspase-3, it did not cause 
overt cell death and appeared not to activate astrocytes in the same manner as synthetic Aß. 
For these reasons, although clearly not ideal, synthetic Aß was used for a large part of the work 
presented here.  
6.4.2 Limitations of DMF treatment of htau mice 
The results from preclinical trials investigating possible effects of DMF on age-related 
pathological changes in the htau mouse model of tauopathy (Chapter 4:) showed very little 
difference between DMF treated and control groups, with the exception of increases in insoluble 
tau amounts in young htau mice. The most likely explanation for this is that DMF is not having 
an effect on the specific parameters investigated here. However, there are some limitations to 
the protocols used in these experiments. Potential statistical noise resulting from variation in 
the precise dose of drug orally administered may have obscured subtle drug effects. However, 
the decision to use this method of administration was based on the welfare of the mice, which 
is of the utmost importance (Eichenbaum et al., 2011). 
In particular, behavioural testing of older (mid-disease stage) htau mice showed high levels of 
variability within groups, and no statistically significant differences between either htau and 
wild-type mice or between htau mice dosed with DMF or vehicle in the Morris water maze. 
The Morris water maze is one of the most commonly used behavioural tests for experimental 
rodents and has been widely characterised (Wahlsten et al., 2005; Bromley-Brits et al., 2011; 
Vorhees and Williams, 2014a). It is cheap, easy to use and requires rodents to undergo only basic 
training. Furthermore, having undergone extensive testing, the water maze has been 
demonstrated as a robust test of allocentric spatial learning (spatial learning and memory) based 
on external, environmental cues (Vorhees and Williams, 2014a)). All these advantages make the 
Morris water maze the most popular, and usually first, choice for assessing spatial memory 
deficits in rodents. However, this maze was originally designed for use with rats and there have 
been some suggestions that the task is less appropriate for mice (Vorhees and Williams, 2014b). 
In particular, the water maze has been found to be significantly affected by mouse strain 
262 
 
differences, however a previous study with C57BL/6 mice (the background strain used in these 
studies) suggest that the performance of this strain in the maze is good (Wahlsten et al., 2005).  
Additionally, performance in the water maze can be affected by high levels of anxiety. Studies 
suggest some mice find the Morris water maze stressful, demonstrating increased corticosteroid 
levels that negatively correlate with maze performance (Harrison et al., 2009). Animals with high 
stress levels often display ‘wall hugging’ or floating behaviours (Wahlsten et al., 2005). Although 
not quantitatively measured, wall hugging and a tendency to continual circle the maze was 
observed in htau mice in this study, possibly suggesting anxiety and potentially obscuring 
differences in spatial memory abilities between groups.  
Finally, the water maze is not a suitable test for animal with motor impairments. Research shows 
htau locomotor activity is equal to that of control mice (Polydoro et al., 2009). Generally, this 
was also found in this study of the mice, however, one mouse displayed swimming problems 
due to problems with back limb control. This mouse showed no signs of pain or distress outside 
of the maze, however the mouse was removed from water maze experiments and excluded 
from analysis. It is most likely that motor problems were unrelated to the htau phenotype, 
possibly caused by spontaneous illness (e.g. ischaemia), as no other mice in the experiment were 
affected by similar impairments. 
Additionally, it is possible that DMF treatment could be affecting htau mouse behaviour in ways 
undetectable by the Morris water maze. Ideally multiple behavioural tests would have been 
carried out in this study. In particular, novel object recognition paradigms could have yielded 
interesting results as this is another area in which htau mice have been found to show 
impairment (Polydoro et al., 2009). However, in general, rodent behavioural tests are time 
consuming and often have higher statistical noise due to high variability in general behaviour 
between animals, making significant results difficult to obtain, particularly in relatively small 
groups (Hanell and Marklund, 2014).  
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6.4.3 Limitations of using post-mortem brain samples 
Studies using human post-mortem brain samples to investigate changes in AD, like the 
experiments described in Chapter 5:, have the advantage of being one of the only ways to view 
disease-related changes in a human brain. While mouse, cell culture and computational models 
of disease are useful to provide insights into signalling pathways and mechanisms underlying 
disease development and progression, it is important to validate findings in diseased brain. 
However, there are some general limitations to using post-mortem brain that need to be 
considered when interpreting the experimental results described in Chapter 5:. 
First and foremost, it is vital to remember that the human tissues are obtained post-mortem. 
Therefore, even using Braak-staged tissues does not allow comment on the development of 
disease events, but rather represents a snap-shot of changes taking place at distinct times in 
different brains. Similarly, legal and ethical considerations make it difficult to collect a donated 
brain for some time after death. The time between death and the collection of a brain is referred 
to as the post-mortem delay and the length of delay has significant effects on the quality of the 
brain samples. The post-mortem delay for each human brain sample used is recorded in the 
sample tables of methods section of Chapter 5 (section 5.2). These tables demonstrate the 
variation of this delay, from several hours to several days. While some research from the field 
suggests brain samples maintain their integrity for several days (Gonzalez-Maeso et al., 2002), 
there is evidence of biochemical changes and particularly sample degradation occurring from as 
early as 6 hours in rat brain (De Groot et al., 1995). In addition, there are many other variables 
that can affect the quality and degradation of post-mortem brain samples (Stan et al., 2006). For 
example, brain pH has been found to have significant effects on hippocampal gene expression 
profiles, and has been shown to have greater predictive value than disease in a group of control 
and schizophrenic post-mortem brain samples (Mexal et al., 2006). Information detailing the 
collection of post-mortem brain used in these studies did not include variables such as pH or 
time taken to cool brains, therefore effects caused by such variables may explain some of the 
variation between samples but no final conclusions can be drawn. 
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Additionally, there is often considerable variation between post-mortem brain that is not seen 
in relatively homogenous colonies of transgenic mice. This is due to genetic variation and 
environmental factors including illnesses suffered, medications being taken and factors such as 
whether or not an individual smoked (Harrison, 2011). It is also difficult to obtain tissues from 
very early disease stages, particularly from the hippocampus for which there is great demand. 
Therefore, low sample sizes can make it difficult to generate statistically meaningful data. 
Nevertheless, further understanding the differences in signalling mechanisms underlying 
neurodegeneration in different brain regions (and no doubt in different individuals) will 
hopefully aid the development of stage-specific disease-modifying drugs, allowing for a more 
‘personalised’ approach to the treatment of AD and other brain diseases. 
 
6.5 Future directions 
Data presented in this thesis demonstrates differences in astrocyte contribution in hippocampus 
and cortex at different stages of AD using both primary cell culture and human post-mortem 
brain samples. In addition, it shows repurposing of drugs could help accelerate drug trial 
procedures, despite pre-clinical trials with the anti-inflammatory DMF being inconclusive. With 
more time, future experiments could investigate the precise mechanisms underlying the 
regional differences in AD and the molecular targets of DMF. The following are some suggestions 
of possible future research avenues. 
6.5.1 The role of astrocytes and inflammation in disease-associated tau processing in 
primary cell culture models 
Previous data from this laboratory determined a range of inflammatory mediators upregulated 
by Aß that are associated with changes in tau phosphorylation (Garwood et al., 2011). 
Experiments could be designed to determine the effects of specific targeting of these molecules. 
For example, immunodepleting astrocyte-conditioned culture medium of a specific cytokine 
prior to application of this medium to neurons, downregulating cytokines or cytokine receptors 
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using siRNAs, or blocking cytokine receptors with specific antagonists allow inhibition of specific 
signalling pathways that could start to elucidate the role of astrocyte-derived inflammatory 
mediators in Aß-induced hippocampal cell death. Some attempts were made to conduct these 
experiments (data not shown), but cytokine antibodies are generally quite poor, making it 
difficult to ascertain the quality of immunodepletion experiments. Alternatively, while 
inflammatory mediators have been implicated in disease-associated tau processing, other 
astrocytic secretions (for example, gliotransmitters) may also be important. Proteomic analysis 
assessing astrocytic secretions in the conditioned medium of control and Aß-treated astrocyte 
cultures could highlight astrocytic released proteins, whether those proteins are inflammatory 
mediators or other astrocytic secretions, that contribute to abnormal tau processing in primary 
cell culture models (Dowell et al., 2009; Han et al., 2014). 
To determine if it is hippocampal astrocytes rather than increased susceptibility of hippocampal 
neurons to AD-like insults that is important, hippocampal astrocytes could be co-cultured with 
cortical neurons, and vice versa.  
In addition, if specific astrocytic signalling pathways are found to contribute to hippocampal Aß-
induced changes, drugs targeting key steps in these pathways could be tested to investigate 
potential beneficial effects of inhibiting or activating these events. Drug discovery via evidence 
of the involvement of specific pathways is likely to give better results than trials of general anti-
inflammatories, such as NSAIDs (Miguel-Alvarez et al., 2015). 
Furthermore, experiments described in Chapter 3: show astrocytes play a role in the 
maintenance of extracellular tau levels in primary cortical cultures. These experiments were only 
preliminary and there are many further experiments that could be carried out to further 
investigate this avenue of research, including:  
1. Investigations into regional differences in tau release. All experiments investigating the 
role of astrocytes in tau release were carried out in primary cortical cultures. Other 
experiments described in this thesis have suggested that astrocytes may play an 
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increasingly important role in the hippocampus, therefore a natural extension of this 
work would be to examine the effect of astrocytes on tau release in hippocampal 
cultures.  
2. Investigations into Aß-induced tau release using the tau sandwich ELISA. Experiments 
investigating the role of astrocytes in Aß-induced tau release were carried out at Eli Lilly 
using Alphascreens. It was expected that Alphascreens would be sensitive enough to 
detect differences extracellular tau in concentrated medium, but results showed no 
change in the level of extracellular tau in neuronal cultures treated with AraC to prevent 
astrocyte proliferation. However, in a tau sandwich ELISA developed in-house, the 
presence of astrocytes in cortical mixed cultures was robustly associated with increased 
accumulation of extracellular tau, suggesting that the Alphascreen may not be sensitive 
enough to detect small changes in tau levels. Therefore, it is worth using the tau ELISA 
to look at conditioned medium from cultures treated with Aß and/or minocycline.  
3. Investigations into astrocytic uptake of extracellular tau. Experiments described in this 
thesis have demonstrated astrocytes play a role in maintaining extracellular tau levels, 
however, there are several mechanisms that could underlie maintenance of tau levels. 
Previous research in the field has shown it is possible for astrocytes to take up tau 
following its trans-synaptic propagation (de Calignon et al., 2012), therefore providing 
one possible mechanism for astrocytic control of extracellular tau. Simple ICC 
experiments investigating tau uptake in cultured astrocytes, with and without neuronal 
stimulation, could elucidate whether this is an important mechanism used to maintain 
extracellular tau levels. A likely limitation of this experiment will be the low levels of tau 
released and potentially taken up which may be below the sensitivity of conventional 
immunofluorescence imaging techniques.  
4. Investigations into the role of astrocytic glutamate uptake in tau release. Alternatively, 
astrocytes may influence tau release via the contributions they make to maintaining 
synaptic glutamate levels (Anderson and Swanson, 2000). Increased glutamate in the 
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synapse can lead to increased post-synaptic activity, known to increase levels of tau 
released (Pooler et al., 2013; Talantova et al., 2013). By modifying glutamate 
transporters in primary astrocytic cultures or culturing cells from glutamate transporter 
knock-out mice and measuring levels of extracellular tau compared to wildtype cultures, 
it would be possible to determine if astrocytic glutamate uptake was involved in 
mediating neuronal tau release. 
Finally, in terms of the culture model itself, in the brain, astrocytes interact with neurons in a 
three-dimensional fashion, and consequently the two-dimensional culturing methods used here 
have a limited ability to emulate this physiological environment (Maclean et al., 2015). In 
addition to reduced GFAP expression, astrocytes grown on nanofiber scaffolds also exhibit 
increased expression of BDNF and EAAT2, consistent with a ‘healthy brain’ phenotype (Lau et 
al., 2014). Astrocytes grown on such three-dimensional structures actively proliferate, migrate 
into these scaffolds and adopt a stellate morphology, thus mimicking in vivo phenotypes (Lau et 
al., 2014). Future studies using neural cells grown on such three-dimensional scaffolds may allow 
us to explore further the influence of astrocytes under more physiological conditions, and 
investigate whether they retain the highly heterogenic morphology and cell size observed in our 
culture conditions. 
As mentioned in the limitations section of this chapter (section 6.4.1), species differences 
between rat and human astrocytes limit the use of the primary culture model used in these 
experiments (Oberheim et al., 2009). To overcome this problem, motor neurons differentiated 
from iPS cells from control individuals and those with amyotrophic lateral sclerosis (ALS)/FTD 
have been used to investigate differences in signalling pathways in human motor neuron 
cultures in this disease (Serio et al., 2013). In the same way, neurons and astrocytes 
differentiated from iPS cells from AD patients could be compared with those from control 
individuals to investigate differences in astrocytic signalling pathways. Similarly, neuronal cells 
differentiated from embryonic stem cells could be cultured with primary human astrocytes from 
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control and AD brain to investigate the effects of aged and AD astrocytes on young control 
neurons (Re et al., 2014).  
6.5.2 Identification of DMF targets 
If time had allowed, further experiments could have been conducted to further elucidate the 
molecular targets of DMF in cell cultures and htau mice. Experiments investigating the effects 
of DMF in primary cortical cultures found treatment significantly reduced tau phosphorylation 
at Ser199/202/Thr205. However, there was no change in GFAP levels in primary cultures despite 
DMF having known anti-inflammatory effects. However, GFAP is not the only indicator of 
astrocytes, and also does not label all activated astrocytes (Garwood et al., 2016). Therefore, it 
is possible that astrocyte activation, or at least changes in some astrocytic signalling pathways, 
may be occurring in the absence of reductions in GFAP levels. 
With more time, experiments investigating whether astrocytes are necessary for DMF-
dependent reductions in tau phosphorylation could easily be carried out. Treating cell cultures 
with AraC at 3 DIV, in the same way as experiments described in Chapter 3:, would result in 
neuronal primary cultures. Predominantly neuronal and mixed primary cultures could be treated 
with DMF, and if a reduction in tau phosphorylation was not seen following DMF treatment of 
predominantly neuron cultures this would indicate astrocytes are necessary for DMF to be 
effective in reducing tau phosphorylation. 
Additionally, experiments investigating the mechanisms by which DMF reduces tau 
phosphorylation implicated signalling pathways involving cdk5, a tau kinase. In particular, since 
IL-1ß is known to affect cdk5 activity (Kitazawa et al., 2011), the results might suggest DMF could 
reduce the activity of an IL-1ß - cdk5 signalling pathway. In order to test this hypothesis, IL-1ß 
could be targeted using the methods described above and the downstream effects on cdk5 and 
tau determined. 
It would also be interesting to further investigate the impact of DMF on Nrf2 signalling since this 
is important for the selective autophagy of tau aggregates (Jo et al., 2014a). However, these 
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experiments may also prove challenging as antibodies raised against proteins in this signalling 
pathway have so far been found to be of poor quality. 
6.5.3 Further analysis of post-mortem AD brain 
Further information about the role of glia and neuroinflammation in the progression of AD could 
be elucidated using the same human post-mortem brain samples as used in the experiments in 
Chapter 5: by investigating the role of a wide range of cytokines using antibody arrays. This 
would allow the assembly of a regional and Braak-stage specific heat map which may highlight 
specific cytokine families as being important in different tissues or stages of disease. An 
alternative approach would be to use gene expression arrays and network analysis with the help 
of a biostatistician. 
Additionally, with more time, investigations into changes in microglial markers would be a 
priority. Attempts to optimise an anti-Iba1 antibody were carried out but protein bands at the 
correct size were not found in the full set of post-mortem temporal cortex samples. However, 
there are multiple other microglial markers that could be assessed including CD45, CD68 and 
more recently developed Tmem119 (Cuadros et al., 2006; Bennett et al., 2016). It would be 
expected that there would be significant changes in microglia levels and activation, as microglial 
release of cytokines and their anti-inflammatory roles, as mentioned in Chapter 1 (section 1.7), 
have been previously found to be important in the development and progression of AD (Pocock 
and Kettenmann, 2007; Crehan et al., 2012; Gomez-Nicola and Perry, 2016; Perry, 2016; Wes et 
al., 2016). 
Finally, recent papers have shown activated glial cells cluster around amyloid plaques and 
pathological tau aggregates in transgenic mouse and human AD brain (Olabarria et al., 2010; de 
Calignon et al., 2012; Bouvier et al., 2016). Additional IHC experiments using paraffin-fixed 
sections from the same brains as those samples used in the post-mortem studies described in 
Chapter 5: could be carried out to investigate changes in morphology and localisation of 
astrocytes and microglia as disease progresses. Staining of samples from Braak stage I-VI with 
antibodies for glial markers and (phosphorylated) tau or Aß could provide insights into glial 
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behaviour throughout disease, extending studies examining these associations in control and 
late stage AD (Olabarria et al., 2010; Bouvier et al., 2016). Furthermore, it may be possible to 
compare differences in glial morphology and localisation in different brain regions as AD 
progresses, hopefully gaining more information about differences in regional astrocytic 
behaviour. 
 
6.6 Final conclusions 
Overall, the studies presented in this thesis suggest there are likely regional differences in the 
contributions of astrocytes to pathological changes in tau and neurodegeneration during the 
progression of AD. In particular, the contribution of astrocytes appeared to differ between 
cortical and hippocampal regions. These differences can be seen in both primary cell culture 
models and human post-mortem brain samples; this suggests that the primary cell culture 
models used in this thesis are recapitulating at least some important aspects of disease 
successfully. 
Efforts to further understand the implications of these regional differences will be critical for 
increasing our understanding of important disease mechanisms. Furthermore, this knowledge 
will allow better stratification criteria for clinical trials which might result in a higher likelihood 
of promising drugs reaching patients. Together, this would allow the development of more 
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